levodopa has been researched along with Disease Models, Animal in 932 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 65 (6.97) | 18.7374 |
| 1990's | 68 (7.30) | 18.2507 |
| 2000's | 292 (31.33) | 29.6817 |
| 2010's | 402 (43.13) | 24.3611 |
| 2020's | 105 (11.27) | 2.80 |
| Authors | Studies |
|---|---|
| Avdeef, A; Tam, KY | 1 |
| Beauchamp, DA; Boulet, J; Branum, S; Bullington, JL; Chakravarty, D; Damon, S; Davis, S; Demarest, K; Hall, D; Hansen, K; Heintzelman, GR; Jackson, PF; Li, X; Osborne, MC; Palmer, D; Rassnick, S; Reyes, M; Rhodes, K; Rupert, KC; Russell, R; Shook, BC; Tang, Y; Wells, KM; Westover, L; Youells, S | 1 |
| Ardashov, OV; Il'ina, IV; Karpova, EV; Korchagina, DV; Morozova, EA; Pavlova, AV; Salakhutdinov, NF; Tolstikova, TG; Volcho, KP | 1 |
| Bajpai, M; Banerjee, A; Bhateja, DK; Gandhi, MN; Gharat, LA; Gudi, GS; Gullapalli, S; Gupta, PK; Khairatkar-Joshi, N; Patil, S; Pawar, MY; Sangana, RR | 1 |
| Braisted, J; Dranchak, P; Earnest, TW; Gu, X; Hoon, MA; Inglese, J; Oliphant, E; Solinski, HJ | 1 |
| Abrams, RPM; Bachani, M; Balasubramanian, A; Brimacombe, K; Dorjsuren, D; Eastman, RT; Hall, MD; Jadhav, A; Lee, MH; Li, W; Malik, N; Nath, A; Padmanabhan, R; Simeonov, A; Steiner, JP; Teramoto, T; Yasgar, A; Zakharov, AV | 1 |
| Ahn, J; Chung, KS; Han, HS; Huh, E; Lee, HH; Lee, JY; Lee, KT; Moon, GH; Oh, MS; Woo, J; Yang, S | 1 |
| Berghauzen-Maciejewska, K; Konieczny, J; Lenda, T; Matłoka, M; Ossowska, K; Pieczykolan, J; Wieczorek, M | 1 |
| Bartlett, MJ; Falk, T; Morrison, HW; Pottenger, AE; Sherman, SJ | 1 |
| Bezard, E; Friedman, E; Kottmann, AH; Li, Q; Malave, L; Qin, C; Rebholz, H; Starikov, L; Uribe-Cano, S; Zuelke, DR | 1 |
| Kuric, E; Marklund, N; Ruscher, K; Talhada, D; Wieloch, T | 1 |
| Caulfield, ME; Stancati, JA; Steece-Collier, K | 1 |
| Gao, L; González-Rodríguez, P; Guzman, JN; Ilijic, E; Kaplitt, MG; López-Barneo, J; Schumacker, PT; Stavarache, MA; Stout, KA; Surmeier, DJ; Tkatch, T; Wokosin, DL; Yang, B; Zampese, E | 1 |
| Chakraborty, R; Hattar, S; Iuvone, PM; Landis, EG; Mazade, R; Pardue, MT; Stone, RA; Strickland, R; Yang, V | 1 |
| Bédard, D; Clarke, PB; Frouni, I; Hamadjida, A; Huot, P; Kwan, C; Lévesque, C; Lévesque, D; Yesuf, JM | 1 |
| Dagda, R; Dagda, RK; Grigoruta, M; Martinez, B; Vazquez-Mayorga, E | 1 |
| Annarumma, S; Hansen, CA; Khoshbouei, H; Miller, DR; Ramirez-Zamora, A; Rusch, CT | 1 |
| Araki, T; Furusho, T; Ito, M; Kobayashi, S; Kogure, S; Konishi, F; Soeda, Y; Takashima, A; Takekoshi, S; Yamauchi, J | 1 |
| Kimura, T; Kinoshita, I; Kon, T; Miki, Y; Mori, F; Nakamura, T; Nishijima, H; Suzuki, C; Tomiyama, M; Wakabayashi, K | 1 |
| Girasole, AE; Kreitzer, AC; Lee, HY; Nelson, AB; Ptáček, LJ | 1 |
| Araujo, SM; Bortolotto, VC; Janner, DE; La Rosa Novo, D; Meichtry, LB; Mesko, MF; Musachio, EAS; Poetini, MR; Prigol, M; Ramborger, BP; Roehrs, R; Silva, NC | 1 |
| Erives, VH; Hamed, MF; Hernandez, H; Manepalli, S; Martinez, LR; Munzen, ME; Nguyen, LN; Nosanchuk, JD; Zamith-Miranda, D | 1 |
| Arias-García, M; Bargas, J; Calderón, VM; Galarraga, E; Gómez-Paz, A; Lara-González, E; Luna-Leal, A; Ramírez-López, F | 1 |
| Al-Kaleel, A; Aygün, H; Erbaş, O | 1 |
| Kochoian, BA; Leventhal, L; Masilamoni, GJ; McRiner, AJ; Papa, SM; Singh, A; Sinon, CG | 1 |
| Drummond, N; Elabi, OF; Kirkeby, A; Kunath, T; Lane, EL; Nolbrant, S; Parmar, M; Pass, R; Sormonta, I | 1 |
| Bishop, C; Budrow, C; Centner, A; Cohen, SR; Coyle, M; Glinski, J; Lipari, N; Manfredsson, FP; Smith, S; Terry, ML; Wheelis, E | 1 |
| Bui, BV; Finkelstein, DI; Hoang, A; Lim, JKH; Nguyen, CTO; Shahandeh, A; Tran, KKN; Wong, VHY | 1 |
| Murer, MG; Paz, RM; Rela, L; Stahl, AM; Tubert, C | 1 |
| Chen, YH; Hoffer, BJ; Huang, EY; Kuo, TT; Ma, KH; Olson, L; Tseng, KY; Wang, V | 1 |
| Arveiler, B; Decoeur, F; Gazova, I; Gontier, E; Jackson, IJ; Javerzat, S; McKie, L; Mercier, E; Michaud, V; Pinson, B; Tingaud-Sequeira, A | 1 |
| Anceaume, E; Caboche, J; Calabrese, V; Calabresi, P; Campanelli, F; Charvin, D; Conquet, F; Cuoc, E; Ghiglieri, V; Heck, N; Marino, G; Natale, G; Picconi, B; Sciaccaluga, M; Tozzi, A | 1 |
| Cui, C; Han, Y; Li, G; Li, H; Yu, H; Zhang, B | 1 |
| Chen, X; Dai, F; Jiang, Y; Li, Z; Liu, L; Luo, Y; Mao, T; Shang, Y; Song, J; Sun, T; Tan, D; Tong, X; Zhang, J; Zhou, L | 1 |
| Casado-Polanco, R; Castela, I; Costa, RM; da Silva, JA; Hernandez, LF; Marquez, R; Moratalla, R; Obeso, J; Pro, B; Redgrave, P; Rubio, YV | 1 |
| Blandini, F; Cerri, S; Cesaroni, V | 1 |
| Bishop, C; Centner, A; Cohen, S; Glinski, J; Lipari, N; Manfredsson, FP | 1 |
| Cenci, MA; Espa, E; Fanni, S; Skovgård, K; Song, L | 1 |
| Cao, X; Lian, P; Wu, Y; Xu, Y; Yuan, Y; Zhang, X | 1 |
| Braccagni, G; Carta, M; Caruso, D; Cioffi, L; Corsi, S; Diviccaro, S; Fanni, S; Frau, R; Gambarana, C; Gentile, M; Melcangi, RC; Pardu, A; Scheggi, S; Stancampiano, R | 1 |
| Chen, YH; Choi, HI; Greig, NH; Hoffer, BJ; Huang, EY; Jung, J; Kuo, TT; Ma, KH; Olson, L; Tseng, KY; Wang, V | 1 |
| Abdel-Aleem, GA; Abdel-Fattah, DS; El-Sheikh, TF; Elbatch, MM; Mohamed, AS | 1 |
| Furukawa, T; Kinoshita, I; Kon, T; Murakami, Y; Nakamura, T; Nishijima, H; Suzuki, C; Tomiyama, M | 1 |
| Buberwa, W; Gao, D; Kambey, PA; Liu, WY; Nyalali, AMK; Saro, A; Tang, C; Wu, J | 1 |
| Bi, Y; Deng, Y; Guan, J; Wang, P; Wang, Z; Yang, H; Yu, J; Zhang, W | 1 |
| Del-Bel, E; Dias, FJ; Escobar-Espinal, D; Jacob, G; Leal-Luiz, G; Malzone, BL; Milan, BA; Nascimento, GC; Vivanco-Estela, AN | 1 |
| Bartlett, MJ; Falk, T; Flores, AJ; Heien, ML; Lu, D; Porreca, F; Samtani, G; Seaton, BT; Sexauer, MR; Sherman, SJ; Siegenthaler, JR; Weintraub, NC | 1 |
| Griffiths, H; Keeling, E; Lee, H; Lotery, AJ; Lynn, SA; Macdonald, SL; Newall, T; Ratnayaka, JA; Sanchez-Bretano, A; Scott, JA; Self, JE; Soundara-Pandi, SP | 1 |
| Dunnett, SB; Lane, EL; Lelos, MJ; Lindgren, HS; Murphy, EM | 1 |
| Bao, J; Chen, Q; Chen, Y; Dai, J; Feng, S; Guo, P; Hong, Z; Jiang, X; Li, A; Li, T; Li, X; Li, Y; Lin, J; Lin, Y; Liu, J; Liu, K; Liu, T; Lu, Z; Shan, L; Wang, J; Wilde, JJ; Zhang, T | 1 |
| Goehring, CM; Herfert, K; Kuebler, L; Pichler, BJ; Walker, M | 1 |
| Beck, G; Mochizuki, H; Mouradian, MM; Papa, SM; Park, ES; Potts, LF; Singh, A; Woo, JM; Zhang, J | 1 |
| Chatani, M; Handa, K; Hosonuma, M; Inagaki, K; Ishikawa, K; Karakawa, A; Kiuchi, Y; Kiyohara, S; Negishi-Koga, T; Sakai, N; Takami, M; Tsuji, M; Yamakawa, T | 1 |
| Guerrero, MF; López, JL; Olaya, MDP; Vergel, NE; Viña, MD | 1 |
| Abe, H; Jitsuki, S; Takahashi, T | 1 |
| Clark, I; Egan, T; Rentsch, P; Stayte, S; Vissel, B | 1 |
| Afonso, ND; Chapela, D; Coelho, JE; Ferreira, JJ; Lopes, LV; Outeiro, TF; Sousa, S; Vaz, RL | 1 |
| Barroso, SDS; Gomes, MZ; Lopes, LES; Santos, KS | 1 |
| Che, Y; Feng, X; Liu, Q; Tang, X; Zhang, S; Zhu, D | 1 |
| Afonso, ND; Chapela, D; Correia, AD; Outeiro, TF; Sousa, S; van der Linde, HC; Vaz, RL; Willemsen, R | 1 |
| Ashby, R; Karouta, C; Kelly, T; Morgan, I; Thomson, K | 2 |
| Bishop, C | 1 |
| Danilchenko, V; Dhar, A; Matiashova, L; Miranda, AV; Papakosta, V; Tsagkaris, C; Zacharopoulou, L | 1 |
| Chen, N; Du, TT; Fan, SY; Guo, CJ; Han, CL; Jiang, Y; Liu, YP; Meng, FG; Shimabukuro, M; Sui, YP; Wang, KL; Wang, Q; Yuan, F; Zhang, JG | 1 |
| Barth, AL; Brotchie, JM; Cearley, CN; Hill, MP; Johnston, TH; Moskal, JR; Schneider, JS | 1 |
| Campos, J; Domingues, AV; Salgado, AJ; Teixeira, FG; Vilaça-Faria, H | 1 |
| Bergen, M; Chakraborty, R; Chrenek, MA; Iuvone, PM; Landis, EG; Pardue, MT; Strickland, R; Yang, V | 1 |
| Castello, J; Cortés, M; Friedman, E; Kottmann, A; Malave, L; Rebholz, H; Sibley, DR | 1 |
| Igarashi, S; Ishioh, M; Kumei, S; Nozu, T; Ohhira, M; Okumura, T | 1 |
| Fukunaga, K; Haga, H; Izumi, H; Kawahata, I; Miyachi, H; Shinoda, Y; Yamada, R | 1 |
| Bartlett, MJ; Falk, T; Heien, ML; Parent, KL; Polt, R; Sherman, SJ; Skinner, DP; So, LY; Szabò, L; Vanderah, TW | 1 |
| Chen, X; Cheng, C; Le, W; Wang, Y; Wu, H | 1 |
| Chen, S; Duan, S; Fang, J; Le, Y; Li, D; Li, F; Qing, W; Tan, L; Tong, J; Wang, Y; Yang, J; Zhang, B | 1 |
| Auger, F; Barthelemy, C; Bezard, E; Bordet, R; Carta, N; Defebvre, L; Demailly, A; Deramecourt, V; Devedjian, JC; Devos, D; Duce, J; Fisichella, M; Kuchcinski, G; Laloux, C; Lannoy, D; Li, Q; Moreau, C; Odou, P; Pioli, E; Rolland, AS | 1 |
| Koski, SK; Leino, S; Panula, P; Rannanpää, S; Salminen, O | 1 |
| Duty, S; Fisher, R; Jackson, M; Lincoln, L; Mann, E; Rose, S | 1 |
| Chonpathompikunlert, P; Hutamekalin, P; Nagasaki, Y; Sato, Y; Tanasawet, S; Vong, LB | 1 |
| Aragão Catunda Junior, FE; Basto Souza, R; da Cunha Ferreira, NM; de Sousa Dos Reis, TD; Hardy Lima Pontes, N; Maranguape Silva da Cunha, R; Moreira Vasconcelos, CF; Vasconcelos Aguiar, LM | 1 |
| Ayikobua, ET; Eze, ED; Jjesero, E; Kalange, M; Kasolo, J; Kasozi, KI; Kimanje, KR; Kiyimba, K; Mwandah, DC; Namulema, J; Nansunga, M; Ninsiima, HI; Okpanachi, AO; Safiriyu, A; Semuyaba, I; Ssempijja, F | 1 |
| Castela, I; Hernandez, LF | 1 |
| Aristieta Arbelaiz, A; Degos, B; Derousseaux, W; Gangarossa, G; Piette, C; Touboul, J; Valverde, S; Vandecasteele, M; Venance, L | 1 |
| Bermúdez de León, M; González-Hernández, B; González-Horta, A; Leija-Salazar, M | 1 |
| Bezard, E; Crynen, G; De Rosa, A; Eshraghi, M; Galli, N; Li, Q; Nuzzo, T; Ramírez-Jarquín, UN; Rivera, O; Scharager-Tapia, C; Shahani, N; Subramaniam, S; Swarnkar, S; Thiolat, ML; Tsaprailis, G; Usiello, A | 1 |
| Kuo, CC; Pan, MK; Tai, CH; Tseng, SH; Wang, TR | 1 |
| Gao, H; Li, W | 1 |
| Bédard, D; Frouni, I; Gourdon, JC; Hamadjida, A; Huot, P; Kwan, C; Nuara, SG | 2 |
| Asakawa, T; Kobayashi, S; Kurozumi, K; Nozaki, T; Sameshima, T; Sugiyama, K | 1 |
| Bonastre, M; Fuentes, M; Marin, C; Mullol, J | 2 |
| Ashby, R; Karouta, C; Morgan, I; Thomson, K | 1 |
| Brotchie, JM; Depoortere, R; Fox, SH; Johnston, TH; Newman-Tancredi, A | 1 |
| Labandeira, CM; Labandeira-Garcia, JL; Lopez-Lopez, A; Muñoz, A | 1 |
| Altwal, F; Moon, C; Steiner, H; West, AR | 1 |
| Anderson, C; Booth, S; Jackson, MF; Kirouac, G; Ko, JH; Lu, L; Ramadan, A; Zhang, D | 1 |
| Bonifácio, MJ; Soares-da-Silva, P; Sousa, F | 1 |
| Costa, G; Marongiu, J; Morelli, M; Serra, M; Simola, N | 1 |
| Altschüler, J; Böckmann, S; Güttler, C; Haumesser, JK; Kühn, AA; Nikulin, VV; Tanev, K; van Riesen, C | 1 |
| Huang, X; Mailman, RB; Yang, Y | 1 |
| Bishop, C; Chambers, NE; Clark, SD; Coyle, M; Lanza, K; Saito, C; Sergio, J; Topping, B | 1 |
| Altun, M; Bezard, E; Borgkvist, A; Dehay, B; Feyder, M; Fisone, G; Li, Q; Lieberman, OJ; Nilsson, P; Piccin, A; Plewnia, C; Santini, E; Spigolon, G; Sulzer, D; Urbina, L | 1 |
| Andrén, PE; Bezard, E; Crossman, AR; Fernagut, PO; Fridjonsdottir, E; Nilsson, A; Odell, LR; Schembri, LS; Shariatgorji, R; Svenningsson, P; Vallianatou, T | 1 |
| Agostinho, P; Aguiar, AS; Cunha, RA; Ferreira, SG; Prediger, RD; Silva, HB; Speck, AE; Tomé, ÂR | 1 |
| Chiken, S; Dwi Wahyu, I; Hasegawa, T; Nambu, A; Sano, H | 1 |
| Geng, X; Kan, D; Li, Y; Liu, C; Liu, H; Wei, S; Xie, J; Zhang, H | 1 |
| Beck, G; Fong, K; Mochizuki, H; Mouradian, MM; Papa, SM; Zhang, J | 1 |
| Bortolanza, M; Del-Bel, E; do Nascimento, GC; Raisman-Vozari, R | 1 |
| Enomoto, T; Fujii, Y; Goda, M; Ikeda, K; Kitamura, A; Nakako, T; Wada, E | 1 |
| Sgambato, V | 1 |
| Khurana, N; Muthuraman, A; Sharma, N; Utreja, P | 1 |
| Gourdon, JC; Huot, P; Kwan, C; Nuara, SG | 1 |
| Al Jamal, KT; Aly, MMS; Hawkins, K; Patterson, AK; Rodrigo, AC; Smith, DK; Sun, J; Wang, JT | 1 |
| Du, YS; Guo, HM; Hu, KR; Hu, YZ; Li, CJ; Liang, Y; Sun, H; Wang, GJ; Wang, H; Xie, L; Xu, WS; Yu, TJ | 1 |
| Murer, MG; Paz, RM | 1 |
| Fan, HX; Li, JJ; Li, XX; Sheng, S; Zhang, F; Zheng, CQ | 1 |
| Asensio, MJ; García-Montes, JR; Garcia-Sanz, P; Herranz, AS; Hiroi, N; Kang, G; Moratalla, R; Solís, O | 1 |
| Dilmukhametova, LK; Kurina, AU; Maleev, GV; Pronina, TS; Ugrumov, MV | 1 |
| Di Paolo, T; Morissette, M | 1 |
| Funamizu, Y; Mizukami, H; Nishijima, H; Tomiyama, M; Ueno, S; Ueno, T; Yagihashi, S | 1 |
| Ahn, S; Hong, S; Jang, J; Jeon, S; Jung, YR; Kim, J; Oh, JY; Park, HJ; Park, SU; Shin, HS; Song, MA; Song, TJ | 1 |
| Alam, M; Grothe, C; Jin, X; Krauss, JK; Ratzka, A; Rumpel, R; Schwabe, K; Tschirner, SK; von Wrangel, C | 1 |
| Liu, J; Liu, X; Long, Y; Qin, C; Tong, L; Zheng, F; Zheng, Y | 1 |
| Bastide, MF; Bézard, E; Bourdenx, M; Doudnikoff, E; Dumont, ÉC; Fernagut, PO; Georges, F; Glangetas, C; Li, Q | 1 |
| Bassil, F; Bezard, E; Dutheil, N; Fernagut, PO; Guerin, PA; Klugmann, M; Li, Q; Meissner, WG | 1 |
| Casteels, C; de Vries, EFJ; Dierckx, RAJO; Doorduin, J; Elsinga, PH; Zhou, X | 1 |
| Avraham, Y; Berry, EM; Magen, I; Paturski, I; Vorobiev, L | 1 |
| Jiang, MD; Wang, JL; Wang, YF; Zheng, Y | 1 |
| Bishop, C; Cantu, MA; Chotibut, T; Kasanga, EA; McInnis, T; Meadows, S; Salvatore, MF | 1 |
| Chen, NH; Heng, Y; Huang, JY; Mou, Z; Yuan, YH; Zhang, QS | 1 |
| Cai, J; Li, M; Li, N; Luo, F; Wang, J; Wang, N; Wang, Q; Xiao, H; Xie, Z; Zhang, W | 1 |
| Almqvist, F; Chorell, E; Kucia, WE; Pawełek, K; Pokrzywa, M; Sarbak, S; Wittung-Stafshede, P | 1 |
| Kim, HJ; Kim, KS; Lee, KE; Lee, MK; Park, HJ; Shin, KS; Zhao, TT | 1 |
| Gourdon, JC; Hamadjida, A; Huot, P; Nuara, SG | 1 |
| Attia, HN; Maklad, YA | 1 |
| Bourque, M; Di Paolo, T; Grégoire, L | 1 |
| Bacino, CA; Barbieri-Welge, RL; Barnes, GN; Bird, LM; Chu, HC; Erickson, CA; Fu, C; Haas, KF; Horowitz, LT; Hundley, RJ; Jeremy, R; Kothare, SV; Nespeca, MP; Noll, LM; Olson, HE; Poduri, A; Rotenberg, A; Rufo, PA; Sadhwani, A; Skinner, SA; Slavotinek, A; Tan, WH; Weeber, EJ; Willen, JM; Wink, LK | 1 |
| Caine, C; Homma, S; Kim, JK; Monani, UR; Mosharov, EV; Nakanishi, K; Shohat, M | 1 |
| Ai, Y; Andersen, AH; Evans, A; Forman, E; Gash, DM; Grondin, R; Hardy, PA; Yue, G; Yue, J; Zhang, R; Zhang, Z | 1 |
| Bloem, BR; Klemann, CJHM; Martens, GJM; Poelmans, G; Visser, JE; Xicoy, H | 1 |
| Choi, DH; Go, J; Hwang, JH; Kim, KS; Kim, YH; Lee, CH; Lee, TG; Noh, JR; Park, HY; Ryu, YK | 1 |
| Baekelandt, V; Casteels, C; Crabbé, M; Himmelreich, U; Van der Perren, A; Van Laere, K; Weerasekera, A | 1 |
| Cronin, A; Grealy, M | 1 |
| Ando, K; Inoue, R; Kawai, K; Nishime, C; Nishinaka, E; Tsutsumi, H; Urano, K | 1 |
| Cicchetti, F; David, LS; Lamontagne-Proulx, J; Saint-Pierre, M | 1 |
| Beck, JP; Bruns, RF; Carter, G; Chernet, E; Eastwood, BJ; Falcone, JF; Hao, J; Harper, AJ; Katner, JS; Li, X; Love, PL; Maren, DL; Masquelin, ME; Menezes, MM; Mitchell, SN; Murray, TK; O'Neill, MJ; Ryder, JW; Schaus, JM; Shanks, EA; Svensson, KA; Thompson, LK; Wafford, KA; Wang, H; Witkin, JM; Yang, CR; Zhang, L | 1 |
| Lin, JY; Liu, ZG; Wang, MH; Wang, XJ; Xie, CL; Zhang, SF | 1 |
| Borgkvist, A; Lieberman, OJ; Sulzer, D | 1 |
| Brotchie, JM; Corey, R; Fox, SH; Hill, MP; Howson, PA; Johnston, TH; Ravenscroft, P; Reidenberg, BE; Versi, E | 1 |
| Feher, M; Fernandez-Villalba, E; Gaszner, B; Gil-Martinez, AL; Herrero, MT; Reglodi, D; Tamas, A | 1 |
| Bernardi, MA; Ferrario, JE; Gershanik, OS; Gomez, G; Saborido, MD; Taravini, IR | 1 |
| Francardo, V; Tronci, E | 1 |
| Brys, I; Halje, P; Newman-Tancredi, A; Petersson, P; Scheffer-Teixeira, R; Varney, M | 1 |
| Blesa, J; Del Rey, NL; Trigo-Damas, I | 1 |
| Bair-Marshall, CJ; Girasole, AE; Guenthner, CJ; Kreitzer, AC; Lum, MY; Luo, L; Nathaniel, D; Nelson, AB | 1 |
| Alhadhrami, A; Alharthi, SS; Alrobaian, MM; Kabel, AM; Omar, MS | 1 |
| Cui, G; Ding, X; Hua, F; Wang, X; Xiang, J; Yang, X; Zhu, Z | 1 |
| Cenci, MA; Crossman, AR | 1 |
| Beck, G; Chang, PL; Maehara, S; Papa, SM | 1 |
| Hoshino, N; Ishikawa, T; Muraoka, S; Nishimura, T; Okano, M; Satoyoshi, H; Takahata, K; Tsunekawa, H | 1 |
| Du, CX; Liu, J; Sun, YN; Wang, HS; Wang, Y; Yao, L; Zhang, GJ; Zhang, L | 1 |
| Ikram, R; Riaz, B; Sikandar, B | 1 |
| Gupta, S; Patel, RK; Sharma, AK; Wardhan, N | 1 |
| Ando, R; Choudhury, ME; Kannou, M; Kubo, M; Kyaw, WT; Nagai, M; Nishikawa, N; Nomoto, M; Tanaka, J; Yamanishi, Y | 1 |
| Mbiydzenyuy, NE; Ninsiima, HI; Pieme, CA; Valladares, MB | 1 |
| Baufreton, J; Bessière, B; Bezard, E; Chazalon, M; Courtine, G; Farjot, G; Ko, WKD; Li, Q; McGuire, S; Milekovic, T; Milet, A; Moraud, EM; Morin, S; Normand, E; Pioli, E; Porras, G; Pype, J; Sun, S | 1 |
| Brotchie, JM; Fox, SH; Johnston, TH; Lacoste, AMB; Lang, AE; Visanji, NP | 1 |
| Breger, LS; Cenci, MA; Fieblinger, T; Lockowandt, M; Lundberg, C; Quintino, L; Sebastianutto, I; Zanetti, L | 1 |
| Cunha, RA; Prediger, RD; S Aguiar, A; Schamne, MG; Speck, AE | 1 |
| Beaudoin-Gobert, M; Duperrier, S; Météreau, E; Sgambato, V; Thobois, S; Tremblay, L | 1 |
| Li, L; Sagot, B; Zhou, FM | 2 |
| Ba, M; Kong, M; Wang, Y; Yang, H; Yu, G; Yu, L | 1 |
| Bezard, E; Charvin, D; Conquet, F; Di Paolo, T; Duvey, G; Gregoire, L; Halldin, C; Medori, R; Pioli, E; Takano, A | 1 |
| du Mee, D; Elgersma, Y; Kingma, J; Santos, SS; Sonzogni, M; van Woerden, GM; Wallaard, I | 1 |
| Bezard, E; Calabresi, P; Campanelli, F; Di Luca, M; Gardoni, F; Ghiglieri, V; Li, Q; Longhi, A; Marino, G; Mellone, M; Picconi, B; Stanic, J; Thiolat, ML; Zianni, E | 1 |
| Brugnoli, A; Caccia, C; Gardoni, F; Keywood, C; Kulisevsky, J; Mellone, M; Melloni, E; Morari, M; Novello, S; Padoani, G; Pisanò, CA; Sosti, V; Vailati, S | 1 |
| Berry, H; Cornil, A; Cui, Y; de Kerchove d'Exaerde, A; Degos, B; Detraux, B; Perez, S; Prokin, I; Venance, L; Xu, H | 1 |
| Caldarone, B; Dettmer, U; Ericsson, M; Minakaki, G; Müller, CP; Nuber, S; Rajsombath, M; Selkoe, DJ; Winkler, J | 1 |
| Barta, C; Glennon, J; Hengerer, B; Hildebrandt, T; Nespoli, E; Pagliaroli, L; Poelmans, G; Widomska, J | 1 |
| Avnor, Y; Bishop, C; Chambers, NE; Conti, MM; Gross, L; Lanza, K; Meadows, SM; Ostock, CY | 1 |
| Denibaud, AS; Drieu La Rochelle, C; Loiodice, S; Méot, B; Montagne, P; Rion, B; Viel, R; Wing Young, H | 1 |
| Che, Y; Feng, X; Li, X; Liu, Q; Zhu, D | 1 |
| Gao, G; Gao, Y; Geng, X; Han, H; He, F; Wang, M; Wang, X; Wang, Y; Xie, J; Yao, X; Zhang, H; Zhang, X | 1 |
| Adlard, PA; Billings, JL; Bush, AI; Doble, PA; Finkelstein, DI; Gordon, SL; Hare, DJ; Rawling, T | 1 |
| Griffiths, H; Lee, H; Lotery, A; Scott, J; Self, JE | 1 |
| Keifman, E; Moratalla, R; Murer, MG; Pafundo, DE; Paz, RM; Ruiz-DeDiego, I; Solís, O | 1 |
| Bian, ZX; Chan, HY; Cheung, CY; Li, Y; Lyu, H; Poon, WS; Wang, KKW; Zheng, ZV | 1 |
| Urs, NM | 1 |
| Che, Y; Feng, X; Jiang, P; Lang, Q; Liu, Q; Tang, X; Yu, Q; Zhang, S; Zhu, D | 1 |
| Iggena, D; Klein, C; Rasińska, J; Sparenberg, M; Steiner, B; Winter, Y | 1 |
| Collier, NJ; Collier, TJ; Manfredsson, FP; Mercado, NM; Sandoval, IM; Sortwell, CE; Stancati, JA; Steece-Collier, K | 1 |
| Jia, J; Jiang, X; Su, W; Wang, K; Wei, J; Yan, Y | 1 |
| Bezard, E; Fernagut, PO; Li, Q | 1 |
| Bezard, E; Delamarre, A; Galitzky, M; Li, Q; Meissner, WG; Rascol, O; Tison, F | 1 |
| Goto, S; Kasahara, J; Ogawa, M; Tsuji, R; Zhou, Y | 1 |
| Döbrössy, M; Garcia, J; Göbel, G; Granata, R; Jellinger, K; Kaindlstorfer, C; Krismer, F; Stefanova, N; Wenning, GK | 1 |
| Ahmed, MR; Ahmed, MS; Jayakumar, M; Job, JK; Li, EH; Ohtsu, H; Pittenger, C; Rajadas, J; Tao, J; Zamaleeva, AI | 1 |
| Bourque, MJ; Cannon, T; Cayrol, R; Desjardins, M; Ducrot, C; Fahmy, AM; Gruenheid, S; Laplante, A; Le Campion, A; Matheoud, D; McBride, HM; Penttinen, AM; Ramet, L; Trudeau, LE; Voisin, A; Zhu, L | 1 |
| Graybiel, AM; Hernandez, LF; Howe, MW; Hu, D; Kubota, Y; Lemaire, N | 1 |
| Ahmed, SH; Baekelandt, V; Bezard, E; Cador, M; Engeln, M; Fasano, S; Fernagut, PO | 1 |
| Contini, A; De Deurwaerdère, P; Lagière, M; Navailles, S | 1 |
| Dixit, A; Mishra, M; Prakash, O; Singh, MP; Singh, PK; Srivastava, G; Verma, D | 1 |
| Bordia, T; Campos, C; Jordan, K; Letchworth, S; McIntosh, JM; Quik, M; Strachan, JP; Zhang, J | 1 |
| Boulanger, N; Kerkerian-Le Goff, L; Lacombe, E; Lortet, S; Nguyen, C; Rihet, P; Salin, P | 1 |
| Campos, FL; Carvalho, MM; Coimbra, B; Lima, R; Pêgo, JM; Rodrigues, AJ; Rodrigues, C; Salgado, AJ; Sousa, N | 1 |
| Müller, T | 1 |
| Kuric, E; Ruscher, K; Wieloch, T | 1 |
| Brown, JA; Conyers, S; Dearborn, JT; Diggs-Andrews, KA; Gutmann, DH; Izumi, Y; Tokuda, K; Wozniak, DF; Yuede, CM; Zorumski, CF | 1 |
| Arcaya, JL; Salazar, U; Silva, EJ; Tejeda, CM; Urdaneta, K; Varela, K | 1 |
| Breger, LS; Lane, EL | 1 |
| Björklund, T; Cederfjäll, E; Chu, Y; Kirik, D; Kordower, JH; Nikitidou, E; Nilsson, N; Sahin, G | 1 |
| Bleickardt, C; Hodgson, R; Jones, N; Mullins, D; Parker, E | 1 |
| Bencherif, M; Carroll, FI; Letchworth, S; Mallela, A; Quik, M; Sohn, D; Zhang, D | 1 |
| Dunnett, SB; Heuer, A; Klein, A; Lane, EL; Smith, GA; Vinh, NN | 1 |
| Acher, F; Bonito-Oliva, A; Fisone, G; Lopez, S; Pallottino, S | 1 |
| Jackson, MJ; Jenner, P; Pearce, RK; Swart, T | 1 |
| Campbell, B; Hider, RC; Hobbs, CJ; Jairaj, M; Jenner, P; Rose, S; Syme, A; Tayarani-Binazir, KA; Zhou, T | 1 |
| Dominguez-Meijide, A; Garrido-Gil, P; Guerra, MJ; Labandeira-Garcia, JL; Sierrra-Paredes, G; Villar-Cheda, B | 1 |
| Carta, M; Collu, M; Devoto, P; Fidalgo, C; Lisci, C; Stancampiano, R; Tronci, E | 1 |
| Bishop, C; Dupre, KB; Eskow Jaunarajs, KL; Goldenberg, AA; Lindenbach, D; Ostock, CY | 1 |
| Mamalyga, ML | 1 |
| Björklund, A; Carta, M; Fidalgo, C; Lisci, C; Shin, E; Stancampiano, R; Tronci, E | 1 |
| González-Aparicio, R; Moratalla, R | 1 |
| Bargas, J; Barroso-Flores, J; Duhne, M; Galarraga, E; Pérez-Ortega, JE; Plata, V | 1 |
| Barraud, Q; Bezard, E; Ghorayeb, I; Hyacinthe, C; Tison, F | 1 |
| Cenci, MA; Francardo, V | 1 |
| Morelli, M; Pinna, A | 1 |
| Aristieta, A; Azkona, G; Pérez-Navarro, E; Ruíz-Ortega, JA; Sagarduy, A; Sánchez-Pernaute, R; Ugedo, L; Vazquez, N; Zubillaga, V | 1 |
| Liu, Z; Song, L; Wei, J; Wu, N; Yang, X | 1 |
| Farag, NE; Hammad, LN; Zaitone, SA | 1 |
| Armentero, MT; Baqi, Y; Bonaventura, J; Canela, EI; Casadó, V; Cortés, A; Costa, G; Farré, D; Franco, R; Lanciego, JL; Lluís, C; Mallol, J; Martínez-Pinilla, E; McCormick, P; Müller, CE; Pinna, A; Sánchez, M; Simola, N | 1 |
| Bezard, E; De Deurwaerdere, P; Li, Q; Marti, M; Meissner, WG; Morari, M; Morgenstern, R; Porras, G; Sohr, R | 1 |
| Abey, J; Aseem, F; Aung, MH; Han, MK; Iuvone, PM; Obertone, TS; Pardue, MT; Park, HN; Thule, PM | 1 |
| Dézsi, L; Vécsei, L | 1 |
| Carta, M; Collu, M; Fidalgo, C; Gardoni, F; Morelli, M; Stancampiano, R; Tronci, E; Zianni, E | 1 |
| Aglan, H; Ahmed, H; Atta, H; Ghazy, M; Salem, A | 1 |
| Arai, A; Baba, M; Funamizu, Y; Haga, R; Ichinohe, N; Kimura, T; Kon, T; Meguro, R; Migita, K; Miki, Y; Nishijima, H; Suzuki, C; Suzuki, S; Tomiyama, M; Ueno, S; Ueno, T; Yamada, J | 1 |
| Calabresi, P; Picconi, B | 1 |
| Bezard, E; Dufour, A; Facheris, MF; Ko, WK; Li, Q; McGuire, S; Pioli, E; Sherer, TB | 1 |
| André, E; Calo', G; Cavalcante, JC; Costa, MS; Didonet, JJ; Gavioli, EC; Guerrini, R; Soares-Rachetti, Vde P; Souza, Lde S | 1 |
| Dollé, F; Hantraye, P; Kirik, D; Lavisse, S; Ozgur, M; Rbah-Vidal, L; Sahin, G; Thompson, LH | 1 |
| Doo, AR; Hahm, DH; Jeon, S; Kim, J; Kim, SN; Lee, H; Park, HJ; Park, JY; Park, SU; Yoo, HH | 1 |
| Chen, CH; Chen, NF; Chen, WF; Feng, CW; Hsiao, CD; Huang, SY; Hung, HC; Wang, HM; Wen, ZH; Yang, SN | 1 |
| Björklund, A; Carta, M; Devoto, P; Rogers, JT; Shin, E | 1 |
| Georgieva, SG; Kerkerian-Le Goff, L; Khaindrava, VG; Khakimova, GR; Kozina, EA; Krasnov, AN; Kucheryanu, VG; Ugrumov, MV; Vorobyeva, NE | 1 |
| Bliwise, D; Devergnas, A; Pittard, D; Wichmann, T | 1 |
| Bezard, E; De Deurwaerdère, P; Engeln, M; Fernagut, PO; Li, Q | 1 |
| Bishop, C; Goldenberg, AA; Kampton, E; Lindenbach, D; Ostock, CY | 1 |
| Ampe, B; Aourz, N; Bentea, E; De Deurwaerdère, P; El Arfani, A; Massie, A; Michotte, Y; Sarre, S; Smolders, I; Van Eeckhaut, A | 1 |
| Bezard, E; Girard, F; Keywood, C; Li, Q; Mutel, V; Pioli, EY; Poli, SM; Rascol, O; Tison, F | 1 |
| Charlton, CG; Dent, L; Griffin, B; King, J; Mackey, V; Muthian, G; Smith, ML | 1 |
| Alken, RG; Feltmann, K; Konradsson-Geuken, Å; Malmlöf, T; Schilström, B; Schneider, F; Svensson, TH | 1 |
| Artuch-Iriberri, R; de la Caridad, O; Esteller, M; Fourcade, S; Huertas, D; Molero-Luis, M; Petazzi, P; Pujol, A; Roa, L; Saez, MA; Soler, M; Szczesna, K; Vidal, A | 1 |
| Di Paolo, T; Fox, S; Gasparini, F; Gomez-Mancilla, B; Kenney, C; Rascol, O | 1 |
| Fang, X; Guo, L; Jia, J; Liu, Z; Lu, W; Yang, Z; Ye, N; Zhang, A; Zhao, B; Zhao, J; Zhao, R; Zhen, X; Zheng, L | 1 |
| Huang, C; Liu, J; Wang, HS; Wang, T; Wang, Y | 1 |
| Di Paolo, T; Grégoire, L; Morin, N; Morissette, M | 1 |
| Bagetta, V; Branchi, I; Calabresi, P; Ghiglieri, V; Latagliata, EC; Morelli, E; Pascucci, T; Pendolino, V; Picconi, B; Poggini, S; Puglisi-Allegra, S; Sgobio, C | 1 |
| Brazhnik, E; Cruz, AV; McCoy, AJ; Novikov, N; Walters, JR | 1 |
| Brogan, B; Jansen, RL; Okello, EJ; Whitworth, AJ | 1 |
| Bastide, MF; Bezard, E; Boué-Grabot, E; Bourdenx, M; Dehay, B; Doudnikoff, E; Engeln, M; Fernagut, PO; Gross, CE; Li, Q; Pisani, A; Toulmé, E | 1 |
| Booth, HM; Kleven, GA; Ronca, AE; Voogd, M | 1 |
| Fox, SH; Johnston, TM | 1 |
| Dominguez-Meijide, A; Garrido-Gil, P; Labandeira-Garcia, JL; Muñoz, A | 1 |
| Chung, BH; Han, PL; Hwang, JH; Kang, Y; Kang, YM; Kim, KS; Kim, MR; Kim, YH; Lee, CH; Nam, KH; Park, HY; Park, TS; Ryu, YK | 1 |
| Brotchie, JM; Chen, B; Gertler, TS; Lo, C; Nash, JE; Surmeier, JD; Thiele, SL; Warre, R | 1 |
| Di Paolo, T; Elbast, W; Feuerbach, D; Gomez-Mancilla, B; Grégoire, L; Weiss, M | 1 |
| Di Paolo, T; Grégoire, L; Jourdain, VA; Morin, N; Morissette, M | 2 |
| Berretta, N; Bonito-Oliva, A; Cappellacci, L; Fisone, G; Ledonne, A; Mango, D; Mercuri, NB; Nisticò, R; Petrelli, R | 1 |
| Kuric, E; Ruscher, K | 1 |
| Lohr, KM; Miller, GW | 1 |
| Caboche, J; Feyder, M; Fisone, G; Gomes, AL; Hansen, K; Kryh, H; Lerdrup, M; Södersten, E; Spigolon, G | 1 |
| Del-Bel, EA; Espadas, I; Moratalla, R; Solís, O | 1 |
| Brotchie, JM; Espinosa, MC; Fox, SH; Huot, P; Johnston, TH; Koprich, JB; Reyes, MG | 1 |
| Liu, Z; Wang, Q; Xie, C; Zhang, S | 1 |
| Fujita, M; Hagino, Y; Hashimoto, M; Ikeda, K; Kasai, S; Kobayashi, K; Meltzer, HY; Setogawa, S; Yamaura, H; Yanagihara, D | 1 |
| Jeon, SR; Kim, YH; Shin, ES; Yoon, HH | 1 |
| Bastide, MF; Bézard, E; Boraud, T; de la Crompe, B; Doudnikoff, E; Fernagut, PO; Gross, CE; Mallet, N | 1 |
| Bortolanza, M; Cavalcanti-Kiwiatkoski, R; da-Silva, CA; Del-Bel, E; Mitkovski, M; Padovan-Neto, FE; Raisman-Vozari, R | 1 |
| Ba, M; Kong, M; Ma, G | 1 |
| Ba, M; Kong, M; Liu, C; Qiu, H; Zhang, H; Zhang, Y | 1 |
| Calcagno, M; Castelli, F; Contado, C; Cortesi, R; Di Stefano, A; Drechsler, M; Esposito, E; Giuffrida, MC; Longo, F; Morari, M; Ravani, L; Sarpietro, MG; Sozio, P | 1 |
| Baracchi, F; Bassetti, CL; Galati, S; Kaelin-Lang, A; Möller, JC; Pace, M; Salvadè, A; Sarasso, S; Städler, C; Stanzione, P | 1 |
| Cenci, MA; Iderberg, H; McCreary, AC; Newman-Tancredi, A; Varney, MA | 1 |
| Ding, Y; Hitchcock, SA; Kang, UJ; Lim, SAO; McGehee, DS; Ray, WJ; Won, L; Xia, R | 1 |
| Ji, C; Liu, Y; Ren, Z; Wang, T; Yang, N; Zheng, J; Zuo, P | 1 |
| Bortolanza, M; Del-Bel, E; Issy, AC; Lazzarini, M; Padovan-Neto, FE | 1 |
| Abrams, MB; Galter, D; Gellhaar, S; Marcellino, D | 1 |
| Collier, TJ; Gebremedhin, KG; O'Malley, J; Paumier, KL; Rademacher, DJ; Sisson, KA; Sortwell, CE; Stancati, JA; Steece-Collier, K | 1 |
| Cao, X; Chen, Z; Shi, Q; Tang, B; Wang, T; Zhang, T | 1 |
| Gut, NK; Winn, P | 1 |
| Bordia, T; Drenan, RM; McGregor, M; McIntosh, JM; Quik, M | 1 |
| Braithwaite, SP; Dyavar Shetty, BL; Mouradian, MM; Papa, SM; Park, ES; Potts, LF; Singh, A; Voronkov, M; Woo, JM | 1 |
| Carlsson, T; Depboylu, C; Höglinger, GU; Keber, U; Klietz, M; Oertel, WH; Schäfer, MK; Weihe, E | 1 |
| Huettner, DP; Kortagere, S; Simms, SL | 1 |
| Bezard, E; Carta, M; Chuan, Q; Fidalgo, C; Ko, WK; Li, Q; Stancampiano, R; Tronci, E | 1 |
| Duan, SJ; Han, B; Lu, Y; Wang, LJ; Wang, SY; Wang, T; Zhu, Q | 1 |
| Bass, CE; Bezard, E; Bido, S; Caron, MG; Daigle, TL; Gainetdinov, RR; Peterson, SM; Urs, NM | 1 |
| Cruz, AV; Delaville, C; Gerber, CM; McCoy, AJ; Walters, JR | 1 |
| Fernández, E; Fresno, C; Gershanik, OS; Gomez, G; González, GA; Larramendy, C; Murer, MG; Saborido, MD; Spaans, F; Taravini, IR | 1 |
| Cui, G; Hua, F; Shen, X; Shi, H; Wang, X; Yang, X; Zhang, S; Zhang, W; Zhang, Z; Zhao, H; Zu, J | 1 |
| Bardin, L; Cenci, MA; Depoortère, R; Iderberg, H; Kleven, MS; Koek, W; McCreary, AC; Newman-Tancredi, A; Varney, MA | 1 |
| Ahmed, MR; Bychkov, E; Gurevich, EV; Gurevich, VV; Li, L | 1 |
| Arena, AC; de Santana Aquino, DF; Kassuya, CA; Piccinelli, AC; Salvador, MJ; Soares, FL | 1 |
| Bäckman, CM; Cadet, JL; Chiang, YH; Diaz, O; Hoffer, BJ; Ladenheim, B; Olson, L; Shan, L; Zhang, Y | 1 |
| Ballanger, B; Bars, DL; Beaudoin-Gobert, M; Bonnefoi, F; Broussolle, E; Costes, N; Duperrier, S; Epinat, J; Lavenne, F; Liger, F; Météreau, E; Neumane, S; Sgambato-Faure, V; Thobois, S; Tourvielle, C; Tremblay, L | 1 |
| Chammas, C; Soghomonian, JJ; Zhang, K | 1 |
| Arcuri, L; Brugnoli, A; Mercatelli, D; Morari, M; Paolone, G | 1 |
| Fan, X; Harrast, P; Heinzer, AK; Hess, EJ; Jinnah, HA; Pare, JF; Raike, RS; Rose, SJ; Smith, Y; Thompson, VB; Weinshenker, D; Yu, XY | 1 |
| Allegri, G; Baumann, CR; Becu-Villalobos, D; Bindoff, LA; Fingerhut, R; Flydal, MI; Hole, M; Konrad, D; Korner, G; Lauber-Biason, A; Martinez, A; Noain, D; Pillai, S; Rassi, A; Scherer, T; Thöny, B; Wueest, S; Ying, M | 1 |
| Czarnecka, A; Konieczny, J; Lenda, T; Lorenc-Koci, E | 1 |
| De Wolf, C; Downey, P; Michel, A; Scheller, D; Schwarting, R; Van Damme, X | 1 |
| Franklin, A; Miguelez, C; Raskind, MA; Sikkema, C; Szot, P; Ugedo, L; Vidaurrazaga, I; Wang, Y; Wilkinson, CW | 1 |
| Bishop, C; Conti, MM; Dupre, KB; Lindenbach, D; Ostock, CY | 1 |
| Lee, KE; Lee, MK; Park, HJ; Park, KH; Shin, KS; Zhao, TT | 1 |
| Adrien, J; Belaid, H; François, C; Hirsch, EC; Karachi, C | 1 |
| Daniels, WM; Mabandla, MV; Ndlovu, BC | 1 |
| Alvarsson, A; Kadkhodaei, B; Millan, MJ; Perlmann, T; Schintu, N; Stan, TL; Svenningsson, P; Zhang, X | 1 |
| Bastide, MF; Bézard, E; Bido, S; Duteil, N | 1 |
| Brugnoli, A; Morari, M; Napolitano, F; Usiello, A | 1 |
| Case, DT; Collier, TJ; Divito, CB; Edwards, RH; Rubio, ME; Seal, RP; Sortwell, CE; Stancati, JA; Steece-Collier, K; Sulzer, D; Williams, SP; Zhang, H; Zhi, L | 1 |
| Beaudoin-Gobert, M; Sgambato-Faure, V; Tremblay, L | 1 |
| Cruz, AV; Delaville, C; Dupre, KB; Eyring, KW; Gerber, CM; McCoy, AJ; Walters, JR | 1 |
| Bezard, E; Cenci, MA; Conn, PJ; Fieblinger, T; Francardo, V; Greengard, P; Ko, WK; Li, Q; Lindsley, CW; Neubig, RR; Plotkin, JL; Shen, W; Surmeier, DJ; Wess, J; Xie, Z | 1 |
| Llorente, J; Miguelez, C; Morera-Herreras, T; Ruiz-Ortega, JA; Sagarduy, A; Ugedo, L | 1 |
| Daumas, S; El Mestikawy, S; Gangarossa, G; Guzman, M; Prado, MA; Prado, VF; Valjent, E | 1 |
| Brys, I; Halje, P; Ivica, N; Petersson, P; Richter, U; Tamtè, M | 1 |
| Alegre-Abarrategui, J; Bannerman, DM; Bolam, JP; Brimblecombe, K; Cioroch, M; Connor-Robson, N; Cragg, SJ; Deltheil, T; Dodson, PD; Exley, R; Kaufmann, AK; Magill, PJ; Potgieter, D; Sloan, M; Threlfell, S; Wade-Martins, R; Wallings, R | 1 |
| Carta, M; Cenci, MA | 1 |
| Bird, LM; Tan, WH | 1 |
| Bezard, E; Contamin, H; Li, Q; Thiollier, T; Wu, C; Zhang, J | 1 |
| Hultborn, H; Ren, LQ; Wienecke, J; Zhang, M | 1 |
| Aristieta, A; Miguelez, C; Morera-Herreras, T; Ruiz-Ortega, JA; Ugedo, L | 1 |
| Atlas, D | 1 |
| Bezard, E; Carta, M; Costa, G; Fidalgo, C; Ko, WK; Li, Q; Morelli, M; Pinna, A; Simola, N; Tabrizi, MA; Tronci, E | 1 |
| Choi, DH; Go, J; Hwang, JH; Kim, KS; Kim, YH; Lee, CH; Park, HY; Park, TS; Rhee, M; Ryu, YK | 1 |
| Barbon, A; Bono, F; Busi, C; Fiorentini, C; Missale, C; Savoia, P; Savoldi, D | 1 |
| Hwang, E; Hwang, O; Jeon, SR; Lee, CJ; Min, J; Suh, JK; Yoon, HH | 1 |
| Brauer, AF; Ciucci, MR; Kelm-Nelson, CA | 1 |
| Bariotto-Dos-Santos, KD; Bortolanza, M; da-Silva, CA; Del-Bel, E; Dos-Santos-Pereira, M | 1 |
| Capper-Loup, C; Kaelin-Lang, A; Paganetti, P; Sgroi, S | 1 |
| Boon, WC; Chua, HK; Horne, M; Stanic, D; Tomas, D; White, K | 1 |
| Chang, J; Li, M; Li, X; Luo, F; Wang, J; Wang, N; Wang, Q; Wen, P; Xiao, H; Xie, Z; Yang, Y; Zhang, W; Zhou, M | 1 |
| Cirnaru, MD; Di Luca, M; Gardoni, F; Mellone, M; Perez-Carrion, M; Piccoli, G; Stanic, J; Zianni, E | 1 |
| Benazzouz, A; De Deurwaerdère, P; Delaville, C; Lagière, M; Marquis, L; Miguelez, C; Navailles, S; Ugedo, L | 1 |
| Bhattacharjee, N; Borah, A; Choudhury, A; Choudhury, S; Mazumder, MK; Paul, R | 1 |
| Eskow Jaunarajs, KL; Figge, DA; Standaert, DG | 1 |
| Bez, F; Cenci, MA; Francardo, V | 1 |
| Carlsson, T; Chiu, WH; Depboylu, C; Höglinger, GU; Keber, U; Klietz, M; Schäfer, MK; Weihe, E | 1 |
| Akazawa-Ogawa, Y; Fujimura, H; Hagihara, Y; Hamakubo, T; Hara, Y; Hisahara, S; Itoh, S; Kobayashi, M; Kusunoki, S; Matsumura, A; Mita, Y; Noguchi, N; Saigoh, K; Saito, Y; Shichiri, M; Shimohama, S; Sutou, K; Takamatsu, H; Yoshida, Y | 1 |
| Geng, X; Han, H; Hou, Y; Lei, C; Li, M; Wang, M; Wang, X; Xie, J; Yao, X; Zhang, Q; Zhang, X | 1 |
| Agorastos, S; Bimpisidis, Z; Cenci, MA; Dewey, SL; Eidelberg, D; Lerner, RP; Scherrer, S | 1 |
| Amalric, M; Beurrier, C; Camon, J; Guiraudie-Capraz, G; Kerkerian-Le Goff, L; Liberge, M; Maurice, N; Ztaou, S | 1 |
| Cenci, MA; Hopkins, CR; Maslava, N; Sebastianutto, I | 1 |
| Aguado, C; Lujan, R; Moratalla, R; Solis, O; Suarez, LM | 1 |
| Ba, M; Guan, L; Kong, M; Yi, M; Zhang, H | 1 |
| Bishop, C; Conti, MM; George, JA; Goldenberg, AA; Lindenbach, D; Melikhov-Sosin, M; Nuss, EE; Ostock, CY | 1 |
| Hardy, GA; Lee, HJ; Schallert, T; Smith, ES | 1 |
| Bender, D; Bjarkam, CR; Doudet, D; Glud, AN; Mogensen, P; Møller, A; Nielsen, MS; Sørensen, JC | 1 |
| Angius, F; Batetta, B; Carboni, E; Carta, AR; Cossu, G; Espa, E; Fenu, S; Giuffrida, A; Jadžić, D; Lecca, D; Mulas, G; Pillai, E; Simbula, G; Spiga, S; Spolitu, S | 1 |
| Chan, P; Tang, R; Tao, G; Yue, F; Zeng, S | 1 |
| Cao, LF; Chen, LH; Cheng, RX; Huang, Y; Liu, T; Luo, WF; Peng, XY; Wang, B; Zhou, FM | 1 |
| Adiele, C; Aso, Y; Birman, S; Cichewicz, K; Garren, EJ; Hirsh, J; Rubin, GM; Wang, Z; Wu, M | 1 |
| Cho, YJ; Kim, KS; Kim, SH; Lee, KE; Lee, MK; Park, HJ; Shin, KS; Zhao, TT | 1 |
| Bankiewicz, KS; Ciesielska, A; Dickson, DW; Forsayeth, J; Goldman, S; Samaranch, L; San Sebastian, W | 1 |
| Damberg, P; Monnot, C; Nikkhou-Aski, S; Svenningsson, P; Zhang, X | 1 |
| Bordia, T; Perez, XA; Quik, M; Zhang, D | 1 |
| Castela, I; F Hernández, L; Moratalla, R; Obeso, JA; Ruiz-DeDiego, I | 1 |
| A Figge, D; Standaert, DG | 1 |
| Ben, J; de Oliveira, PA; Matheus, FC; Moreira, ELG; Prediger, RD; Rial, D; Schwarzbold, ML; Walz, R | 1 |
| Arai, A; Kannari, K; Kawarabayashi, T; Kimura, T; Shen, H; Shoji, M; Suzuki, C; Tomiyama, M; Watanabe, M | 1 |
| Kelly, AM; Kennedy, GA; Willis, GL | 1 |
| Desole, MS; Marchetti, B; Miele, E; Pluchino, S; Serra, PA | 1 |
| Carta, AR; Frau, L; Morelli, M; Pinna, A; Pontis, S | 1 |
| Aceves, J; Erlij, D; Florán, B; Floran, L; García-Ramírez, M; Rangel-Barajas, C; Sánchez-Lemus, E; Silva, I | 1 |
| Ferrario, JE; Gershanik, OS; Larramendy, C; Murer, MG; Saborido, MD; Taravini, IR | 1 |
| Busi, C; Fiorentini, C; Missale, C; Spano, P | 1 |
| Bordia, T; Campos, C; Huang, L; Quik, M | 1 |
| DeLong, MR; Liang, L; Papa, SM | 1 |
| Buck, K; Ferger, B; Nicholas, AP | 1 |
| Collier, TJ; Freeman, TB; McGuire, SO; Meredith, G; Soderstrom, KE; Sortwell, CE; Steece-Collier, K; Wu, Q | 1 |
| Brundin, P; Cenci, MA; Lane, EL; Soulet, D; Vercammen, L | 1 |
| Barnum, CJ; Bishop, C; Blandino, P; Deak, T; Dupre, K; Eskow, KL | 1 |
| Danysz, W; Dekundy, A; Gravius, A; Morè, L; Nagel, J; Pietraszek, M | 1 |
| Amalric, M; De Leonibus, E; Giordani, F; Lopez, S; Managò, F; Mele, A; Oliverio, A; Petrosino, F | 1 |
| Jin, GZ; Mo, J; Sun, PH; Yu, LP; Zhang, H; Zhen, X | 1 |
| Goto, S; Graybiel, AM; Ichinose, H; Ikemoto, K; Ito, M; Kaji, R; Nagahiro, S; Nagatsu, I; Nomura, T; Sako, W; Sato, K; Sumi-Ichinose, C | 1 |
| Glavan, G | 1 |
| Ferrario, JE; Gomes, MZ; Hunot, S; Raisman-Vozari, R; Rojas-Mayorquín, AE; Saldaña-Ortega, M; Salum, C | 1 |
| Brotchie, JM; de Bie, RM; Fox, SH; Johnston, TH; McCreary, AC; Visanji, NP | 1 |
| Danysz, W; Dekundy, A; Quack, G; Valastro, B | 1 |
| Brotchie, JM; Chuang, R; Fox, SH | 1 |
| Olanow, CW | 1 |
| Schapira, AH | 1 |
| Kelsey, JE; Langelier, NA; Oriel, BS; Reedy, C | 1 |
| Abdin, AA; Hamouda, HE | 1 |
| Allbutt, HN; Billing, R; Coster, MJ; Henderson, JM; Kassiou, M; Radford, J; Warraich, ST | 1 |
| Bi, M; Fath, T; Götz, J; Gunning, P; Ittner, LM; Ke, YD; Li, KM; van Eersel, J | 1 |
| Domino, EF; Ni, L | 1 |
| Aubert, I; Berthet, A; Bezard, E; Bloch, B; Cenci, MA; Doudnikoff, E; Hengerer, B; Ittrich, C; Rylander, D; Schuster, S; Surmeier, DJ | 1 |
| Bezard, E; Björklund, A; Carlsson, T; Carta, M; Di Luca, M; Gardoni, F; Kirik, D; Li, Q; Marcello, E; Muñoz, A; Qin, C | 1 |
| Caron, MG; Gainetdinov, RR; Hallett, PJ; Isacson, O; Patterson, M; Reske-Nielsen, C; Sotnikova, TD; Vinuela, A | 1 |
| Allbutt, HN; Coster, MJ; Henderson, JM; Kassiou, M; Truong, L | 1 |
| Marti, M; Morari, M; Trapella, C | 1 |
| Dunnett, SB; Lane, EL; Monville, C; Pekarik, V; Torres, EM | 1 |
| Dechant, G; Hainzer, M; Köllensperger, M; Nikkhah, G; Pallua, A; Poewe, W; Puschban, Z; Reindl, M; Stefanova, N; Wenning, GK | 1 |
| Brotchie, JM; Fox, SH; Johnston, T; Millan, MJ; Reyes, G; Visanji, NP | 1 |
| Barodia, SK; Luthra, PM; Raghubir, R | 1 |
| Buck, K; Ferger, B | 4 |
| McCairn, KW; Turner, RS | 1 |
| de la Fuente-Fernandez, R; Dinelle, K; Doudet, D; Holden, JE; Ruth, TJ; Schulzer, M; Sossi, V; Stoessl, AJ; Topping, GJ | 1 |
| af Bjerkén, S; Cenci, MA; Gerhardt, GA; Lundblad, M; Pomerleau, F; Strömberg, I | 1 |
| Bartoszyk, GD; Bédard, PJ; Di Paolo, T; Graham, J; Grégoire, L; Samadi, P | 1 |
| Iida, A; Inoue, N; Kakiuchi, T; Kondo, Y; Muramatsu, S; Nakano, I; Nakayama, T; Okuno, T; Ono, F; Suzuki, Y; Takino, N; Terao, K; Tsukada, H | 1 |
| Berger, SP; Brudney, EG; Foley, K; Johnson, SW; Meshul, CK; Paquette, MA | 1 |
| Del-Bel, EA; Echeverry, MB; Padovan-Neto, FE; Tumas, V | 1 |
| Cenci, MA; Danysz, W; Dekundy, A; Mela, F; Recchia, A; Rylander, D | 1 |
| Brundin, P; Cenci, MA; Lane, EL | 1 |
| Decamp, E; Schneider, JS | 1 |
| Ding-Fang, C; Guo-Hua, W; Hong-Min, T; Hua-Wei, L; Jun, M; Jun-Peng, G; Shan, S; Wen-Wei, L; Xiang-Yu, W; Ya-Ling, H; Yan-Hong, T; Yi, F; Yue, F; Yun-Ke, Y | 1 |
| Ballero, M; Kasture, S; Longoni, R; Morelli, M; Pinna, A; Pontis, S; Schintu, N; Simola, N; Spina, L | 1 |
| Brundin, P; Cenci, MA; Lane, EL; Vercammen, L | 1 |
| Collier, TJ; Maries-Lad, E; Soderstrom, KE; Sortwell, CE; Steece-Collier, K | 1 |
| Barman, PK; Borah, A; Mohanakumar, KP; Pandey, M; Usha, R; Varghese, M | 1 |
| Cassin, J; Harris, O; Kelsey, JE | 1 |
| Francescutti-Verbeem, DM; Kuhn, DM; Thomas, DM | 2 |
| Blume, SR; Cass, DK; Tseng, KY | 1 |
| Barbanoj, M; Gich, I; Kulisevsky, J; Pérez, V; Rodríguez-Alvarez, J; Rubio, A; Sosti, V | 1 |
| Aubert, I; Berton, O; Bezard, E; Bioulac, BH; Dileone, RJ; Gross, CE; Guigoni, C; Li, Q; Nestler, EJ | 1 |
| Björklund, A; Carlsson, T; Carta, M; Kirik, D; Muñoz, A; Tronci, E | 1 |
| Ballion, B; Chetrit, J; Frenois, F; Gonon, F; Murer, MG; Zold, CL | 1 |
| Beal, MF; Bogdanov, M; Burke, RE; Geghman, K; Jackson-Lewis, V; Li, C; Li, Y; Liu, W; Oo, TF; Przedborski, S; Tang, Y; Wang, L; Zhou, C | 1 |
| Ares, S; Darmopil, S; De Diego, IR; Martín, AB; Moratalla, R | 1 |
| Di Paolo, T; Grégoire, L; Lévesque, D; Morissette, M; Ouattara, B; Rouillard, C; Samadi, P; Tamim, MK | 1 |
| Cenci, MA; Lindgren, HS; Ohlin, KE | 1 |
| Kerkerian-Le Goff, L; Khaindrava, V; Lacombe, E; Melon, C; Oueslati, A; Salin, P | 1 |
| Iravani, MM; Jackson, MJ; Jenner, P; Olanow, CW; Rose, S; Scheller, D; Smith, LA; Stockwell, KA; Tayarani-Binazir, K | 1 |
| Klann, E | 1 |
| Di Paolo, T; Gilbert, F; Grégoire, L; Lévesque, D; Mahmoudi, S; Morissette, M; Ouattara, B; Rouillard, C; Samadi, P | 1 |
| Aguilar, E; Bonastre, M; Jiménez, A; Marin, C | 2 |
| Ikeda, K; Kurokawa, T; Mochizuki, H; Nakao, K; Yoshikawa, S; Yuzawa, N | 1 |
| Kostrzewa, RA; Kostrzewa, RM; Nowak, P; Skaba, D | 1 |
| Ahn, YH; Lee, PH; Park, HJ; Shin, JY | 1 |
| Iravani, MM; Jackson, MJ; Jenner, P; Rose, S; Scheller, DK; Smith, LA; Stockwell, KA | 1 |
| Cantero, M; Cediel, R; Contreras, J; Montoliu, L; Murillo-Cuesta, S; Varela-Nieto, I; Zurita, E | 1 |
| Buck, K; Ferger, B; Voehringer, P | 1 |
| Li, F; Liu, S; Mao, J; Qin, W; Tan, Q; Wu, X | 1 |
| Cristalli, G; Morelli, M; Pinna, A; Pontis, S; Schintu, N; Simola, N; Tronci, E; Volpini, R | 1 |
| Di Paolo, T; Lévesque, D; Morissette, M; Samadi, P | 1 |
| Bélanger, N; Di Paolo, T; Hadj Tahar, A; Morissette, M; Samadi, P | 1 |
| Andersson, DR; Cenci, MA; Lagerkvist, S; Lindgren, HS; Nissbrandt, H | 1 |
| Bureau, G; Chagniel, L; Cyr, M; Lebel, M | 1 |
| Anderson, AM; Johnson, SW; Lewis, JR; Meshul, CK; Paquette, MA; Paul Berger, S | 1 |
| Anaya-Martinez, V; Avila-Costa, MR; Corona, DR; Gutierrez-Valdez, AL; Martinez-Fong, D; Montiel-Flores, E; Ordoñez-Librado, JL | 1 |
| Ekstrand, MI; Galter, D | 1 |
| Stocchi, F | 1 |
| Bioulac, B; De Deurwaerdère, P; Gross, C; Navailles, S | 2 |
| Collier, TJ; Levine, ND; O'Malley, JA; Soderstrom, KE; Sortwell, CE; Steece-Collier, K | 1 |
| Jackson, MJ; Jenner, P; Olanow, CW; Rose, S; Tayarani-Binazir, KA | 1 |
| Cenci, MA; Ohlin, KE | 1 |
| Björklund, T; Carlsson, T; Carta, M; Cederfjäll, EA; Kirik, D | 1 |
| Brotchie, JM; Fox, SH; Gomez-Ramirez, J; Huot, P; Johnston, T; Reyes, G; Visanji, N | 1 |
| Björklund, A; Carlsson, T; Carta, M; Kirik, D; Muñoz, A | 1 |
| Gil, S; Koh, H; Lee, J; Park, C | 1 |
| Brotchie, JM; Fox, SH; Johnston, TH; van der Meij, A | 1 |
| Cunha, MM; De Castro, RA; Ferreira, FR; Lopes-Bezerra, LM; Penha, CV; Rozental, S; Teixeira, PA; Torres, AP | 1 |
| Andersen, ML; Barnabé, GF; Dombrowski, PA; Lima, MM; Reksidler, AB; Tufik, S; Vital, MA | 1 |
| Baishen, R; Bezard, E; Cenci, MA; Danysz, W; Dekundy, A; Iderberg, H; Li, H; Li, Q; Rylander, D; Zhang, J | 1 |
| Borah, A; Mohanakumar, KP | 1 |
| Guan, Q; He, Y; Jin, L; Liu, X; Zhao, L | 1 |
| Cao, X; Mochizuki, H; Mouradian, MM; Papa, SM; Uthayathas, S; Watts, RL; Yasuda, T | 1 |
| Alachkar, A; Brotchie, JM; Jones, OT | 2 |
| Angoa-Perez, M; Bishop, C; Eskow Jaunarajs, KL; Kuhn, DM | 1 |
| Belujon, P; Grace, AA; Lodge, DJ | 1 |
| Liu, Z; Ren, T; Song, L; Wu, N; Yang, X; Yuan, W | 1 |
| Fuxe, K; Galter, D; Lindqvist, E; Marcellino, D; Müller, CE; Olson, L; Schneider, M | 1 |
| Jouve, L; Kerkerian-Le Goff, L; Melon, C; Salin, P | 1 |
| Fang, C; Gao, C; Wang, Y; Xu, H; Xu, Z; Yin, J; Zhou, H | 1 |
| Barraud, Q; Bezard, E; Fernagut, PO; Ghorayeb, I; Tison, F | 1 |
| Cobacho, N; De la Calle, JL; González-Escalada, JR; Paíno, CL | 1 |
| Brotchie, JM; Fox, SH; Johnston, TH; Piggott, MJ; Savola, JM | 1 |
| Burdett, TC; Cassin, JJ; Chen, JF; Fredholm, BB; Healy, B; Schwarzschild, MA; Xiao, D | 1 |
| Jackson, MJ; Jenner, P; McCreary, AC; Rose, S; Tayarani-Binazir, K | 1 |
| Bezard, E; Cenci, MA; Descarries, L; Dovero, S; Lees, AJ; O'Sullivan, SS; Parent, M; Rylander, D | 1 |
| Brotchie, JM; Fox, SH | 2 |
| Dowd, E; Finn, DP; Gorman, AM; Walsh, S | 1 |
| Bartolini, WP; Brotchie, JM; Fox, SH; Huot, P; Johnston, TH; Milne, GT; Pearson, JP; Sykes, KA; Wakefield, JD | 1 |
| Auguet, M; Chabrier, PE; Charnet, C; Cornet, S; Roubert, V; Spinnewyn, B | 1 |
| Hamann, M; Lange, N; Richter, A; Shashidharan, P | 1 |
| da-Silva, CA; Del Bel, EA; Novaretti, N; Padovan-Neto, FE; Tumas, V | 1 |
| Marin, C; Obeso, JA | 1 |
| Archer, T; Fredriksson, A; Johansson, B | 1 |
| Bezard, E; Brambilla, R; Cenci, MA; Cerovic, M; D'Antoni, A; Doveró, S; Fasano, S; Francardo, V; Indrigo, M; Qin, L | 1 |
| Danysz, W; Dekundy, A; Gravius, A; Hechenberger, M; Mela, F; Nagel, J; Parsons, CG; Pietraszek, M; Tober, C; van der Elst, M | 1 |
| Britt, JP; Ding, Y; Kang, UJ; Lim, SA; McGehee, DS; Won, L | 1 |
| Gerlach, M; Grünblatt, E; Riederer, P; Scheller, DK; Schmidt, WJ | 1 |
| Daly, CS; Dunnett, SB; Lane, EL; Smith, GA | 1 |
| Campos, C; Huang, LZ; Ivy Carroll, F; Ly, J; Quik, M | 1 |
| Bartoszyk, GD; Dean, O; Gerlach, M; Riederer, P; van den Buuse, M | 1 |
| Beck, J; Gerlach, M; Riederer, P; van den Buuse, M | 1 |
| Andersson, D; Cenci, MA; Francardo, V; Nissbrandt, H; Popovic, N; Recchia, A | 1 |
| Bilbe, G; Di Paolo, T; Gasparini, F; Gomez-Mancilla, B; Grégoire, L; Johns, D; Morin, N; Ouattara, B; Sahasranaman, S; Vranesic, I | 1 |
| Brotchie, JM; Fahana, N; Johnston, TH; Khademullah, CS; Lam, D; Lo, C; Nash, JE; Talwar, S; Thiele, SL; Warre, R | 1 |
| Del-Bel, E; Lazzarini, M; Padovan-Neto, FE; Raisman-Vozari, R | 1 |
| Barnum, CJ; Bhide, N; Bishop, C; Dupre, KB; Eskow Jaunarajs, KL; Lindenbach, D; Ostock, CY | 1 |
| Brotchie, JM; DeHaven, RN; DeHaven-Hudkins, DL; Dolle, RE; Fox, SH; Goodman, A; Johnston, TH; Koprich, JB; Le Bourdonnec, B; Little, PJ | 1 |
| Abe, H; Ebihara, K; Ishida, Y; Kawai, K; Magata, Y; Matsuo, H; Nishimori, T; Takeda, R | 1 |
| Af Bjerkén, S; Gerhardt, GA; Lundblad, M; Nevalainen, N; Strömberg, I | 1 |
| Fonseca-Ornelas, L; Hernández-Vargas, R; López-González, I; Reynaud, E; Riesgo-Escovar, J; Zurita, M | 1 |
| Egeland, M; Svenningsson, P; Zhang, X | 1 |
| Andersson, M; Bergquist, J; Fälth, M; Hanrieder, J; Ljungdahl, A; Mammo, SE | 1 |
| Barroso-Chinea, P; Berthet, A; Bezard, E; Canron, MH; Charron, G; Delalande, F; Doudnikoff, E; Giros, B; Goumon, Y; Laux, A; Li, Q; Nosten-Bertrand, M; Porras, G; Qin, C; Van Dorsselaer, A; Vital, A | 1 |
| Kabuto, H; Yamanushi, TT | 1 |
| Cenci, MA; Francardo, V; Konradi, C; Lees, AJ; Lindgren, HS; Luksik, AS; O'Sullivan, SS; Ohlin, KE; Sillivan, SE; Vassoler, FM | 1 |
| Calabresi, P; Di Luca, M; Gardoni, F; Pendolino, V; Picconi, B; Sgobio, C | 1 |
| Cai, Y; Liu, Z; Ren, T; Wu, N; Yang, X; Yuan, W | 1 |
| Bezard, E; Carta, M | 1 |
| Forsberg, MM; Kääriäinen, TM; Käenmäki, M; Männistö, PT; Oinas, N; Tammimäki, A | 1 |
| Cai, XY; Fang, Q; Kong, XM; Ning, P; Xu, YJ; Xue, SR; Zhang, B | 1 |
| Abdin, AA; Sarhan, NI | 1 |
| Ivanova, EA; Kapitsa, IG; Kokshenev, II; Nepoklonov, AV; Val'dman, EA; Voronina, TA | 1 |
| Johnston, TH; Lane, EL | 1 |
| Asada, M; Asada, N; Fehling, HJ; Fukatsu, A; Kimura, T; Kita, T; Minegishi, N; Nagoshi, N; Nakamura, J; Oguchi, A; Okano, H; Rao, TN; Shibata, S; Suzuki, N; Takase, M; Yamamoto, M; Yamamura, K; Yanagita, M | 1 |
| Carlsson, T; Döbrössy, M; García, J; Nikkhah, G; Winkler, C | 2 |
| Brotchie, JM; Visanji, NP | 1 |
| Crossman, AR; Hill, MP; Kobylecki, C; Ravenscroft, P | 1 |
| Geng, XC; Yin, LL; Zhu, XZ | 1 |
| Barnum, CJ; Bhide, N; Bishop, C; Goldenberg, AA; Klioueva, A; Lindenbach, D; Surrena, MA; Tignor, S; Walters, H | 1 |
| Iwamuro, H; Kita, H; Nambu, A; Tachibana, Y; Takada, M | 1 |
| de Fabregues, O; Marin, C; Rodriguez-Oroz, MC | 1 |
| Herrero, MT; Linazasoro, G; Pagonabarraga, J | 1 |
| Amalric, M; Blobaum, AL; Bode, J; Bridges, TM; Bubser, M; Conn, PJ; Daniels, JS; Dickerson, JW; Engers, DW; Hopkins, CR; Italiano, K; Jadhav, S; Jones, CK; Lindsley, CW; Morrison, RD; Niswender, CM; Thompson, AD; Turle-Lorenzo, N | 1 |
| Chesselet, MF; Richter, F | 1 |
| Chao, OY; Huston, JP; Mattern, C; Nikolaus, S; Pum, ME; Ruocco, LA; Silva, AM; Wessler, J | 1 |
| Alstrup, AK; Doudet, DJ; Gjedde, A; Høltzermann, M; Jakobsen, S; Landau, AM; Møller, A; Nahimi, A; Simonsen, M; Vang, K; Wegener, G | 1 |
| Liang, L; Pu, X; Wang, J; Wang, X; Wu, Q; Xiang, Y; Zhang, Q; Zhang, X | 1 |
| Guertin, PA; Rouleau, P; Ung, RV | 1 |
| Barrow, R; Errico, F; Kim, S; Mealer, RG; Napolitano, F; Shahani, N; Snyder, SH; Subramaniam, S; Tyagi, R; Usiello, A | 1 |
| Björklund, A; Decressac, M; Lundblad, M; Mattsson, B; Weikop, P | 1 |
| Fields, V; Goldberg, NR; Meshul, CK; Pflibsen, L; Salvatore, MF | 1 |
| Cacciatore, I; Conte, C; Cornacchia, C; Minelli, A; Pinnen, F | 1 |
| Barroso-Chinea, P; Baufreton, J; Berthet, A; Bezard, E; Bloch, B; Dehay, B; Fasano, S; Giros, B; Li, Q; Martin-Negrier, ML; Martinez, A; Nosten-Bertrand, M; Porras, G; Thiolat, ML | 1 |
| Caron, MG; Espinoza, S; Gainetdinov, RR; Managò, F; Premont, RT; Salahpour, A; Sotnikova, TD | 1 |
| Konitsiotis, S; Maranis, S; Stamatis, D; Tsironis, C | 1 |
| Andolina, D; Cabib, S; Conversi, D; Cruciani, F; Giacovazzo, G; Pascucci, T; Puglisi-Allegra, S | 1 |
| Björklund, A; Carta, M; Shin, E; Tronci, E | 1 |
| Francardo, V; Iderberg, H; Pioli, EY | 1 |
| Bacolod, MD; Bennouar, KE; Cajina, M; Doller, D; Gubellini, P; Jimenez, HN; Kerkerian-Le Goff, L; Melon, C; Uberti, MA | 1 |
| Ionov, ID; Severtsev, NN | 1 |
| Calabresi, P; Costa, C; de Iure, A; Di Filippo, M; Di Luca, M; Gardoni, F; Ghiglieri, V; Latagliata, EC; Marti, M; Morari, M; Pascucci, T; Pendolino, V; Picconi, B; Puglisi-Allegra, S; Sgobio, C; Siliquini, S; Spillantini, MG; Tantucci, M; Tozzi, A | 1 |
| Billet, F; Costentin, J; Dourmap, N | 1 |
| Björklund, A; Carta, M; Garcia, J; Shin, E; Winkler, C | 1 |
| Hickey, P; Stacy, M | 1 |
| Gerlach, M; Halley, P; Riederer, P; van den Buuse, M | 1 |
| Bishop, C; Eskow Jaunarajs, KL; George, JA | 1 |
| Afzal, M; Jyoti, S; Khan, S; Naz, F; Shakya, B; Siddique, YH | 1 |
| Desrayaud, S; Di Paolo, T; Gasparini, F; Gomez-Mancilla, B; Grégoire, L; Morin, N; Morissette, M | 1 |
| Anaya-Martínez, V; Avila-Costa, MR; Espinosa-Villanueva, J; Gutierrez-Valdez, AL; Montiel-Flores, E; Ordoñez-Librado, JL; Reynoso-Erazo, L; Sanchez-Betancourt, J | 1 |
| Liu, ZG; Song, L; Wei, JL; Wu, N; Yang, XX | 1 |
| Bankiewicz, KS; Cummins, A; Eberling, J; Kohutnicka, M; Oiwa, Y; Sanchez-Pernaute, R | 1 |
| Kanemaru, A; Kojima, T; Tokashiki, S; Ueda, Y | 1 |
| Hermann, A; Huehnchen, P; Klaissle, P; Lesemann, A; Steiner, B; Storch, A | 1 |
| Jenner, P; McCreary, AC; Papathanou, M; Rose, S; van der Laan, R | 1 |
| Chen, Y; Hong, X; Liu, Z; Song, L; Wu, N; Yang, X; Yuan, W | 1 |
| Lane, EL; Winkler, C | 1 |
| Fukui, M; Kang, KS; Wen, Y; Yamabe, N; Zhu, BT | 1 |
| Bezard, E; Jianzhong, Y; Li, Q; Pioli, EY; Schneider, JS | 1 |
| Apple, DM; Chotibut, T; Jefferis, R; Salvatore, MF | 1 |
| Aron Badin, R; Auguet, M; Bertrand, A; Boulet, S; Brouillet, E; Chabrier, PE; Dollé, F; Gaillard, MC; Guillermier, M; Hantraye, P; Jan, C; Malgorn, C; Savasta, M; Spinnewyn, B; Van Camp, N | 1 |
| Kanda, T; Miyauchi, N; Yamada, K | 1 |
| Crossman, AR; Kobylecki, C; Ravenscroft, P | 1 |
| Bordia, T; McIntosh, JM; Quik, M | 1 |
| Berger, SP; Bhide, N; Bishop, C; Goldenberg, AA; Lindenbach, D; Paquette, MA; Surrena, MA | 1 |
| Bezard, E; Björklund, A; Carta, M; Li, Q; Pioli, EY; Porras, G; Tronci, E | 1 |
| Björklund, A; Cenci, MA; Kirik, D; Winkler, C | 1 |
| Bar-Gad, I; Bergman, H; Goldberg, JA; Heimer, G | 1 |
| Chang, JW; Kang, UJ; Lee, WY; Milstien, S | 1 |
| Cenci, MA | 2 |
| Kondo, T | 1 |
| Bibbiani, F; Chase, TN; Oh, JD | 1 |
| Ausubel, FM; Calderwood, SB; Heitman, J; Mylonakis, E; Perfect, JR | 1 |
| Bédard, PJ; Calon, F; Di Paolo, T; Grégoire, L; Grondin, R; Hadj Tahar, A | 1 |
| Bioulac, B; Fernagut, PO; Ghorayeb, I; Stefanova, N; Tison, F; Wenning, GK | 1 |
| Caudle, WM; Miller, GW; Reverón, ME; Tillerson, JL | 1 |
| Al-Barghouthy, G; Jackson, M; Jenner, P; Kuoppamäki, M; Quinn, N; Smith, L; Zeng, BY | 1 |
| Angelucci, ME; Canteras, NS; Da Cunha, C; Takahashi, RN; Wonnacott, S | 1 |
| Bonastre, M; Hirsch, EC; Marin, C; Périer, C; Tolosa, E | 1 |
| Cannizzaro, C; Jackson, MJ; Jenner, P; Maratos, EC; Pearce, RK | 1 |
| Brotchie, JM; Crossman, AR; Mora, F; Segovia, G | 1 |
| Kulkarni, SK; Singh, A | 1 |
| Bezard, E; Bioulac, B; Dovero, S; Gross, CE; Jaber, M; Ravenscroft, P | 1 |
| Cenci, MA; Lundblad, M; Vaudano, E | 1 |
| Gonzalez, FJ; John, SW; Libby, RT; Martin, JE; Savinova, OV; Smith, RS; Zabaleta, A | 1 |
| Di Monte, DA; McCormack, AL | 1 |
| Arai, A; Kannari, K; Matsunaga, M; Shen, H; Yamato, H | 1 |
| Bari, M; Battista, N; Bernardi, G; Calabresi, P; Centonze, D; Finazzi-Agrò, A; Gubellini, P; Maccarrone, M; Picconi, B | 1 |
| Gilgun-Sherki, Y; Melamed, E; Offen, D; Ziv, I | 1 |
| Chassain, C; Durif, F; Eschalier, A | 2 |
| Iida, Y; Saji, H; Shimazu, S; Takahata, K; Tamashiro, A; Yoneda, F | 1 |
| Bonastre, M; Hirsch, EC; Jimenez, A; Marin, C; Périer, C; Tolosa, E | 1 |
| Bonastre, M; Bové, J; Marin, C; Tolosa, E | 1 |
| Albin, RL; Desmond, TJ; Frey, KA; Kemmerer, ES; Kilbourn, MR | 1 |
| Jenner, P | 2 |
| Asbrock, N; Ferrer, B; Giuffrida, A; Kathuria, S; Piomelli, D | 1 |
| Cao, X; Sun, S; Xu, Y | 1 |
| Colpaert, F; Domino, EF; Marien, M; Ni, L | 1 |
| Iravani, MM; Jackson, MJ; Jenner, P; Kuoppamäki, M; Smith, LA | 1 |
| Moser, A; Qadri, F; Thümen, A | 1 |
| Bergman, J; Eskola, O; Forsback, S; Grönroos, T; Haapalinna, A; Haaparanta, M; Marjamäki, P; Niemi, R; Rinne, J; Solin, O | 1 |
| Bonastre, M; Bové, J; Jiménez, A; Marin, C; Tolosa, E | 1 |
| Delfino, MA; Douhou, A; Ferrario, JE; Gershanik, OS; Murer, MG; Raisman-Vozari, R; Stefano, AV; Zbarsky, V | 1 |
| Kang, UJ; Kim, YS; Lee, EA; Lee, WY | 1 |
| Carta, AR; Morelli, M; Pinna, A; Tronci, E | 1 |
| Bastia, E; Chen, JF; Fredduzzi, S; Moratalla, R; Ongini, E; Schwarzschild, MA; Yu, L | 1 |
| Aoyama, S; Bedard, P; Borrelli, E; Chase, TN; Hauser, RA; Ichimura, M; Ikeda, K; Ishii, A; Jenner, P; Kanda, T; Kase, H; Koga, K; Koike, N; Kurokawa, M; Kuwana, Y; Mori, A; Nakamura, J; Nonaka, H; Ochi, M; Richardson, PJ; Saki, M; Shimada, J; Shindou, T; Shiozaki, S; Suzuki, F; Takeda, M; Yanagawa, K | 1 |
| Bara-Jimenez, W; Bibbiani, F; Chase, TN; Dimitrova, T; Oh-Lee, JD | 1 |
| Ghil, GS; Joo, WS; Kim, EY; Kim, YS; Lee, YJ; Lim, J; Park, S; Wang, KC | 1 |
| Collier, TJ; Danielson, PD; Kurlan, R; Sladek, JR; Steece-Collier, K; Yurek, DM | 1 |
| Brotchie, JM; Chalon, S; Crossman, AR; Ravenscroft, P | 1 |
| Nakagawa, M; Nishizawa, Y; Ogura, H; Ohgoh, M | 1 |
| Flisar, D; Pirtosek, Z | 1 |
| Brocco, M; Brotchie, J; Crossman, A; Di Cara, B; Gobert, A; Hill, M; Jackson, M; Jenner, P; Joyce, JN; McGuire, S; Millan, MJ; Peglion, JL; Smith, L | 1 |
| Bédard, PJ; Bézard, E; Grondin, R; Gross, CE; Hadj Tahar, A | 1 |
| Bezard, E; Brotchie, JM; Crossman, AR; Grimée, R; Hill, MP; Klitgaard, H; Michel, A; Ravenscroft, P | 1 |
| Bédard, PJ; Bélanger, N; Darré, A; Grégoire, L; Hadj Tahar, A; Meltzer, L | 1 |
| Bartus, RT; Basile, AS; Cooper, T; Emerich, D; Fu, K; Lafreniere, D; Lo, ES; Novak, L; Salzberg-Brenhouse, H; Snodgrass-Belt, P | 1 |
| Cenci, MA; Lundblad, M; Poewe, W; Stefanova, N; Tison, F; Wenning, GK | 1 |
| De Groote, C; Fischer, G; Jenner, P; Kemp, JA; Klockgether, T; Löschmann, PA; Smith, L; Wüllner, U | 1 |
| Der, TC; Hagner, D; Joyce, JN; Osredkar, T; Renish, L; Reploge, M; Sakakibara, S; Ueda, S | 1 |
| Schmidt, WJ; Srinivasan, J | 1 |
| Ben Shachar, D; Stephenson, G; Youdim, MB | 1 |
| Arnold, LA; Egami, K; Hyland, K; Jinnah, HA; Kasim, S | 1 |
| Gluck, MR; Granson, H; Santana, LA; Yahr, MD | 1 |
| Aubin, N; Barneoud, P; Burnier, P; Caille, D; Carter, C; Charieras, T; Curet, O; Gardes, A; George, P; Jegham, S; Le Kim, A; Lolivier, J; Marc, C; Pandini, M; Perron, C; Puech, F; Scatton, B; Sontag, N | 1 |
| Bernardi, G; Calabresi, P; Cenci, MA; Centonze, D; Di Luca, M; Gardoni, F; Mauceri, D; Picconi, B | 1 |
| Itakura, T; Kakishita, K; Nakao, N; Shintani-Mizushima, A | 1 |
| Brotchie, JM; Crossman, AR; Millan, MJ; Nicholson, SL; Ravenscroft, P; Silverdale, MA | 1 |
| Cenci, MA; Lindgren, H; Lundblad, M; Picconi, B | 1 |
| Brotchie, JM; Crossman, AR; McGuire, S; Menniti, FS; Nash, JE; Ravenscroft, P | 1 |
| Linazasoro, G | 2 |
| Agnati, LF; Ferré, S; Franco, R; Fuxe, K; Hockemeyer, J; Leo, G; Lluis, C; Martínez, E; Vergoni, AV | 1 |
| Guertin, PA; Landry, ES | 1 |
| Auberson, YP; Greenamyre, JT; Papa, SM | 1 |
| Aubert, I; Barthe, N; Bezard, E; Bioulac, BH; Bloch, B; Dovero, S; Fisone, G; Gross, CE; Guigoni, C; Håkansson, K; Li, Q | 1 |
| Delville, Y; Fleming, SM; Schallert, T | 1 |
| Brotchie, JM; Crossman, AR; Nicholson, SL; Silverdale, MA | 1 |
| Ogawa, N; Tanaka, K | 1 |
| Bielicki, G; Chassain, C; Donnat, JP; Durif, F; Eschalier, A; Renou, JP | 1 |
| Björklund, A; Burger, C; Carlsson, T; Cenci, A; Kirik, D; Mandel, RJ; Muzyczka, N; Winkler, C | 1 |
| Benovic, JL; Bezard, E; Gross, CE; Gurevich, EV; Gurevich, VV; Qin, L | 1 |
| Aguilar, E; Bonastre, M; Marin, C; Obeso, JA; Tolosa, E | 1 |
| Brotchie, JM; Collingridge, GL; Garner, CC; Johnston, TH; Nash, JE | 1 |
| Bernardi, G; Calabresi, P; Centonze, D; Pisani, A | 1 |
| Amalric, M; Baunez, C; Breysse, N; Turle-Lorenzo, N | 1 |
| Gerlach, M; Reichmann, H; Riederer, P | 1 |
| Iravani, MM; Jackson, MJ; Jenner, P; Johnston, LC; Smith, LA; Syed, E | 1 |
| Cristalli, G; Morelli, M; Pinna, A; Volpini, R | 1 |
| Godlevskii, LS; Kobolev, EV | 1 |
| Connell, MA; Emborg, ME; Li, Q; Meglasson, MD; Merchant, K; Simmons, C; Stephenson, DT | 1 |
| Baba, M; Kannari, K; Kimura, T; Maeda, T; Matsunaga, M; Tomiyama, M | 1 |
| Landry, E; Lévesque, D; Rouillard, C; St-Hilaire, M | 1 |
| Carta, M; Cenci, MA; Fisone, G; Håkansson, K; Lundblad, M; Usiello, A | 1 |
| Ding, JH; Hu, G; Liu, SY; Liu, X; Long, Y; Sun, YH; Wang, F; Wang, H; Wu, J; Yang, Y; Yao, HH | 1 |
| Bédard, PJ; Grégoire, L; Guidetti, P; Izzo, E; Rassoulpour, A; Samadi, P; Schwarcz, R | 1 |
| Asanuma, M; Diaz-Corrales, FJ; Miyazaki, I; Ogawa, N; Shimizu, M; Tanaka, K | 1 |
| Morelli, M; Pinna, A; Simola, N; Wardas, J | 1 |
| Bédard, PJ; Di Paolo, T; Grégoire, L; Hadj Tahar, A; Rouillard, C; Samadi, P | 1 |
| Cheetham, SC; Jenner, P; Lane, EL | 1 |
| Brotchie, JM | 1 |
| Brown, AM; Colbran, RJ; Deutch, AY | 1 |
| Aubert, I; Bezard, E; Bioulac, BH; Bloch, B; Dovero, S; Gross, CE; Guigoni, C; Gurevich, EV; Li, Q | 1 |
| Barak, LS; Beaulieu, JM; Caron, MG; Gainetdinov, RR; Sotnikova, TD; Wetsel, WC | 1 |
| Glavan, G; Zivin, M | 1 |
| Berk, L; Clackson, T; Cunningham, J; Feng, L; Forsayeth, JR; Rivera, VM; Sanftner, LM; Suzuki, BM; Zhou, S | 1 |
| Martín, AB; Mendialdua, A; Moratalla, R; Pavón, N | 1 |
| Lavado, A; Montoliu, L | 1 |
| Chambon, P; Ichinose, H; Ikeguchi, K; Kodera, M; Li, XG; Metzger, D; Muramatsu, C; Muramatsu, S; Nakano, I; Nara, Y; Okada, T; Ozawa, K; Takino, N; Urano, F | 1 |
| Bibbiani, F; Chase, TN; Collins, MA; Kielaite, A; Oh, JD; Smith, C | 1 |
| Chen, JF; Schwarzschild, MA; Yu, L | 1 |
| Benabid, AL; Berger, F; Buggia, V; Gilbert, F; Lévesque, D; Sgambato-Faure, V | 1 |
| Chen, SD; Du, YL; Liu, ZG; Lu, GQ | 1 |
| Dunnett, SB; Monville, C; Torres, EM | 1 |
| Goto, S; Kaji, R; Kuratsu, J; Yamada, K | 1 |
| Bankiewicz, KS; Bringas, J; Cunningham, J; Daadi, M; Eberling, JL; Forsayeth, JR; Pivirotto, P; Sanftner, L | 1 |
| Willis, GL | 1 |
| Brundin, P; Cenci, MA; Lane, EL; Winkler, C | 1 |
| Bédard, PJ; Di Paolo, T; Grégoire, L; Lévesque, D; Rouillard, C; Samadi, P | 1 |
| Aguilar, E; Marin, C; Obeso, JA | 1 |
| Bédard, PJ; Berthiaume, L; Calon, F; Di Paolo, T; Hadj-Tahar, A; Julien, C; Julien, P; Rajput, AH | 1 |
| Brundin, P; Popovic, N | 1 |
| Brotchie, JM; Fox, SH; Gomez-Ramirez, J; Johnston, TH; Visanji, NP | 1 |
| Carta, M; Cenci, MA; Fadda, F; Lindgren, HS; Lundblad, M; Stancampiano, R | 1 |
| Cenci, MA; Danysz, W; Dekundy, A; Pietraszek, M; Schaefer, D | 1 |
| Morelli, M; Pinna, A; Pontis, S | 1 |
| Konitsiotis, S; Tsironis, C | 1 |
| Bang, JH; Choi, HB; Hong, SH; Joo, IS; Kim, KS; Kim, SU; Kim, TH; Kim, YS; Lee, CS; Lee, MA; Park, IH | 1 |
| Andren, PE; Svenningsson, P; Zhang, X | 1 |
| Baraldi, PG; Fenu, S; Morelli, M; Simola, N; Tabrizi, MA | 1 |
| Obeso, JA; Olanow, CW; Stocchi, F | 1 |
| Bourhis, E; Lévesque, D; Rouillard, C; St-Hilaire, M | 1 |
| Ai, Y; Andersen, AH; Gash, DM; Gerhardt, GA; Hardy, PA; Loveland, A; Zhang, Z | 1 |
| Brotchie, JM; Fox, SH; Gomez-Ramirez, J; Johnston, TH; Pires, D; Visanji, NP; Voon, V | 1 |
| Brotchie, JM; Fox, SH; Gomez-Ramirez, J; Johnston, TH; Visanji, NP; Voon, V | 1 |
| Brundin, P; Cenci, MA; Gardi, J; Lindgren, HS; Mohapel, P; Nyengaard, JR; Westin, JE | 1 |
| Brotchie, JM; Crossman, AR; Hill, MP; McGuire, SG; Millan, MJ; Ravenscroft, P; Rochat, C | 1 |
| Eusebio, A; Gubellini, P; Kerkerian-Le Goff, L; Melon, C; Oueslati, A; Salin, P | 1 |
| Caccia, C; Calabresi, M; Curatolo, L; Faravelli, L; Fariello, RG; Maestroni, S; Maj, R; Salvati, P | 1 |
| Alm, H; Andrén, PE; Bezard, E; Crossman, AR; Kultima, K; Lönnstedt, I; Scholz, B; Sköld, K; Svensson, M | 1 |
| Colebrooke, RE; Emson, PC; Humby, T; Lynch, PJ; McGowan, DP; Xia, J | 1 |
| Ba, M; Chen, S; Kong, M; Liu, Z; Lu, G; Ma, G; Yang, H | 1 |
| Avila, I; Bibbiani, F; Chase, TN; Collins, MA; Oh, JD; Smith, CP | 1 |
| Nicholas, AP | 1 |
| Köllensperger, M; Poewe, W; Reindl, M; Stefanova, N; Wenning, GK | 1 |
| Jenner, P; Ramsay Croft, N; Rose, S | 1 |
| Bartalucci, A; Biagioni, F; Ferrucci, M; Fornai, F; Fulceri, F; Galli, V; Lazzeri, G; Paparelli, A; Ruggieri, S | 1 |
| Brachet, P; Damier, P; Henry, V; Lescaudron, L; Paillé, V | 1 |
| Cenci, MA; Danysz, W; Dekundy, A; Lundblad, M | 1 |
| Amri, M; Gubellini, P; Kachidian, P; Kerkerian-Le Goff, L; Melon, C; Oueslati, A; Salin, P; Sgambato-Faure, V | 1 |
| Asai, M; Matsuya, T; Miyoshi, S; Mizoguchi, H; Murakami, Y; Nagai, T; Nishimura, S; Noda, A; Sato, K; Takuma, K; Yamada, K | 1 |
| Cenci, MA; Danysz, W; Dekundy, A; Marti, M; Mela, F; Morari, M | 1 |
| Ding, Y; Hwang, DY; Kang, UJ; Kim, KS; Restrepo, J; Won, L | 1 |
| Chung, EJ; Jeon, MY; Kang, HY; Lee, WY | 1 |
| Cenci, MA; Danysz, W; Dekundy, A; James, P; Krogh, M; Lundblad, M; Quack, G; Valastro, B | 1 |
| Bishop, C; Dupre, KB; Eskow, KL; Negron, G | 1 |
| Chen, J; Ma, L; Wang, F; Zhang, H; Zhen, X | 1 |
| Aimi, Y; Arai, R; Kudo, M; Nagatsu, I; Taki, K; Yamada, H | 1 |
| Borgkvist, A; Carta, M; Fisone, G; Girault, JA; Greengard, P; Hervé, D; Santini, E; Usiello, A; Valjent, E | 1 |
| Cao, X; Factor, S; Greenamyre, JT; Griffith, DA; Hadcock, JR; Iredale, PA; Liang, L; Menniti, FS; Papa, SM | 1 |
| Björklund, A; Carlsson, T; Carta, M; Kirik, D; Winkler, C | 1 |
| Belknap, JK; Johnson, SW; Kozell, LB; Munhall, AC; Putterman, DB | 1 |
| Juckel, G; Klein, J; Kupsch, A; Lee, T; Morgenstern, R; Mundt, A; Petrus, D; von Rumohr, A; Winter, C | 1 |
| Calon, F; Di Paolo, T; Dridi, M; Huot, P; Lévesque, M; Morissette, M; Parent, A | 1 |
| Calon, F; Di Paolo, T; Morelli, M; Schwarzschild, MA; Wardas, J; Xiao, D | 1 |
| Bédard, PJ; Di Paolo, T; Grégoire, L; Guidetti, P; Izzo, E; Rassoulpour, A; Samadi, P; Schwarcz, R | 1 |
| Funakoshi, T; Iwata, S; Wakamatsu, M; Yoshimoto, M | 1 |
| Dunnett, S; Lane, E | 1 |
| Armentero, MT; Bazzini, E; Blandini, F; Levandis, G; Nappi, G | 1 |
| García-Horsman, JA; Huotari, M; Kääriäinen, TM; Männistö, PT; Piltonen, M | 1 |
| Bédard, PJ; Belanger, N; Calon, F; Di Paolo, T; Dridi, M; Hadj Tahar, A; Meltzer, LT; Morissette, M; Samadi, P | 1 |
| Angela Cenci, M; Bagetta, V; Barone, I; Bernardi, G; Calabresi, P; Ghiglieri, V; Lindgren, HS; Paillé, V; Picconi, B | 1 |
| Ambrée, O; de Souza Silva, MA; Dere, E; Herring, A; Keyvani, K; Lewejohann, L; Paulus, W; Richter, H; Sachser, N; Schäbitz, WR | 1 |
| Brotchie, JM; Gomez-Ramirez, J; Johnston, TH; Lee, J; Visanji, N | 1 |
| Asanuma, M; Diaz-Corrales, FJ; Eslava-Alva, MJ; Higashi, Y; Miyazaki, I; Ogawa, N; Shimizu, M | 1 |
| Maeda, T; Nagata, K; Yoshida, Y | 1 |
| Andren, PE; Greengard, P; Svenningsson, P; Zhang, X | 1 |
| Dovedova, EL; Khudoerkov, RM; Voronkov, DN | 1 |
| Alm, H; Andrén, PE; Bezard, E; Crossman, AR; Doudnikoff, E; Fälth, M; Guigoni, C; Kultima, K; Li, Q; Scholz, B; Sköld, K; Svensson, M | 1 |
| Berger, SP; Brudney, EG; Johnson, SW; Meshul, CK; Paquette, MA; Putterman, DB | 1 |
| Cenci, MA; Lindgren, HS | 1 |
| Bezard, E; Brotchie, JM; Fox, SH; Hallett, PJ; Lubin, FD; Nicholas, AP; Ravenscroft, P; Standaert, DG; Sweatt, JD; Vattem, P; Zhou, S | 1 |
| Andren, PE; Chergui, K; Svenningsson, P; Zhang, X | 1 |
| Cenci, MA; Lundblad, M | 1 |
| Hefti, F; Liebman, J; Melamed, E; Schlosberg, AJ; Wurtman, RJ | 1 |
| Carvey, P; Goetz, CG; Klawans, HL | 1 |
| Woodbury, DM | 1 |
| Burns, RS; Chiueh, CC; Ebert, MH; Jacobowitz, DM; Kopin, IJ; Markey, SP | 1 |
| Deupree, JD; Murrin, LC; Pfeiffer, RF; Schneider, MB | 1 |
| Baumeister, AA; Breese, GR; Emerick, SG; Frye, GD; McCown, TJ; Mueller, RA | 1 |
| Caraceni, T; Cocchi, D; Giovannini, P; Martinez-Campos, A; Müller, EE; Parati, EA; Zanardi, P | 1 |
| Barbeau, A | 1 |
| Cooper, DR; Jenner, P; Marrel, C; Marsden, CD; Quinn, N; Testa, B; van de Waterbeemd, H | 1 |
| Ossowska, K | 1 |
| Albino-Teixeira, A; Fernandes, MH; Pestana, M; Soares-da-Silva, P; Vieira-Coelho, MA | 1 |
| During, MJ; Geller, AI; Naegele, JR; O'Malley, KL | 1 |
| Inoue, A; Misu, Y; Nakata, Y; Okumura, F; Ozaki, N; Sato, K; Ueda, H; Yue, JL | 1 |
| Bentlage, C; Björklund, A; Nikkhah, G; Olsson, M | 1 |
| Biboso, A; Bowers, RR; Kridel, S; Lujan, J; Varkey, C | 1 |
| Lang, A; Männistö, PT; Rauhala, P; Vasar, E | 1 |
| Carmichael, SW; Cook, JA; Merkel, GJ; Stoddard, SL; Zinsmeister, AR | 1 |
| Fukuda, T; Irifune, M; Nomoto, M | 1 |
| Nezlin, L; Sakharov, D; Voronezhskaya, E | 1 |
| Klockgether, T; Löschmann, PA; Wüllner, U | 1 |
| Carey, RJ; Dai, H; Huston, JP; Pinheiro-Carrera, M; Tomaz, C | 1 |
| Kanazawa, I; Kimura, M; Murata, M | 1 |
| Hossain, MA; Weiner, N | 1 |
| Stern, G | 1 |
| Gash, DM; Kurlan, R; McDermott, M; Smith, RD; Zhang, Z | 1 |
| DiStefano, L; Kean, A; Schneider, JS | 1 |
| Misu, Y; Okumura, F; Sato, K; Ueda, H | 1 |
| Brunner-Guenat, M; Carrupt, PA; Jenner, P; Lisa, G; Rose, S; Testa, B; Thomas, K; Ventura, P | 1 |
| Akiyama, K; Ishihara, T; Kashihara, K; Shiro, Y; Shohmori, T | 1 |
| Jackson, M; Jenner, P; Marsden, CD; Pearce, RK; Smith, L | 1 |
| Hashiguchi, H; Ishida, Y; Kuwahara, I; Mitsuyama, Y; Todaka, K | 1 |
| Blurton-Jones, M; Cherry, SR; DeSalles, AA; Huang, SC; Melega, WP; Morton, GG; Phelps, ME; Raleigh, MJ; Stout, DB | 1 |
| Brooks, S; Kaur, S; Starr, BS; Starr, MS | 1 |
| Goshima, Y; Misu, Y; Okamura, H; Ueda, H | 1 |
| Chan, GL; Doudet, DJ; Holden, JE; Morrison, KS; Ruth, TJ; Wyatt, RJ | 1 |
| Blaney, TJ; Chandonait, SE; Emerich, DF; Lindner, MD; Mullins, TD; Plone, MA; Sherman, SS; Stott, JA; Winn, SR | 1 |
| Bencsics, C; Kang, UJ; Wachtel, SR | 1 |
| Bezard, E; Bioulac, B; Deloire, X; Gross, CE; Imbert, C | 1 |
| Sugiura, K; Yokoyama, M; Yoshimura, H | 1 |
| Allen, SM; Davis, WM; Freeman, JN | 1 |
| Agid, Y; Dziewczapolski, G; García, MC; Gershanik, O; Menalled, LB; Murer, MG; Raisman-Vozari, R | 1 |
| Bernardi, G; Bonci, A; Federici, M; Mercuri, NB; Scarponi, M; Siniscalchi, A | 1 |
| Chase, TN | 1 |
| Cohen, LK; Leff, SE; Mandel, RJ; Rendahl, KG; Snyder, RO; Spratt, SK | 1 |
| Kang, UJ; Leff, SE; Mandel, RJ; Rendahl, KG; Spratt, SK | 1 |
| Brotchie, JM; Crossman, AR; Henry, B | 2 |
| Guerra, MJ; Labandeira-García, JL; López-Martín, E; Rozas, G | 1 |
| Fujita, M; Ito, Y; Kusuoka, H; Nishimura, T; Okada, T; Shimada, S; Tohyama, M; Watanabe, Y | 1 |
| Bédard, PJ; Hadj Tahar, A | 1 |
| Britton, DR; Jackson, M; Jenner, P; Marsden, CD; Pearce, RK; Shiosaki, K | 1 |
| Damhaut, P; Dethy, S; Goldman, S; Laute, MA | 1 |
| Andersen, AH; Avison, MJ; Cass, WA; Chen, Q; Gash, DM; Ovadia, A; Zhang, Z | 1 |
| Bonastre, M; Jiménez, A; Marin, C; Tolosa, E | 1 |
| Brotchie, JM; Crossman, AR; Fox, SH; Henry, B; Peggs, D | 1 |
| Boxer, PA; Gregory, TF; Meltzer, LT; Serpa, KA; Wise, LD; Wright, JL | 1 |
| Alexander, GM; Azizi, SA; Prockop, DJ; Schwarz, EJ | 1 |
| Andersson, M; Cenci, MA; Hilbertson, A | 1 |
| Dunah, AW; Huganir, RL; Kameyama, K; Standaert, DG; Wang, Y; Wolfe, BB; Yasuda, RP | 1 |
| Mandel, RJ | 1 |
| Bezard, E; Boraud, T; Gross, CE; Guitraud, S; Imbert, C | 1 |
| Jackson, MJ; Jenner, P; Kanda, T; Kase, H; Kuwana, Y; Nakamura, J; Pearce, RK; Smith, LA | 1 |
| Damier, P; Féger, J; Hirsch, EC; Tremblay, L | 1 |
| Di Monte, DA; Jakowec, M; Langston, JW; Petzinger, G; Quik, M | 1 |
| Blanchet, PJ; Chase, TN; Konitsiotis, S; Lamers, E; Verhagen, L | 1 |
| Aubert, I; Bezard, E; Fernagut, PO; Ghorayeb, I; Poewe, W; Tison, F; Wenning, GK | 1 |
| Stoessl, AJ; Van Kampen, JM | 1 |
| Feldon, J; Mintz, M; Mura, A | 1 |
| Bennett, NK; Campbell, JM; Davies, RW; Favor, G; Payne, AP; Russell, D; Stone, TW; Sutcliffe, RG | 1 |
| Di Monte, DA; He, L; Langston, JW; Quik, M | 1 |
| Andren, PE; Gunne, L; Svenningsson, P | 1 |
| Artieda, J; Gonzalo, N; Lanciego, JL; Obeso, JA; Olanow, CW; Rodríguez, M; Rodríguez-Oroz, MC | 1 |
| Bédard, PJ; Blanchet, PJ; Calon, F; Di Paolo, T; Doucet, JP; Goulet, M; Grondin, R; Hadj Tahar, A; Morissette, M; Nestler, E; Robertson, GS | 1 |
| Cannizzaro, C; Costa, S; Iravani, MM; Jackson, MJ; Jenner, P; Pearce, RK; Tel, BC | 1 |
| Mueller, J; Poewe, W; Puschban, Z; Scherfler, C; Seppi, K; Stefanova, N; Wenning, GK | 1 |
| Andersson, KE; Andersson, M; Cenci, MA; Johansson, PA | 1 |
| Andrén, PE; Gunne, L; Hurd, YL; Pirker, W; Pontén, H; Tedroff, J | 1 |
| Cyong, J; Itokazu, N; Ouchi, Y; Yamamoto, K | 1 |
| Blunt, SB; Datla, KP; Dexter, DT | 1 |
| Baillet, C; Callizot, N; Guénet, JL; Poindron, P; Warter, JM | 1 |
| Bezard, E; Brotchie, JM; Gross, CE | 1 |
| Brotchie, JM; Crossman, AR; Fox, SH; Henry, B | 1 |
| Bankiewicz, KS; Cunningham, J; Harvey-White, J; Sánchez-Pernaute, R | 1 |
| Abe, K; Miyatake, T; Ren, J; Sano, T; Shinohara, T; Taguchi, K; Utsunomiya, I; Wasai, T | 1 |
| Andersson, M; Cenci, MA; Lundblad, M; Westin, JE | 1 |
| Groenewegen, HJ; Van De Witte, SV; Voorn, P | 1 |
| Hillman, R; Parvez, F; Pendleton, RG; Sayed, M | 1 |
| Abe, K; Kashihara, K; Manabe, Y; Murakami, T | 1 |
| Weiner, WJ | 1 |
| Hickey, MA; Morton, AJ; Reynolds, GP | 1 |
| Dill, RE; Dorris, RL; Phillips-Thonnard, I | 1 |
| Baldessarini, RJ; Fischer, JE | 1 |
| Blanc, F; Brissac, C; Joyeux, A; Joyeux, H; Raoux, P; Solassol, C | 1 |
| Halbhübner, K; Herken, H; Loos, D | 2 |
| Snead, OC | 1 |
| Crossman, AR; Sambrook, MA; Slater, P | 1 |
| Sato, M | 1 |
| Filion, M; Langelier, P; Larochelle, L; Poirier, L | 1 |
| Anlezark, GM; Marsden, CD; Meldrum, BS | 1 |
| Albizzati, MG; Frattola, L; Scarlato, G; Trabucchi, M | 1 |
| De Ryck, M; Ramirez, VD; Schallert, T; Teitelbaum, P; Whishaw, IQ | 1 |
| Goetz, C; Klawans, HL; Nausieda, PA; Weiner, WJ | 1 |
| Bonnet, K; Friedhoff, AJ; Rosengarten, H | 1 |
| Poirier, LJ | 2 |
| Filion, M; Larochelle, L; Péchadre, JC; Poirier, LJ | 1 |
| Battista, AF; Goldstein, M; Matsumoto, Y; Miyamoto, T | 1 |
| Duvoisin, RC | 1 |
| Yamori, Y | 1 |
| Annau, Z; Fechter, LD | 1 |
| Ljungberg, T; Ungerstedt, U | 1 |
| Kolodny, D; Sherman, L; Smithline, F | 1 |
| Sassin, JF | 1 |
| Klawans, HL; Margolin, DI | 1 |
| Duvoisin, RC; Jenner, P; Marsden, CD; Parkes, JD; Pycock, C; Tarsy, D | 1 |
| Costall, B; Naylor, RJ | 1 |
| Crosset, P; Dana, N; Klawans, HL; Margolin, DI | 1 |
| Popovic, P; Popovic, V; Schaffer, R | 1 |
| Asano, J; Bowers, RR; Harmon, J; Prescott, S; Wynne, S | 1 |
| Wagner, GC; Walsh, SL | 1 |
| Naor, D; Sharon, R | 2 |
| Bédard, PJ; Blanchette, P; Di Paolo, T; Gagnon, C; Mancilla, BG | 1 |
| Markham, CH | 1 |
| Arai, N; Goshima, Y; Misu, Y; Misugi, K | 1 |
| Belichenko, PV; Orlova, EI; Tsaĭner, B | 1 |
| Astarloa, R; García de Yébenes, J; Mena, M | 1 |
| Beaman, BL; Kohbata, S | 1 |
| Honoré, T; Jähnig, P; Jenner, P; Kunow, M; Lange, KW; Löschmann, PA; Marsden, CD; Rettig, KJ; Turski, L; Wachtel, H | 1 |
| Carey, RJ | 1 |
| Asari, S; Goldstein, M; Nakashima, H; Nishimoto, A | 1 |
| Close, SP; Elliott, PJ; Hayes, AG; Marriott, AS; Walsh, DM | 1 |
| Darchen, F; Henry, JP; Horellou, P; Mallet, J; Marlier, L; Privat, A; Scherman, D | 1 |
| Gash, DM; Kim, MH; Kurlan, R | 1 |
| Kanazawa, I | 1 |
| Archer, T; Fredriksson, A; Sundström, E | 1 |
| Bakay, RA; Byrd, LD; Colbassani, HJ; Herring, CJ; Iuvone, PM; Mandir, A; Sweeney, KM; Watts, RL | 1 |
| Boyce, S; Iversen, SD; Rupniak, NM; Steventon, M | 1 |
| Fisher, LJ; Friedmann, T; Iuvone, PM; Jinnah, HA; Langlais, PJ; O'Malley, KL; Rosenberg, MB; Shimohama, S; Wolff, JA; Xu, L | 1 |
| Jenner, P; Marsden, CD; Rupniak, NM | 1 |
| Boyce, S; Clarke, CE; Crossman, AR; Sambrook, MA | 1 |
| Hirose, Y; Kajita, S; Mizukawa, K; Ogawa, N; Ohara, S; Watanabe, Y | 1 |
| Cooper, DR; Jenner, P; Marrel, C; Marsden, CD; Testa, B; van de Waterbeemd, H | 1 |
| Ohmoto, T | 1 |
| Pranzatelli, MR; Snodgrass, SR | 1 |
| Jenner, P; Marsden, CD | 1 |
| Bioulac, B; Doudet, D; Gross, C; Lebrun-Grandié, P | 1 |
| Etemadzadeh, E; Kaakkola, S; Lindén, IB; Männistö, P; Nissinen, E; Pohto, P | 1 |
| Mizukawa, K; Ogawa, N; Sora, YH | 1 |
| Calne, DB; Guttman, M; Kebabian, JC; Mak, E; Pate, BD; Wolters, EC | 1 |
| Bankiewicz, KS; Chiueh, CC; Doppman, JL; Jacobowitz, DM; Kopin, IJ; Oldfield, EH | 1 |
| Friedman, J | 1 |
| Clarke, CE; Crossman, AR; Mitchell, IJ; Sambrook, MA | 1 |
| Jacobs, BL | 1 |
| Herbster, G; Koller, WC | 1 |
| Godlevskiĭ, LS; Kryzhanovskiĭ, GN; Makul'kin, RF; Rozhkov, VS; Shandra, AA | 1 |
| Hirose, Y; Ogawa, N; Ohara, S; Ono, T; Watanabe, Y | 1 |
| Backlund, EO; Freed, W; Herrera-Marschitz, M; Hoffer, B; Olson, L; Seiger, A; Strömberg, I | 1 |
| Angel, A | 1 |
| Bédard, P; Boucher, R; Langelier, P; Larochelle, L; Parent, A; Poirier, LJ; Roberge, AG | 1 |
| Goto, A; Kosaka, K; Miyazaki, S; Narabayashi, H | 1 |
| Bartholini, G; Bigler, R; Brossi, A; Burns, JJ; Kaiser, A; Pletscher, A; Pool, W; Sheppard, H | 1 |
| Ljungberg, T; Steg, G; Ungerstedt, U | 1 |
| Mawson, AR | 1 |
99 review(s) available for levodopa and Disease Models, Animal
| Article | Year |
|---|---|
Levodopa-induced dyskinesia: a historical review of Parkinson's disease, dopamine, and modern advancements in research and treatment.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2022 |
Dyskinesia and Parkinson's disease: animal model, drug targets, and agents in preclinical testing.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Neurodegenerative Diseases; Oxidopamine; Parkinson Disease; Quality of Life | 2022 |
Impaired cognitive and motor function are coincident with L-DOPA-induced dyskinesia in a model of Parkinson's disease.
Topics: Animals; Cognition; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley | 2023 |
Pharmacological Enhancement of Stroke Rehabilitation.
Topics: Animals; Dextroamphetamine; Disease Models, Animal; Humans; Levodopa; Neuronal Plasticity; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Stroke; Stroke Rehabilitation; Synapses | 2019 |
Technological prospection: patents mapping involving compounds for the treatment of L-DOPA-induced dyskinesias.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Patents as Topic | 2019 |
Gene Therapy for Angelman Syndrome: Contemporary Approaches and Future Endeavors.
Topics: Angelman Syndrome; Animals; Anti-Anxiety Agents; Antiparkinson Agents; Buspirone; Diet, Ketogenic; Dietary Supplements; Disease Models, Animal; Gene Silencing; Genetic Therapy; Humans; Levodopa; Mice; Minocycline; Neurons; Signal Transduction; Topoisomerase I Inhibitors; Ubiquitin-Protein Ligases | 2020 |
Research advances on L-DOPA-induced dyskinesia: from animal models to human disease.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Levodopa; Mice; Oxidopamine; Parkinson Disease; Rats | 2020 |
Shedding light on dyskinesias.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesias; Humans; Levodopa | 2021 |
Mechanisms of Antiparkinsonian Anticholinergic Therapy Revisited.
Topics: Animals; Antiparkinson Agents; Cholinergic Antagonists; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Levodopa; Oxidopamine; Parkinson Disease | 2021 |
Non-human primate models of PD to test novel therapies.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Levodopa; Parkinson Disease; Parkinson Disease, Secondary | 2018 |
Synaptic plasticity may underlie l-DOPA induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Levodopa; Neuronal Plasticity; Parkinson Disease | 2018 |
Animal models of L-DOPA-induced dyskinesia: the 6-OHDA-lesioned rat and mouse.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Mice; Oxidopamine; Parkinsonian Disorders; Rats | 2018 |
Novel models for Parkinson's disease and their impact on future drug discovery.
Topics: Aged; Animals; Antiparkinson Agents; Disease Models, Animal; Drug Design; Drug Discovery; Humans; Levodopa; Models, Biological; Parkinson Disease | 2018 |
Animal models of l-dopa-induced dyskinesia in Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Parkinson Disease, Secondary | 2018 |
Repurposing drugs to treat l-DOPA-induced dyskinesia in Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Drug Repositioning; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic | 2019 |
Multisite intracerebral microdialysis to study the mechanism of L-DOPA induced dopamine and serotonin release in the parkinsonian brain.
Topics: Animals; Antiparkinson Agents; Brain; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Levodopa; Microdialysis; Neostriatum; Parkinson Disease; Rats; Serotonergic Neurons; Serotonin | 2013 |
Suitability of the adenosine antagonist istradefylline for the treatment of Parkinson's disease: pharmacokinetic and clinical considerations.
Topics: Adenosine; Adenosine A2 Receptor Antagonists; Animals; Blood-Brain Barrier; Disease Models, Animal; Dopamine Agonists; Dyskinesias; Half-Life; Humans; Levodopa; Parkinson Disease; Purines; Treatment Outcome | 2013 |
L-DOPA and graft-induced dyskinesia: different treatment, same story?
Topics: Animals; Cell Transplantation; Disease Models, Animal; Dyskinesias; Humans; Levodopa | 2013 |
Investigating the molecular mechanisms of L-DOPA-induced dyskinesia in the mouse.
Topics: Animals; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Levodopa; Mice; Oxidopamine; Parkinson Disease; Tyrosine 3-Monooxygenase | 2014 |
A critical evaluation of behavioral rodent models of motor impairment used for screening of antiparkinsonian activity: The case of adenosine A(2A) receptor antagonists.
Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Disease Models, Animal; Humans; Levodopa; Mice; Motor Activity; Parkinsonian Disorders; Rats | 2014 |
Clinical implications of irregular ADMET properties with levodopa and other antiparkinson's drugs.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Humans; Levodopa; Parkinson Disease | 2014 |
Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesias; Humans; Levodopa; Parkinson Disease; Receptor, Metabotropic Glutamate 5 | 2014 |
Symptomatic Models of Parkinson's Disease and L-DOPA-Induced Dyskinesia in Non-human Primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Primates | 2015 |
Pharmacological therapies for Angelman syndrome.
Topics: Angelman Syndrome; Animals; Clinical Trials as Topic; Disease Models, Animal; Gene Silencing; Levodopa; Mice; Minocycline; Oligoribonucleotides, Antisense; Seizures; Sleep Wake Disorders; Topoisomerase Inhibitors; Ubiquitin-Protein Ligases | 2017 |
The MPTP mouse model: cues on DA release and neural stem cell restorative role.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Cues; Disease Models, Animal; Dopamine; Humans; Levodopa; Mice; MPTP Poisoning; Stem Cell Transplantation; Stem Cells | 2008 |
Direct and indirect striatal efferent pathways are differentially influenced by low and high dyskinetic drugs: behavioural and biochemical evidence.
Topics: Animals; Antiparkinson Agents; Behavior; Brain Chemistry; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Efferent Pathways; Gene Expression Regulation; Humans; Levodopa; Oxidopamine; Parkinson Disease; Rats | 2008 |
Role of receptor heterodimers in the development of L-dopa-induced dyskinesias in the 6-hydroxydopamine rat model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Levodopa; Models, Molecular; Oxidopamine; Parkinson Disease; Protein Subunits; Rats; Receptors, Dopamine; Receptors, N-Methyl-D-Aspartate | 2008 |
Parkinson's disease--opportunities for novel therapeutics to reduce the problems of levodopa therapy.
Topics: Animals; Basal Ganglia; Clinical Trials as Topic; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Protein Isoforms; Receptors, Serotonin; Serotonin | 2008 |
Levodopa/dopamine replacement strategies in Parkinson's disease--future directions.
Topics: Animals; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Corpus Striatum; Disease Models, Animal; Dopamine; Drug Administration Schedule; Enzyme Inhibitors; Humans; Levodopa; Neurons; Parkinson Disease; Substantia Nigra | 2008 |
Thwarting dyskinesia by targeting mTORC1.
Topics: Animals; Antiparkinson Agents; Carrier Proteins; Disease Models, Animal; Humans; Levodopa; Mechanistic Target of Rapamycin Complex 1; Mice; Multiprotein Complexes; Parkinson Disease; Phosphotransferases (Alcohol Group Acceptor); Proteins; Signal Transduction; TOR Serine-Threonine Kinases; Transcription Factors | 2009 |
The MitoPark Mouse - an animal model of Parkinson's disease with impaired respiratory chain function in dopamine neurons.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; DNA-Binding Proteins; Dopamine; Electron Transport; Humans; Levodopa; Mice; Mice, Transgenic; Mitochondrial Diseases; Mitochondrial Proteins; Neurons; Parkinson Disease; Transcription Factors | 2009 |
The therapeutic concept of continuous dopaminergic stimulation (CDS) in the treatment of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Drug Administration Schedule; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2009 |
Rodent models of treatment-induced motor complications in Parkinson's disease.
Topics: Animals; Brain Tissue Transplantation; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Levodopa; Mice; Motor Skills Disorders; Parkinson Disease; Rats | 2009 |
Potential mechanisms underlying anxiety and depression in Parkinson's disease: consequences of l-DOPA treatment.
Topics: Animals; Antiparkinson Agents; Anxiety; Depression; Disease Models, Animal; Humans; Levodopa; Neurotransmitter Agents; Parkinson Disease | 2011 |
L-DOPA-induced dyskinesia in Parkinson's disease: a drug discovery perspective.
Topics: Animals; Disease Models, Animal; Drug Discovery; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2010 |
The MPTP-lesioned non-human primate models of Parkinson's disease. Past, present, and future.
Topics: alpha-Synuclein; Animals; Antiparkinson Agents; Basal Ganglia; Cognition Disorders; Disease Models, Animal; Dopamine; Drug Discovery; Endpoint Determination; Humans; Levodopa; Movement; MPTP Poisoning; Neurons; Neuroprotective Agents; Parkinson Disease, Secondary; Primates; Psychoses, Substance-Induced; Sleep Wake Disorders | 2010 |
Catechol-O-methyltransferase inhibitors in preclinical models as adjuncts of L-dopa treatment.
Topics: Animals; Antiparkinson Agents; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Disease Models, Animal; Drug Therapy, Combination; Levodopa; Parkinson Disease, Secondary | 2010 |
Exercise alleviates Parkinsonism: clinical and laboratory evidence.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Exercise; Exercise Therapy; Humans; Levodopa; Neurotoxins; Parkinsonian Disorders; Quality of Life | 2011 |
Role of nitric oxide in motor control: implications for Parkinson's disease pathophysiology and treatment.
Topics: Animals; Brain; Disease Models, Animal; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Humans; Levodopa; Models, Neurological; Motor Activity; Nitric Oxide; Nitric Oxide Synthase; Parkinson Disease; Signal Transduction; Synaptic Transmission | 2011 |
Contribution of pre-synaptic mechanisms to L-DOPA-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Oxidopamine; Parkinson Disease; Positron-Emission Tomography; Presynaptic Terminals; Rats; Serotonergic Neurons; Serotonin | 2011 |
Continuous dopaminergic stimulation: clinical aspects and experimental bases.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Disease Models, Animal; Dopamine; Dopamine Agents; Dopamine Agonists; Dyskinesias; Humans; Levodopa; Neuropeptides; Parkinson Disease; Receptors, Dopamine; Receptors, GABA-A | 2011 |
Neuroprotective role of dopamine agonists: evidence from animal models and clinical studies.
Topics: Animals; Antiparkinson Agents; Clinical Trials as Topic; Disease Models, Animal; Disease Progression; Dopamine Agonists; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease | 2011 |
Modelling of Parkinson's disease in mice.
Topics: Animals; Disease Models, Animal; Levodopa; Mice; Neuroprotective Agents; Parkinson Disease | 2011 |
Animal models of L-DOPA-induced dyskinesia: an update on the current options.
Topics: Animals; Disease Models, Animal; Drug Discovery; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Reproducibility of Results | 2012 |
Adenosine A2A antagonists in Parkinson's disease: what's next?
Topics: Adenosine A2 Receptor Antagonists; Animals; Basal Ganglia; Disease Models, Animal; Humans; Levodopa; Parkinson Disease; Receptor, Adenosine A2A | 2012 |
L-DOPA- and graft-induced dyskinesia following transplantation.
Topics: Animals; Antiparkinson Agents; Brain Tissue Transplantation; Disease Models, Animal; Dyskinesias; Humans; Levodopa; Parkinson Disease | 2012 |
[Subcutaneous apomorphine injection: rescue management of motor fluctuations associated with levodopa-therapy].
Topics: Animals; Antiparkinson Agents; Apomorphine; Circadian Rhythm; Clinical Trials as Topic; Disease Models, Animal; Dopamine Agents; Humans; Injections, Subcutaneous; Levodopa; Parkinson Disease; Receptors, Dopamine; Salvage Therapy; Self Administration | 2013 |
Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists.
Topics: Animals; Antiparkinson Agents; Bromocriptine; Contraindications; Disease Models, Animal; Disease Progression; Dopamine Agonists; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine | 2002 |
New insights in Parkinson's disease therapy: can levodopa-induced dyskinesia ever be manageable.
Topics: Animals; Brain; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Neural Pathways; Parkinson Disease; Receptors, Dopamine | 2003 |
The lesion of the rat substantia nigra pars compacta dopaminergic neurons as a model for Parkinson's disease memory disabilities.
Topics: Animals; Caffeine; Disease Models, Animal; Humans; Levodopa; Memory Disorders; Neurons; Parkinsonian Disorders; Rats; Receptors, Dopamine; Receptors, Purinergic P1; Substantia Nigra | 2002 |
The MPTP-treated primate as a model of motor complications in PD: primate model of motor complications.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine Agonists; Drug Resistance; Dyskinesia, Drug-Induced; Levodopa; Motor Activity; Parkinsonian Disorders; Primates | 2003 |
Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson's disease.
Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Clinical Trials as Topic; Corpus Striatum; Disease Models, Animal; Drug Evaluation, Preclinical; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Globus Pallidus; Humans; Levodopa; Mice; Mice, Knockout; Motor Activity; Neurons; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Primates; Purines; Rats; Receptor, Adenosine A2A; Receptors, Dopamine D2 | 2003 |
Translating A2A antagonist KW6002 from animal models to parkinsonian patients.
Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Clinical Trials as Topic; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Synergism; Humans; Levodopa; Macaca fascicularis; Male; Motor Activity; Neurons; Parkinsonian Disorders; Purines; Rats; Rats, Sprague-Dawley; Receptors, AMPA | 2003 |
Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Catechols; Disease Models, Animal; Dopamine Agonists; Drug Administration Schedule; Drug Evaluation, Preclinical; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Levodopa; Nitriles; Parkinson Disease, Secondary; Primates; Rats | 2004 |
Neuroprotection and dopamine agonists.
Topics: Animals; Cell Death; Clinical Trials as Topic; Disease Models, Animal; Dopamine Agonists; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease | 2004 |
[Pathophysiology and therapy of L-Dopa-induced dyskinesia].
Topics: Animals; Basal Ganglia; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Receptors, Adrenergic; Receptors, Dopamine; Receptors, Glutamate; Receptors, Opioid; Receptors, Purinergic P1 | 2003 |
Recent failures of new potential symptomatic treatments for Parkinson's disease: causes and solutions.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenergic Agents; Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Globus Pallidus; Humans; Levodopa; Movement Disorders; Neurons; Neurosurgical Procedures; Oxidopamine; Parkinson Disease; Treatment Failure | 2004 |
Striatal synaptic plasticity: implications for motor learning and Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Learning; Levodopa; Motor Skills; Neural Pathways; Neuronal Plasticity; Parkinson Disease; Rats; Synapses | 2005 |
New therapies for the treatment of Parkinson's disease: adenosine A2A receptor antagonists.
Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesias; Humans; Levodopa; Parkinson Disease; Primates; Purines; Receptor, Adenosine A2A | 2005 |
Nondopaminergic mechanisms in levodopa-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Biogenic Monoamines; Brain; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Synaptic Transmission | 2005 |
New animal models to study the role of tyrosinase in normal retinal development.
Topics: Albinism; Albinism, Oculocutaneous; Animals; Chromosomes, Artificial, Bacterial; Chromosomes, Artificial, Yeast; Crosses, Genetic; Disease Models, Animal; Exons; Gene Expression Regulation; Levodopa; Melanins; Mice; Mice, Transgenic; Models, Genetic; Monophenol Monooxygenase; Mutation; Phenotype; Retina; Transcriptional Activation; Transgenes | 2006 |
The role of ML-23 and other melatonin analogues in the treatment and management of Parkinson's disease.
Topics: 5-Methoxytryptamine; Animals; Antiparkinson Agents; Disease Models, Animal; Humans; Levodopa; Melatonin; Parkinson Disease | 2005 |
Therapeutic potential of controlled drug delivery systems in neurodegenerative diseases.
Topics: Alzheimer Disease; Animals; Brain; Delayed-Action Preparations; Diffusion; Disease Models, Animal; Drug Carriers; Drug Stability; Humans; Huntington Disease; Levodopa; Microspheres; Nerve Growth Factor; Neurodegenerative Diseases; Neuroprotective Agents; Parkinsonian Disorders; Polymers; Solubility | 2006 |
Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Disease Models, Animal; Dopamine Agents; Drug Administration Schedule; Dyskinesia, Drug-Induced; Humans; Levodopa; Neural Networks, Computer; Parkinson Disease; Receptors, Dopamine | 2006 |
Safinamide: from molecular targets to a new anti-Parkinson drug.
Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Brain Ischemia; Disease Models, Animal; Gerbillinae; Humans; Kainic Acid; Levodopa; Mice; MPTP Poisoning; Neurons; Rats; Veratridine | 2006 |
Pathophysiology of motor complications in Parkinson disease: postsynaptic mechanisms are crucial.
Topics: Animals; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Motor Activity; Parkinson Disease; Synapses | 2007 |
Role of adenosine A2A receptors in parkinsonian motor impairment and l-DOPA-induced motor complications.
Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Basal Ganglia; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Receptor, Adenosine A2A; Receptor, Metabotropic Glutamate 5; Receptors, Dopamine D2; Receptors, Metabotropic Glutamate | 2007 |
Animal models of Parkinson's disease and L-dopa induced dyskinesia: how close are we to the clinic?
Topics: Animals; Animals, Genetically Modified; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Levodopa; MPTP Poisoning; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Reproducibility of Results; Sympatholytics | 2008 |
L-DOPA-induced dyskinesia: cellular mechanisms and approaches to treatment.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinsonian Disorders | 2007 |
Advances in understanding L-DOPA-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Models, Neurological; Neural Pathways; Synaptic Transmission | 2007 |
Animal models of tardive dyskinesia: their use in the search for new treatment methods.
Topics: Age Factors; Amphetamine; Animals; Antipsychotic Agents; Apomorphine; Carbidopa; Corpus Striatum; Disease Models, Animal; Dopamine; Drug Combinations; Drug Interactions; Dyskinesia, Drug-Induced; Guinea Pigs; Haloperidol; Haplorhini; Humans; Levodopa; Lithium; Male; Parasympatholytics; Rats; Receptors, Dopamine; Stereotyped Behavior | 1983 |
Growth hormone secretion in neurological disorders.
Topics: Benserazide; Disease Models, Animal; Dopamine; Growth Hormone; Humans; Huntington Disease; Levodopa; Nervous System Diseases; Parkinson Disease | 1981 |
The role of excitatory amino acids in experimental models of Parkinson's disease.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Amphetamine; Animals; Catalepsy; Disease Models, Animal; Excitatory Amino Acids; Levodopa; N-Methylaspartate; Oxidopamine; Parkinson Disease; Rats | 1994 |
New medical and surgical treatments for Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Brain Tissue Transplantation; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Clozapine; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Electric Stimulation; Excitatory Amino Acid Antagonists; Humans; Levodopa; Parkinson Disease; Stereotaxic Techniques; Substantia Nigra; Thalamic Nuclei | 1994 |
Die Pathoklise [Parkinson's disease].
Topics: Animals; Brain; Cells, Cultured; Disease Models, Animal; Fetus; Humans; Levodopa; Neurons; Parkinson Disease; Rats; Selegiline; Substantia Nigra | 1993 |
Neurobiology of L-DOPAergic systems.
Topics: Afferent Pathways; Animals; Antiparkinson Agents; Brain Stem; Cardiovascular Physiological Phenomena; Central Nervous System; Corpus Striatum; Disease Models, Animal; Humans; Hypothalamus; Levodopa; Models, Neurological; Motor Activity; Neurons; Neurotransmitter Agents; Parkinson Disease; Parkinson Disease, Secondary; Pressoreceptors; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Receptors, Neurotransmitter | 1996 |
Levodopa therapy: consequences of the nonphysiologic replacement of dopamine.
Topics: Animals; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Delayed-Action Preparations; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Humans; Levodopa; Parkinson Disease | 1998 |
Characterization of a rodent model in which to investigate the molecular and cellular mechanisms underlying the pathophysiology of L-dopa-induced dyskinesia.
Topics: Animals; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Levodopa; Rats | 1998 |
[Understanding and treating levodopa-induced dyskinesias].
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 1998 |
[Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (or phenomenon of priming)].
Topics: Animals; Antiparkinson Agents; Biological Transport, Active; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Enkephalins; Haplorhini; Humans; Levodopa; Neural Pathways; Neuronal Plasticity; Neurons, Efferent; Parkinson Disease; Receptors, Dopamine D2; Substance P; Time Factors | 2000 |
Investigating levodopa-induced dyskinesias in the parkinsonian primate.
Topics: Animals; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Levodopa; Parkinson Disease, Secondary; Primates | 2000 |
The AS/AGU rat: a spontaneous model of disruption and degeneration in the nigrostriatal dopaminergic system.
Topics: Animals; Basal Ganglia Diseases; Disease Models, Animal; Dopamine; Genes, Recessive; Levodopa; Rats; Rats, Mutant Strains | 2000 |
Pathophysiology of the basal ganglia in Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Levodopa; Models, Neurological; Neural Pathways; Neurons; Parkinson Disease; Pulse Therapy, Drug; Receptors, Dopamine | 2000 |
Pathophysiology of levodopa-induced dyskinesia: potential for new therapies.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2001 |
Brain nervous mechanisms involved in the so-called extra pyramidal motor and psychomotor disturbances.
Topics: Animals; Athetosis; Basal Ganglia Diseases; Brain; Brain Stem; Cats; Corpus Striatum; Disease Models, Animal; Dopa Decarboxylase; Dopamine; Extrapyramidal Tracts; Globus Pallidus; Haplorhini; Homovanillic Acid; Humans; Levodopa; Monoamine Oxidase; Neural Pathways; Olivary Nucleus; Psychomotor Disorders; Red Nucleus; Tyrosine 3-Monooxygenase | 1975 |
Physiopathology of experimental Parkinsonism in the monkey.
Topics: Animals; Cerebellum; Corpus Striatum; Disease Models, Animal; Dopamine; Haplorhini; Levodopa; Motor Cortex; Movement Disorders; Muscle Rigidity; Neural Pathways; Olivary Nucleus; Parkinson Disease, Secondary; Red Nucleus; Substantia Nigra; Tremor | 1975 |
Prolactin and breast carcinoma.
Topics: Adrenalectomy; Animals; Benz(a)Anthracenes; Breast; Breast Neoplasms; Castration; Depression, Chemical; Disease Models, Animal; Ergot Alkaloids; Estrogens; Female; Humans; Hypophysectomy; Levodopa; Mammary Neoplasms, Experimental; Mice; Prolactin; Rats; Species Specificity | 1975 |
Drug-induced dyskinesia in monkeys.
Topics: Amphetamine; Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Azides; Carbachol; Caudate Nucleus; Chlorpromazine; Disease Models, Animal; Dronabinol; Hydroxydopamines; Levodopa; Movement Disorders; Phenothiazines; Primates; Stereotaxic Techniques; Substantia Nigra; Tegmentum Mesencephali | 1975 |
Levodopa-induced dyskinesia: facts and fancy. What does the MPTP monkey model tell us?
Topics: Animals; Disease Models, Animal; Dyskinesia, Drug-Induced; Haplorhini; Humans; Levodopa; MPTP Poisoning | 1992 |
The dystonias.
Topics: Animals; Basal Ganglia; Botulinum Toxins; Cebus; Chromosomes, Human, Pair 9; Disease Models, Animal; Dystonia; Dystonia Musculorum Deformans; Humans; Injections, Intramuscular; Levodopa; Magnetic Resonance Imaging; Muscle Contraction; Muscles; Neurologic Examination; Tomography, Emission-Computed; Tomography, X-Ray Computed | 1992 |
[Physiopathology of dystonia].
Topics: Animals; Basal Ganglia; Brain Stem; Central Nervous System Diseases; Disease Models, Animal; Dopamine; Dystonia; Humans; Levodopa; Metabolism, Inborn Errors; Models, Neurological; Norepinephrine; Rats; Synaptic Transmission | 1991 |
[Model of choreic movement in monkey--contribution for understanding the mechanism of chorea in Huntington's disease].
Topics: Animals; Disease Models, Animal; Dopamine; Haplorhini; Huntington Disease; Kainic Acid; Levodopa | 1990 |
Acute dystonia induced by neuroleptic drugs.
Topics: Acute Disease; alpha-Methyltyrosine; Animals; Antipsychotic Agents; Brain; Chlorpromazine; Disease Models, Animal; Drug Synergism; Dystonia; Fluphenazine; Haloperidol; Histamine H1 Antagonists; Levodopa; Mastication; Methyltyrosines; Movement Disorders; Parasympatholytics; Physostigmine; Primates; Rats | 1986 |
The pharmacology of myoclonus.
Topics: 5-Hydroxytryptophan; Adrenocorticotropic Hormone; Animals; Anticonvulsants; Benzodiazepines; Brain; Disease Models, Animal; gamma-Aminobutyric Acid; Guinea Pigs; Humans; Levodopa; Muscimol; Myoclonus; Narcotics; Papio; Receptors, GABA-A; Receptors, Opioid; Receptors, Serotonin; Serotonin; Thyrotropin-Releasing Hormone | 1985 |
The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Benzazepines; Callithrix; Corpus Striatum; Disease Models, Animal; Dopamine; Ergolines; Humans; Levodopa; Macaca mulatta; Neural Pathways; Pargyline; Parkinson Disease; Parkinson Disease, Secondary; Pyridines; Quinpirole; Rats; Saimiri; Selegiline; Species Specificity; Substantia Nigra | 1986 |
Motor activity and the brain serotonin system.
Topics: Animals; Brain; Cats; Disease Models, Animal; Electroencephalography; Humans; Hypoxia; Levodopa; Monoamine Oxidase Inhibitors; Motor Activity; Myoclonus; Rats; Serotonin | 1986 |
Transplantation of monoamine-producing cell systems in oculo and intracranially: experiments in search of a treatment for Parkinson's Disease.
Topics: Adrenal Medulla; Amines; Animals; Brain; Chromaffin System; Denervation; Disease Models, Animal; Dopamine; Electrophysiology; Epinephrine; Eye; Female; Graft Survival; Hippocampus; Humans; Levodopa; Locus Coeruleus; Male; Middle Aged; Nerve Fibers; Nerve Growth Factors; Nerve Tissue; Neurons; Norepinephrine; Parkinson Disease; Parkinson Disease, Secondary; Rats; Receptors, Dopamine; Substantia Nigra | 1985 |
Nervous mechanisms involved in experimentally induced extrapyramidal disturbances.
Topics: Animals; Basal Ganglia Diseases; Benztropine; Brain; Cats; Caudate Nucleus; Cerebellar Nuclei; Chlorpromazine; Corpus Striatum; Disease Models, Animal; Dopamine; Haloperidol; Haplorhini; Humans; Levodopa; Movement Disorders; Olivary Nucleus; Parkinson Disease; Putamen; Rats; Red Nucleus; Substantia Nigra; Thalamic Nuclei; Tremor | 1974 |
Anorexia nervosa and the regulation of intake: a review.
Topics: Adolescent; Adult; Amygdala; Androgens; Animals; Anorexia Nervosa; Appetite Regulation; Brain; Child; Chlorpromazine; Disease Models, Animal; Dogs; Eating; Electroconvulsive Therapy; Epinephrine; Estrogens; Female; Gonadotropins, Pituitary; Hippocampus; Humans; Levodopa; Male; Norepinephrine; Rats; Septum Pellucidum | 1974 |
3 trial(s) available for levodopa and Disease Models, Animal
| Article | Year |
|---|---|
A randomized controlled trial of levodopa in patients with Angelman syndrome.
Topics: Angelman Syndrome; Animals; Biomarkers; Calcium; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Disease Models, Animal; Humans; Levodopa; Long-Term Potentiation; Mice; Neuropsychological Tests; Treatment Outcome | 2018 |
The ability of grafted human sympathetic neurons to synthesize and store dopamine: a potential mechanism for the clinical effect of sympathetic neuron autografts in patients with Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Aromatic-L-Amino-Acid Decarboxylases; Brain Tissue Transplantation; Corpus Striatum; Denervation; Disease Models, Animal; Dopamine; Female; Ganglia, Sympathetic; Graft Survival; Humans; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Middle Aged; Neurons; Neuropeptides; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Reserpine; Transplantation, Heterologous; Tyrosine 3-Monooxygenase; Up-Regulation; Vesicular Biogenic Amine Transport Proteins; Vesicular Monoamine Transport Proteins | 2004 |
Die Pathoklise [Parkinson's disease].
Topics: Animals; Brain; Cells, Cultured; Disease Models, Animal; Fetus; Humans; Levodopa; Neurons; Parkinson Disease; Rats; Selegiline; Substantia Nigra | 1993 |
831 other study(ies) available for levodopa and Disease Models, Animal
| Article | Year |
|---|---|
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
Topics: Animals; Disease Models, Animal; Dogs; Humans; Jejunal Diseases; Kidney Diseases; Models, Biological; Permeability; Porosity; Regression Analysis | 2010 |
In vivo characterization of a dual adenosine A2A/A1 receptor antagonist in animal models of Parkinson's disease.
Topics: Adenosine A1 Receptor Antagonists; Adenosine A2 Receptor Antagonists; Administration, Oral; Animals; Antiparkinson Agents; Callithrix; Disease Models, Animal; Female; Indenes; Macaca fascicularis; Male; Mice; Mice, Inbred BALB C; Parkinson Disease; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A | 2010 |
Highly potent activity of (1R,2R,6S)-3-methyl-6-(prop-1-en-2-yl)cyclohex-3-ene-1,2-diol in animal models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Cyclohexanols; Disease Models, Animal; Dopamine Antagonists; Drug Synergism; Haloperidol; Levodopa; Mice; Mice, Inbred C57BL; Molecular Conformation; Motor Activity; Neurotoxins; Parkinson Disease; Parkinsonian Disorders; Rats; Rats, Wistar; Receptors, Neurotransmitter; Stereoisomerism | 2011 |
Imidazopyridazinones as novel PDE7 inhibitors: SAR and in vivo studies in Parkinson's disease model.
Topics: Animals; Cyclic Nucleotide Phosphodiesterases, Type 7; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Stability; Enzyme Inhibitors; Humans; Imidazoles; Isoenzymes; Male; Mice; Mice, Inbred C57BL; Microsomes, Liver; Molecular Structure; Parkinson Disease; Pyridones; Recombinant Proteins; Structure-Activity Relationship | 2012 |
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, Spinal; Humans; Mice, Inbred C57BL; Mice, Knockout; Neurons; Pruritus; Receptors, Atrial Natriuretic Factor; Reproducibility of Results; Signal Transduction; Small Molecule Libraries | 2019 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Drug Evaluation, Preclinical; High-Throughput Screening Assays; Immunocompetence; Inhibitory Concentration 50; Methacycline; Mice, Inbred C57BL; Protease Inhibitors; Quantitative Structure-Activity Relationship; Small Molecule Libraries; Vero Cells; Zika Virus; Zika Virus Infection | 2020 |
In vitro and in vivo neuroprotective effect of novel mPGES-1 inhibitor in animal model of Parkinson's disease.
Topics: Animals; Disease Models, Animal; Dopaminergic Neurons; Mice; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Prostaglandins E; Rats | 2022 |
Antiparkinsonian-like effects of CPL500036, a novel selective inhibitor of phosphodiesterase 10A, in the unilateral rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; GABAergic Neurons; Humans; Levodopa; Male; Oxidopamine; Parkinson Disease, Secondary; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Rats; Severity of Illness Index | 2021 |
Evaluation of microglia in a rodent model of Parkinson's disease primed with L-DOPA after sub-anesthetic ketamine treatment.
Topics: Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Humans; Ketamine; Levodopa; Male; Microglia; Parkinson Disease; Phagocytosis; Rats; Receptors, N-Methyl-D-Aspartate; Substantia Nigra | 2021 |
Dopaminergic co-transmission with sonic hedgehog inhibits abnormal involuntary movements in models of Parkinson's disease and L-Dopa induced dyskinesia.
Topics: Animals; Disease Models, Animal; Dopamine; Dyskinesias; Female; Hedgehog Proteins; Levodopa; Male; Mice; Parkinson Disease | 2021 |
Plasticity-Enhancing Effects of Levodopa Treatment after Stroke.
Topics: Animals; Brain Ischemia; Disease Models, Animal; Dopamine Agents; Dopaminergic Neurons; Down-Regulation; GAP-43 Protein; Infarction, Middle Cerebral Artery; Levodopa; Male; Mice; Neuronal Plasticity; Nogo Proteins; Nogo Receptors; Oligodendrocyte Transcription Factor 2; Oligodendroglia; Rats, Wistar; Stroke; Thrombosis | 2021 |
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease.
Topics: Animals; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Dyskinesias; Levodopa; Oxidopamine; Parkinson Disease; Rats | 2021 |
Disruption of mitochondrial complex I induces progressive parkinsonism.
Topics: Animals; Axons; Cell Death; Dendrites; Disease Models, Animal; Disease Progression; Dopamine; Dopaminergic Neurons; Electron Transport Complex I; Female; Levodopa; Male; Mice; Motor Skills; NADH Dehydrogenase; Parkinsonian Disorders; Phenotype; Substantia Nigra | 2021 |
Melanopsin modulates refractive development and myopia.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Axial Length, Eye; Cornea; Disease Models, Animal; Dopamine; Dopamine Agents; Female; Levodopa; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Myopia; Refraction, Ocular; Retina; Retinal Ganglion Cells; Rod Opsins; Visual Pathways | 2022 |
Autoradiographic labelling of 5-HT
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Ondansetron; Oxidopamine; Rats; Rats, Sprague-Dawley; Serotonin; Subthalamic Nucleus | 2022 |
Intraperitoneal Administration of Forskolin Reverses Motor Symptoms and Loss of Midbrain Dopamine Neurons in PINK1 Knockout Rats.
Topics: Animals; Colforsin; Disease Models, Animal; Dopaminergic Neurons; Humans; Levodopa; Mesencephalon; Neurodegenerative Diseases; Parkinson Disease; Protein Kinases; Rats; Substantia Nigra | 2022 |
Administration of mucuna beans (Mucuna pruriences (L.) DC. var. utilis) improves cognition and neuropathology of 3 × Tg-AD mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain Chemistry; Cognition; Diet; Disease Models, Animal; Female; Levodopa; Mice, Transgenic; Mucuna; tau Proteins | 2022 |
Cabergoline, a long-acting dopamine agonist, attenuates L-dopa-induced dyskinesia without L-dopa sparing in a rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Cabergoline; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; RNA, Messenger | 2022 |
Striatal Indirect Pathway Dysfunction Underlies Motor Deficits in a Mouse Model of Paroxysmal Dyskinesia.
Topics: Animals; Chorea; Corpus Striatum; Disease Models, Animal; Dyskinesias; Female; Levodopa; Male; Mice; Neurons | 2022 |
Improvement of non-motor and motor behavioral alterations associated with Parkinson-like disease in Drosophila melanogaster: Comparative effects of treatments with hesperidin and L-dopa.
Topics: Animals; Disease Models, Animal; Dopamine; Drosophila melanogaster; Hesperidin; Levodopa; Parkinson Disease | 2022 |
Methamphetamine Enhances Cryptococcus neoformans Melanization, Antifungal Resistance, and Pathogenesis in a Murine Model of Drug Administration and Systemic Infection.
Topics: Animals; Antifungal Agents; Cryptococcosis; Cryptococcus neoformans; Disease Models, Animal; HIV Infections; Humans; Levodopa; Mammals; Melanins; Methamphetamine; Mice; Saccharomyces cerevisiae; Sepsis | 2022 |
Striatal Neuronal Ensembles Reveal Differential Actions of Amantadine and Clozapine to Ameliorate Mice L-DOPA-Induced Dyskinesia.
Topics: Amantadine; Animals; Antiparkinson Agents; Calcium; Clozapine; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Mice; Neurons; Oxidopamine | 2022 |
The effect of Madopar on absence‑like seizures in WAG/Rij rats.
Topics: Animals; Benserazide; Disease Models, Animal; Drug Combinations; Electroencephalography; Epilepsy, Absence; Levodopa; Male; Rats; Rats, Wistar; Seizures | 2022 |
Phosphodiesterase 9 inhibition prolongs the antiparkinsonian action of l-DOPA in parkinsonian non-human primates.
Topics: Animals; Antiparkinson Agents; Disabled Persons; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Motor Disorders; Parkinson Disease; Phosphoric Diester Hydrolases; Primates | 2022 |
Human Embryonic Stem Cell-Derived Dopaminergic Grafts Alleviate L-DOPA Induced Dyskinesia.
Topics: Amphetamines; Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Human Embryonic Stem Cells; Humans; Levodopa; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley | 2022 |
The multimodal serotonin compound Vilazodone alone, but not combined with the glutamate antagonist Amantadine, reduces l-DOPA-induced dyskinesia in hemiparkinsonian rats.
Topics: Amantadine; Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Humans; Levodopa; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Serotonin; Vilazodone Hydrochloride | 2022 |
Characterization of retinal function and structure in the MPTP murine model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Levodopa; Mice; Mice, Inbred C57BL; MPTP Poisoning; Parkinson Disease; Retina; Tyrosine 3-Monooxygenase | 2022 |
D1/D5 Inverse Agonists Restore Striatal Cholinergic Interneuron Physiology in Dyskinetic Mice.
Topics: Animals; Antiparkinson Agents; Cholinergic Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Interneurons; Levodopa; Mice; Oxidopamine; Parkinson Disease | 2022 |
Tetrabenazine Mitigates Aberrant Release and Clearance of Dopamine in the Nigrostriatal System, and Alleviates L-DOPA-Induced Dyskinesia in a Mouse Model of Parkinson's Disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Mice; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Serotonin; Tetrabenazine | 2022 |
The
Topics: Albinism; Albinism, Oculocutaneous; Animals; Disease Models, Animal; Humans; Intramolecular Oxidoreductases; Levodopa; Melanosomes; Mice; Monophenol Monooxygenase | 2022 |
A positive allosteric modulator of mGlu4 receptors restores striatal plasticity in an animal model of l-Dopa-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Rats | 2022 |
Curcumin-driven reprogramming of the gut microbiota and metabolome ameliorates motor deficits and neuroinflammation in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Creatine; Curcumin; Disease Models, Animal; Gastrointestinal Microbiome; Levodopa; Metabolome; Methionine; Mice; Mice, Inbred C57BL; Neuroinflammatory Diseases; Neuroprotective Agents; Parkinson Disease; RNA, Ribosomal, 16S; Sarcosine | 2022 |
Lycium barbarum polysaccharide improves dopamine metabolism and symptoms in an MPTP-induced model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antioxidants; Disease Models, Animal; Dopamine; Drugs, Chinese Herbal; Levodopa; Mice; Mice, Inbred C57BL; Parkinson Disease, Secondary; Tyrosine 3-Monooxygenase | 2022 |
Selective activation of striatal indirect pathway suppresses levodopa induced-dyskinesias.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesias; Levodopa; Mice; Oxidopamine; Parkinson Disease | 2023 |
Characterizing the relationship between L-DOPA-induced-dyskinesia and psychosis-like behaviors in a bilateral rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Parkinson Disease; Psychotic Disorders; Quality of Life; Rats; Rats, Sprague-Dawley | 2023 |
Dopamine Agonist Cotreatment Alters Neuroplasticity and Pharmacology of Levodopa-Induced Dyskinesia.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine Agonists; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Rats; Rats, Sprague-Dawley | 2023 |
ONO-2506 Can Delay Levodopa-induced Dyskinesia in the Early Stage.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Parkinson Disease; Rats | 2023 |
Pregnenolone for the treatment of L-DOPA-induced dyskinesia in Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dutasteride; Dyskinesia, Drug-Induced; Levodopa; Male; Neurosteroids; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley | 2023 |
PT320, a Sustained-Release GLP-1 Receptor Agonist, Ameliorates L-DOPA-Induced Dyskinesia in a Mouse Model of Parkinson's Disease.
Topics: Animals; Antiparkinson Agents; Delayed-Action Preparations; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Glucagon-Like Peptide-1 Receptor; Levodopa; Mice; Oxidopamine; Parkinson Disease | 2023 |
Biochemical study of the effect of mesenchymal stem cells-derived exosome versus L-Dopa in experimentally induced Parkinson's disease in rats.
Topics: alpha-Synuclein; Animals; Disease Models, Animal; Exosomes; Humans; Levodopa; Male; Mesenchymal Stem Cells; MicroRNAs; Neurodegenerative Diseases; Parkinson Disease; Rats; RNA, Circular; Ubiquitin-Protein Ligases | 2023 |
Altered amantadine effects after repetitive treatment for l-dopa-induced involuntary movements in a rat model of Parkinson's disease.
Topics: Amantadine; Animals; Antiparkinson Agents; Benserazide; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley | 2023 |
Amphiregulin blockade decreases the levodopa-induced dyskinesia in a 6-hydroxydopamine Parkinson's disease mouse model.
Topics: Amphiregulin; Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Mice; Oxidopamine; Parkinson Disease | 2023 |
Eltoprazine modulated gamma oscillations on ameliorating L-dopa-induced dyskinesia in rats.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Gamma Rhythm; Levodopa; Motor Cortex; Piperazines; Rats; Serotonin Receptor Agonists | 2023 |
Brainstem Modulates Parkinsonism-Induced Orofacial Sensorimotor Dysfunctions.
Topics: Animals; Antiparkinson Agents; Brain Stem; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Rats | 2023 |
Antagonism of kappa opioid receptors accelerates the development of L-DOPA-induced dyskinesia in a preclinical model of moderate dopamine depletion.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptors, Opioid, kappa | 2023 |
Human equivalent doses of L-DOPA rescues retinal morphology and visual function in a murine model of albinism.
Topics: Albinism; Animals; Carbidopa; Disease Models, Animal; Humans; Levodopa; Mice; Mice, Inbred C57BL | 2023 |
Circuit-specific gene therapy reverses core symptoms in a primate Parkinson's disease model.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Genetic Therapy; Humans; Levodopa; Mice; Neurons; Parkinson Disease; Primates; Receptors, Dopamine D1 | 2023 |
Imaging SERT Availability in a Rat Model of L-DOPA-Induced Dyskinesia.
Topics: Animals; Brain; Carbon Radioisotopes; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Levodopa; Male; Motor Activity; Positron-Emission Tomography; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Serotonin Plasma Membrane Transport Proteins | 2020 |
Role of striatal ΔFosB in l-Dopa-induced dyskinesias of parkinsonian nonhuman primates.
Topics: Animals; Animals, Genetically Modified; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Macaca fascicularis; Male; Neostriatum; Parkinson Disease; Protein Isoforms; Proto-Oncogene Proteins c-fos; Up-Regulation | 2019 |
Bone loss caused by dopaminergic degeneration and levodopa treatment in Parkinson's disease model mice.
Topics: Animals; Antiparkinson Agents; Bone Diseases, Metabolic; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Female; Levodopa; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Osteoporosis; Parkinson Disease | 2019 |
Coumarin analogue 3-methyl-7H-furo[3,2-g] chromen-7-one as a possible antiparkinsonian agent
Topics: Animals; Antiparkinson Agents; Carbidopa; Catalepsy; Coumarins; Disease Models, Animal; Drug Combinations; Drug Evaluation, Preclinical; Haloperidol; Levodopa; Locomotion; Male; Mice; Mice, Inbred ICR; Monoamine Oxidase Inhibitors; Parkinson Disease, Secondary; Reserpine | 2019 |
Targeting the cannabinoid receptor CB2 in a mouse model of l-dopa induced dyskinesia.
Topics: Amantadine; Animals; Antiparkinson Agents; Camphanes; Cannabinoid Receptor Agonists; Cannabinoids; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Levodopa; Male; Mice; Mice, Inbred C57BL; Parkinsonian Disorders; Pyrazoles; Receptor, Cannabinoid, CB2 | 2020 |
Tapentadol Prevents Motor Impairments in a Mouse Model of Dyskinesia.
Topics: Adrenergic Uptake Inhibitors; Animals; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Male; Mice; Motor Disorders; Oxidopamine; Parkinsonian Disorders; Tapentadol | 2020 |
The parthenolide derivative ACT001 synergizes with low doses of L-DOPA to improve MPTP-induced Parkinson's disease in mice.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antiparkinson Agents; Apoptosis; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Female; Inflammation; Levodopa; Male; Mice; Mice, Inbred BALB C; Nerve Degeneration; Parkinson Disease; Parkinsonian Disorders; Sesquiterpenes | 2020 |
Identification of antiparkinsonian drugs in the 6-hydroxydopamine zebrafish model.
Topics: Amantadine; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dopaminergic Neurons; Drug Repositioning; Indans; Isradipine; Larva; Levodopa; Locomotion; Motor Activity; Oxidopamine; Parkinson Disease; Phenotype; Zebrafish | 2020 |
Effectiveness and safety of topical levodopa in a chick model of myopia.
Topics: Administration, Topical; Animals; Atropine; Chickens; Disease Models, Animal; Dopamine; Electroretinography; Eye; Humans; Intraocular Pressure; Levodopa; Mice; Myopia; Retina; Sensory Deprivation; Vision, Ocular | 2019 |
Neuroinflammation: Fanning the fire of l-dopa-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Cytokines; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Inflammation; Levodopa; Nervous System Diseases; Tumor Necrosis Factor-alpha | 2019 |
Integrated transcriptome expression profiling reveals a novel lncRNA associated with L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Biomarkers; Computational Biology; Disease Models, Animal; Dyskinesias; Gene Expression Profiling; Gene Regulatory Networks; Immunohistochemistry; Levodopa; Models, Biological; Parkinson Disease; Rats; RNA, Long Noncoding; Transcriptome | 2020 |
NYX-458 Improves Cognitive Performance in a Primate Parkinson's Disease Model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Cognition; Disease Models, Animal; Levodopa; Parkinson Disease; Primates | 2020 |
Preclinical Comparison of Stem Cells Secretome and Levodopa Application in a 6-Hydroxydopamine Rat Model of Parkinson's Disease.
Topics: Animals; Disease Models, Animal; Humans; Levodopa; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Motor Activity; Neostriatum; Oxidopamine; Parkinson Disease; Phenotype; Rats, Sprague-Dawley; Reproducibility of Results; Substantia Nigra | 2020 |
Increased endogenous dopamine prevents myopia in mice.
Topics: Animals; Biomarkers; Disease Models, Animal; Dopamine; Dopamine Agents; Female; Levodopa; Male; Mice; Mice, Inbred C57BL; Myopia; Refraction, Ocular; Retina; Tomography, Optical Coherence | 2020 |
The Dopamine D5 receptor contributes to activation of cholinergic interneurons during L-DOPA induced dyskinesia.
Topics: Animals; Cholinergic Neurons; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Humans; Interneurons; Levodopa; MAP Kinase Signaling System; Mice; Mice, Knockout; Oxidopamine; Parkinson Disease; Receptors, Dopamine D5 | 2020 |
5-HT
Topics: Analgesics; Animals; Behavior, Animal; Brain; Colon; Disease Models, Animal; Humans; Levodopa; Nociception; Nociceptive Pain; Pain Threshold; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT2A; Receptors, Cannabinoid; Serotonin 5-HT2 Receptor Agonists | 2020 |
Novel fatty acid-binding protein 3 ligand inhibits dopaminergic neuronal death and improves motor and cognitive impairments in Parkinson's disease model mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Antiparkinson Agents; Blood-Brain Barrier; Cell Death; Cognitive Dysfunction; Disease Models, Animal; Dopaminergic Neurons; Fatty Acid Binding Protein 3; Levodopa; Ligands; Male; Mice; Mice, Inbred C57BL; Motor Activity; Neuroprotective Agents; Parkinson Disease; Protein Aggregation, Pathological | 2020 |
Highly-selective µ-opioid receptor antagonism does not block L-DOPA-induced dyskinesia in a rodent model.
Topics: Animals; Disease Models, Animal; Dyskinesia, Drug-Induced; Glycopeptides; Levodopa; Male; Morphine; Narcotic Antagonists; Nociception; Rats, Sprague-Dawley; Receptors, Opioid, mu | 2020 |
Small dose of L-dopa/Benserazide hydrochloride improved sepsis-induced neuroinflammation and long-term cognitive dysfunction in sepsis mice.
Topics: Animals; Benserazide; Brain; Cognitive Dysfunction; Disease Models, Animal; Drug Combinations; Hippocampus; Levodopa; Male; Mice; Mice, Inbred C57BL; Neuroimmunomodulation; Receptors, Dopamine D1; Receptors, Dopamine D2; Sepsis; Sepsis-Associated Encephalopathy | 2020 |
Intraventricular dopamine infusion alleviates motor symptoms in a primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Dopamine Agonists; Dyskinesia, Drug-Induced; Infusions, Intraventricular; Levodopa; Macaca; Male; Motor Activity; Parkinson Disease; Parkinsonian Disorders; Pilot Projects | 2020 |
Genetic lack of histamine upregulates dopamine neurotransmission and alters rotational behavior but not levodopa-induced dyskinesia in a mouse model of Parkinson's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Levodopa; Mice; Oxidopamine; Parkinson Disease; Synaptic Transmission; Up-Regulation | 2020 |
Antiparkinsonian Effects of a Metabotropic Glutamate Receptor 4 Agonist in MPTP-Treated Marmosets.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Disabled Persons; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Motor Activity; Motor Disorders; Parkinson Disease; Receptors, Metabotropic Glutamate | 2020 |
Self-assembled polydopamine nanoparticles improve treatment in Parkinson's disease model mice and suppress dopamine-induced dyskinesia.
Topics: Animals; Cattle; Cell Line; Disease Models, Animal; Dopamine; Dyskinesias; Indoles; Levodopa; Male; Mice, Inbred C57BL; Mice, Inbred ICR; Nanoparticles; Parkinson Disease; Polymers | 2020 |
Eugenol and its association with levodopa in 6-hydroxydopamine-induced hemiparkinsonian rats: Behavioural and neurochemical alterations.
Topics: Animals; Behavior, Animal; Body Weight; Brain; Disease Models, Animal; Eugenol; Glutathione; Levodopa; Lipid Peroxidation; Male; Motor Activity; Neuroprotective Agents; Nitrites; Oxidative Stress; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar | 2020 |
Synergistic action of propolis with levodopa in the management of Parkinsonism in Drosophila melanogaster.
Topics: Animals; Antioxidants; Disease Models, Animal; Drosophila melanogaster; Drosophila Proteins; Drug Synergism; Drug Therapy, Combination; Ethanol; Levodopa; Longevity; Motor Activity; Oxidative Stress; Parkinsonian Disorders; Plant Extracts; Propolis; Protein Serine-Threonine Kinases | 2020 |
Deep brain stimulation-guided optogenetic rescue of parkinsonian symptoms.
Topics: Algorithms; Animals; Antiparkinson Agents; Deep Brain Stimulation; Disease Models, Animal; Electrophysiological Phenomena; Female; Humans; Levodopa; Male; Mice, Inbred C57BL; Mice, Transgenic; Motor Cortex; Optogenetics; Oxidopamine; Parkinsonian Disorders; Pyramidal Cells; Somatostatin; Subthalamic Nucleus | 2020 |
Arachidonyl-2'-chloroethylamide (ACEA), a synthetic agonist of cannabinoid receptor, increases CB
Topics: Animals; Arachidonic Acids; Cannabinoid Receptor Agonists; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Gene Expression; Levodopa; Male; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; RNA, Messenger | 2020 |
RasGRP1 is a causal factor in the development of l-DOPA-induced dyskinesia in Parkinson's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; DNA-Binding Proteins; Dyskinesia, Drug-Induced; Guanine Nucleotide Exchange Factors; Humans; Levodopa; Mammals; Parkinson Disease; TOR Serine-Threonine Kinases | 2020 |
Hyperpolarization of the subthalamic nucleus alleviates hyperkinetic movement disorders.
Topics: Animals; Cell Polarity; Deep Brain Stimulation; Disease Models, Animal; Humans; Hyperkinesis; Levodopa; Male; Nitro Compounds; Propionates; Rats; Subthalamic Nucleus; Treatment Outcome | 2020 |
Effects of Combined Bushen Zhichan Recipe and Levodopa in a Rodent Model of Parkinson Disease: Potential Mechanisms.
Topics: Animals; Behavior, Animal; Cistanche; Cornus; Corpus Striatum; Dioscorea; Disease Models, Animal; Dopaminergic Neurons; Drugs, Chinese Herbal; Excitatory Amino Acid Transporter 1; Excitatory Amino Acid Transporter 2; Fallopia multiflora; Forelimb; Levodopa; Medial Forebrain Bundle; Mesencephalon; Open Field Test; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Rats; Rehmannia | 2020 |
Monoamine oxidase A inhibition as monotherapy reverses parkinsonism in the MPTP-lesioned marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Basal Ganglia; Behavior, Animal; Callithrix; Disease Models, Animal; Female; Levodopa; Male; Moclobemide; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Motor Activity; Parkinsonian Disorders | 2020 |
Monoamine oxidase A inhibition with moclobemide enhances the anti-parkinsonian effect of L-DOPA in the MPTP-lesioned marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Basal Ganglia; Behavior, Animal; Callithrix; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Moclobemide; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Motor Activity; Parkinsonian Disorders; Psychoses, Substance-Induced | 2020 |
Development of a novel gripping test for the evaluation of the finger fine motor ability in MPTP-treated monkeys.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Deep Brain Stimulation; Disease Models, Animal; Fingers; Levodopa; Macaca fascicularis; Male; Motor Activity; Motor Skills; MPTP Poisoning; Neuropsychological Tests; Parkinson Disease; Reproducibility of Results; Subthalamic Nucleus | 2020 |
Lack of correlation between dyskinesia and pallidal serotonin transporter expression-induced by L-Dopa and Pramipexole in hemiparkinsonian rats.
Topics: Animals; Disease Models, Animal; Dopamine Agonists; Dyskinesia, Drug-Induced; Globus Pallidus; Levodopa; Male; Oxidopamine; Parkinson Disease, Secondary; Pramipexole; Rats; Rats, Sprague-Dawley; Serotonin; Serotonin Plasma Membrane Transport Proteins; Signal Transduction | 2020 |
Globus pallidus, but not entopeduncular nucleus, 6-OHDA-induced lesion attenuates L-Dopa-induced dyskinesia in the rat model of Parkinson's disease.
Topics: Animals; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Entopeduncular Nucleus; Globus Pallidus; Levodopa; Male; Medial Forebrain Bundle; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Serotonin; Serotonin Plasma Membrane Transport Proteins; Signal Transduction | 2020 |
Levodopa inhibits the development of lens-induced myopia in chicks.
Topics: Animals; Benzazepines; Chickens; Disease Models, Animal; Dose-Response Relationship, Drug; Intravitreal Injections; Lenses; Levodopa; Male; Myopia; Ophthalmic Solutions; Receptors, Dopamine D2; Spiperone | 2020 |
The selective 5-HT
Topics: Amantadine; Animals; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Parkinsonian Disorders; Piperidines; Pyridines; Serotonin 5-HT1 Receptor Agonists | 2020 |
Rho kinase inhibitor fasudil reduces l-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Parkinson Disease; Rats; rho-Associated Kinases | 2020 |
The Multimodal Serotonergic Agent Vilazodone Inhibits L-DOPA-Induced Gene Regulation in Striatal Projection Neurons and Associated Dyskinesia in an Animal Model of Parkinson's Disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesias; Gene Expression Regulation; Levodopa; Male; Neurons; Parkinson Disease; Rats; Rats, Sprague-Dawley; Serotonin; Vilazodone Hydrochloride | 2020 |
The Vasomotor Response to Dopamine Is Altered in the Rat Model of l-dopa-Induced Dyskinesia.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Oxidopamine; Parkinson Disease; Rats | 2021 |
Opicapone enhances the reversal of MPTP-induced Parkinson-like syndrome by levodopa in cynomolgus monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Catechol O-Methyltransferase Inhibitors; Disease Models, Animal; Drug Therapy, Combination; Erythrocytes; Female; Levodopa; Locomotion; Macaca fascicularis; Oxadiazoles; Parkinsonian Disorders; Time Factors | 2021 |
Increased emissions of 50-kHz ultrasonic vocalizations in hemiparkinsonian rats repeatedly treated with dopaminomimetic drugs: A potential preclinical model for studying the affective properties of dopamine replacement therapy in Parkinson's disease.
Topics: Affect; Animals; Apomorphine; Desipramine; Disease Models, Animal; Dopamine Agents; Levodopa; Male; Parkinsonian Disorders; Pramipexole; Rats; Rats, Sprague-Dawley; Ultrasonic Waves; Vocalization, Animal | 2021 |
Levodopa-Induced Dyskinesia Are Mediated by Cortical Gamma Oscillations in Experimental Parkinsonism.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Rats | 2021 |
D
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Brain; Bromocriptine; Chlorocebus aethiops; Disease Models, Animal; Dopamine Agonists; Levodopa; Male; Motor Activity; Parkinsonian Disorders; Phenanthridines; Receptors, Dopamine D1; Receptors, Dopamine D2 | 2021 |
Effects of pedunculopontine nucleus cholinergic lesion on gait and dyskinesia in hemiparkinsonian rats.
Topics: Animals; Cholinergic Agents; Disease Models, Animal; Dyskinesias; Gait; Gait Disorders, Neurologic; Levodopa; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley | 2021 |
Involvement of Autophagy in Levodopa-Induced Dyskinesia.
Topics: Animals; Antiparkinson Agents; Autophagy; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Levodopa; Mice; Oxidopamine; Parkinsonian Disorders | 2021 |
Mass spectrometry imaging identifies abnormally elevated brain l-DOPA levels and extrastriatal monoaminergic dysregulation in l-DOPA-induced dyskinesia.
Topics: Animals; Brain; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Mass Spectrometry | 2021 |
Exercise decreases aberrant corticostriatal plasticity in an animal model of l-DOPA-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Benserazide; Cerebral Cortex; Corpus Striatum; Dihydroxyphenylalanine; Disease Models, Animal; Dyskinesia, Drug-Induced; Exercise Therapy; Levodopa; Long-Term Potentiation; Long-Term Synaptic Depression; Male; Mice, Inbred C57BL; Motor Activity; Neuronal Plasticity; Parkinsonian Disorders; Running; Time Factors | 2021 |
Abnormal Cortico-Basal Ganglia Neurotransmission in a Mouse Model of l-DOPA-Induced Dyskinesia.
Topics: Animals; Basal Ganglia; Cerebral Cortex; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Male; Mice; Mice, Inbred ICR; Motor Activity; Synaptic Transmission | 2021 |
Levodopa affects spike and local field synchronisation in the pedunculopontine nucleus of a rat model of Parkinson's disease.
Topics: Action Potentials; Animals; Disease Models, Animal; Dopaminergic Neurons; Levodopa; Locomotion; Male; Oxidopamine; Parkinsonian Disorders; Pedunculopontine Tegmental Nucleus; Rats; Rats, Wistar | 2021 |
Striatal ΔFosB gene suppression inhibits the development of abnormal involuntary movements induced by L-Dopa in rats.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Levodopa; Oxidopamine; Rats | 2021 |
Doxycycline and its derivative, COL-3, decrease dyskinesia induced by l-DOPA in hemiparkinsonian rats.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Doxycycline; Dyskinesia, Drug-Induced; Levodopa; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 3; Matrix Metalloproteinase 9; Oxidopamine; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reactive Oxygen Species; Tetracyclines | 2021 |
A novel phosphodiesterase 1 inhibitor reverses L-dopa-induced dyskinesia, but not motivation deficits, in monkeys.
Topics: Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine Antagonists; Dyskinesia, Drug-Induced; Levodopa; Macaca mulatta; Male; Motivation; Motor Activity; Parkinsonian Disorders; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases | 2021 |
Breathing new life into neurotoxic-based monkey models of Parkinson's disease to study the complex biological interplay between serotonin and dopamine.
Topics: Animals; Diffusion Tensor Imaging; Disease Models, Animal; Dopamine; Haplorhini; Humans; Levodopa; N-Methyl-3,4-methylenedioxyamphetamine; Parkinson Disease; Serotonin | 2021 |
Coadministration With Carbidopa Enhances the Antimyopic Effects of Levodopa in Chickens.
Topics: Administration, Topical; Animals; Animals, Newborn; Biomarkers; Carbidopa; Chickens; Disease Models, Animal; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Drug Combinations; Injections, Intraperitoneal; Levodopa; Male; Mitosis; Myopia; Ophthalmic Solutions; Sensory Deprivation; Vitreous Body | 2021 |
Pharmacological evaluation of vanillic acid in rotenone-induced Parkinson's disease rat model.
Topics: Animals; Antioxidants; Antiparkinson Agents; Behavior, Animal; Body Weight; Carbidopa; Catalase; Catalepsy; Disease Models, Animal; Dopamine; Drug Combinations; Female; Glutathione; Levodopa; Locomotion; Male; Mesencephalon; Muscular Diseases; Oxidative Stress; Parkinson Disease; Postural Balance; Rats, Sprague-Dawley; Rotenone; Superoxides; Thiobarbituric Acid Reactive Substances; Vanillic Acid | 2021 |
Further characterisation of psychosis-like behaviours induced by L-DOPA in the MPTP-lesioned marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Callithrix; Disease Models, Animal; Female; Levodopa; Male; Parkinsonian Disorders; Psychotic Disorders | 2021 |
Enhanced Delivery of Neuroactive Drugs via Nasal Delivery with a Self-Healing Supramolecular Gel.
Topics: Administration, Intranasal; Animals; Antiparkinson Agents; Cell Line, Tumor; Disease Models, Animal; Drug Delivery Systems; Female; Humans; Hydrogels; Levodopa; Mice; Mice, Inbred BALB C; Nasal Mucosa | 2021 |
Exogenous glutathione exerts a therapeutic effect in ischemic stroke rats by interacting with intrastriatal dopamine.
Topics: Animals; Carbidopa; Cytokines; Disease Models, Animal; Dopamine; Glutathione; Homocystine; Infarction, Middle Cerebral Artery; Ischemic Stroke; Levodopa; Male; Oxidative Stress; Proteomics; Rats; Rats, Wistar; Reperfusion Injury; Tyrosine 3-Monooxygenase; Up-Regulation | 2022 |
Resveratrol Alleviates Levodopa-Induced Dyskinesia in Rats.
Topics: Animals; Biomarkers; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Dyskinesias; Levodopa; Male; Oxidopamine; Parkinson Disease; Rats; Resveratrol; Substantia Nigra | 2021 |
Human COMT over-expression confers a heightened susceptibility to dyskinesia in mice.
Topics: Animals; Antiparkinson Agents; Armadillo Domain Proteins; Catechol O-Methyltransferase; Cell Adhesion Molecules; Corpus Striatum; Disease Models, Animal; Disease Susceptibility; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Mice, Inbred C57BL; Mice, Transgenic; Motor Activity; Oxidopamine; Parkinsonian Disorders; Phosphoproteins; Proto-Oncogene Proteins c-fos; Serotonin; Thioredoxin Reductase 2 | 2017 |
Cooperative Synthesis of Dopamine in Rat Mediobasal Hypothalamus as a Compensatory Mechanism in Hyperprolactinemia.
Topics: Adrenergic Neurons; Animals; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Hippocampus; Hyperprolactinemia; Levodopa; Male; Rats; Rats, Wistar | 2017 |
Morphological dendritic spine changes of medium spiny neurons in the nucleus accumbens in 6-hydroxydopamine-lesioned rats treated with levodopa.
Topics: Animals; Apomorphine; Dendritic Spines; Disease Models, Animal; Dopamine Agents; Levodopa; Male; Medial Forebrain Bundle; Neurons; Nucleus Accumbens; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Wistar; Statistics, Nonparametric; Sympatholytics; Time Factors; Tyrosine 3-Monooxygenase | 2017 |
Effects of a combination treatment of KD5040 and
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Cyclic AMP Response Element-Binding Protein; Disease Models, Animal; Dopamine and cAMP-Regulated Phosphoprotein 32; Dyskinesia, Drug-Induced; Enkephalins; Extracellular Signal-Regulated MAP Kinases; Levodopa; Magnoliopsida; Male; Mice, Inbred C57BL; Movement; Parkinson Disease; Phytotherapy; Plant Extracts; Proto-Oncogene Proteins c-fos; Substance P | 2017 |
Altered somatosensory cortex neuronal activity in a rat model of Parkinson's disease and levodopa-induced dyskinesias.
Topics: Action Potentials; Animals; Antiparkinson Agents; Apomorphine; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Glutamate Decarboxylase; Levodopa; Motor Cortex; Nerve Tissue Proteins; Neurons; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Receptors, GABA; RNA, Messenger; Sympatholytics; Tandem Mass Spectrometry | 2017 |
Preliminary Analysis of Parkinson-like Motor Coordination Abnormityin Brain-specific hS100B Transgenic Mice.
Topics: Animals; Brain; Disease Models, Animal; Dopamine; G-Protein-Coupled Receptor Kinase 2; Homovanillic Acid; Levodopa; Mice; Mice, Knockout; Mice, Transgenic; Parkinson Disease; Receptors, Dopamine D2; S100 Calcium Binding Protein beta Subunit; Tyrosine 3-Monooxygenase | 2017 |
Involvement of the bed nucleus of the stria terminalis in L-Dopa induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Daunorubicin; Disease Models, Animal; Dyskinesia, Drug-Induced; Gene Expression; Levodopa; Male; Neurons; Parkinson Disease; Proto-Oncogene Proteins c-fos; Rats, Sprague-Dawley; Septal Nuclei | 2017 |
Viral-mediated oligodendroglial alpha-synuclein expression models multiple system atrophy.
Topics: alpha-Synuclein; Animals; Animals, Genetically Modified; Corpus Striatum; Dependovirus; Disease Models, Animal; Dopamine Agents; Gene Expression Regulation; Haplorhini; Humans; Levodopa; Male; Multiple System Atrophy; Myelin Basic Protein; Nerve Tissue Proteins; Oligodendroglia; Phosphorylation; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Substantia Nigra | 2017 |
Altered adenosine 2A and dopamine D2 receptor availability in the 6-hydroxydopamine-treated rats with and without levodopa-induced dyskinesia.
Topics: Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Levodopa; Oxidopamine; Parkinson Disease, Secondary; Positron-Emission Tomography; Rats; Rats, Wistar; Receptor, Adenosine A2A; Receptors, Dopamine D2; Sympatholytics | 2017 |
2-Arachidonoylglycerol as a possible treatment for anorexia nervosa in animal model in mice.
Topics: Animals; Anorexia Nervosa; Arachidonic Acids; Cannabinoid Receptor Modulators; Cognition; Disease Models, Animal; Dopamine; Eating; Endocannabinoids; Female; Glycerides; Hippocampus; Hypothalamus; Levodopa; Mice; Neurotransmitter Agents; Random Allocation | 2017 |
Drug induces depression-like phenotypes and alters gene expression profiles in Drosophila.
Topics: Animals; Chlorpromazine; Depressive Disorder, Major; Disease Models, Animal; Dose-Response Relationship, Drug; Drosophila melanogaster; Eating; Female; Gene Expression; Levodopa; Male; Malondialdehyde; Maternal Exposure; Paternal Exposure; Serotonin; Sexual Behavior, Animal; Superoxide Dismutase | 2017 |
Ceftriaxone reduces L-dopa-induced dyskinesia severity in 6-hydroxydopamine parkinson's disease model.
Topics: Animals; Anti-Bacterial Agents; Ceftriaxone; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Excitatory Amino Acid Transporter 2; Levodopa; Male; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Sympatholytics | 2017 |
Reassessment of subacute MPTP-treated mice as animal model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Antiparkinson Agents; Astrocytes; Behavior, Animal; Benserazide; Benzothiazoles; Blood-Brain Barrier; Chromatography, High Pressure Liquid; Corpus Striatum; Disease Models, Animal; Drug Combinations; Levodopa; Male; Mice; Mice, Inbred C57BL; Microscopy, Electron; Parkinsonian Disorders; Pramipexole; Selegiline | 2017 |
Granger causality supports abnormal functional connectivity of beta oscillations in the dorsolateral striatum and substantia nigra pars reticulata in hemiparkinsonian rats.
Topics: Animals; Antiparkinson Agents; Beta Rhythm; Corpus Striatum; Disease Models, Animal; Electroencephalography Phase Synchronization; Levodopa; Male; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Pars Reticulata; Rats; Rats, Sprague-Dawley | 2017 |
Effects of small-molecule amyloid modulators on a Drosophila model of Parkinson's disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; alpha-Synuclein; Amyloid; Animals; Animals, Genetically Modified; Behavior, Animal; Brain; Disease Models, Animal; Drosophila melanogaster; Female; Humans; Levodopa; Locomotion; Motor Activity; Parkinson Disease; Pyridones; Recombinant Proteins; Spectroscopy, Fourier Transform Infrared | 2017 |
Gypenosides ameliorate memory deficits in MPTP-lesioned mouse model of Parkinson's disease treated with L-DOPA.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Brain Chemistry; Disease Models, Animal; Gynostemma; Levodopa; Male; Maze Learning; Memory Disorders; Mice; Mice, Inbred C57BL; Parkinsonian Disorders; Plant Extracts; Spatial Memory | 2017 |
The effect of mianserin on the severity of psychosis and dyskinesia in the parkinsonian marmoset.
Topics: Animals; Antidepressive Agents, Second-Generation; Callithrix; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Mianserin; MPTP Poisoning; Psychotic Disorders; Severity of Illness Index; Time Factors; Treatment Outcome | 2018 |
Neuroprotective effects of coenzyme Q10 on paraquat-induced Parkinson's disease in experimental animals.
Topics: Animals; Disease Models, Animal; Levodopa; Male; Mice; Mitochondria; Neurons; Neuroprotective Agents; Oxidative Stress; Paraquat; Parkinson Disease; Protein Carbonylation; Ubiquinone | 2018 |
The plasmalogen precursor analog PPI-1011 reduces the development of L-DOPA-induced dyskinesias in de novo MPTP monkeys.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; MPTP Poisoning; Ovariectomy; Plasmalogens; Time Factors | 2018 |
A pathogenic S250F missense mutation results in a mouse model of mild aromatic l-amino acid decarboxylase (AADC) deficiency.
Topics: Amino Acid Metabolism, Inborn Errors; Animals; Aromatic-L-Amino-Acid Decarboxylases; Corpus Striatum; Disease Models, Animal; Dopamine; Female; Genetic Therapy; Humans; Levodopa; Male; Mice; Mutation, Missense; Neostriatum; Parkinson Disease; Polymorphism, Single Nucleotide; Serotonin; Substantia Nigra | 2017 |
Objectively measuring effects of electro-acupuncture in parkinsonian rhesus monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acupuncture Therapy; Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Electroacupuncture; Female; Levodopa; Macaca mulatta; Magnetic Resonance Imaging; Motor Activity; Motor Cortex; Parkinson Disease; Parkinson Disease, Secondary | 2018 |
Physical Exercise Modulates L-DOPA-Regulated Molecular Pathways in the MPTP Mouse Model of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Gene Expression Regulation; Levodopa; Male; Mice, Inbred C57BL; Motor Activity; Parkinson Disease; Physical Conditioning, Animal; RNA, Messenger; Signal Transduction; Substantia Nigra; Tyrosine 3-Monooxygenase | 2018 |
Metformin Inhibits the Development of L-DOPA-Induced Dyskinesia in a Murine Model of Parkinson's Disease.
Topics: Amantadine; Animals; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Male; Metformin; Mice, Inbred C57BL; Parkinson Disease; Signal Transduction | 2018 |
Altered mGluR5 binding potential and glutamine concentration in the 6-OHDA rat model of acute Parkinson's disease and levodopa-induced dyskinesia.
Topics: Acute Disease; Animals; Cerebral Cortex; Disease Models, Animal; Dyskinesias; Female; Glutamine; Levodopa; Oxidopamine; Parkinson Disease; Positron-Emission Tomography; Proton Magnetic Resonance Spectroscopy; Putamen; Rats, Wistar; Receptor, Metabotropic Glutamate 5 | 2018 |
Neuroprotective and Neuro-restorative Effects of Minocycline and Rasagiline in a Zebrafish 6-Hydroxydopamine Model of Parkinson's Disease.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Disease Models, Animal; Dopaminergic Neurons; Drug Administration Schedule; Embryo, Nonmammalian; Indans; Isradipine; Levodopa; Locomotion; Minocycline; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Time Factors; Tyrosine 3-Monooxygenase; Zebrafish | 2017 |
Differential effects of dopaminergic drugs on spontaneous motor activity in the common marmoset following pretreatment with a bilateral brain infusion of 6-hydroxydopamine.
Topics: Animals; Apomorphine; Area Under Curve; Callithrix; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dopaminergic Neurons; Dose-Response Relationship, Drug; Immunohistochemistry; Levodopa; Male; Methamphetamine; Motor Activity; Oxidopamine; Parkinsonian Disorders; Substantia Nigra; Tyrosine 3-Monooxygenase | 2017 |
The effects of cysteamine in a mouse model of levodopa-induced dyskinesias.
Topics: Animals; Cysteamine; Cystine Depleting Agents; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Levodopa; Mice | 2018 |
Preclinical profile of a dopamine D1 potentiator suggests therapeutic utility in neurological and psychiatric disorders.
Topics: Animals; Antipsychotic Agents; Blinking; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Isoquinolines; Levodopa; Macaca mulatta; Male; Maze Learning; Mice; Mice, Inbred C57BL; Mice, Transgenic; Nervous System Diseases; Prefrontal Cortex; Psychotic Disorders; Receptors, Dopamine D1; Reserpine; Sleep; Wakefulness | 2018 |
Lipoic acid alleviates L‑DOPA‑induced dyskinesia in 6‑OHDA parkinsonian rats via anti‑oxidative stress.
Topics: Animals; Antioxidants; Caspase 3; Disease Models, Animal; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Female; Levodopa; Oxidative Stress; Parkinson Disease; Poly(ADP-ribose) Polymerases; Rats; Reactive Oxygen Species; Substantia Nigra; Thioctic Acid | 2018 |
DPI-289, a novel mixed delta opioid agonist / mu opioid antagonist (DAMA), has L-DOPA-sparing potential in Parkinson's disease.
Topics: Adrenergic Agents; Analgesics, Opioid; Animals; Benzamides; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Guinea Pigs; Levodopa; Macaca; Male; Mice; Mice, Inbred C57BL; Movement; Narcotic Antagonists; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Piperazines; Rats, Sprague-Dawley; Receptors, Opioid, delta; Receptors, Opioid, mu; Vas Deferens | 2018 |
Alteration of the PAC1 Receptor Expression in the Basal Ganglia of MPTP-Induced Parkinsonian Macaque Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Antiparkinson Agents; Basal Ganglia; Caudate Nucleus; Corpus Striatum; Disease Models, Animal; Gene Expression Regulation; Levodopa; Macaca fascicularis; Male; MPTP Poisoning; Phosphopyruvate Hydratase; Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I; Tyrosine 3-Monooxygenase | 2018 |
Regulation of Pleiotrophin and Fyn in the striatum of rats undergoing L-DOPA-induced dyskinesia.
Topics: Animals; Carrier Proteins; Corpus Striatum; Cytokines; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Male; Neurons; Parkinson Disease; Proto-Oncogene Proteins c-fyn; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate | 2018 |
Neurophysiological effects in cortico-basal ganglia-thalamic circuits of antidyskinetic treatment with 5-HT
Topics: Animals; Basal Ganglia; Brain Waves; Cerebral Cortex; Disease Models, Animal; Dyskinesias; Electric Stimulation; Evoked Potentials; Female; Levodopa; Neural Pathways; Parkinson Disease, Secondary; Piperazines; Piperidines; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Serotonin 5-HT1 Receptor Agonists; Serotonin Antagonists; Thalamus | 2018 |
A Subpopulation of Striatal Neurons Mediates Levodopa-Induced Dyskinesia.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Mice, Inbred C57BL; Mice, Transgenic; Motor Cortex; Neural Pathways; Neurons; Optogenetics; Parkinson Disease | 2018 |
Linagliptin potentiates the effect of l-dopa on the behavioural, biochemical and immunohistochemical changes in experimentally-induced Parkinsonism: Role of toll-like receptor 4, TGF-β1, NF-κB and glucagon-like peptide 1.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Carbidopa; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Combinations; Drug Synergism; Glucagon-Like Peptide 1; Levodopa; Linagliptin; Mice; Mice, Inbred BALB C; NF-kappa B; Parkinsonian Disorders; Toll-Like Receptor 4; Transforming Growth Factor beta1 | 2018 |
CaMKII inhibition ameliorated levodopa-induced dyskinesia by downregulating tyrosine hydroxylase activity in an experimental model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Benzylamines; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Male; Mice, Inbred C57BL; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; PC12 Cells; Protein Kinase Inhibitors; Rats; Signal Transduction; Sulfonamides; Sympatholytics; Tyrosine 3-Monooxygenase | 2018 |
A Selective Phosphodiesterase 10A Inhibitor Reduces L-Dopa-Induced Dyskinesias in Parkinsonian Monkeys.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Male; MPTP Poisoning; Organic Chemicals; Phosphodiesterase Inhibitors | 2018 |
Selegiline increases on time without exacerbation of dyskinesia in 6-hydroxydopamine-lesioned rats displaying l-Dopa-induced wearing-off and abnormal involuntary movements.
Topics: Animals; Antiparkinson Agents; Benserazide; Cytoskeletal Proteins; Disease Models, Animal; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enkephalins; Levodopa; Male; Movement; Nerve Tissue Proteins; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Rats, Sprague-Dawley; RNA, Messenger; Selegiline; Time Factors | 2018 |
Identification of metabolite biomarkers for L-DOPA-induced dyskinesia in a rat model of Parkinson's disease by metabolomic technology.
Topics: Animals; Antiparkinson Agents; Apomorphine; Arachidonic Acids; Biomarkers; Cannabinoid Receptor Agonists; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; Dyskinesia, Drug-Induced; Endocannabinoids; Glycerides; Levodopa; Male; Metabolome; Metabolomics; Motor Activity; Oxidopamine; Parkinsonian Disorders; Polyunsaturated Alkamides; Rats, Sprague-Dawley | 2018 |
Anticataleptic activity of Zamzam water in chlorpromazine induced animal model of Parkinson disease.
Topics: Animals; Brain; Carbidopa; Catalepsy; Chlorpromazine; Disease Models, Animal; Drug Combinations; Hydrogen-Ion Concentration; Levodopa; Parkinsonian Disorders; Rats; Water | 2018 |
Haloperidol-induced parkinsonism is attenuated by varenicline in mice.
Topics: Animals; Catalepsy; Disease Models, Animal; Dopamine; Female; Haloperidol; Levodopa; Male; Mice; Neurons; Parkinsonian Disorders; Varenicline | 2018 |
Modafinil alleviates levodopa-induced excessive nighttime sleepiness and restores monoaminergic systems in a nocturnal animal model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Arousal; Benzhydryl Compounds; Biogenic Monoamines; Disease Models, Animal; Disorders of Excessive Somnolence; Drug Therapy, Combination; Levodopa; Male; Mice, Inbred C57BL; Modafinil; Parkinson Disease; Photoperiod | 2018 |
Zinc and linoleic acid pre-treatment attenuates biochemical and histological changes in the midbrain of rats with rotenone-induced Parkinsonism.
Topics: Animals; Antioxidants; Disease Models, Animal; Female; Glutathione; Levodopa; Linoleic Acid; Lipid Peroxidation; Parkinsonian Disorders; Rats, Wistar; Rotenone; Zinc | 2018 |
Inhaling xenon ameliorates l-dopa-induced dyskinesia in experimental parkinsonism.
Topics: Administration, Inhalation; Animals; Antiparkinson Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Gait Disorders, Neurologic; Green Fluorescent Proteins; Levodopa; Mice; Mice, Transgenic; MPTP Poisoning; Oxidopamine; Parkinsonian Disorders; Rats; Sensation Disorders; Sympatholytics; Time Factors; Xenon | 2018 |
Striatonigral neurons divide into two distinct morphological-physiological phenotypes after chronic L-DOPA treatment in parkinsonian rats.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Female; Levodopa; Mice; Mice, Transgenic; Neostriatum; Neurons; Parkinson Disease; Phenotype; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Striatonigral Degeneration | 2018 |
Treadmill Exercise Attenuates L-DOPA-Induced Dyskinesia and Increases Striatal Levels of Glial Cell-Derived Neurotrophic Factor (GDNF) in Hemiparkinsonian Mice.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Glial Cell Line-Derived Neurotrophic Factor; Levodopa; Male; Mice, Inbred C57BL; Motor Activity; Parkinson Disease; Physical Conditioning, Animal; Tyrosine 3-Monooxygenase | 2019 |
Pathophysiology of levodopa-induced dyskinesia: Insights from multimodal imaging and immunohistochemistry in non-human primates.
Topics: Animals; Brain; Diffusion Tensor Imaging; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Immunohistochemistry; Levodopa; Macaca fascicularis; MPTP Poisoning; Multimodal Imaging; N-Methyl-3,4-methylenedioxyamphetamine; Nerve Fibers; Parkinson Disease, Secondary; Positron-Emission Tomography; Serotonin Agents; Serotonin Plasma Membrane Transport Proteins | 2018 |
Hyperactive Response of Direct Pathway Striatal Projection Neurons to L-dopa and D1 Agonism in Freely Moving Parkinsonian Mice.
Topics: Animals; Behavior, Animal; Denervation; Disease Models, Animal; Dopamine Agonists; Dopaminergic Neurons; Homeodomain Proteins; Hyperkinesis; Levodopa; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neostriatum; Neurons; Parkinson Disease; Receptors, Dopamine D1; Substantia Nigra; Transcription Factors | 2018 |
Tat-Src reduced NR2B tyrosine phosphorylation and its interaction with NR2B in levodopa-induced dyskinetic rats model.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Levodopa; Parkinson Disease; Peptides; Phosphorylation; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; src-Family Kinases | 2019 |
An mGlu4-Positive Allosteric Modulator Alleviates Parkinsonism in Primates.
Topics: Allosteric Regulation; Animals; Antiparkinson Agents; Cognition Disorders; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Levodopa; Macaca fascicularis; Parkinsonian Disorders; Positron-Emission Tomography; Receptors, Metabotropic Glutamate; Time Factors | 2018 |
A behavioral test battery for mouse models of Angelman syndrome: a powerful tool for testing drugs and novel
Topics: Angelman Syndrome; Animals; Behavior Rating Scale; Behavior, Animal; Disease Models, Animal; Female; Levodopa; Male; Mice, Mutant Strains; Minocycline; Mutation; Phenotype; Ubiquitin-Protein Ligases | 2018 |
NMDA receptor GluN2D subunit participates to levodopa-induced dyskinesia pathophysiology.
Topics: Animals; Cholinergic Neurons; Corpus Striatum; Disease Models, Animal; Disks Large Homolog 4 Protein; Dyskinesia, Drug-Induced; Interneurons; Levodopa; Macaca mulatta; Male; Neurons; Parkinson Disease; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Synapses | 2019 |
Safinamide Modulates Striatal Glutamatergic Signaling in a Rat Model of Levodopa-Induced Dyskinesia.
Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Excitatory Amino Acid Agents; Levodopa; Male; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Signal Transduction | 2018 |
Dopamine-endocannabinoid interactions mediate spike-timing-dependent potentiation in the striatum.
Topics: Action Potentials; Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Endocannabinoids; Levodopa; Long-Term Potentiation; Long-Term Synaptic Depression; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Neostriatum; Parkinson Disease; Rats, Sprague-Dawley; Receptors, Dopamine D2 | 2018 |
Abrogating Native α-Synuclein Tetramers in Mice Causes a L-DOPA-Responsive Motor Syndrome Closely Resembling Parkinson's Disease.
Topics: alpha-Synuclein; Animals; Antiparkinson Agents; Brain; Disease Models, Animal; Levodopa; Mice; Mice, Inbred C57BL; Mice, Transgenic; Mutation, Missense; Neurons; Parkinsonian Disorders; Protein Conformation | 2018 |
Riluzole Attenuates L-DOPA-Induced Abnormal Involuntary Movements Through Decreasing CREB1 Activity: Insights from a Rat Model.
Topics: Animals; Cyclic AMP Response Element-Binding Protein; Disease Models, Animal; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Levodopa; Male; Oxidopamine; Protein Interaction Maps; Random Allocation; Rats; Rats, Wistar; Riluzole | 2019 |
Diverse serotonin actions of vilazodone reduce l-3,4-dihidroxyphenylalanine-induced dyskinesia in hemi-parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Gene Expression Regulation; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Piperazines; Protein Precursors; Proto-Oncogene Proteins c-fos; Pyridines; Rats; Rats, Sprague-Dawley; Receptors, Serotonin; RNA, Messenger; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Antagonists; Time Factors; Vilazodone Hydrochloride | 2018 |
Implication of nigral dopaminergic lesion and repeated L-dopa exposure in neuropsychiatric symptoms of Parkinson's disease.
Topics: Amphetamine; Animals; Antiparkinson Agents; Anxiety; Benserazide; Disease Models, Animal; Dopamine; Forelimb; Gait Disorders, Neurologic; Interpersonal Relations; Levodopa; Locomotion; Male; Maze Learning; Memory Disorders; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Recognition, Psychology; Substantia Nigra; Sympatholytics; Tyrosine 3-Monooxygenase | 2019 |
Preparation of levodopa-loaded crystalsomes through thermally induced crystallization reverses functional deficits in Parkinsonian mice.
Topics: Animals; Antiparkinson Agents; Crystallization; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Carriers; Emulsions; Female; Levodopa; Mice; Mice, Inbred BALB C; Molecular Structure; Nanoparticles; Parkinson Disease; Structure-Activity Relationship; Temperature | 2019 |
Spike and Local Field Synchronization Between the Pedunculopontine Nucleus and Primary Motor Cortex in a Rat Model of Parkinson's Disease.
Topics: Action Potentials; Animals; Disease Models, Animal; Levodopa; Male; Motor Cortex; Oxidopamine; Parkinsonian Disorders; Pedunculopontine Tegmental Nucleus; Rats; Rats, Wistar | 2019 |
l-3,4-dihydroxyphenylalanine (l-DOPA) modulates brain iron, dopaminergic neurodegeneration and motor dysfunction in iron overload and mutant alpha-synuclein mouse models of Parkinson's disease.
Topics: alpha-Synuclein; Animals; Antiparkinson Agents; Brain; Disease Models, Animal; Dopaminergic Neurons; Humans; Iron; Iron Overload; Levodopa; Mice; Mice, Transgenic; Nerve Degeneration; Oxidative Stress; Parkinson Disease | 2019 |
Oral levodopa rescues retinal morphology and visual function in a murine model of human albinism.
Topics: Administration, Oral; Albinism, Oculocutaneous; Animals; Antiparkinson Agents; Disease Models, Animal; Humans; Levodopa; Mice; Mice, Inbred C57BL; Retina; Vision, Ocular | 2019 |
Optostimulation of striatonigral terminals in substantia nigra induces dyskinesia that increases after L-DOPA in a mouse model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Lasers; Levodopa; Mice, Inbred C57BL; Optogenetics; Oxidopamine; Parkinsonian Disorders; Photic Stimulation; Substantia Nigra | 2019 |
Baicalein enhances the effect of low dose Levodopa on the gait deficits and protects dopaminergic neurons in experimental Parkinsonism.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopaminergic Neurons; Flavanones; Gait; Levodopa; Male; Mice; Neuroprotective Agents; Parkinsonian Disorders; Plant Extracts; Scutellaria baicalensis | 2019 |
Methods to Investigate the Role of β-Arrestin Signaling in Parkinson's Disease.
Topics: Animals; beta-Arrestins; Disease Models, Animal; Dopamine; Dyskinesias; Humans; Levodopa; Locomotion; Mice, Knockout; Molecular Biology; Parkinson Disease; Signal Transduction; Stereotaxic Techniques | 2019 |
Resveratrol synergizes with low doses of L-DOPA to improve MPTP-induced Parkinson disease in mice.
Topics: Animals; Antioxidants; Antiparkinson Agents; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Female; Levodopa; Mice; Mice, Inbred BALB C; MPTP Poisoning; Resveratrol | 2019 |
Physical activity sustains memory retrieval in dopamine-depleted mice previously treated with L-Dopa.
Topics: Animals; Antiparkinson Agents; Benserazide; Corpus Striatum; Disease Models, Animal; Dopamine; Drug Combinations; Female; Green Fluorescent Proteins; Hippocampus; Levodopa; Maze Learning; Memory; Mice, Inbred C57BL; Mice, Transgenic; Motor Activity; MPTP Poisoning; Neurogenesis; Random Allocation; Sedentary Behavior | 2019 |
Genetic silencing of striatal CaV1.3 prevents and ameliorates levodopa dyskinesia.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Calcium Channels; Disease Models, Animal; Dyskinesia, Drug-Induced; Green Fluorescent Proteins; Levodopa; Luminescent Agents; Medial Forebrain Bundle; Neostriatum; Oxidopamine; Parkinsonian Disorders; Rats; RNA Interference; RNA, Small Interfering; Substantia Nigra; Tyrosine 3-Monooxygenase | 2019 |
Brain state-dependent alterations of corticostriatal synchronized oscillations in awake and anesthetized parkinsonian rats.
Topics: Anesthesia; Animals; Basal Ganglia; Beta Rhythm; Brain; Corpus Striatum; Disease Models, Animal; Levodopa; Male; Motor Cortex; Neural Pathways; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Wakefulness | 2019 |
l-Dopa-free learned dyskinetic behavior in a Parkinson's primate model.
Topics: Animals; Antiparkinson Agents; Conditioning, Psychological; Disease Models, Animal; Dyskinesia, Drug-Induced; Dyskinesias; Levodopa; Macaca; Parkinsonian Disorders | 2019 |
Assessment of plasma creatine kinase as biomarker for levodopa-induced dyskinesia in Parkinson's disease.
Topics: Aged; Animals; Antiparkinson Agents; Biomarkers; Creatine Kinase; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Levodopa; Macaca; Middle Aged; Parkinson Disease; Randomized Controlled Trials as Topic; Severity of Illness Index | 2019 |
Video-based assessments of the hind limb stepping in a mouse model of hemi-parkinsonism.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Gait; Hindlimb; Levodopa; Male; Mice; Mice, Inbred C57BL; Oxidopamine; Parkinsonian Disorders; Tyrosine 3-Monooxygenase | 2020 |
L-dopa response pattern in a rat model of mild striatonigral degeneration.
Topics: Animals; Behavior, Animal; Corpus Striatum; Denervation; Disease Models, Animal; Levodopa; Motor Activity; Multiple System Atrophy; Quinolinic Acid; Rats; Striatonigral Degeneration | 2019 |
Pharmacological antagonism of histamine H2R ameliorated L-DOPA-induced dyskinesia via normalization of GRK3 and by suppressing FosB and ERK in PD.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; G-Protein-Coupled Receptor Kinase 3; Histamine H2 Antagonists; Levodopa; MAP Kinase Signaling System; Mice, Inbred C57BL; Parkinson Disease; Proto-Oncogene Proteins c-fos; Ranitidine; Receptors, Histamine H2 | 2019 |
Intestinal infection triggers Parkinson's disease-like symptoms in Pink1
Topics: Animals; Antigen Presentation; Autoantigens; Axons; CD8-Positive T-Lymphocytes; Citrobacter rodentium; Disease Models, Animal; Dopaminergic Neurons; Enterobacteriaceae Infections; Female; Intestines; Levodopa; Male; Mice; Mitochondria; Neostriatum; Parkinson Disease; Protein Kinases; Ubiquitin-Protein Ligases | 2019 |
Selective effects of dopamine depletion and L-DOPA therapy on learning-related firing dynamics of striatal neurons.
Topics: Action Potentials; Analysis of Variance; Animals; Animals, Newborn; Conditioning, Operant; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Electric Stimulation; Electrochemical Techniques; Learning Disabilities; Levodopa; Male; Maze Learning; Neural Pathways; Neurotoxins; Oxidopamine; Rats; Rats, Sprague-Dawley; Reaction Time; Time Factors | 2013 |
Levodopa gains psychostimulant-like properties after nigral dopaminergic loss.
Topics: Adenoviridae; alpha-Synuclein; Animals; Antiparkinson Agents; Conditioning, Operant; Disease Models, Animal; Dopaminergic Neurons; Food Preferences; Humans; Levodopa; Male; Mutation; Parkinson Disease; Rats; Rats, Wistar; Reward; Saccharin; Substantia Nigra; Sweetening Agents; Taste; Transduction, Genetic; Tyrosine 3-Monooxygenase; Ubiquitin | 2013 |
Minocycline, levodopa and MnTMPyP induced changes in the mitochondrial proteome profile of MPTP and maneb and paraquat mice models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Homeodomain Proteins; Levodopa; Male; Maneb; Metalloporphyrins; Mice; Microglia; Minocycline; Mitochondria; Paraquat; Parkinson Disease, Secondary; Proteome; Stathmin; Superoxide Dismutase | 2013 |
α4β2 Nicotinic receptors play a role in the nAChR-mediated decline in L-dopa-induced dyskinesias in parkinsonian rats.
Topics: Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Azabicyclo Compounds; Corpus Striatum; Cyclopropanes; Disease Models, Animal; Dopamine Agonists; Drug Tolerance; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Nerve Tissue Proteins; Neurons; Nicotinic Agonists; Parkinson Disease; Protein Subunits; Rats; Rats, Sprague-Dawley; Receptors, Nicotinic; Synaptosomes | 2013 |
Striatal molecular signature of subchronic subthalamic nucleus high frequency stimulation in parkinsonian rat.
Topics: Animals; Behavior, Animal; Cluster Analysis; Corpus Striatum; Deep Brain Stimulation; Denervation; Disease Models, Animal; Electric Stimulation; Gene Expression Profiling; Gene Expression Regulation; Levodopa; Metabolic Networks and Pathways; Parkinson Disease; Rats; Subthalamic Nucleus | 2013 |
Behavioral characterization of the 6-hydroxidopamine model of Parkinson's disease and pharmacological rescuing of non-motor deficits.
Topics: Adrenergic Agents; Animals; Antidepressive Agents; Antiparkinson Agents; Behavior, Animal; Bupropion; Disease Models, Animal; Immunohistochemistry; Levodopa; Mood Disorders; Motor Activity; Oxidopamine; Parkinsonian Disorders; Paroxetine; Rats; Rats, Wistar | 2013 |
Dopamine receptor activation increases glial cell line-derived neurotrophic factor in experimental stroke.
Topics: Analysis of Variance; Animals; Astrocytes; Brain; Brain Infarction; Cells, Cultured; Cerebral Cortex; Disease Models, Animal; Dopamine Agents; Gene Expression Regulation; Glial Cell Line-Derived Neurotrophic Factor; Glial Fibrillary Acidic Protein; Levodopa; Male; Nestin; Rats; Rats, Wistar; Receptors, Dopamine; Stroke | 2013 |
Motivational disturbances and effects of L-dopa administration in neurofibromatosis-1 model mice.
Topics: Animals; Behavior, Animal; Depression; Disease Models, Animal; Dopamine Agents; Electrophysiology; Female; Humans; Integrases; Levodopa; Male; Maze Learning; Memory Disorders; Mice; Mice, Knockout; Mice, Transgenic; Motivation; Neurofibromatosis 1; Neurofibromin 1 | 2013 |
[Copper intoxication decreases lifespan and induces neurologic alterations in Drosophila melanogaster].
Topics: Age Factors; Animals; Copper Sulfate; Disease Models, Animal; Disease Progression; Dopamine Agents; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Dopaminergic Neurons; Drosophila melanogaster; Female; Fluphenazine; Hepatolenticular Degeneration; Humans; Levodopa; Longevity; Male; Motor Activity; Sampling Studies; Synaptic Transmission | 2013 |
Continuous DOPA synthesis from a single AAV: dosing and efficacy in models of Parkinson's disease.
Topics: Animals; Dependovirus; Disease Models, Animal; Genetic Vectors; Levodopa; Parkinson Disease; Rats; Transduction, Genetic; Transgenes | 2013 |
A2A receptor antagonists do not induce dyskinesias in drug-naive or L-dopa sensitized rats.
Topics: Adenosine A2 Receptor Antagonists; Adrenergic Agents; Analysis of Variance; Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Catalepsy; Disease Models, Animal; Dyskinesia, Drug-Induced; Haloperidol; Levodopa; Male; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Severity of Illness Index; Time Factors | 2013 |
Nicotinic receptor agonists reduce L-DOPA-induced dyskinesias in a monkey model of Parkinson's disease.
Topics: Animals; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Nicotine; Nicotinic Agonists; Parkinson Disease; Receptors, Nicotinic; Saimiri | 2013 |
Amphetamine-induced dyskinesia in the transplanted hemi-Parkinsonian mouse.
Topics: Adrenergic Agents; Amphetamine; Animals; Antiparkinson Agents; Cell Transplantation; Corpus Striatum; Disease Models, Animal; Dopamine Uptake Inhibitors; Dyskinesia, Drug-Induced; Embryo, Mammalian; Functional Laterality; Levodopa; Male; Mesencephalon; Mice; Mice, Inbred C57BL; Neurons; Oxidopamine; Parkinson Disease; Stereotyped Behavior | 2012 |
Activation of metabotropic glutamate 4 receptors decreases L-DOPA-induced dyskinesia in a mouse model of Parkinson's disease.
Topics: Adrenergic Agents; Aminobutyrates; Animals; Antiparkinson Agents; Benserazide; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Excitatory Amino Acid Agonists; Gene Expression Regulation; Levodopa; Male; Mice; Mice, Inbred C57BL; Oxidopamine; Parkinson Disease; Phosphinic Acids; Receptors, Metabotropic Glutamate; Time Factors | 2011 |
Cholinergic manipulation of motor disability and L-DOPA-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated common marmosets.
Topics: Animals; Antiparkinson Agents; Callithrix; Carbidopa; Cholinergic Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Motor Activity; MPTP Poisoning; Statistics, Nonparametric | 2014 |
Design, synthesis and biological evaluation of peptide derivatives of L-dopa as anti-parkinsonian agents.
Topics: Animals; Antiparkinson Agents; Dipeptides; Disease Models, Animal; Drug Design; Levodopa; Male; Molecular Structure; Motor Activity; Peptides; Rats; Rats, Wistar | 2013 |
Effect of chronic treatment with angiotensin type 1 receptor antagonists on striatal dopamine levels in normal rats and in a rat model of Parkinson's disease treated with L-DOPA.
Topics: Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Corpus Striatum; Disease Models, Animal; Dopamine; Levodopa; Male; Motor Activity; Neuroprotective Agents; Oxidopamine; Parkinson Disease, Secondary; Rats; Receptor, Serotonin, 5-HT1B; Receptors, Dopamine; Serotonin; Tetrazoles | 2014 |
5-Hydroxy-tryptophan for the treatment of L-DOPA-induced dyskinesia in the rat Parkinson's disease model.
Topics: 5-Hydroxytryptophan; Adrenergic Agents; Animals; Caudate Nucleus; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Female; Levodopa; Motor Activity; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Serotonin | 2013 |
Effects of 5-HT1A receptor stimulation on striatal and cortical M1 pERK induction by L-DOPA and a D1 receptor agonist in a rat model of Parkinson's disease.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Corpus Striatum; Disease Models, Animal; Extracellular Signal-Regulated MAP Kinases; Levodopa; Male; MAP Kinase Signaling System; Parkinson Disease; Phosphorylation; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D1; Serotonin 5-HT1 Receptor Agonists; Serotonin Receptor Agonists | 2013 |
[Сhanges in heart rate variability in presymptomatic and symptomatic stages of Parkinson's disease under pharmacological influences: an experimental study].
Topics: Animals; Antiparkinson Agents; Autonomic Nervous System; Circadian Rhythm; Disease Models, Animal; Electrocardiography; Heart; Heart Rate; Levodopa; Male; Mice; Mice, Inbred C57BL; Parkinson Disease | 2013 |
The anti-dyskinetic effect of dopamine receptor blockade is enhanced in parkinsonian rats following dopamine neuron transplantation.
Topics: Amphetamine; Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Benzazepines; Buspirone; Disease Models, Animal; Dopamine Agonists; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Female; Indoles; Levodopa; Mesencephalon; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Salicylamides; Serotonin Receptor Agonists | 2014 |
Oleoylethanolamide reduces L-DOPA-induced dyskinesia via TRPV1 receptor in a mouse model of Parkinson´s disease.
Topics: Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Endocannabinoids; Levodopa; Male; Mice; Mice, Inbred C57BL; Motor Activity; Oleic Acids; Oxidopamine; Parkinson Disease; TRPV Cation Channels | 2014 |
Direct evaluation of L-DOPA actions on neuronal activity of Parkinsonian tissue in vitro.
Topics: Animals; Calcium; Corpus Striatum; Disease Models, Animal; Humans; Levodopa; Mice; Molecular Imaging; Neurons; Parkinson Disease; Rats | 2013 |
D1 receptor agonist improves sleep-wake parameters in experimental parkinsonism.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Analysis of Variance; Animals; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Electrocardiography; Electroencephalography; Electromyography; Female; Levodopa; Macaca fascicularis; Macaca mulatta; Parkinsonian Disorders; Quinpirole; Sleep; Sleep Disorders, Circadian Rhythm; Telemetry; Time Factors; Wakefulness | 2014 |
Buspirone anti-dyskinetic effect is correlated with temporal normalization of dysregulated striatal DRD1 signalling in L-DOPA-treated rats.
Topics: Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Buspirone; Corpus Striatum; Cyclic AMP Response Element-Binding Protein; Disease Models, Animal; Dopamine and cAMP-Regulated Phosphoprotein 32; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Levodopa; Mitogen-Activated Protein Kinase 1; Parkinsonian Disorders; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D3; Serotonin 5-HT1 Receptor Agonists; Severity of Illness Index; Signal Transduction | 2014 |
Effect of Tianqi antitremor granules on behavioral manifestations and expression of G protein-coupled receptor kinase 6 and β-arrestin1 in levodopa-induced dyskinesia in a rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Arrestins; Behavior, Animal; beta-Arrestins; Blotting, Western; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Dyskinesia, Drug-Induced; Female; G-Protein-Coupled Receptor Kinases; Immunohistochemistry; Levodopa; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley | 2013 |
Antioxidant potential of melatonin enhances the response to L-dopa in 1-methyl 4-phenyl 1,2,3,6-tetrahydropyridine-parkinsonian mice.
Topics: Animals; Antioxidants; Antiparkinson Agents; Basal Ganglia; Behavior, Animal; Carbidopa; Catalase; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Drug Synergism; Glutathione; Glutathione Peroxidase; Levodopa; Lipid Peroxidation; Male; Malondialdehyde; Melatonin; Mice; Motor Activity; Oxidative Stress; Parkinsonian Disorders; Superoxide Dismutase | 2013 |
L-DOPA disrupts adenosine A(2A)-cannabinoid CB(1)-dopamine D(2) receptor heteromer cross-talk in the striatum of hemiparkinsonian rats: biochemical and behavioral studies.
Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Cannabinoid Receptor Antagonists; Cholinesterase Inhibitors; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dose-Response Relationship, Drug; Drug Interactions; Functional Laterality; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Piperidines; Protein Binding; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor Cross-Talk; Rimonabant; Tacrine; Time Factors; Tremor | 2014 |
L-dopa-induced dyskinesia: beyond an excessive dopamine tone in the striatum.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benserazide; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Drug Combinations; Dyskinesias; Female; Levodopa; Macaca mulatta; Male; Parkinson Disease | 2014 |
Dopamine deficiency contributes to early visual dysfunction in a rodent model of type 1 diabetes.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetic Retinopathy; Disease Models, Animal; Dopamine; Female; Levodopa; Male; Mice; Mice, Knockout; Rats; Rats, Long-Evans; Retina | 2014 |
Effect of memantine on L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease.
Topics: Amantadine; Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesias; Excitatory Amino Acid Antagonists; Levodopa; Male; Memantine; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley | 2014 |
Do adipose tissue-derived mesenchymal stem cells ameliorate Parkinson's disease in rat model?
Topics: Adipose Tissue; Amino Acids; Animals; Antigens, CD; Brain; Brain-Derived Neurotrophic Factor; Carbidopa; Cell Differentiation; Cells, Cultured; Chemokine CCL2; Disease Models, Animal; Drug Combinations; Female; Gene Expression; Genes, sry; Levodopa; Male; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Ovariectomy; Parkinson Disease; Rats, Sprague-Dawley; Rotenone; Transforming Growth Factor beta; Tyrosine 3-Monooxygenase | 2014 |
Morphologic changes of dendritic spines of striatal neurons in the levodopa-induced dyskinesia model.
Topics: Animals; Corpus Striatum; Dendritic Spines; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Male; Neostriatum; Neurites; Neurons; Parkinson Disease; Rats, Wistar; Synapses | 2014 |
Targeting metabotropic glutamate receptors as a new strategy against levodopa-induced dyskinesia in Parkinson's disease?
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Receptors, Metabotropic Glutamate | 2014 |
Combined fenobam and amantadine treatment promotes robust antidyskinetic effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease.
Topics: Amantadine; Analysis of Variance; Animals; Antiparkinson Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Imidazoles; Levodopa; Macaca fascicularis; MPTP Poisoning | 2014 |
Neuropeptide S counteracts 6-OHDA-induced motor deficits in mice.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Area Under Curve; Disease Models, Animal; Dopamine Agents; Female; Levodopa; Mice; Movement Disorders; Oxidopamine; Receptors, G-Protein-Coupled; Rotarod Performance Test; Substantia Nigra; Tyrosine 3-Monooxygenase | 2014 |
Differential dopamine receptor occupancy underlies L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
Topics: Animals; Benzamides; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Extracellular Space; Female; Levodopa; Microdialysis; Neostriatum; Nomifensine; Parkinson Disease; Positron-Emission Tomography; Proto-Oncogene Proteins c-fos; Pyrrolidines; Rats, Sprague-Dawley; Receptors, Dopamine; Serotonin | 2014 |
Gastrodia elata Blume alleviates L-DOPA-induced dyskinesia by normalizing FosB and ERK activation in a 6-OHDA-lesioned Parkinson's disease mouse model.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Gastrodia; Levodopa; Male; MAP Kinase Signaling System; Mice, Inbred C57BL; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Phytotherapy; Plant Extracts; Proto-Oncogene Proteins c-fos | 2014 |
Effects of 6-hydroxydopamine exposure on motor activity and biochemical expression in zebrafish (Danio rerio) larvae.
Topics: Animals; Antiparkinson Agents; Anxiety; Biomarkers; Blotting, Western; Carbidopa; Disease Models, Animal; Drug Combinations; Levodopa; Minocycline; Motor Activity; Oxidopamine; Parkinsonian Disorders; Real-Time Polymerase Chain Reaction; Sympatholytics; Vitamin E; Zebrafish; Zebrafish Proteins | 2014 |
Noradrenaline neuron degeneration contributes to motor impairments and development of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
Topics: Adrenergic Agents; Adrenergic Neurons; Amphetamine; Animals; Antiparkinson Agents; Apomorphine; Benzylamines; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Levodopa; Motor Activity; Nerve Degeneration; Oxidopamine; Parkinson Disease; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Ribosome Inactivating Proteins, Type 1; Saporins; Stereotyped Behavior | 2014 |
Tyrosine hydroxylase expression and activity in nigrostriatal dopaminergic neurons of MPTP-treated mice at the presymptomatic and symptomatic stages of parkinsonism.
Topics: Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Corpus Striatum; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Electrochemistry; Gene Expression Regulation; Hydrazines; Levodopa; Male; Mice; Mice, Inbred C57BL; Motor Activity; MPTP Poisoning; RNA, Messenger; Substantia Nigra; Tyrosine 3-Monooxygenase | 2014 |
Relationship between oscillatory activity in the cortico-basal ganglia network and parkinsonism in MPTP-treated monkeys.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Basal Ganglia; Brain Waves; Disease Models, Animal; Electroencephalography; Fourier Analysis; Globus Pallidus; Levodopa; Macaca mulatta; Motor Activity; Motor Cortex; MPTP Poisoning; Neural Pathways; Physical Stimulation; Sleep; Subthalamic Nucleus; Time Factors; Wakefulness | 2014 |
Widespread Monoaminergic Dysregulation of Both Motor and Non-Motor Circuits in Parkinsonism and Dyskinesia.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Biogenic Monoamines; Brain; Chromatography, High Pressure Liquid; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca mulatta; MPTP Poisoning; Neural Pathways; Time Factors | 2015 |
Effects of noradrenergic denervation by anti-DBH-saporin on behavioral responsivity to L-DOPA in the hemi-parkinsonian rat.
Topics: Animals; Corpus Striatum; Denervation; Disease Models, Animal; Dopamine; Dopamine Agonists; Dopamine beta-Hydroxylase; Dyskinesia, Drug-Induced; Levodopa; Male; Medial Forebrain Bundle; Motor Activity; Neurons; Norepinephrine; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Ribosome Inactivating Proteins, Type 1; Saporins | 2014 |
NMDA receptor antagonism potentiates the L-DOPA-induced extracellular dopamine release in the subthalamic nucleus of hemi-parkinson rats.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dizocilpine Maleate; Dopamine; Excitatory Amino Acid Antagonists; Extracellular Space; Functional Laterality; Glutamic Acid; Levodopa; Male; Microdialysis; Oxidopamine; Parkinsonian Disorders; Rats, Wistar; Receptors, N-Methyl-D-Aspartate; Substantia Nigra; Subthalamic Nucleus | 2014 |
The mGluR5 negative allosteric modulator dipraglurant reduces dyskinesia in the MPTP macaque model.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Imidazoles; Levodopa; Macaca mulatta; Male; Motor Activity; MPTP Poisoning; Pyridines; Receptor, Metabotropic Glutamate 5; Severity of Illness Index; Time Factors | 2014 |
Effects of acute and sub-chronic L-dopa therapy on striatal L-dopa methylation and dopamine oxidation in an MPTP mouse model of Parkinsons disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Catechol O-Methyltransferase; Corpus Striatum; Disease Models, Animal; Dopamine; Drug Administration Schedule; Levodopa; Male; Methylation; Mice; Mice, Inbred C57BL; Oxidation-Reduction; Parkinsonian Disorders; Time Factors | 2014 |
Deuterium-substituted L-DOPA displays increased behavioral potency and dopamine output in an animal model of Parkinson's disease: comparison with the effects produced by L-DOPA and an MAO-B inhibitor.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Behavior, Animal; Brain; Deuterium; Disease Models, Animal; Dopamine; Forelimb; Levodopa; Male; Microdialysis; Monoamine Oxidase Inhibitors; Motor Activity; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; Selegiline; Tyrosine 3-Monooxygenase | 2015 |
Improvement of the Rett syndrome phenotype in a MeCP2 mouse model upon treatment with levodopa and a dopa-decarboxylase inhibitor.
Topics: Animals; Anti-Dyskinesia Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Body Weight; Brain; Cell Enlargement; Dendrites; Disease Models, Animal; Dopa Decarboxylase; Dopaminergic Neurons; Levodopa; Male; Methyl-CpG-Binding Protein 2; Mice, Inbred C57BL; Mice, Knockout; Movement; Phenotype; Respiration; Rett Syndrome | 2014 |
(6aR)-11-amino-N-propyl-noraporphine, a new dopamine D2 and serotonin 5-HT1A dual agonist, elicits potent antiparkinsonian action and attenuates levodopa-induced dyskinesia in a 6-OHDA-lesioned rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Aporphines; Base Sequence; Disease Models, Animal; DNA Primers; Dopamine Agonists; Drug Interactions; Dyskinesia, Drug-Induced; Levodopa; Male; Oxidopamine; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D2; Reverse Transcriptase Polymerase Chain Reaction; Serotonin Receptor Agonists | 2014 |
L-DOPA-induced dyskinesia in a rat model of Parkinson's disease is associated with the fluctuational release of norepinephrine in the sensorimotor striatum.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Benzylamines; Chromatography, High Pressure Liquid; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Idazoxan; Levodopa; Male; Microdialysis; Neurotransmitter Agents; Norepinephrine; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Time Factors; Tyrosine 3-Monooxygenase | 2014 |
Effect of a chronic treatment with an mGlu5 receptor antagonist on brain serotonin markers in parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Benserazide; Brain; Disease Models, Animal; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Drug Combinations; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Homovanillic Acid; Levodopa; Macaca fascicularis; Ovariectomy; Parkinsonian Disorders; Protein Binding; Pyridines; Serotonin | 2015 |
l-DOPA reverses the impairment of Dentate Gyrus LTD in experimental parkinsonism via β-adrenergic receptors.
Topics: Animals; Antiparkinson Agents; Benzazepines; Dentate Gyrus; Disease Models, Animal; Dopamine; Dopamine Antagonists; Electric Stimulation; Functional Laterality; Levodopa; Long-Term Synaptic Depression; Male; Microdialysis; Norepinephrine; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Sulpiride | 2014 |
Functional correlates of exaggerated oscillatory activity in basal ganglia output in hemiparkinsonian rats.
Topics: Action Potentials; Adrenergic Agents; Animals; Antiparkinson Agents; Basal Ganglia; Brain Waves; Disease Models, Animal; Dopamine Antagonists; Functional Laterality; Levodopa; Male; Neural Pathways; Oxidopamine; Parkinsonian Disorders; Piperazines; Pyridines; Rats; Rats, Long-Evans; Salicylamides; Serotonin Antagonists; Substantia Nigra | 2014 |
Effects of five Ayurvedic herbs on locomotor behaviour in a Drosophila melanogaster Parkinson's disease model.
Topics: Animals; Bacopa; Centella; Disease Models, Animal; Drosophila melanogaster; Drosophila Proteins; India; Levodopa; Medicine, Ayurvedic; Motor Activity; Mucuna; Parkinson Disease; Plant Extracts; Plants, Medicinal; Protein Serine-Threonine Kinases; Withania | 2014 |
Selective Inactivation of Striatal FosB/ΔFosB-Expressing Neurons Alleviates L-DOPA-Induced Dyskinesia.
Topics: Animals; Antiparkinson Agents; Daunorubicin; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Macaca fascicularis; Male; Neostriatum; Neurons; Oxidopamine; Parkinson Disease; Patch-Clamp Techniques; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1 | 2016 |
L-dopa reverses behavioral deficits in the Pitx3 mouse fetus.
Topics: Analysis of Variance; Animals; Disease Models, Animal; Dopamine Agents; Dose-Response Relationship, Drug; Extremities; Female; Fetal Diseases; Homeodomain Proteins; Levodopa; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Motor Activity; Mouth; Pregnancy; Substantia Nigra; Transcription Factors | 2014 |
Angiotensin type 1 receptor blockage reduces l-dopa-induced dyskinesia in the 6-OHDA model of Parkinson's disease. Involvement of vascular endothelial growth factor and interleukin-1β.
Topics: Adrenergic Agents; Angiotensin II Type 1 Receptor Blockers; Animals; Antiparkinson Agents; Benzimidazoles; Biphenyl Compounds; Disease Models, Animal; Dyskinesia, Drug-Induced; In Vitro Techniques; Interleukin-1beta; Levodopa; Male; Mice; Mice, Inbred C57BL; Motor Activity; Oxidopamine; Parkinson Disease; Tetrazoles; Vascular Endothelial Growth Factor A | 2014 |
Inhibition of adenylyl cyclase type 5 prevents L-DOPA-induced dyskinesia in an animal model of Parkinson's disease.
Topics: Adenylyl Cyclase Inhibitors; Adenylyl Cyclases; Animals; Antiparkinson Agents; Blotting, Western; Disease Models, Animal; Dyskinesia, Drug-Induced; Immunohistochemistry; Levodopa; Mice; Mice, Inbred C57BL; Mice, Knockout; Parkinsonian Disorders; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction | 2014 |
Selective loss of bi-directional synaptic plasticity in the direct and indirect striatal output pathways accompanies generation of parkinsonism and l-DOPA induced dyskinesia in mouse models.
Topics: Animals; Animals, Newborn; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Excitatory Postsynaptic Potentials; Functional Laterality; Green Fluorescent Proteins; In Vitro Techniques; Levodopa; Mice; Mice, Transgenic; Neural Pathways; Neuronal Plasticity; Oxidopamine; Parkinsonian Disorders; Purinergic Agents; Receptor, Adenosine A2A; Receptors, Dopamine D1 | 2014 |
AQW051, a novel and selective nicotinic acetylcholine receptor α7 partial agonist, reduces l-Dopa-induced dyskinesias and extends the duration of l-Dopa effects in parkinsonian monkeys.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Analysis of Variance; Animals; Antiparkinson Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Motor Activity; MPTP Poisoning; Nicotinic Agonists; Ovariectomy; Time Factors | 2014 |
Subthalamotomy-induced changes in dopamine receptors in parkinsonian monkeys.
Topics: Animals; Antiparkinson Agents; Chromatography, High Pressure Liquid; Disease Models, Animal; Dopamine Plasma Membrane Transport Proteins; Female; Levodopa; Macaca fascicularis; MPTP Poisoning; Ovariectomy; Protein Binding; Radioligand Assay; Receptors, Dopamine; Subthalamus | 2014 |
Adenosine A1 receptor stimulation reduces D1 receptor-mediated GABAergic transmission from striato-nigral terminals and attenuates l-DOPA-induced dyskinesia in dopamine-denervated mice.
Topics: Action Potentials; Age Factors; Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Inhibitory Postsynaptic Potentials; Levodopa; Male; Mice; Mice, Inbred C57BL; Motor Activity; Neurons; Parkinson Disease; Pars Reticulata; Receptor, Adenosine A1; Receptors, Dopamine D1; Xanthines | 2014 |
Dynamics of major histocompatibility complex class II-positive cells in the postischemic brain--influence of levodopa treatment.
Topics: Animals; Antigen-Presenting Cells; Benserazide; Brain; Cytokines; Disease Models, Animal; Dopamine Agents; Drug Combinations; Flow Cytometry; Functional Laterality; Histocompatibility Antigens Class II; Infarction, Middle Cerebral Artery; Levodopa; Macrophages; Male; Microglia; Rats; Rats, Sprague-Dawley; Rats, Wistar | 2014 |
VMAT2 and Parkinson's disease: harnessing the dopamine vesicle.
Topics: Animals; Disease Models, Animal; Dopamine; Humans; Levodopa; Mice; Neurons; Parkinson Disease; Vesicular Monoamine Transport Proteins | 2014 |
Dopamine signaling leads to loss of Polycomb repression and aberrant gene activation in experimental parkinsonism.
Topics: Animals; Disease Models, Animal; Dopamine; Dopamine and cAMP-Regulated Phosphoprotein 32; Female; Gene Expression Regulation; Genetic Loci; Histones; Levodopa; Mice; Mice, Knockout; Parkinsonian Disorders; Phosphorylation; Polycomb-Group Proteins; Protein Binding; Ribosomal Protein S6 Kinases, 90-kDa; RNA, Messenger; Signal Transduction; Transcriptional Activation | 2014 |
Nitric oxide synthase inhibition decreases l-DOPA-induced dyskinesia and the expression of striatal molecular markers in Pitx3(-/-) aphakia mice.
Topics: Animals; Antiparkinson Agents; Benserazide; Cell Count; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Gene Expression Regulation; Homeodomain Proteins; Indazoles; Levodopa; Mice; Mice, Knockout; Molsidomine; Nitric Oxide Donors; Parkinson Disease; Signal Transduction; Time Factors; Transcription Factors | 2015 |
L-745,870 reduces the expression of abnormal involuntary movements in the 6-OHDA-lesioned rat.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Female; Levodopa; Oxidopamine; Parkinsonian Disorders; Pyridines; Pyrroles; Rats; Rats, Sprague-Dawley; Species Specificity | 2015 |
Interactions of CaMKII with dopamine D2 receptors: roles in levodopa-induced dyskinesia in 6-hydroxydopamine lesioned Parkinson's rats.
Topics: Amino Acid Motifs; Animals; Binding Sites; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Corpus Striatum; Disease Models, Animal; Dyskinesias; Female; Levodopa; Neurons; Oxidopamine; Parkinson Disease; Protein Binding; Protein Interaction Domains and Motifs; Rats; Receptors, Dopamine D2 | 2014 |
Involvement of cholinergic system in hyperactivity in dopamine-deficient mice.
Topics: Acetylcholine; Akathisia, Drug-Induced; Animals; Anti-Dyskinesia Agents; Antipsychotic Agents; Central Nervous System Stimulants; Choline O-Acetyltransferase; Clozapine; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Extracellular Space; Haloperidol; Levodopa; Locomotion; Mice, Inbred C57BL; Piperazines; Psychomotor Agitation; Thiazoles | 2015 |
A rat model of striatonigral degeneration generated by simultaneous injection of 6-hydroxydopamine into the medial forebrain bundle and quinolinic acid into the striatum.
Topics: Animals; Apomorphine; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine Plasma Membrane Transport Proteins; Glucose; Injections, Intraperitoneal; Levodopa; Male; Medial Forebrain Bundle; Oxidopamine; Parkinson Disease; Positron-Emission Tomography; Quinolinic Acid; Rats; Rats, Wistar; Striatonigral Degeneration; Touch | 2014 |
Inhibiting Lateral Habenula Improves L-DOPA-Induced Dyskinesia.
Topics: Animals; Corpus Striatum; Daunorubicin; Deoxyglucose; Disease Models, Animal; Dyskinesia, Drug-Induced; Electrophysiology; Female; Genes, Immediate-Early; Habenula; Levodopa; Macaca fascicularis; Male; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley | 2016 |
Glial activation is associated with l-DOPA induced dyskinesia and blocked by a nitric oxide synthase inhibitor in a rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Indazoles; Inflammation; Levodopa; Male; Neuroglia; Neuroprotective Agents; Nitric Oxide; Nitric Oxide Synthase; Parkinson Disease; Rats; Rats, Wistar; Up-Regulation | 2015 |
Postsynaptic density protein 95-regulated NR2B tyrosine phosphorylation and interactions of Fyn with NR2B in levodopa-induced dyskinesia rat models.
Topics: Animals; Disease Models, Animal; Disks Large Homolog 4 Protein; Dyskinesia, Drug-Induced; Female; Intracellular Signaling Peptides and Proteins; Levodopa; Membrane Proteins; Oxidopamine; Parkinson Disease; Phosphorylation; Proto-Oncogene Proteins c-fyn; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate | 2015 |
NR2B antagonist CP-101,606 inhibits NR2B phosphorylation at tyrosine-1472 and its interactions with Fyn in levodopa-induced dyskinesia rat model.
Topics: Animals; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Levodopa; Phosphorylation; Piperidines; Proto-Oncogene Proteins c-fyn; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Tyrosine | 2015 |
Lipid nanocarriers containing a levodopa prodrug with potential antiparkinsonian activity.
Topics: Animals; Antiparkinson Agents; Calorimetry, Differential Scanning; Cryoelectron Microscopy; Disease Models, Animal; Drug Carriers; Lecithins; Levodopa; Lipids; Mice, Inbred C57BL; Parkinson Disease; Prodrugs; Spectroscopy, Fourier Transform Infrared; Triglycerides | 2015 |
Evidence of an association between sleep and levodopa-induced dyskinesia in an animal model of Parkinson's disease.
Topics: Animals; Disease Models, Animal; Disease Progression; Dyskinesia, Drug-Induced; Homeostasis; Levodopa; Male; Neuronal Plasticity; Parkinson Disease; Rats, Sprague-Dawley; Sleep; Sleep Deprivation | 2015 |
Activity of serotonin 5-HT(1A) receptor 'biased agonists' in rat models of Parkinson's disease and L-DOPA-induced dyskinesia.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Motor Activity; Neurotransmitter Agents; Oxidopamine; Parkinson Disease; Piperidines; Psychomotor Performance; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Serotonin; Serotonin 5-HT1 Receptor Agonists; Tyrosine 3-Monooxygenase | 2015 |
Enhanced histamine H2 excitation of striatal cholinergic interneurons in L-DOPA-induced dyskinesia.
Topics: Action Potentials; Animals; Cholinergic Neurons; Corpus Striatum; Dicyclomine; Disease Models, Animal; Dyskinesia, Drug-Induced; Famotidine; Histamine H2 Antagonists; Interneurons; Levodopa; Mice; Mice, Inbred C57BL; Parkinson Disease; Receptors, Histamine H2 | 2015 |
Neuroprotective effects of 5-(4-hydroxy-3-dimethoxybenzylidene)-thiazolidinone in MPTP induced Parkinsonism model in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Animals, Newborn; Benzylidene Compounds; Cells, Cultured; Disease Models, Animal; Levodopa; Male; Membrane Potential, Mitochondrial; Mesencephalon; Mice; Mice, Inbred C57BL; Mitochondria; Mitochondrial Proteins; MPTP Poisoning; Neuroblastoma; Neurons; Neuroprotective Agents; Neurotoxins; Psychomotor Performance; rho GTP-Binding Proteins; Thiazolidinediones; Time Factors; Tyrosine 3-Monooxygenase | 2015 |
Disturbance of sensorimotor filtering in the 6-OHDA rodent model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Disease Models, Animal; Humans; Levodopa; Male; Mice; Oxidopamine; Parkinson Disease, Secondary; Prepulse Inhibition; Rats; Rats, Wistar | 2015 |
Chronic L-DOPA induces hyperactivity, normalization of gait and dyskinetic behavior in MitoPark mice.
Topics: Animals; Behavior, Animal; Benserazide; Disease Models, Animal; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Gait; Levodopa; Male; Mice; Mice, Inbred C57BL; Motor Activity; Parkinson Disease; Random Allocation | 2015 |
Interrogating the aged striatum: robust survival of grafted dopamine neurons in aging rats produces inferior behavioral recovery and evidence of impaired integration.
Topics: Aging; Amphetamine; Animals; Corpus Striatum; Disease Models, Animal; Dopamine and cAMP-Regulated Phosphoprotein 32; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Embryo, Mammalian; Functional Laterality; Levodopa; Neurites; Oxidopamine; Parkinson Disease; Proto-Oncogene Proteins c-fos; Rats; Rats, Inbred F344; Recovery of Function; Stem Cell Transplantation; Substance P | 2015 |
Effect of simvastatin on L-DOPA-induced abnormal involuntary movements of hemiparkinsonian rats.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Levodopa; Male; MAP Kinase Signaling System; Oncogene Proteins v-fos; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Simvastatin; Time Factors | 2015 |
Deep brain stimulation of different pedunculopontine targets in a novel rodent model of parkinsonism.
Topics: Animals; Cell Survival; Cholinergic Neurons; Deep Brain Stimulation; Disease Models, Animal; Dopaminergic Neurons; Gait; Ibotenic Acid; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Pedunculopontine Tegmental Nucleus; Postural Balance; Rats | 2015 |
Evidence for a role for α6(∗) nAChRs in l-dopa-induced dyskinesias using Parkinsonian α6(∗) nAChR gain-of-function mice.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Antiparkinson Agents; Benserazide; Cocaine; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Levodopa; Male; Mice; Mice, Transgenic; Nicotine; Nicotinic Agonists; Oxidopamine; Parkinsonian Disorders; Protein Binding; Receptors, Nicotinic | 2015 |
Dual κ-agonist/μ-antagonist opioid receptor modulation reduces levodopa-induced dyskinesia and corrects dysregulated striatal changes in the nonhuman primate model of Parkinson disease.
Topics: Analgesics, Opioid; Animals; Antiparkinson Agents; Disease Models, Animal; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca; Male; Nalbuphine; Neostriatum; Parkinson Disease; Receptors, Opioid, kappa; Receptors, Opioid, mu | 2015 |
Striatal tyrosine hydroxylase-positive neurons are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice.
Topics: Amphetamine; Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Functional Laterality; Levodopa; Male; Medial Forebrain Bundle; Mice; Mice, Inbred C57BL; Neurons; Oxidopamine; Parkinson Disease; Phosphopyruvate Hydratase; Proto-Oncogene Proteins c-fos; Serotonin Plasma Membrane Transport Proteins; Statistics, Nonparametric; Tyrosine 3-Monooxygenase | 2015 |
In vivo characterization of a novel dopamine D3 receptor agonist to treat motor symptoms of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Butylamines; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Levodopa; Male; Motor Activity; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D3 | 2016 |
Effect of serotonin transporter blockade on L-DOPA-induced dyskinesia in animal models of Parkinson's disease.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Citalopram; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Male; MPTP Poisoning; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Time Factors; Tyrosine 3-Monooxygenase | 2015 |
Coadministration of hydroxysafflor yellow A with levodopa attenuates the dyskinesia.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Antiparkinson Agents; Apomorphine; Chalcone; Disease Models, Animal; Levodopa; Male; Motor Activity; Olfaction Disorders; Oxidopamine; Parkinson Disease; Quinones; Rats; Receptors, Dopamine D3; Time Factors | 2015 |
Targeting β-arrestin2 in the treatment of L-DOPA-induced dyskinesia in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Arrestins; Behavior, Animal; beta-Arrestins; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Dyskinesias; Gene Deletion; Levodopa; Macaca; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Neurons; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Signal Transduction; Up-Regulation | 2015 |
Subthalamic nucleus activity in the awake hemiparkinsonian rat: relationships with motor and cognitive networks.
Topics: Action Potentials; Adrenergic Agents; Animals; Antiparkinson Agents; Benzazepines; Cognition Disorders; Disease Models, Animal; Dopamine Antagonists; Evoked Potentials; Functional Laterality; Levodopa; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Long-Evans; Subthalamic Nucleus; Time Factors; Tyrosine 3-Monooxygenase; Wakefulness | 2015 |
Changes in glutamate receptors in dyskinetic parkinsonian monkeys after unilateral subthalamotomy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Basal Ganglia; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca; Parkinsonian Disorders; Receptors, Glutamate; Subthalamic Nucleus | 2015 |
Similar L-dopa-stimulated motor activity in mice with adult-onset 6-hydroxydopamine-induced symmetric dopamine denervation and in transcription factor Pitx3 null mice with perinatal-onset symmetric dopamine denervation.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopaminergic Neurons; Homeodomain Proteins; Levodopa; Male; Mice; Mice, Knockout; Motor Activity; Oxidopamine; Parkinsonian Disorders; Transcription Factors | 2015 |
Contrasting gene expression patterns induced by levodopa and pramipexole treatments in the rat model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Benzothiazoles; Cluster Analysis; Disease Models, Animal; Dose-Response Relationship, Drug; Gene Expression Regulation; Levodopa; Male; Microarray Analysis; Oxidopamine; Parkinson Disease; Pramipexole; Rats; Rats, Wistar; Tyrosine 3-Monooxygenase | 2016 |
Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Apomorphine; Disease Models, Animal; Dopamine; Dopamine Agonists; Drug Administration Schedule; Dyskinesia, Drug-Induced; Gene Expression Regulation; Indoles; Levodopa; Male; MAP Kinase Signaling System; Motor Activity; Neurokinin-1 Receptor Antagonists; Oxidopamine; Parkinson Disease; Piperidines; Rats; Rats, Sprague-Dawley; Substantia Nigra; Time Factors | 2015 |
NLX-112, a novel 5-HT1A receptor agonist for the treatment of L-DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Brain; Catalepsy; Disease Models, Animal; Drug Interactions; Dyskinesia, Drug-Induced; Female; Haloperidol; Levodopa; Movement; Neurotransmitter Agents; Oxidopamine; Piperidines; Psychomotor Performance; Pyridines; Rats; Rats, Sprague-Dawley; Serotonin 5-HT1 Receptor Agonists; Serotonin Syndrome; Swimming; Vocalization, Animal | 2015 |
GRK3 suppresses L-DOPA-induced dyskinesia in the rat model of Parkinson's disease via its RGS homology domain.
Topics: Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dyskinesias; G-Protein-Coupled Receptor Kinase 3; Gene Expression; Gene Knockdown Techniques; Levodopa; Parkinson Disease; Protein Interaction Domains and Motifs; Rats; RGS Proteins; RNA Interference; RNA, Small Interfering; Signal Transduction | 2015 |
Anti-hyperalgesic and Anti-inflammatory Activity of Alternanthera Maritima Extract and 2″-O-α-L-rhamnopyranosylvitexin in Mice.
Topics: Amaranthaceae; Analgesics; Animals; Anti-Inflammatory Agents; Apigenin; Carrageenan; Chemotaxis, Leukocyte; Disaccharides; Disease Models, Animal; Dose-Response Relationship, Drug; Edema; Female; Flavones; Hyperalgesia; Levodopa; Male; Mice; Pain Threshold; Phytotherapy; Plant Components, Aerial; Plant Extracts; Plants, Medicinal; Pleurisy; Time Factors; Tumor Necrosis Factor-alpha | 2015 |
L-Dopa induced dyskinesias in Parkinsonian mice: Disease severity or L-Dopa history.
Topics: Animals; Antidiarrheals; Benserazide; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Locomotion; Mice; Parkinson Disease; Receptors, Neurotransmitter; Severity of Illness Index; Time Factors | 2015 |
Behavioural impact of a double dopaminergic and serotonergic lesion in the non-human primate.
Topics: Aniline Compounds; Animals; Antiparkinson Agents; Brain; Brain Mapping; Chlorocebus aethiops; Disease Models, Animal; Dopamine; Dopamine Agents; Female; Levodopa; Macaca fascicularis; Male; Mental Disorders; MPTP Poisoning; N-Methyl-3,4-methylenedioxyamphetamine; Nortropanes; Radionuclide Imaging; Serotonin; Serotonin Agents; Sulfides | 2015 |
Loss of glutamic acid decarboxylase (Gad67) in striatal neurons expressing the Drdr1a dopamine receptor prevents L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned mice.
Topics: Animals; Antiparkinson Agents; Benzazepines; Corpus Striatum; Disease Models, Animal; Dopamine Antagonists; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Glutamate Decarboxylase; Levodopa; Medial Forebrain Bundle; Mice; Mice, Inbred C57BL; Mice, Transgenic; Motor Activity; Oxidopamine; Parkinson Disease; Psychomotor Performance; Receptors, Dopamine D1; Receptors, G-Protein-Coupled | 2015 |
Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Functional Laterality; gamma-Aminobutyric Acid; Gene Expression Regulation; Glutamic Acid; Levodopa; Male; MAP Kinase Signaling System; Motor Activity; Oxidopamine; Parkinson Disease; Piperazines; Rats; Rats, Sprague-Dawley; Serotonin Receptor Agonists; Time Factors | 2015 |
A new knock-in mouse model of l-DOPA-responsive dystonia.
Topics: Animals; Benzazepines; Brain; Catecholamines; Disease Models, Animal; Dopamine Agents; Dopamine Antagonists; Dopamine Plasma Membrane Transport Proteins; Dystonia; Humans; Levodopa; Mice; Mice, Inbred C57BL; Mice, Transgenic; Motor Activity; Mutation; Radionuclide Imaging; Stereotyped Behavior; Tritium; Tyrosine 3-Monooxygenase | 2015 |
Brain catecholamine depletion and motor impairment in a Th knock-in mouse with type B tyrosine hydroxylase deficiency.
Topics: Animals; Biopterins; Brain; Catecholamines; Disease Models, Animal; Dopamine Agents; Eating; Female; Gene Expression Regulation; Gene Knock-In Techniques; Levodopa; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Motor Activity; Movement Disorders; Mutation; Thyroxine; Tyrosine 3-Monooxygenase | 2015 |
The preferential nNOS inhibitor 7-nitroindazole and the non-selective one N(G)-nitro-L-arginine methyl ester administered alone or jointly with L-DOPA differentially affect motor behavior and monoamine metabolism in sham-operated and 6-OHDA-lesioned rats.
Topics: Adrenergic Agents; Animals; Apomorphine; Biogenic Monoamines; Brain; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Interactions; Indazoles; Levodopa; Locomotion; Male; Movement Disorders; Neuroprotective Agents; NG-Nitroarginine Methyl Ester; Oxidopamine; Rats; Rats, Wistar; Time Factors | 2015 |
Behavioural Assessment of the A2a/NR2B Combination in the Unilateral 6-OHDA-Lesioned Rat Model: A New Method to Examine the Therapeutic Potential of Non-Dopaminergic Drugs.
Topics: Adenosine A2 Receptor Antagonists; Animals; Benserazide; Benzothiazoles; Disease Models, Animal; Dopamine; Dopamine Agents; Drug Combinations; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease; Rats; Receptors, N-Methyl-D-Aspartate | 2015 |
Depressive-like behavior observed with a minimal loss of locus coeruleus (LC) neurons following administration of 6-hydroxydopamine is associated with electrophysiological changes and reversed with precursors of norepinephrine.
Topics: Action Potentials; Adrenergic Agents; Animals; Catecholamines; Depression; Disease Models, Animal; Dopamine Agents; Dose-Response Relationship, Drug; Food Preferences; Levodopa; Locus Coeruleus; Male; Mice; Mice, Inbred C57BL; Neurons; Oxidopamine; Phenazines; Sucrose; Swimming; Time Factors | 2016 |
Alterations in primary motor cortex neurotransmission and gene expression in hemi-parkinsonian rats with drug-induced dyskinesia.
Topics: AIDS-Related Complex; Animals; Benzazepines; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Functional Laterality; Gene Expression; Levodopa; Male; Medial Forebrain Bundle; Motor Cortex; Oxidopamine; Parkinsonian Disorders; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Severity of Illness Index; Synaptic Transmission | 2015 |
L-DOPA modulates cell viability through the ERK-c-Jun system in PC12 and dopaminergic neuronal cells.
Topics: Adrenergic Agents; Animals; Caspase 3; Cell Survival; Cells, Cultured; Disease Models, Animal; Dopamine Agents; Dopaminergic Neurons; Embryo, Mammalian; Enzyme Inhibitors; Gene Expression Regulation; Levodopa; MAP Kinase Signaling System; Mesencephalon; Oxidopamine; Parkinson Disease; PC12 Cells; Proto-Oncogene Proteins c-jun; Rats; Rats, Sprague-Dawley; Time Factors | 2016 |
Effect of melatonin on sleep disorders in a monkey model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Central Nervous System Depressants; Disease Models, Animal; Levodopa; Macaca fascicularis; Male; Melatonin; Parkinson Disease; Sleep Wake Disorders | 2015 |
Amelioration of L-Dopa-Associated Dyskinesias with Triterpenoic Acid in a Parkinsonian Rat Model.
Topics: Adrenergic Agents; Age Factors; Animals; Animals, Newborn; Antiparkinson Agents; Catalase; Disease Models, Animal; Dyskinesia, Drug-Induced; Extremities; Female; Glutathione; Levodopa; Male; Movement; Oleanolic Acid; Oxidopamine; Parkinsonian Disorders; Pregnancy; Rats; Rats, Sprague-Dawley; Statistics, Nonparametric | 2016 |
Modulation by Trace Amine-Associated Receptor 1 of Experimental Parkinsonism, L-DOPA Responsivity, and Glutamatergic Neurotransmission.
Topics: Adrenergic Agents; Akathisia, Drug-Induced; Animals; Antiparkinson Agents; Cocaine; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine and cAMP-Regulated Phosphoprotein 32; Dopamine Plasma Membrane Transport Proteins; Glutamic Acid; Levodopa; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Oligodeoxyribonucleotides, Antisense; Oxidopamine; Parkinsonian Disorders; Radiopharmaceuticals; Receptors, G-Protein-Coupled; Stereotyped Behavior; Synaptic Transmission; Time Factors; Tyrosine 3-Monooxygenase | 2015 |
Striatal NELF-mediated RNA polymerase II stalling controls L-dopa induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Cell Culture Techniques; Corpus Striatum; Cytoskeletal Proteins; Disease Models, Animal; Dyskinesia, Drug-Induced; Early Growth Response Protein 1; Levodopa; Male; Nerve Tissue Proteins; Neurons; Proto-Oncogene Proteins c-fos; Rats, Sprague-Dawley; RNA Polymerase II; Transcription Factors | 2016 |
Genetic deletion of Rhes or pharmacological blockade of mTORC1 prevent striato-nigral neurons activation in levodopa-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Glutamic Acid; GTP-Binding Proteins; Levodopa; Male; Mechanistic Target of Rapamycin Complex 1; Mice, Inbred C57BL; Mice, Knockout; Motor Activity; Multiprotein Complexes; Neurons; Neuroprotective Agents; Sirolimus; Substantia Nigra; TOR Serine-Threonine Kinases | 2016 |
Loss of VGLUT3 Produces Circadian-Dependent Hyperdopaminergia and Ameliorates Motor Dysfunction and l-Dopa-Mediated Dyskinesias in a Model of Parkinson's Disease.
Topics: Amino Acid Transport Systems, Acidic; Animals; Circadian Rhythm; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Mice; Mice, 129 Strain; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Motor Skills Disorders; Parkinsonian Disorders | 2015 |
[An implication of serotonergic fibers which goes beyond Levodopa-induced dyskinesia].
Topics: Animals; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Levodopa; Macaca; Parkinson Disease; Serotonergic Neurons | 2015 |
Effects of L-dopa priming on cortical high beta and high gamma oscillatory activity in a rodent model of Parkinson's disease.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Benzazepines; Disease Models, Animal; Dopamine Agonists; Dyskinesia, Drug-Induced; Gamma Rhythm; Levodopa; Male; Motor Activity; Motor Cortex; Neurons; Oxidopamine; Parkinsonian Disorders; Quinpirole; Rats; Rats, Sprague-Dawley; Serotonin Receptor Agonists | 2016 |
M4 Muscarinic Receptor Signaling Ameliorates Striatal Plasticity Deficits in Models of L-DOPA-Induced Dyskinesia.
Topics: Allosteric Regulation; Animals; Cerebral Cortex; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Glutamic Acid; Levodopa; Long-Term Potentiation; Long-Term Synaptic Depression; Macaca mulatta; Mice; Mice, Transgenic; Neostriatum; Neuronal Plasticity; Neurons; Parkinsonian Disorders; Receptor, Muscarinic M4; RGS Proteins; Signal Transduction | 2015 |
Buspirone requires the intact nigrostriatal pathway to reduce the activity of the subthalamic nucleus via 5-HT1A receptors.
Topics: Action Potentials; Adrenergic Agents; Adrenergic Uptake Inhibitors; Animals; Buspirone; Desipramine; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Neurons; Neurotoxicity Syndromes; Oxidopamine; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Serotonin Receptor Agonists; Subthalamic Nucleus | 2016 |
Role of the atypical vesicular glutamate transporter VGLUT3 in l-DOPA-induced dyskinesia.
Topics: Amino Acid Transport Systems, Acidic; Animals; Antiparkinson Agents; Cell Count; Cell Size; Choline O-Acetyltransferase; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Male; Mice, Inbred C57BL; Mice, Transgenic; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neurons; Oxidopamine; Parkinsonian Disorders; Phosphorylation; Receptors, AMPA; Ribosomal Protein S6; Vesicular Acetylcholine Transport Proteins | 2016 |
Systems-level neurophysiological state characteristics for drug evaluation in an animal model of levodopa-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Brain Waves; Disease Models, Animal; Dopaminergic Neurons; Drug Evaluation, Preclinical; Dyskinesia, Drug-Induced; Electroencephalography; Female; Levodopa; Rats; Rats, Sprague-Dawley | 2016 |
LRRK2 BAC transgenic rats develop progressive, L-DOPA-responsive motor impairment, and deficits in dopamine circuit function.
Topics: Action Potentials; Aging; Amino Acid Substitution; Animals; Antiparkinson Agents; Cell Death; Chromosomes, Artificial, Bacterial; Corpus Striatum; Disease Models, Animal; Dopaminergic Neurons; Female; Humans; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Levodopa; Male; Mutation; Parkinson Disease; Promoter Regions, Genetic; Protein Domains; Rats; Rats, Transgenic; Substantia Nigra | 2016 |
On the Effect of Eltoprazine in Dyskinetic Hemiparkinsonian Rats.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Parkinson Disease; Piperazines; Rats; Serotonin Receptor Agonists | 2016 |
Permeability of blood-brain barrier in macaque model of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Blood-Brain Barrier; Brain; Disease Models, Animal; Dopamine; Levodopa; Macaca; Male; Parkinson Disease; Parkinson Disease, Secondary; Permeability; Pyridines | 2016 |
Production of Dopamine by Aromatic l-Amino Acid Decarboxylase Cells after Spinal Cord Injury.
Topics: Animals; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Aromatic-L-Amino-Acid Decarboxylases; Disease Models, Animal; Dopamine; Levodopa; Male; Motor Neurons; Rats; Rats, Wistar; Spinal Cord Injuries | 2016 |
Chronic L-DOPA administration increases the firing rate but does not reverse enhanced slow frequency oscillatory activity and synchronization in substantia nigra pars reticulata neurons from 6-hydroxydopamine-lesioned rats.
Topics: Action Potentials; Animals; Brain; Brain Waves; Cerebral Cortex; Disease Models, Animal; Dyskinesia, Drug-Induced; GABAergic Neurons; Levodopa; Neurons; Oxidopamine; Parkinsonian Disorders; Pars Reticulata; Rats; Rats, Sprague-Dawley; Subthalamic Nucleus | 2016 |
DopAmide: Novel, Water-Soluble, Slow-Release l-dihydroxyphenylalanine (l-DOPA) Precursor Moderates l-DOPA Conversion to Dopamine and Generates a Sustained Level of Dopamine at Dopaminergic Neurons.
Topics: Amphetamine; Analysis of Variance; Animals; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Carbidopa; Central Nervous System Stimulants; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Dose-Response Relationship, Drug; Levodopa; Male; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; Rotation; Sympatholytics; Time Factors | 2016 |
Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Male; Parkinson Disease; Piperazines; Pyrimidines; Rats; Rats, Sprague-Dawley; Serotonin Receptor Agonists; Triazoles | 2016 |
Gadd45β ameliorates L-DOPA-induced dyskinesia in a Parkinson's disease mouse model.
Topics: Animals; Antigens, Differentiation; Cyclic AMP-Dependent Protein Kinases; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Male; MAP Kinase Signaling System; Mice; Mice, Knockout; Motor Activity; Oxidopamine; Parkinsonian Disorders; Receptors, Dopamine D1; RNA, Messenger; Substantia Nigra | 2016 |
Shp-2 knockdown prevents l-dopa-induced dyskinesia in a rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Down-Regulation; Dyskinesia, Drug-Induced; Levodopa; Male; Neostriatum; Parkinson Disease; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Rats; Rats, Wistar | 2016 |
Optogenetic Inhibition of the Subthalamic Nucleus Reduces Levodopa-Induced Dyskinesias in a Rat Model of Parkinson's Disease.
Topics: Animals; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Optogenetics; Parkinson Disease; Rats; Subthalamic Nucleus | 2016 |
Vocal training, levodopa, and environment effects on ultrasonic vocalizations in a rat neurotoxin model of Parkinson disease.
Topics: Animals; Antiparkinson Agents; Apomorphine; Carbidopa; Communication Disorders; Disease Models, Animal; Dopamine; Dopamine Agonists; Drug Combinations; Fourier Analysis; Levodopa; Male; Neurotoxins; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Long-Evans; Stereotyped Behavior; Time Factors; Ultrasonics; Vocalization, Animal | 2016 |
Antidyskinetic Effect of 7-Nitroindazole and Sodium Nitroprusside Associated with Amantadine in a Rat Model of Parkinson's Disease.
Topics: Amantadine; Animals; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Indazoles; Levodopa; Male; Medial Forebrain Bundle; Microinjections; Nitroprusside; Oxidopamine; Parkinson Disease; Rats | 2016 |
Enkephalin and dynorphin neuropeptides are differently correlated with locomotor hypersensitivity and levodopa-induced dyskinesia in parkinsonian rats.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Disease Models, Animal; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Female; Gene Expression Regulation; Levodopa; Oxidopamine; Parkinson Disease; Protein Precursors; Rats; Rats, Sprague-Dawley; Receptors, Dopamine; RNA, Messenger; Statistics as Topic; Sympatholytics; Tyrosine 3-Monooxygenase | 2016 |
Restoration of the Dopamine Transporter through Cell Therapy Improves Dyskinesia in a Rat Model of Parkinson's Disease.
Topics: Animals; Behavior, Animal; Brain; Cell Line; Cell- and Tissue-Based Therapy; Disease Models, Animal; Dopamine; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Levodopa; Male; Mice; Neural Stem Cells; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar | 2016 |
The network of causal interactions for beta oscillations in the pedunculopontine nucleus, primary motor cortex, and subthalamic nucleus of walking parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Beta Rhythm; Disease Models, Animal; Levodopa; Male; Motor Cortex; Oxidopamine; Parkinson Disease; Pedunculopontine Tegmental Nucleus; Rats; Rats, Sprague-Dawley; Spectrum Analysis; Subthalamic Nucleus; Tyrosine 3-Monooxygenase; Walking | 2016 |
LRRK2 phosphorylation level correlates with abnormal motor behaviour in an experimental model of levodopa-induced dyskinesias.
Topics: Animals; Disease Models, Animal; Dyskinesias; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease; Phosphorylation; Protein Kinase Inhibitors; Rats, Sprague-Dawley | 2016 |
L-DOPA elicits non-vesicular releases of serotonin and dopamine in hemiparkinsonian rats in vivo.
Topics: Action Potentials; Animals; Antiparkinson Agents; Cholestanols; Citalopram; Disease Models, Animal; Dopamine Agents; Dopaminergic Neurons; Dose-Response Relationship, Drug; Hippocampus; Hydroxyindoleacetic Acid; Levodopa; Male; Organ Specificity; Parkinson Disease; Prefrontal Cortex; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Serotonergic Neurons; Serotonin; Single-Cell Analysis; Synaptic Transmission | 2016 |
L-DOPA treatment in MPTP-mouse model of Parkinson's disease potentiates homocysteine accumulation in substantia nigra.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopaminergic Neurons; Homocysteine; Levodopa; Male; Mice; Motor Activity; Parkinsonian Disorders; Substantia Nigra; Tyrosine 3-Monooxygenase | 2016 |
Dynamic DNA Methylation Regulates Levodopa-Induced Dyskinesia.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Corpus Striatum; Dioxygenases; Disease Models, Animal; DNA Methylation; Dopamine; Dyskinesia, Drug-Induced; Enzyme Inhibitors; GADD45 Proteins; Gene Expression Regulation; Immunoprecipitation; Intracellular Signaling Peptides and Proteins; Levodopa; Male; Medial Forebrain Bundle; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Phthalimides; Rats; Rats, Sprague-Dawley; Tryptophan | 2016 |
Dramatic differences in susceptibility to l-DOPA-induced dyskinesia between mice that are aged before or after a nigrostriatal dopamine lesion.
Topics: Aging; Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Mice, Inbred C57BL; Motor Activity; Oxidopamine; Parkinson Disease | 2016 |
l-DOPA-induced dyskinesia is associated with a deficient numerical downregulation of striatal tyrosine hydroxylase mRNA-expressing neurons.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Down-Regulation; Dyskinesia, Drug-Induced; Enkephalins; Levodopa; Male; Medial Forebrain Bundle; Mice, Inbred C57BL; Neuronal Plasticity; Neurons; Oxidopamine; Protein Precursors; RNA, Messenger; Tyrosine 3-Monooxygenase | 2016 |
Oxidation and interaction of DJ-1 with 20S proteasome in the erythrocytes of early stage Parkinson's disease patients.
Topics: Aged; Animals; Cysteine; Disease Models, Animal; Erythrocytes; Female; Humans; Levodopa; Macaca fascicularis; Male; Middle Aged; Oxidative Stress; Parkinson Disease; Proteasome Endopeptidase Complex; Protein Deglycase DJ-1; Protein Multimerization | 2016 |
Effect of l-DOPA on local field potential relationship between the pedunculopontine nucleus and primary motor cortex in a rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Benserazide; Conditioning, Operant; Disease Models, Animal; Evoked Potentials; Fourier Analysis; Levodopa; Locomotion; Male; Motor Cortex; Oxidopamine; Parkinson Disease; Pedunculopontine Tegmental Nucleus; Rats; Rats, Wistar; Time Factors | 2016 |
Dissociation of metabolic and hemodynamic levodopa responses in the 6-hydroxydopamine rat model.
Topics: Analgesics; Animals; Antiparkinson Agents; Cerebrovascular Circulation; Disease Models, Animal; Female; Fluorodeoxyglucose F18; Hemodynamics; Isoflurane; Ketamine; Levodopa; Oxidopamine; Parkinson Disease; Positron-Emission Tomography; Rats; Rats, Sprague-Dawley; Sympatholytics | 2016 |
Involvement of Striatal Cholinergic Interneurons and M1 and M4 Muscarinic Receptors in Motor Symptoms of Parkinson's Disease.
Topics: Adrenergic Agents; Amphetamine; Analysis of Variance; Animals; Choline O-Acetyltransferase; Cholinergic Neurons; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Exploratory Behavior; Functional Laterality; Genotype; Hypokinesia; Levodopa; Luminescent Proteins; Male; Maze Learning; Mice; Mice, Inbred C57BL; Mice, Transgenic; Mutation; Optogenetics; Oxidopamine; Parkinson Disease; Receptor, Muscarinic M1; Receptor, Muscarinic M4; Transduction, Genetic | 2016 |
Validation of an improved scale for rating l-DOPA-induced dyskinesia in the mouse and effects of specific dopamine receptor antagonists.
Topics: Analysis of Variance; Animals; Disease Models, Animal; Dopamine Agents; Dopamine Antagonists; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Exploratory Behavior; Levodopa; Male; Mice; Mice, Inbred C57BL; Movement; Outcome Assessment, Health Care; Oxidopamine; Parkinson Disease; Reproducibility of Results; Time Factors | 2016 |
L-DOPA Oppositely Regulates Synaptic Strength and Spine Morphology in D1 and D2 Striatal Projection Neurons in Dyskinesia.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Excitatory Postsynaptic Potentials; Female; Levodopa; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neurons; Oxidopamine; Parkinson Disease, Secondary; Receptors, Dopamine D1; Receptors, Dopamine D2; Spine; Sympatholytics | 2016 |
Repetitive transcranial magnetic stimulation (rTMS) improves behavioral and biochemical deficits in levodopa-induced dyskinetic rats model.
Topics: Animals; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Female; Glial Cell Line-Derived Neurotrophic Factor; Humans; Levodopa; Parkinson Disease; Problem Behavior; Proto-Oncogene Proteins c-fyn; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Transcranial Magnetic Stimulation; Tyrosine 3-Monooxygenase | 2016 |
The Role of Primary Motor Cortex (M1) Glutamate and GABA Signaling in l-DOPA-Induced Dyskinesia in Parkinsonian Rats.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Excitatory Amino Acid Agents; GABA Agents; gamma-Aminobutyric Acid; Glutamic Acid; Levodopa; Male; Motor Cortex; Movement; Oxidopamine; Parkinsonian Disorders; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Signal Transduction; Sympatholytics; Tardive Dyskinesia | 2016 |
The impact of l-dopa on attentional impairments in a rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Attention; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Male; Medial Forebrain Bundle; Motor Activity; Oxidopamine; Parkinson Disease; Rats, Sprague-Dawley | 2016 |
Continuous MPTP intoxication in the Göttingen minipig results in chronic parkinsonian deficits.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Drinking; Drug Administration Schedule; Drug Delivery Systems; Eating; Female; Injections, Intramuscular; Levodopa; Neurotoxins; Parkinsonian Disorders; Severity of Illness Index; Swine; Swine, Miniature; Time Factors | 2016 |
Differential induction of dyskinesia and neuroinflammation by pulsatile versus continuous l-DOPA delivery in the 6-OHDA model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Cytokines; Disease Models, Animal; Drug Delivery Systems; Dyskinesia, Drug-Induced; Encephalitis; Functional Laterality; Gene Expression Regulation; Levodopa; Lipopolysaccharides; Male; Nerve Tissue Proteins; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; RNA, Messenger; Sympatholytics; Tumor Necrosis Factor-alpha | 2016 |
MPTP Induces Systemic Parkinsonism in Middle-Aged Cynomolgus Monkeys: Clinical Evolution and Outcomes.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Female; Levodopa; Macaca fascicularis; Male; Motor Activity; MPTP Poisoning; Severity of Illness Index; Time Factors; Treatment Outcome; Video Recording | 2017 |
Restoring Spinal Noradrenergic Inhibitory Tone Attenuates Pain Hypersensitivity in a Rat Model of Parkinson's Disease.
Topics: Animals; Benzylamines; Corpus Striatum; Disease Models, Animal; Levodopa; Male; Norepinephrine; Oxidopamine; Pain; Parkinson Disease; Rats, Sprague-Dawley; Spinal Cord | 2016 |
A new brain dopamine-deficient Drosophila and its pharmacological and genetic rescue.
Topics: Animals; Brain; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Drosophila; Levodopa; Male; Neurotransmitter Agents; Tyrosine 3-Monooxygenase | 2017 |
Gynostemma pentaphyllum Ethanolic Extract Protects Against Memory Deficits in an MPTP-Lesioned Mouse Model of Parkinson's Disease Treated with L-DOPA.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Cyclic AMP Response Element-Binding Protein; Disease Models, Animal; Dopamine; Extracellular Signal-Regulated MAP Kinases; Gynostemma; Humans; Levodopa; Male; Memory; Mice; Mice, Inbred C57BL; Parkinson Disease; Plant Extracts; Protective Agents; Substantia Nigra | 2017 |
Depletion of AADC activity in caudate nucleus and putamen of Parkinson's disease patients; implications for ongoing AAV2-AADC gene therapy trial.
Topics: Aged; Aged, 80 and over; Animals; Aromatic-L-Amino-Acid Decarboxylases; Caudate Nucleus; Corpus Striatum; Dependovirus; Disease Models, Animal; Dopamine; Enzyme Activation; Female; Genetic Therapy; Genetic Vectors; Humans; Levodopa; Macaca mulatta; Male; Parkinson Disease; Putamen; Rats | 2017 |
Asymmetric dopaminergic degeneration and levodopa alter functional corticostriatal connectivity bilaterally in experimental parkinsonism.
Topics: Animals; Corpus Striatum; Diffusion Tensor Imaging; Disease Models, Animal; Dopamine; Levodopa; Male; Medial Forebrain Bundle; Parkinsonian Disorders; Rats, Sprague-Dawley; Substantia Nigra | 2017 |
Striatal D1 medium spiny neuron activation induces dyskinesias in parkinsonian mice.
Topics: Animals; Antiparkinson Agents; Channelrhodopsins; Cocaine; Corpus Striatum; Disease Models, Animal; Dopamine Plasma Membrane Transport Proteins; Dyskinesias; Female; Gene Expression Regulation; Levodopa; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neurons; Oxidopamine; Parkinsonian Disorders; Receptors, Dopamine D1; Sympatholytics | 2017 |
Striatal activation by optogenetics induces dyskinesias in the 6-hydroxydopamine rat model of Parkinson disease.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Brain; Channelrhodopsins; Corpus Striatum; Disease Models, Animal; Dynorphins; Dyskinesias; Functional Laterality; Levodopa; Male; Optogenetics; Oxidopamine; Parkinson Disease; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Transduction, Genetic; Tyrosine 3-Monooxygenase | 2017 |
Dysregulation of BET proteins in levodopa-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Azepines; Chromatin Immunoprecipitation; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Protein Domains; Proteins; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; RNA, Messenger; Transcription, Genetic; Triazoles | 2017 |
Moderate traumatic brain injury increases the vulnerability to neurotoxicity induced by systemic administration of 6-hydroxydopamine in mice.
Topics: Animals; Behavior, Animal; Blood-Brain Barrier; Brain; Brain Injuries; Brain Injuries, Traumatic; Corpus Striatum; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Glial Fibrillary Acidic Protein; Levodopa; Mice; Neurodegenerative Diseases; Neurotoxicity Syndromes; Oxidopamine; Tyrosine 3-Monooxygenase | 2017 |
Reuptake of L-DOPA-derived extracellular DA in the striatum of a rodent model of Parkinson's disease via norepinephrine transporter.
Topics: Animals; Antidepressive Agents, Tricyclic; Corpus Striatum; Denervation; Desipramine; Disease Models, Animal; Dopamine; Extracellular Matrix; Levodopa; Male; Microdialysis; Neurons; Norepinephrine; Norepinephrine Plasma Membrane Transport Proteins; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Synapses; Synaptic Transmission | 2008 |
Compromised circadian function in Parkinson's disease: enucleation augments disease severity in the unilateral model.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Behavior, Animal; Circadian Rhythm; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Eye Enucleation; Functional Laterality; Hypothalamic Area, Lateral; Injections, Intraperitoneal; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Severity of Illness Index; Stereotyped Behavior; Substantia Nigra | 2008 |
6-OHDA-induced hemiparkinsonism and chronic L-DOPA treatment increase dopamine D1-stimulated [(3)H]-GABA release and [(3)H]-cAMP production in substantia nigra pars reticulata of the rat.
Topics: 1-Methyl-3-isobutylxanthine; Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Cyclic AMP; Disease Models, Animal; Dopamine Agents; Functional Laterality; gamma-Aminobutyric Acid; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Phosphodiesterase Inhibitors; Rats; Rats, Wistar; Receptors, Dopamine D1; Substantia Nigra; Time Factors; Tritium | 2008 |
Cabergoline and pramipexole fail to modify already established dyskinesias in an animal model of parkinsonism.
Topics: Amphetamine; Animals; Antiparkinson Agents; Behavior, Animal; Benzothiazoles; Cabergoline; Disease Models, Animal; Dopamine Antagonists; Drug Interactions; Dyskinesia, Drug-Induced; Ergolines; Female; Levodopa; Mesencephalon; Oxidopamine; Parkinsonian Disorders; Pramipexole; Rats; Rats, Wistar; Stereotyped Behavior; Tyrosine 3-Monooxygenase | 2008 |
Continuous and intermittent nicotine treatment reduces L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesias in a rat model of Parkinson's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Infusion Pumps; Levodopa; Male; Nicotine; Parkinson Disease; Rats; Rats, Sprague-Dawley | 2008 |
Inversion of dopamine responses in striatal medium spiny neurons and involuntary movements.
Topics: Action Potentials; Analysis of Variance; Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesias; Female; Levodopa; Macaca mulatta; Neurons; Parkinsonian Disorders | 2008 |
Effects of levodopa on striatal monoamines in mice with levodopa-induced hyperactivity.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Biogenic Monoamines; Chromatography, High Pressure Liquid; Corpus Striatum; Disease Models, Animal; Electrochemistry; Hyperkinesis; Levodopa; Mice; Mice, Inbred C57BL; MPTP Poisoning; Olfactory Bulb | 2008 |
The synaptic impact of the host immune response in a parkinsonian allograft rat model: Influence on graft-derived aberrant behaviors.
Topics: Adrenergic Agents; Amphetamine; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dyskinesias; Histocompatibility Antigens Class II; Levodopa; Male; Microscopy, Electron, Transmission; Motor Activity; Oxidopamine; Parkinson Disease; Rats; Synapses; Tissue Transplantation; Tyrosine 3-Monooxygenase | 2008 |
Neuroinflammation in the generation of post-transplantation dyskinesia in Parkinson's disease.
Topics: Adrenergic Agents; Amphetamine; Analgesics, Non-Narcotic; Analysis of Variance; Animals; Antiparkinson Agents; Brain Tissue Transplantation; Central Nervous System Stimulants; Corpus Striatum; Disease Models, Animal; Dyskinesias; Embryo, Mammalian; Encephalitis; Female; Interleukin-2; Interleukin-2 Receptor alpha Subunit; Levodopa; Mesencephalon; Motor Activity; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Rats, Wistar; Skin Transplantation | 2008 |
Exogenous corticosterone reduces L-DOPA-induced dyskinesia in the hemi-parkinsonian rat: role for interleukin-1beta.
Topics: Animals; Anti-Inflammatory Agents; Corpus Striatum; Corticosterone; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Encephalitis; Interleukin 1 Receptor Antagonist Protein; Interleukin-1beta; Levodopa; Male; Medial Forebrain Bundle; Neural Pathways; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; RNA, Messenger; Substantia Nigra; Sympatholytics; Up-Regulation | 2008 |
Investigation on tolerance development to subchronic blockade of mGluR5 in models of learning, anxiety, and levodopa-induced dyskinesia in rats.
Topics: Animals; Antiparkinson Agents; Anxiety Disorders; Brain; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Tolerance; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Glutamic Acid; Learning Disabilities; Levodopa; Male; Maze Learning; Memory Disorders; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Synaptic Transmission; Thiazoles | 2008 |
Metabotropic glutamate receptors 5 blockade reverses spatial memory deficits in a mouse model of Parkinson's disease.
Topics: Animals; Association Learning; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Levodopa; Male; Memory Disorders; Mice; Movement; Oxidopamine; Parkinson Disease; Pyridines; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Space Perception; Vision Disorders | 2009 |
L-stepholidine reduced L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Analysis of Variance; Animals; Antiparkinson Agents; Antipsychotic Agents; Benzazepines; Berberine; CHO Cells; Corpus Striatum; Cricetinae; Cricetulus; Disease Models, Animal; Dopamine Agents; Drug Administration Schedule; Drug Interactions; Dyskinesias; Gene Expression Regulation; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; RNA, Messenger; Serotonin Receptor Agonists; Transfection; Tritium | 2010 |
Differential involvement of striosome and matrix dopamine systems in a transgenic model of dopa-responsive dystonia.
Topics: Age Factors; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dystonic Disorders; Humans; Levodopa; Metabolic Networks and Pathways; Mice; Mice, Transgenic; Motor Skills Disorders; Phosphorus-Oxygen Lyases; Tyrosine 3-Monooxygenase | 2008 |
Intermittent L-DOPA treatment differentially alters synaptotagmin 4 and 7 gene expression in the striatum of hemiparkinsonian rats.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Female; Functional Laterality; Gene Expression; Levodopa; Motor Activity; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; RNA, Messenger; Synaptotagmins; Time Factors | 2008 |
Pleiotrophin receptor RPTP-zeta/beta expression is up-regulated by L-DOPA in striatal medium spiny neurons of parkinsonian rats.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Drug Interactions; Levodopa; Male; Neurons; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Receptor-Like Protein Tyrosine Phosphatases, Class 5; RNA, Messenger; Up-Regulation | 2008 |
The nociceptin/orphanin FQ (NOP) receptor antagonist J-113397 enhances the effects of levodopa in the MPTP-lesioned nonhuman primate model of Parkinson's disease.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Benzimidazoles; Callithrix; Disability Evaluation; Disease Models, Animal; Drug Synergism; Levodopa; MPTP Poisoning; Nociceptin; Opioid Peptides; Piperidines; Time Factors | 2008 |
Oral creatine supplementation attenuates L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned rats.
Topics: Administration, Oral; Analysis of Variance; Animals; Creatine; Dietary Supplements; Disease Models, Animal; Dyskinesia, Drug-Induced; Energy Metabolism; Enkephalins; Female; In Vitro Techniques; Levodopa; Neostriatum; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Phosphocreatine; Protein Precursors; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; RNA, Messenger; Statistics, Nonparametric | 2009 |
The clinical relevance of levodopa toxicity in the treatment of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Blood-Brain Barrier; Clinical Trials as Topic; Disease Models, Animal; Humans; Levodopa; Parkinson Disease | 2008 |
The effects of systemic, intrastriatal, and intrapallidal injections of caffeine and systemic injections of A2A and A1 antagonists on forepaw stepping in the unilateral 6-OHDA-lesioned rat.
Topics: Adenosine A1 Receptor Antagonists; Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Caffeine; Central Nervous System Stimulants; Corpus Striatum; Disease Models, Animal; Globus Pallidus; Injections; Levodopa; Male; Oxidopamine; Parkinson Disease; Rats; Rats, Long-Evans | 2009 |
Mechanism of the neuroprotective role of coenzyme Q10 with or without L-dopa in rotenone-induced parkinsonism.
Topics: Adenosine Triphosphate; Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Levodopa; Mitochondria; NAD; Neurons; Parkinsonian Disorders; Proto-Oncogene Proteins c-bcl-2; Psychomotor Performance; Rats; Rotenone; Spectrophotometry; Ubiquinone; Ultrasonography; Vitamins | 2008 |
Evaluation of behavioural effects of a selective NMDA NR1A/2B receptor antagonist in the unilateral 6-OHDA lesion rat model.
Topics: Administration, Oral; Adrenergic Agents; Animals; Antiparkinson Agents; Benzamidines; Disease Models, Animal; Dopamine; Drug Therapy, Combination; Excitatory Amino Acid Antagonists; Female; Immunohistochemistry; Levodopa; Medial Forebrain Bundle; Motor Activity; Neurons; Oxidopamine; Parkinson Disease, Secondary; Postural Balance; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Tyrosine 3-Monooxygenase | 2009 |
Parkinsonism and impaired axonal transport in a mouse model of frontotemporal dementia.
Topics: Animals; Axonal Transport; Dementia; Disease Models, Animal; Frontal Lobe; Humans; Levodopa; Mice; Mice, Transgenic; Motor Skills Disorders; Mutation, Missense; Parkinsonian Disorders; Phenotype; Sciatic Nerve; Substantia Nigra; tau Proteins; Temporal Lobe | 2008 |
Biperiden enhances L-DOPA methyl ester and dopamine D(l) receptor agonist SKF-82958 but antagonizes D(2)/D(3) receptor agonist rotigotine antihemiparkinsonian actions.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Benzazepines; Biperiden; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Interactions; Female; Levodopa; Macaca nemestrina; Muscarinic Antagonists; Parkinsonian Disorders; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Dopamine D3; Tetrahydronaphthalenes; Thiophenes | 2008 |
Antagonizing L-type Ca2+ channel reduces development of abnormal involuntary movement in the rat model of L-3,4-dihydroxyphenylalanine-induced dyskinesia.
Topics: Animals; Calcium Channel Blockers; Calcium Channels, L-Type; Cerebrum; Dendritic Spines; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Enkephalins; Isradipine; Levodopa; Male; Motor Activity; Nimodipine; Oxidopamine; Protein Precursors; Rats; Rats, Wistar; RNA, Messenger; Sympatholytics | 2009 |
Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Drug Administration Schedule; Drug Evaluation, Preclinical; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Motor Activity; Parkinson Disease; Parkinsonian Disorders; Proto-Oncogene Proteins c-fos; Pyridines; Receptors, N-Methyl-D-Aspartate; Serotonin 5-HT1 Receptor Agonists; Serotonin Receptor Agonists; Treatment Outcome | 2008 |
Implanted reuptake-deficient or wild-type dopaminergic neurons improve ON L-dopa dyskinesias without OFF-dyskinesias in a rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Brain Tissue Transplantation; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Enkephalins; Female; Fetal Tissue Transplantation; Gene Expression Regulation; Graft Survival; Levodopa; Mesencephalon; Microdialysis; Neurons; Parkinson Disease; Protein Precursors; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, N-Methyl-D-Aspartate; RNA, Messenger | 2008 |
Behavioural effects of a selective NMDA NR1A/2B receptor antagonist in rats with unilateral 6-OHDA+parafascicular lesions.
Topics: Administration, Oral; Adrenergic Agents; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dopamine; Excitatory Amino Acid Antagonists; Female; Immunohistochemistry; Intralaminar Thalamic Nuclei; Levodopa; Medial Forebrain Bundle; N-Methylaspartate; Neurons; Oxidopamine; Parkinson Disease, Secondary; Postural Balance; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Rotation; Tyrosine 3-Monooxygenase | 2009 |
The novel nociceptin/orphanin FQ receptor antagonist Trap-101 alleviates experimental parkinsonism through inhibition of the nigro-thalamic pathway: positive interaction with L-DOPA.
Topics: Animals; Antiparkinson Agents; Benzimidazoles; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Functional Laterality; gamma-Aminobutyric Acid; Glutamic Acid; Levodopa; Mice; Mice, Inbred C57BL; Mice, Knockout; Microdialysis; Motor Activity; Narcotic Antagonists; Neural Pathways; Nociceptin Receptor; Oxidopamine; Parkinsonian Disorders; Psychomotor Performance; Pyridines; Rats; Rats, Sprague-Dawley; Receptors, Opioid; Substantia Nigra; Thalamus; Time Factors | 2008 |
Genetic, temporal and diurnal influences on L-dopa-induced dyskinesia in the 6-OHDA model.
Topics: Animals; Antiparkinson Agents; Circadian Rhythm; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Injections, Intraperitoneal; Levodopa; Microinjections; Motor Activity; Oxidopamine; Parkinson Disease; Rats; Rats, Inbred Lew; Rats, Sprague-Dawley; Risk Factors; Rotation; Species Specificity; Sympatholytics; Time Factors; Treatment Outcome | 2009 |
Striatal transplantation in a rodent model of multiple system atrophy: effects on L-Dopa response.
Topics: Analysis of Variance; Animals; Apomorphine; Brain; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Levodopa; Male; Motor Activity; Multiple System Atrophy; Random Allocation; Rats; Rats, Wistar; Transplantation, Homologous | 2009 |
Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Benzopyrans; Callithrix; Corpus Striatum; Disease Models, Animal; Dopamine and cAMP-Regulated Phosphoprotein 32; Dopamine Antagonists; Dyskinesia, Drug-Induced; Enkephalins; Female; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Pyrroles; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Dopamine D3; RNA, Messenger | 2009 |
Antagonism of haloperidol-induced swim impairment in L-dopa and caffeine treated mice: a pre-clinical model to study Parkinson's disease.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Caffeine; Catalepsy; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Glutathione; Haloperidol; Levodopa; Male; Mice; Motor Activity; Parkinsonian Disorders; Posture; Superoxide Dismutase; Swimming | 2009 |
Comparison of intrastriatal administration of noradrenaline and l-DOPA on dyskinetic movements: a bilateral reverse in vivo microdialysis study in 6-hydroxydopamine-lesioned rats.
Topics: Analysis of Variance; Animals; Benserazide; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Levodopa; Male; Microdialysis; Norepinephrine; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Wistar; Severity of Illness Index | 2009 |
Deep brain stimulation of the globus pallidus internus in the parkinsonian primate: local entrainment and suppression of low-frequency oscillations.
Topics: Action Potentials; Algorithms; Animals; Antiparkinson Agents; Deep Brain Stimulation; Disease Models, Animal; Elbow; Electric Stimulation; Female; Globus Pallidus; Levodopa; Macaca fascicularis; Neural Inhibition; Neurons; Parkinsonian Disorders; Periodicity; Time Factors | 2009 |
Dopamine transporter relation to levodopa-derived synaptic dopamine in a rat model of Parkinson's: an in vivo imaging study.
Topics: Animals; Disease Models, Animal; Dopamine Plasma Membrane Transport Proteins; Levodopa; Male; Parkinson Disease; Positron-Emission Tomography; Protein Binding; Rats; Rats, Sprague-Dawley; Synapses | 2009 |
Chronic intermittent L-DOPA treatment induces changes in dopamine release.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agonists; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Levodopa; Parkinson Disease; Potassium; Presynaptic Terminals; Rats; Rats, Sprague-Dawley; Serotonin; Serotonin Plasma Membrane Transport Proteins; Synaptic Transmission | 2009 |
Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Organic Chemicals; Ovariectomy; Parkinsonian Disorders; Serotonin Receptor Agonists | 2009 |
Multitracer assessment of dopamine function after transplantation of embryonic stem cell-derived neural stem cells in a primate model of Parkinson's disease.
Topics: Animals; Carbon Radioisotopes; Cells, Cultured; Cocaine; Disease Models, Animal; Dopamine; Dopamine Agents; Embryonic Stem Cells; Levodopa; Macaca fascicularis; Methamphetamine; Movement Disorders; Neurons; Parkinson Disease; Positron-Emission Tomography; Putamen; Raclopride; Tyrosine 3-Monooxygenase | 2009 |
The sigma-1 antagonist BMY-14802 inhibits L-DOPA-induced abnormal involuntary movements by a WAY-100635-sensitive mechanism.
Topics: Animals; Buspirone; Disease Models, Animal; Dopamine Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Levodopa; Male; Parkinson Disease; Piperazines; Pyridines; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptors, sigma; Serotonin 5-HT1 Receptor Agonists; Serotonin Antagonists; Serotonin Receptor Agonists; Sigma-1 Receptor | 2009 |
Nitric oxide synthase inhibition attenuates L-DOPA-induced dyskinesias in a rodent model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Indazoles; Levodopa; Male; Motor Activity; Nitric Oxide Synthase; Nitroarginine; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; Substantia Nigra | 2009 |
Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signaling.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Female; Glutamic Acid; Levodopa; Motor Activity; Rats; Rats, Sprague-Dawley; Receptors, Metabotropic Glutamate; Synaptic Transmission | 2009 |
Amphetamine-induced abnormal movements occur independently of both transplant- and host-derived serotonin innervation following neural grafting in a rat model of Parkinson's disease.
Topics: 5,7-Dihydroxytryptamine; Adrenergic Agents; Amphetamine; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dopamine Uptake Inhibitors; Dyskinesias; Embryo, Mammalian; Female; Levodopa; Mesencephalon; Oxidopamine; Parkinson Disease; Pregnancy; Rats; Rats, Sprague-Dawley; Serotonin; Serotonin Agents; Transplants; Tyrosine 3-Monooxygenase | 2009 |
Interaction between nicotinic and dopaminergic therapies on cognition in a chronic Parkinson model.
Topics: Animals; Attention; Cognition; Cues; Discrimination Learning; Disease Models, Animal; Dopamine Agents; Drug Combinations; Drug Interactions; Injections, Intramuscular; Injections, Intravenous; Levodopa; Macaca mulatta; Male; Memory; MPTP Poisoning; Nicotine; Nicotinic Agonists; Phenols; Pyrrolidines; Reaction Time; Task Performance and Analysis | 2009 |
New evidences for fractalkine/CX3CL1 involved in substantia nigral microglial activation and behavioral changes in a rat model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Antibodies; Antiparkinson Agents; Apomorphine; Chemokine CX3CL1; Disease Models, Animal; DNA Nucleotidylexotransferase; Dose-Response Relationship, Drug; Drug Interactions; Gene Expression Regulation; Levodopa; Male; Mental Disorders; Nerve Tissue Proteins; Parkinson Disease; Rats; Rats, Sprague-Dawley; Reaction Time; Stereotyped Behavior; Substantia Nigra; Tyrosine 3-Monooxygenase | 2011 |
Assessment of symptomatic and neuroprotective efficacy of Mucuna pruriens seed extract in rodent model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Antiparkinson Agents; CD11b Antigen; Conditioning, Operant; Disease Models, Animal; Dose-Response Relationship, Drug; Glial Fibrillary Acidic Protein; Jaw; Levodopa; Locomotion; Male; Mice; Mice, Inbred C57BL; Movement; Mucuna; Neuroprotective Agents; Oxidopamine; Parasympathomimetics; Parkinson Disease; Phytotherapy; Rats; Rats, Sprague-Dawley; Seeds; Sympatholytics; Tacrine; Time Factors; Vibrissae | 2009 |
Priming for L-DOPA-induced abnormal involuntary movements increases the severity of amphetamine-induced dyskinesia in grafted rats.
Topics: Amphetamine; Animals; Antiparkinson Agents; Brain Tissue Transplantation; Central Nervous System Stimulants; Corpus Striatum; Disease Models, Animal; Drug Synergism; Dyskinesia, Drug-Induced; Female; Levodopa; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Stem Cell Transplantation; Sympatholytics | 2009 |
Effect of levodopa priming on dopamine neuron transplant efficacy and induction of abnormal involuntary movements in parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Brain; Brain Tissue Transplantation; Disease Models, Animal; Dopamine; Drug Administration Schedule; Dyskinesia, Drug-Induced; Graft Survival; Levodopa; Male; Neurons; Parkinsonian Disorders; Rats; Rats, Inbred F344; Treatment Outcome | 2009 |
Striatal dopamine level contributes to hydroxyl radical generation and subsequent neurodegeneration in the striatum in 3-nitropropionic acid-induced Huntington's disease in rats.
Topics: Animals; Convulsants; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Huntington Disease; Hydroxyl Radical; Lameness, Animal; Levodopa; Male; Mitochondria; Nerve Degeneration; Neurotoxins; Nitro Compounds; Oxidative Phosphorylation; Oxidative Stress; Propionates; Rats; Rats, Sprague-Dawley; Tyrosine 3-Monooxygenase | 2009 |
The CB(1) antagonist rimonabant is adjunctively therapeutic as well as monotherapeutic in an animal model of Parkinson's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Hypokinesia; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease; Piperidines; Pyrazoles; Rats; Rats, Long-Evans; Receptor, Cannabinoid, CB1; Rimonabant | 2009 |
Increases in cytoplasmic dopamine compromise the normal resistance of the nucleus accumbens to methamphetamine neurotoxicity.
Topics: Animals; Clorgyline; Cytosol; Disease Models, Animal; Dopamine; Dopamine Agents; Dopamine Plasma Membrane Transport Proteins; Female; Levodopa; Methamphetamine; Mice; Mice, Inbred C57BL; Microglia; Monoamine Oxidase Inhibitors; Neurons; Neurotoxicity Syndromes; Nucleus Accumbens; Plant Lectins; Reserpine; Ribosome Inactivating Proteins; Time Factors; Tyrosine 3-Monooxygenase | 2009 |
Stepping test in mice: a reliable approach in determining forelimb akinesia in MPTP-induced Parkinsonism.
Topics: Animals; Antiparkinson Agents; Cell Count; Disease Models, Animal; Forelimb; Hypokinesia; Lameness, Animal; Levodopa; Male; Mice; Mice, Inbred C57BL; Nerve Degeneration; Neurologic Examination; Parkinsonian Disorders; Predictive Value of Tests; Sensitivity and Specificity; Substantia Nigra | 2009 |
Noradrenergic modulation of the motor response induced by long-term levodopa administration in Parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Benzylamines; Brain; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Levodopa; Male; Movement; Neurotoxins; Norepinephrine; Oxidopamine; Parkinsonian Disorders; Presynaptic Terminals; Rats; Rats, Sprague-Dawley; Recovery of Function; Synaptic Transmission; Time; Treatment Outcome | 2009 |
Striatal overexpression of DeltaJunD resets L-DOPA-induced dyskinesia in a primate model of Parkinson disease.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Benserazide; Corpus Striatum; Disease Models, Animal; Dopamine Plasma Membrane Transport Proteins; Drug Combinations; Dyskinesia, Drug-Induced; Female; Gene Expression Regulation; Genetic Therapy; Genetic Vectors; Green Fluorescent Proteins; Humans; Iodine Radioisotopes; Levodopa; Linear Models; Macaca fascicularis; Male; MPTP Poisoning; Nortropanes; Protein Binding; Proto-Oncogene Proteins c-jun; Radionuclide Imaging; RNA, Messenger | 2009 |
Serotonin neuron-dependent and -independent reduction of dyskinesia by 5-HT1A and 5-HT1B receptor agonists in the rat Parkinson model.
Topics: Animals; Apomorphine; Brain; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Levodopa; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT1B; Receptors, Serotonin; Serotonin; Serotonin 5-HT1 Receptor Agonists; Serotonin Receptor Agonists | 2009 |
D2 receptor stimulation, but not D1, restores striatal equilibrium in a rat model of Parkinsonism.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Action Potentials; Animals; Antiparkinson Agents; Apomorphine; Benserazide; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dopamine Agonists; Levodopa; Male; Neurons; Oxidopamine; Parkinsonian Disorders; Quinpirole; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2 | 2009 |
Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease.
Topics: Age Factors; Animals; Antiparkinson Agents; Apomorphine; Brain; Chromosomes, Artificial, Bacterial; Disease Models, Animal; Dopamine; Dopamine Uptake Inhibitors; Gene Transfer Techniques; Humans; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Levodopa; Mice; Mice, Transgenic; Movement Disorders; Mutation, Missense; Neurons; Nomifensine; Parkinson Disease; Protein Serine-Threonine Kinases | 2009 |
Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation.
Topics: Acetylation; Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dynorphins; Dyskinesia, Drug-Induced; Extracellular Signal-Regulated MAP Kinases; Functional Laterality; Gene Expression Regulation; Histones; Levodopa; Mice; Mice, Knockout; Motor Activity; Neurons; Oxidopamine; Parkinsonian Disorders; Phosphorylation; Proto-Oncogene Proteins c-fos; Receptors, Dopamine D1; Receptors, Dopamine D2; Statistics as Topic; Tyrosine 3-Monooxygenase | 2009 |
Effect of non-dopaminergic drug treatment on Levodopa induced dyskinesias in MPTP monkeys: common implication of striatal neuropeptides.
Topics: Animals; Antiparkinson Agents; Benzoxazoles; Cocaine; Corpus Striatum; Disease Models, Animal; Docosahexaenoic Acids; Dopamine; Dopamine Uptake Inhibitors; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Female; Iodine Isotopes; Levodopa; Macaca fascicularis; Naltrexone; Neuropeptides; Ovariectomy; Parkinsonian Disorders; Piperidines; Protein Precursors; RNA, Messenger; Sulfonamides; Tachykinins; Thiazoles; Time Factors | 2010 |
Differential involvement of D1 and D2 dopamine receptors in L-DOPA-induced angiogenic activity in a rat model of Parkinson's disease.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Aminoacetonitrile; Animals; Antiparkinson Agents; Basal Ganglia; Benzazepines; Bromocriptine; Disease Models, Animal; Dopamine Agents; Dopamine D2 Receptor Antagonists; Extracellular Signal-Regulated MAP Kinases; Female; Levodopa; Neovascularization, Pathologic; Oxidopamine; Parkinsonian Disorders; Protease Inhibitors; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Salicylamides | 2009 |
Different functional basal ganglia subcircuits associated with anti-akinetic and dyskinesiogenic effects of antiparkinsonian therapies.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Disease Models, Animal; Dynorphins; Dyskinesia, Drug-Induced; Electric Stimulation; Electrodes, Implanted; Electron Transport Complex IV; Gene Expression Regulation; Levodopa; Male; Nerve Net; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Protein Subunits; Rats; Rats, Wistar; RNA, Messenger | 2009 |
Continuous administration of rotigotine to MPTP-treated common marmosets enhances anti-parkinsonian activity and reduces dyskinesia induction.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Callithrix; Disease Models, Animal; Drug Administration Schedule; Drug Delivery Systems; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Motor Activity; Motor Skills; MPTP Poisoning; Tetrahydronaphthalenes; Thiophenes | 2009 |
Nur77 mRNA levels and L-Dopa-induced dyskinesias in MPTP monkeys treated with docosahexaenoic acid.
Topics: Acetylcholinesterase; Analysis of Variance; Animals; Antiparkinson Agents; Autoradiography; Brain; Cocaine; Disease Models, Animal; Docosahexaenoic Acids; Drug Interactions; Dyskinesia, Drug-Induced; Female; Iodine Isotopes; Levodopa; Macaca fascicularis; MPTP Poisoning; Nuclear Receptor Subfamily 4, Group A, Member 1; Protein Binding; RNA, Messenger; Statistics as Topic | 2009 |
Effect of the metabotropic glutamate antagonist MPEP on striatal expression of the Homer family proteins in levodopa-treated hemiparkinsonian rats.
Topics: Animals; Antiparkinson Agents; Carrier Proteins; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Gene Expression Regulation; Homer Scaffolding Proteins; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Proto-Oncogene Proteins c-fos; Pyridines; Rats; Rats, Sprague-Dawley; Tyrosine 3-Monooxygenase | 2009 |
TRK-820, a selective kappa opioid receptor agonist, could effectively ameliorate L-DOPA-induced dyskinesia symptoms in a rat model of Parkinson's disease.
Topics: Amantadine; Animals; Behavior, Animal; Disease Models, Animal; Dyskinesias; Extracellular Space; Levodopa; Male; Microdialysis; Morphinans; Neostriatum; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptors, Opioid, kappa; Rotation; Spiro Compounds; Time Factors | 2009 |
Acute L: -DOPA effect on hydroxyl radical- and DOPAC-levels in striatal microdialysates of parkinsonian rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Female; Hydroxyindoleacetic Acid; Hydroxyl Radical; Injections, Intraventricular; Levodopa; Male; Microdialysis; Oxidopamine; Parkinsonian Disorders; Pregnancy; Rats; Sympatholytics; Time Factors | 2010 |
Neuroprotective effect of L-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study.
Topics: Animals; Antiparkinson Agents; bcl-2-Associated X Protein; Benzothiazoles; Cell Count; Disease Models, Animal; Dopamine; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation; Glutathione; Levodopa; Male; Mice; Mice, Inbred C57BL; Neurons; Parkinsonian Disorders; Pramipexole; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Statistics, Nonparametric; Substantia Nigra; Tyrosine 3-Monooxygenase | 2009 |
The selective alpha1 adrenoceptor antagonist HEAT reduces L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Antiparkinson Agents; Brain; Cerebrospinal Fluid; Disease Models, Animal; Dyskinesia, Drug-Induced; Idazoxan; Levodopa; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Plasma; Propranolol; Random Allocation; Rats; Rats, Wistar; Receptors, Adrenergic, alpha-1; Tetralones | 2010 |
Continuous rotigotine administration reduces dyskinesia resulting from pulsatile treatment with rotigotine or L-DOPA in MPTP-treated common marmosets.
Topics: Animals; Callithrix; Disability Evaluation; Disease Models, Animal; Dopamine Agents; Drug Administration Schedule; Drug Delivery Systems; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Motor Activity; MPTP Poisoning; Statistics, Nonparametric; Tetrahydronaphthalenes; Thiophenes; Time Factors | 2010 |
Melanin precursors prevent premature age-related and noise-induced hearing loss in albino mice.
Topics: Aging; Aging, Premature; Albinism; Albinism, Oculocutaneous; Animals; Disease Models, Animal; Evoked Potentials, Auditory, Brain Stem; Gene Expression Regulation, Enzymologic; Genetic Predisposition to Disease; Hearing Loss, Noise-Induced; Hearing Loss, Sensorineural; Levodopa; Melanins; Mice; Mice, Transgenic; Monophenol Monooxygenase; Tyrosine 3-Monooxygenase | 2010 |
The alpha(2) adrenoceptor antagonist idazoxan alleviates L-DOPA-induced dyskinesia by reduction of striatal dopamine levels: an in vivo microdialysis study in 6-hydroxydopamine-lesioned rats.
Topics: Adrenergic Agents; Adrenergic alpha-Antagonists; Analysis of Variance; Animals; Antiparkinson Agents; Chromatography, High Pressure Liquid; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Idazoxan; Levodopa; Male; Microdialysis; Neurotoxicity Syndromes; Oxidopamine; Rats; Rats, Wistar; Tandem Mass Spectrometry | 2010 |
Levodopa inhibits the development of form-deprivation myopia in guinea pigs.
Topics: Animals; Chromatography, High Pressure Liquid; Disease Models, Animal; Dopamine Agents; Form Perception; Guinea Pigs; Injections, Intraperitoneal; Levodopa; Myopia; Retina; Sensory Deprivation; Treatment Outcome | 2010 |
A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenine; Animals; Antiparkinson Agents; Autoradiography; Behavior, Animal; Brain Chemistry; CD11b Antigen; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Early Growth Response Protein 1; Gene Expression Regulation; Jaw; Levodopa; Male; Mice; Mice, Inbred C57BL; Motor Activity; Movement; Nerve Degeneration; Nerve Tissue Proteins; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Psychomotor Performance; Pyrimidines; Rats; Rats, Sprague-Dawley; RNA, Messenger; Rotarod Performance Test; Time Factors; Triazoles; Vibrissae | 2010 |
BDNF levels are not related with levodopa-induced dyskinesias in MPTP monkeys.
Topics: Animals; Antiparkinson Agents; Brain; Brain-Derived Neurotrophic Factor; Disease Models, Animal; Dyskinesia, Drug-Induced; Enzyme-Linked Immunosorbent Assay; Female; Levodopa; Macaca fascicularis; MPTP Poisoning | 2010 |
Striatal Akt/GSK3 signaling pathway in the development of L-Dopa-induced dyskinesias in MPTP monkeys.
Topics: Animals; Antiparkinson Agents; Benzoxazoles; Cabergoline; Corpus Striatum; Disease Models, Animal; Drug Interactions; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Ergolines; Female; Glycogen Synthase Kinase 3; Levodopa; Macaca fascicularis; Oncogene Protein v-akt; Parkinsonian Disorders; Phosphorylation; Piperidines; Serine; Signal Transduction; Statistics as Topic | 2010 |
L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Female; Levodopa; Microdialysis; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Substantia Nigra; Time Factors | 2010 |
Striatal inhibition of PKA prevents levodopa-induced behavioural and molecular changes in the hemiparkinsonian rat.
Topics: Animals; Behavior, Animal; Biomarkers; Corpus Striatum; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Disease Models, Animal; Dopamine; Dopamine and cAMP-Regulated Phosphoprotein 32; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; Gait Disorders, Neurologic; Infusion Pumps, Implantable; Levodopa; Locomotion; Male; Parkinsonian Disorders; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Signal Transduction; Thionucleotides | 2010 |
MK-801 inhibits L-DOPA-induced abnormal involuntary movements only at doses that worsen parkinsonism.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dizocilpine Maleate; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Levodopa; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Rotation; Time Factors | 2010 |
L-DOPA treatment reverses the motor alterations induced by manganese exposure as a Parkinson disease experimental model.
Topics: Acetates; Administration, Inhalation; Animals; Antiparkinson Agents; Chlorides; Corpus Striatum; Disease Models, Animal; Dopamine; Levodopa; Male; Manganese Compounds; Mice; Motor Activity; Organometallic Compounds; Parkinson Disease | 2010 |
Serotonergic neurons mediate ectopic release of dopamine induced by L-DOPA in a rat model of Parkinson's disease.
Topics: 5,7-Dihydroxytryptamine; Animals; Antiparkinson Agents; Brain; Citalopram; Cobra Neurotoxin Proteins; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Extracellular Fluid; Levodopa; Male; Microdialysis; Oxidopamine; Parkinsonian Disorders; Presynaptic Terminals; Raphe Nuclei; Rats; Selective Serotonin Reuptake Inhibitors; Serotonin; Sympatholytics; Synaptic Transmission | 2010 |
Impact of dendritic spine preservation in medium spiny neurons on dopamine graft efficacy and the expression of dyskinesias in parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Calcium Channel Blockers; Cell Transplantation; Dendritic Spines; Disease Models, Animal; Dopamine; Dyskinesias; Female; Levodopa; Male; Neurons; Nimodipine; Parkinson Disease; Pregnancy; Rats; Rats, Sprague-Dawley; Vibrissae | 2010 |
Pramipexole combined with levodopa improves motor function but reduces dyskinesia in MPTP-treated common marmosets.
Topics: Animals; Antiparkinson Agents; Benzothiazoles; Callithrix; Carbidopa; Disability Evaluation; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesias; Levodopa; Male; Motor Activity; MPTP Poisoning; Pramipexole; Time Factors | 2010 |
Optimized adeno-associated viral vector-mediated striatal DOPA delivery restores sensorimotor function and prevents dyskinesias in a model of advanced Parkinson's disease.
Topics: Animals; Chickens; Corpus Striatum; Dependovirus; Disease Models, Animal; Dyskinesias; Female; Gene Transfer Techniques; Genetic Vectors; Humans; Levodopa; Parkinson Disease; Psychomotor Performance; Rats; Rats, Sprague-Dawley | 2010 |
Neuropsychiatric behaviors in the MPTP marmoset model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Behavioral Symptoms; Callithrix; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Hyperkinesis; Levodopa; Parkinsonian Disorders; Reproducibility of Results | 2010 |
Role of serotonin neurons in the induction of levodopa- and graft-induced dyskinesias in Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesias; Humans; Levodopa; Neurons; Parkinson Disease; Serotonin; Transplants | 2010 |
The roles of striatal serotonin and L -amino-acid decarboxylase on L-DOPA-induced Dyskinesia in a Hemiparkinsonian rat model.
Topics: Animals; Aromatic-L-Amino-Acid Decarboxylases; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Levodopa; Movement; Neostriatum; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Serotonin; Tyrosine 3-Monooxygenase | 2010 |
Effect of histamine H2 receptor antagonism on levodopa-induced dyskinesia in the MPTP-macaque model of Parkinson's disease.
Topics: Akathisia, Drug-Induced; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Famotidine; Female; Histamine H2 Antagonists; Levodopa; Macaca fascicularis; Male; MPTP Poisoning; Time Factors | 2010 |
L-DOPA accessibility in culture medium increases melanin expression and virulence of Sporothrix schenckii yeast cells.
Topics: Animals; Colony Count, Microbial; Culture Media; Disease Models, Animal; Histocytochemistry; Levodopa; Liver; Lung; Male; Melanins; Mice; Mice, Inbred C57BL; Microscopy; Spleen; Sporothrix; Sporotrichosis; Survival Analysis; Virulence | 2010 |
Distinct effects of intranigral L-DOPA infusion in the MPTP rat model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Antiparkinson Agents; Cell Count; Disease Models, Animal; Dopamine; Drug Interactions; Gene Expression Regulation; Homovanillic Acid; Levodopa; Male; Movement; Neurons; Neurotoxins; Parkinsonian Disorders; Rats; Rats, Wistar; Reaction Time; Substantia Nigra; Tyrosine 3-Monooxygenase | 2009 |
A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys.
Topics: Analysis of Variance; Animals; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Imidazoles; Levodopa; Macaca mulatta; Male; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Receptors, Metabotropic Glutamate | 2010 |
Salicylic acid protects against chronic L-DOPA-induced 6-OHDA generation in experimental model of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Homovanillic Acid; Levodopa; Male; Medial Forebrain Bundle; Mice; Mice, Inbred BALB C; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Salicylates | 2010 |
Effect of cdk5 antagonist on L-dopa-induced dyskinesias in a rat model of Parkinson's disease.
Topics: Animals; Antiparasitic Agents; Corpus Striatum; Cyclin-Dependent Kinase 5; Disease Models, Animal; Dopamine and cAMP-Regulated Phosphoprotein 32; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Phosphorylation; Protein Kinase Inhibitors; Purines; Random Allocation; Rats; Rats, Sprague-Dawley; Roscovitine; Severity of Illness Index; Treatment Outcome | 2010 |
Striatal overexpression of DeltaFosB reproduces chronic levodopa-induced involuntary movements.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Drug Administration Schedule; Dyskinesias; Functional Laterality; Gene Expression Regulation; Gene Transfer Techniques; Genetic Vectors; Green Fluorescent Proteins; Levodopa; Male; Motor Activity; Mutation; Oxidopamine; Parkinson Disease; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-fos; Proto-Oncogene Proteins c-jun; Rats; Rats, Sprague-Dawley; Statistics, Nonparametric; Sympatholytics; Time Factors | 2010 |
Locomotor response to L-DOPA in reserpine-treated rats following central inhibition of aromatic L-amino acid decarboxylase: further evidence for non-dopaminergic actions of L-DOPA and its metabolites.
Topics: Adrenergic alpha-Antagonists; Adrenergic Uptake Inhibitors; Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Aromatic-L-Amino-Acid Decarboxylases; Benserazide; Brain Chemistry; Disease Models, Animal; Dopamine Agents; Drug Combinations; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Hydrazines; Hyperkinesis; Levodopa; Male; Motor Activity; Rats; Rats, Sprague-Dawley; Reserpine; Serotonin Receptor Agonists | 2010 |
Aberrant striatal plasticity is specifically associated with dyskinesia following levodopa treatment.
Topics: Action Potentials; Animals; Antiparkinson Agents; Behavior, Animal; Cholera Toxin; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Fluorescent Dyes; Levodopa; Long-Term Potentiation; Neuronal Plasticity; Neurons; Oxidopamine; Parkinson Disease; Rats; Substantia Nigra; Tyrosine 3-Monooxygenase | 2010 |
Levodopa/benserazide-loaded biodegradable microspheres reduce dyskinesia in rats.
Topics: Animals; Antiparkinson Agents; Benserazide; Biocompatible Materials; Disease Models, Animal; Disease Progression; Drug Combinations; Drug Synergism; Dyskinesia, Drug-Induced; Female; Lameness, Animal; Levodopa; Microspheres; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Treatment Outcome | 2010 |
Chronic A2A antagonist treatment alleviates parkinsonian locomotor deficiency in MitoPark mice.
Topics: Adenosine A2 Receptor Antagonists; Animals; Disease Models, Animal; Dopamine; Dopamine Agents; Levodopa; Mice; Mice, Inbred Strains; Motor Activity; Parkinson Disease; Time Factors; Treatment Outcome; Xanthines | 2010 |
Deep brain stimulation of the center median-parafascicular complex of the thalamus has efficient anti-parkinsonian action associated with widespread cellular responses in the basal ganglia network in a rat model of Parkinson's disease.
Topics: Animals; Basal Ganglia; Deep Brain Stimulation; Denervation; Disease Models, Animal; Electron Transport Complex IV; Feedback, Sensory; Globus Pallidus; Levodopa; Male; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Protein Precursors; Rats; Rats, Wistar; RNA, Messenger; Substantia Nigra; Subthalamic Nucleus; Tachykinins; Thalamus | 2010 |
Striatal dopaminergic fiber recovery after acute L-DOPA treatment in 6-hydroxydopamine (6-OHDA) lesioned rats.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Female; Levodopa; Medial Forebrain Bundle; Nerve Fibers; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Substantia Nigra | 2011 |
Metabolic activity of the subthalamic nucleus in a primate model of L-dopa-unresponsive parkinsonism.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Energy Metabolism; Female; Levodopa; Macaca fascicularis; Parkinsonian Disorders; Substantia Nigra; Subthalamic Nucleus | 2010 |
Levodopa analgesia in experimental neuropathic pain.
Topics: Analgesics; Animals; Disease Models, Animal; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Interactions; Functional Laterality; Hyperalgesia; Levodopa; Male; Motor Activity; Neuralgia; Pain Measurement; Pain Threshold; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Rotarod Performance Test; Sulpiride; Time Factors | 2010 |
The α₂ adrenergic antagonist fipamezole improves quality of levodopa action in Parkinsonian primates.
Topics: Adrenergic alpha-2 Receptor Antagonists; Analysis of Variance; Animals; Disability Evaluation; Disease Models, Animal; Dopamine Agents; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Imidazoles; Indans; Levodopa; Macaca fascicularis; Male; Motor Activity; Parkinsonian Disorders; Time Factors | 2010 |
Deletion of adenosine A₁ or A(₂A) receptors reduces L-3,4-dihydroxyphenylalanine-induced dyskinesia in a model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Caffeine; Corpus Striatum; Disease Models, Animal; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Gene Expression Regulation; Levodopa; Mice; Mice, Inbred C57BL; Mice, Knockout; Oxidopamine; Parkinson Disease; Protein Precursors; Purinergic P1 Receptor Antagonists; Receptor, Adenosine A1; Receptor, Adenosine A2A; RNA, Messenger; Statistics, Nonparametric; Time Factors | 2011 |
The partial dopamine agonist pardoprunox (SLV308) administered in combination with l-dopa improves efficacy and decreases dyskinesia in MPTP treated common marmosets.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Area Under Curve; Benzoxazoles; Callithrix; Disease Models, Animal; Dopamine Agents; Dose-Response Relationship, Drug; Drug Synergism; Levodopa; Motor Activity; Movement Disorders; Piperazines; Statistics, Nonparametric; Time Factors | 2010 |
Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Animals; Brain-Derived Neurotrophic Factor; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Macaca fascicularis; Male; Neuronal Plasticity; Oxidopamine; Parkinson Disease; Presynaptic Terminals; Radioligand Assay; Rats; Rats, Sprague-Dawley; Serotonin; Serotonin Plasma Membrane Transport Proteins | 2010 |
The effects of cannabinoid drugs on abnormal involuntary movements in dyskinetic and non-dyskinetic 6-hydroxydopamine lesioned rats.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dronabinol; Dyskinesia, Drug-Induced; Levodopa; Male; Parkinsonian Disorders; Piperidines; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Rimonabant | 2010 |
Fatty acid amide hydrolase (FAAH) inhibition reduces L-3,4-dihydroxyphenylalanine-induced hyperactivity in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned non-human primate model of Parkinson's disease.
Topics: Amides; Amidohydrolases; Animals; Benzamides; Callithrix; Carbamates; Disease Models, Animal; Dyskinesia, Drug-Induced; Endocannabinoids; Enzyme Inhibitors; Ethanolamines; Female; Levodopa; Motor Activity; MPTP Poisoning; Oleic Acids; Palmitic Acids; Psychoses, Substance-Induced | 2011 |
An improved model to investigate the efficacy of antidyskinetic agents in hemiparkinsonian rats.
Topics: Adenosine A2 Receptor Antagonists; Amantadine; Animals; Antiparkinson Agents; Behavior, Animal; Benserazide; Biological Assay; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Drug Administration Schedule; Drug Evaluation, Preclinical; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Placebos; Purines; Random Allocation; Rats; Reproducibility of Results; Rotation; Sample Size; Single-Blind Method; Sympatholytics | 2011 |
Behavioural and pharmacological examinations in a transgenic mouse model of early-onset torsion dystonia.
Topics: Amphetamines; Animals; Anxiety; Behavior, Animal; Carbidopa; Chromans; Disease Models, Animal; Dystonia; Levodopa; Locomotion; Mice; Mice, Transgenic; Quinpirole; Raclopride | 2011 |
Lack of tolerance for the anti-dyskinetic effects of 7-nitroindazole, a neuronal nitric oxide synthase inhibitor, in rats.
Topics: Animals; Anti-Dyskinesia Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Indazoles; Levodopa; Male; Nitric Oxide Synthase; Rats; Rats, Wistar; Substantia Nigra | 2010 |
Chronic L-DOPA therapy alters central serotonergic function and L-DOPA-induced dopamine release in a region-dependent manner in a rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Brain; Disease Models, Animal; Dopamine; Drug Administration Schedule; Levodopa; Male; Parkinson Disease; Rats; Rats, Sprague-Dawley; Serotonin | 2011 |
Inhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with L-dopa-induced dyskinesia.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Extracellular Signal-Regulated MAP Kinases; Humans; Levodopa; Mice; Mice, Knockout; Neurons; ras-GRF1; Signal Transduction | 2010 |
Pharmacological characterization of MRZ-8676, a novel negative allosteric modulator of subtype 5 metabotropic glutamate receptors (mGluR5): focus on L: -DOPA-induced dyskinesia.
Topics: Adrenergic Agents; Allosteric Regulation; Analysis of Variance; Animals; Brain; Calcium; Cognition Disorders; Conditioning, Psychological; Disease Models, Animal; Dopamine Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Fear; In Vitro Techniques; Levodopa; Male; Maze Learning; Microdialysis; Monoamine Oxidase Inhibitors; Motor Activity; Oxidopamine; Pain Measurement; Parkinson Disease, Secondary; Picolinic Acids; Psychomotor Performance; Quinolones; Rats; Rats, Sprague-Dawley; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Rotarod Performance Test; Tandem Mass Spectrometry; Time Factors | 2011 |
Enhanced striatal cholinergic neuronal activity mediates L-DOPA-induced dyskinesia in parkinsonian mice.
Topics: Adenosine A2 Receptor Antagonists; Aminoacetonitrile; Animals; Aphakia; Choline O-Acetyltransferase; Cholinergic Fibers; Disease Models, Animal; Dopamine; Dyskinesias; Gene Expression Regulation; Homeodomain Proteins; Levodopa; Mice; Mice, Transgenic; Neurons; Parkinson Disease; Phosphorylation; Transcription Factors | 2011 |
Transcriptional alterations under continuous or pulsatile dopaminergic treatment in dyskinetic rats.
Topics: Analysis of Variance; Animals; Brain; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Functional Laterality; Gene Expression Profiling; Gene Expression Regulation; Levodopa; Male; Nerve Tissue Proteins; Neurotrophin 3; Oligonucleotide Array Sequence Analysis; Oxidopamine; Parkinsonian Disorders; Pulsatile Flow; Rats; Rats, Sprague-Dawley; RNA, Messenger | 2011 |
Context-driven changes in L-DOPA-induced behaviours in the 6-OHDA lesioned rat.
Topics: Animals; Conditioning, Psychological; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Levodopa; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley | 2011 |
Nicotinic receptor agonists decrease L-dopa-induced dyskinesias most effectively in partially lesioned parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Azetidines; Benzazepines; Corpus Striatum; Disease Models, Animal; Dopamine Plasma Membrane Transport Proteins; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Levodopa; Male; Nicotinic Agonists; Oxidopamine; Parkinson Disease; Quinoxalines; Rats; Rats, Sprague-Dawley; Varenicline | 2011 |
Role of dopamine D3 and serotonin 5-HT 1A receptors in L: -DOPA-induced dyskinesias and effects of sarizotan in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Dyskinesia, Drug-Induced; Levodopa; Male; Organic Chemicals; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D3; Serotonin 5-HT1 Receptor Agonists; Time Factors | 2011 |
Flibanserin attenuates L: -DOPA-sensitized contraversive circling in the unilaterally 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Benzimidazoles; Disease Models, Animal; Dose-Response Relationship, Drug; Functional Laterality; Levodopa; Male; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Stereotypic Movement Disorder; Time Factors | 2011 |
Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease.
Topics: Analysis of Variance; Animals; Behavior, Animal; Cell Count; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Immunohistochemistry; Levodopa; Mice; Motor Activity; Neural Pathways; Neurons; Oxidopamine; Parkinson Disease; Substantia Nigra | 2011 |
The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in L-Dopa-treated parkinsonian monkeys.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Parkinsonian Disorders; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate | 2011 |
Generation of a model of L-DOPA-induced dyskinesia in two different mouse strains.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Efferent Pathways; Levodopa; Mice; Mice, Inbred C57BL; Mice, Transgenic | 2011 |
Behavioral and cellular modulation of L-DOPA-induced dyskinesia by beta-adrenoceptor blockade in the 6-hydroxydopamine-lesioned rat.
Topics: Adrenergic beta-Antagonists; Animals; Antiparkinson Agents; Benzoxazines; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Levodopa; Male; Medial Forebrain Bundle; Molecular Targeted Therapy; Motor Activity; Oxazines; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, beta; Time Factors | 2011 |
The selective mu-opioid receptor antagonist ADL5510 reduces levodopa-induced dyskinesia without affecting antiparkinsonian action in MPTP-lesioned macaque model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; CHO Cells; Cricetinae; Cricetulus; Disease Models, Animal; Drug Interactions; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Macaca fascicularis; Male; Naltrexone; Narcotic Antagonists; Parkinsonian Disorders; Receptors, Opioid, mu | 2011 |
The metabotropic glutamate receptor antagonist 2-methyl-6-(phenylethynyl) pyridine decreases striatal VGlut2 expression in association with an attenuation of L-DOPA-induced dyskinesias.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Down-Regulation; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Levodopa; Male; Parkinsonian Disorders; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Vesicular Glutamate Transport Protein 2 | 2011 |
Differential expression of FosB, c-Fos, and Zif268 in forebrain regions after acute or chronic L-DOPA treatment in a rat model of Parkinson's disease.
Topics: Acute Disease; Animals; Chronic Disease; Disease Models, Animal; Dose-Response Relationship, Drug; Early Growth Response Protein 1; Gene Expression Regulation; Levodopa; Male; Parkinsonian Disorders; Prosencephalon; Proto-Oncogene Proteins c-fos; Rats; Rats, Wistar; Tissue Distribution; Treatment Outcome | 2011 |
Dopamine release from serotonergic nerve fibers is reduced in L-DOPA-induced dyskinesia.
Topics: Adrenergic Agents; Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Dopa Decarboxylase; Dopamine; Dyskinesia, Drug-Induced; Electrochemistry; Female; Functional Laterality; Levodopa; Oxidopamine; Potassium Chloride; Presynaptic Terminals; Rats; Rats, Sprague-Dawley; Serotonin; Serotonin Plasma Membrane Transport Proteins; Severity of Illness Index; Stereotyped Behavior; Tyrosine 3-Monooxygenase | 2011 |
Changes in the mRNA levels of α2A and α2C adrenergic receptors in rat models of Parkinson's disease and L-DOPA-induced dyskinesia.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Basal Ganglia; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Locus Coeruleus; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-2; RNA, Messenger | 2012 |
Synphilin suppresses α-synuclein neurotoxicity in a Parkinson's disease Drosophila model.
Topics: alpha-Synuclein; Animals; Animals, Genetically Modified; Antiparkinson Agents; Blotting, Western; Carbidopa; Carrier Proteins; Disease Models, Animal; Drosophila; Female; Humans; Kaplan-Meier Estimate; Levodopa; Male; Motor Activity; Nerve Degeneration; Nerve Tissue Proteins; Neurotoxicity Syndromes; Parkinson Disease; Reverse Transcriptase Polymerase Chain Reaction | 2011 |
Antidepressant-like properties of sarizotan in experimental Parkinsonism.
Topics: Animals; Antidepressive Agents; Antiparkinson Agents; Behavior, Animal; Benserazide; Cell Proliferation; Dentate Gyrus; Depression; Disease Models, Animal; Doublecortin Protein; Drug Combinations; Levodopa; Locomotion; Male; Organic Chemicals; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Swimming | 2011 |
L-DOPA-induced dyskinesia is associated with regional increase of striatal dynorphin peptides as elucidated by imaging mass spectrometry.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Female; Humans; Levodopa; Mice; Neostriatum; Parkinson Disease; Protein Precursors; Rats; Rats, Sprague-Dawley; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2011 |
Endogenous morphine-like compound immunoreactivity increases in parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; alpha-Methyltyrosine; Analysis of Variance; Animals; Brain; Choline O-Acetyltransferase; Chromatography, High Pressure Liquid; Dendrites; Disease Models, Animal; Dopamine; Dopamine Agents; Dopamine and cAMP-Regulated Phosphoprotein 32; Dopamine Plasma Membrane Transport Proteins; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Female; Functional Laterality; Gene Expression Regulation; Glial Fibrillary Acidic Protein; Glutamate Decarboxylase; Humans; Levodopa; Macaca fascicularis; Male; Medial Forebrain Bundle; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microscopy, Immunoelectron; Middle Aged; Nerve Growth Factors; Organic Chemicals; Oxidopamine; Parkinsonian Disorders; Postmortem Changes; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; S100 Calcium Binding Protein beta Subunit; S100 Proteins; Tandem Mass Spectrometry | 2011 |
Effects of zingerone [4-(4-hydroxy-3-methoxyphenyl)-2-butanone] and eugenol [2-methoxy-4-(2-propenyl)phenol] on the pathological progress in the 6-hydroxydopamine-induced Parkinson's disease mouse model.
Topics: Animals; Antioxidants; Ascorbic Acid; Catalase; Corpus Striatum; Disease Models, Animal; Dopamine; Eugenol; Free Radical Scavengers; Glutathione; Glutathione Peroxidase; Guaiacol; Levodopa; Male; Mice; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Superoxide Dismutase | 2011 |
Vascular endothelial growth factor is upregulated by L-dopa in the parkinsonian brain: implications for the development of dyskinesia.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Animals; Antigens, CD; Antigens, Surface; Antiparkinson Agents; Astrocytes; Behavior, Animal; Benserazide; Blood Vessels; Blood-Brain Barrier; Brain; Bromodeoxyuridine; Cell Count; Cells, Cultured; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Embryo, Mammalian; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Female; Humans; Laminin; Levodopa; Male; Neovascularization, Pathologic; Nerve Tissue Proteins; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; RNA, Messenger; Time Factors; Up-Regulation; Vascular Endothelial Growth Factor A | 2011 |
Targeting NR2A-containing NMDA receptors reduces L-DOPA-induced dyskinesias.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Antiparkinson Agents; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Disease Models, Animal; Disks Large Homolog 4 Protein; Dyskinesia, Drug-Induced; Gene Expression Regulation; Intracellular Signaling Peptides and Proteins; Levodopa; Male; Medial Forebrain Bundle; Membrane Proteins; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; Receptors, N-Methyl-D-Aspartate; Subcellular Fractions; Time Factors | 2012 |
Sustained-release formulation of levodopa methyl ester/benserazide for prolonged suppressing dyskinesia expression in 6-OHDA-leisoned rats.
Topics: Animals; Antiparkinson Agents; Benserazide; Delayed-Action Preparations; Disease Models, Animal; Dopamine Agents; Drug Combinations; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Reaction Time | 2011 |
Unpredictable rotational responses to L-dopa in the rat model of Parkinson's disease: the role of L-dopa pharmacokinetics and striatal dopamine depletion.
Topics: Administration, Oral; Animals; Corpus Striatum; Disease Models, Animal; Injections, Intraperitoneal; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; Rotation | 2012 |
An autoradiographic study on the pathogenesis of levodopa-induced dyskinesia: regulation of dopamine transporter by levodopa in a rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Autoradiography; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Levodopa; Male; Parkinson Disease; Rats; Rats, Sprague-Dawley | 2012 |
Intervention of mitochondrial dysfunction-oxidative stress-dependent apoptosis as a possible neuroprotective mechanism of α-lipoic acid against rotenone-induced parkinsonism and L-dopa toxicity.
Topics: Animals; Antiparkinson Agents; Apoptosis; Disease Models, Animal; Levodopa; Mitochondria; Neurons; Neuroprotective Agents; Oxidative Stress; Parkinson Disease; Rats; Rotenone; Thioctic Acid; Uncoupling Agents | 2011 |
[Comparative study of amantadine and hemantane effects on development of levodopa-induced dyskinesia in rat model of parkinsonian syndrome].
Topics: Adamantane; Amantadine; Animals; Behavior, Animal; Benserazide; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Rats; Substantia Nigra | 2011 |
Experimental Models of l-DOPA-Induced Dyskinesia.
Topics: Animals; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Levodopa; Parkinsonian Disorders | 2011 |
Dysfunction of fibroblasts of extrarenal origin underlies renal fibrosis and renal anemia in mice.
Topics: Anemia; Animals; Benserazide; Cell Differentiation; Cell Lineage; Disease Models, Animal; Drug Combinations; Erythropoietin; Female; Fibroblasts; Fibrosis; Kidney; Levodopa; Mice; Mice, Transgenic; Myofibroblasts; Pregnancy | 2011 |
Extent of pre-operative L-DOPA-induced dyskinesia predicts the severity of graft-induced dyskinesia after fetal dopamine cell transplantation.
Topics: Amphetamines; Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dopamine Agonists; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Dyskinesias; Female; Fetal Tissue Transplantation; Levodopa; Oxidopamine; Postoperative Complications; Predictive Value of Tests; Rats; Rats, Sprague-Dawley; Severity of Illness Index; Substantia Nigra; Sympatholytics | 2011 |
MPTP-induced models of Parkinson's disease in mice and non-human primates.
Topics: Animals; Callithrix; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Male; Mice; Mice, Inbred C57BL; MPTP Poisoning | 2005 |
Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson's disease.
Topics: Amantadine; Animals; Antiparkinson Agents; Behavior, Animal; Callithrix; Disease Models, Animal; Dopamine Agonists; Drug Synergism; Dyskinesia, Drug-Induced; Fructose; Levodopa; Male; MPTP Poisoning; Neuroprotective Agents; Parkinson Disease; Rats; Rats, Sprague-Dawley; Topiramate | 2011 |
The involvement of RGS9 in l-3,4-dihydroxyphenylalanine-induced dyskinesias in unilateral 6-OHDA lesion rat model.
Topics: Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Benserazide; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; RGS Proteins | 2011 |
Effects of noradrenergic denervation on L-DOPA-induced dyskinesia and its treatment by α- and β-adrenergic receptor antagonists in hemiparkinsonian rats.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adrenergic Neurons; Animals; Behavior, Animal; Corpus Striatum; Desipramine; Disease Models, Animal; Dyskinesia, Drug-Induced; Hippocampus; Idazoxan; Levodopa; Male; Molecular Targeted Therapy; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Propranolol; Rats; Rats, Sprague-Dawley; Severity of Illness Index; Sympathectomy, Chemical | 2012 |
Subthalamo-pallidal interactions underlying parkinsonian neuronal oscillations in the primate basal ganglia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Action Potentials; Animals; Antiparkinson Agents; Basal Ganglia; Biological Clocks; Brain Waves; Disease Models, Animal; Dopamine; Electric Stimulation; Functional Laterality; Globus Pallidus; Levodopa; Macaca; Male; MPTP Poisoning; Neurons; Statistics, Nonparametric; Subthalamic Nucleus | 2011 |
The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adenosine A2 Receptor Antagonists; Animals; Brain; Calcium Signaling; Catalepsy; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; G Protein-Coupled Inwardly-Rectifying Potassium Channels; Glutamic Acid; Haloperidol; HEK293 Cells; Humans; Levodopa; Male; Monoamine Oxidase; Motor Neuron Disease; Oxidopamine; Parkinson Disease; Picolinic Acids; Protein Binding; Psychomotor Performance; Pyrimidines; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reaction Time; Receptors, G-Protein-Coupled; Receptors, Metabotropic Glutamate; Substantia Nigra; Thallium; Transfection; Triazoles; Tyrosine 3-Monooxygenase | 2012 |
Intranasally applied L-DOPA alleviates parkinsonian symptoms in rats with unilateral nigro-striatal 6-OHDA lesions.
Topics: 3,4-Dihydroxyphenylacetic Acid; Administration, Intranasal; Amphetamine; Analysis of Variance; Animals; Antiparkinson Agents; Benserazide; Chromatography, High Pressure Liquid; Corpus Striatum; Disease Models, Animal; Dopamine; Electrochemistry; Exploratory Behavior; Forelimb; Functional Laterality; Homovanillic Acid; Hydroxyindoleacetic Acid; Levodopa; Male; Motor Activity; Motor Skills; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Substantia Nigra; Sympatholytics | 2012 |
Serotonergic modulation of receptor occupancy in rats treated with L-DOPA after unilateral 6-OHDA lesioning.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Analysis of Variance; Animals; Antiparkinson Agents; Autoradiography; Carbon Isotopes; Cocaine; Disease Models, Animal; Dopamine; Dopamine Uptake Inhibitors; Dyskinesia, Drug-Induced; Female; Functional Laterality; Levodopa; Microdialysis; Motor Activity; Oxidopamine; Parkinson Disease; Positron-Emission Tomography; Protein Binding; Raclopride; Rats; Rats, Sprague-Dawley; Receptors, Dopamine; Receptors, Serotonin; Serotonergic Neurons; Serotonin Receptor Agonists | 2012 |
Chlorotoxin-modified stealth liposomes encapsulating levodopa for the targeting delivery against Parkinson's disease in the MPTP-induced mice model.
Topics: Animals; Cells, Cultured; Disease Models, Animal; Drug Delivery Systems; Levodopa; Liposomes; Male; Mice; Mice, Inbred C57BL; MPTP Poisoning; Parkinson Disease; Random Allocation; Scorpion Venoms | 2012 |
Functional and physiological effects of treadmill training induced by buspirone, carbidopa, and L-DOPA in clenbuterol-treated paraplegic mice.
Topics: Adipose Tissue; Analysis of Variance; Animals; Biomechanical Phenomena; Body Composition; Body Weight; Bone Density; Buspirone; Densitometry; Disease Models, Animal; Dopamine Agents; Exercise Test; Exercise Therapy; Histocompatibility Antigens; Levodopa; Male; Mice; Motor Activity; Muscle Fibers, Skeletal; Muscle, Skeletal; Paraplegia; Recovery of Function; Sacrococcygeal Region; Serotonin Receptor Agonists; Spinal Cord Injuries | 2012 |
Rhes, a striatal-enriched small G protein, mediates mTOR signaling and L-DOPA-induced dyskinesia.
Topics: Adaptor Proteins, Signal Transducing; Adrenergic Agents; Animals; Antiparkinson Agents; Cell Line, Transformed; Corpus Striatum; Culture Media, Serum-Free; Disability Evaluation; Disease Models, Animal; Dyskinesia, Drug-Induced; Functional Laterality; Gene Expression Regulation; GTP-Binding Proteins; Humans; Immunosuppressive Agents; Levodopa; Mice; Mice, Knockout; Movement; Mutation; Neurons; Neurotoxicity Syndromes; Oxidopamine; Phosphorylation; Protein Binding; Radioligand Assay; Ribosomal Protein S6 Kinases; Signal Transduction; Sirolimus; Time Factors; TOR Serine-Threonine Kinases; Transfection | 2011 |
Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of α-synuclein in midbrain dopamine neurons.
Topics: alpha-Synuclein; Amphetamine; Analysis of Variance; Animals; Antiparkinson Agents; Behavioral Symptoms; Cell Count; Chromatography, High Pressure Liquid; Dependovirus; Disease Models, Animal; Disease Progression; Dopamine; Dopaminergic Neurons; ELAV Proteins; Enzyme-Linked Immunosorbent Assay; Female; Gene Expression Regulation; Genetic Vectors; Green Fluorescent Proteins; Humans; Levodopa; Mesencephalon; Nerve Tissue Proteins; Neurodegenerative Diseases; Parkinson Disease; Rats; Rats, Sprague-Dawley; Regulatory Elements, Transcriptional; Stereotyped Behavior; Time Factors; Tyrosine 3-Monooxygenase; Vesicular Monoamine Transport Proteins | 2012 |
Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Cell Count; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Environment; Gene Expression Regulation; Levodopa; Mice; Mice, Inbred C57BL; Motor Activity; Parkinson Disease; Psychomotor Performance; Substantia Nigra; Tyrosine 3-Monooxygenase | 2012 |
Molecular mechanism underlying the cerebral effect of Gly-Pro-Glu tripeptide bound to L-dopa in a Parkinson's animal model.
Topics: Analysis of Variance; Animals; Basal Ganglia; CD11b Antigen; Disease Models, Animal; Dopamine; Drug Evaluation, Preclinical; Gene Expression; Glial Fibrillary Acidic Protein; Glutathione; Heme Oxygenase-1; Levodopa; Male; Mice; Mice, Inbred C57BL; Neuroprotective Agents; NF-E2-Related Factor 2; NF-kappa B; Nitric Oxide Synthase Type II; Oligopeptides; Oxidative Stress; Parkinsonian Disorders; Tumor Necrosis Factor-alpha; Tyrosine 3-Monooxygenase | 2012 |
L-DOPA impairs proteasome activity in parkinsonism through D1 dopamine receptor.
Topics: Animals; Disease Models, Animal; Dopamine Agonists; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca mulatta; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Organ Culture Techniques; Parkinsonian Disorders; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1 | 2012 |
The role of GRK6 in animal models of Parkinson's disease and L-DOPA treatment.
Topics: Animals; Cyclic AMP; Disease Models, Animal; Extracellular Signal-Regulated MAP Kinases; G-Protein-Coupled Receptor Kinases; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Levodopa; Locomotion; Mice; Mice, Inbred C57BL; Mice, Knockout; Mutation; Parkinson Disease; Proto-Oncogene Proteins c-akt; Signal Transduction | 2012 |
Investigation of the antidyskinetic site of action of metabotropic and ionotropic glutamate receptor antagonists. Intracerebral infusions in 6-hydroxydopamine-lesioned rats with levodopa-induced dyskinesia.
Topics: Animals; Anti-Dyskinesia Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Infusions, Intraventricular; Levodopa; Male; Oxidopamine; Phenols; Piperidines; Putamen; Quinoxalines; Rats; Rats, Wistar; Receptor, Metabotropic Glutamate 5; Receptors, AMPA; Receptors, Metabotropic Glutamate; Receptors, N-Methyl-D-Aspartate; Substantia Nigra; Subthalamic Nucleus; Thiazoles | 2012 |
In vivo catecholaminergic metabolism in the medial prefrontal cortex of ENU2 mice: an investigation of the cortical dopamine deficit in phenylketonuria.
Topics: Animals; Catecholamines; Disease Models, Animal; Dopamine; Levodopa; Male; Mice; Mice, Mutant Strains; Phenylalanine Hydroxylase; Phenylketonurias; Prefrontal Cortex; Synaptic Transmission; Tyrosine; Tyrosine 3-Monooxygenase | 2012 |
Amphetamine-induced rotation and L-DOPA-induced dyskinesia in the rat 6-OHDA model: a correlation study.
Topics: Amphetamine; Animals; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Levodopa; Oxidopamine; Rats; Rats, Sprague-Dawley; Rotation | 2012 |
Synergy between L-DOPA and a novel positive allosteric modulator of metabotropic glutamate receptor 4: implications for Parkinson's disease treatment and dyskinesia.
Topics: Allosteric Regulation; Aminobutyrates; Anilides; Animals; Catalepsy; Cyclohexanecarboxylic Acids; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Dyskinesia, Drug-Induced; Excitatory Amino Acid Agonists; Excitatory Postsynaptic Potentials; Haloperidol; Levodopa; Male; Oxidopamine; Parkinson Disease; Phosphinic Acids; Rats; Rats, Sprague-Dawley; Receptors, Metabotropic Glutamate; Synaptic Transmission | 2013 |
Histamine- and haloperidol-induced catalepsy in aged mice: differential responsiveness to L-DOPA.
Topics: Aging; Animals; Antiparkinson Agents; Catalepsy; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Haloperidol; Histamine; Injections, Intraventricular; Levodopa; Male; Mice; Mice, Inbred BALB C; Parkinson Disease; Time Factors | 2012 |
Mechanisms underlying the impairment of hippocampal long-term potentiation and memory in experimental Parkinson's disease.
Topics: alpha-Synuclein; Analysis of Variance; Animals; Antiparkinson Agents; Benserazide; Biophysical Phenomena; Disease Models, Animal; Dopamine; Electric Stimulation; Excitatory Postsynaptic Potentials; Exploratory Behavior; Hippocampus; Humans; Levodopa; Long-Term Potentiation; Male; Memory Disorders; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microdialysis; Mutation; Oxidopamine; Parkinson Disease; Patch-Clamp Techniques; Radionuclide Imaging; Rats; Subcellular Fractions; Sympatholytics; Synaptosomes; Tritium; Tyrosine 3-Monooxygenase | 2012 |
Influence of corticostriatal δ-opioid receptors on abnormal involuntary movements induced by L-DOPA in hemiparkinsonian rats.
Topics: Animals; Cerebral Cortex; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Enkephalin, D-Penicillamine (2,5)-; Levodopa; Male; Neurons; Parkinsonian Disorders; Protein Binding; Rats; Rats, Sprague-Dawley; Receptors, Opioid, delta | 2012 |
Serotonergic and dopaminergic mechanisms in graft-induced dyskinesia in a rat model of Parkinson's disease.
Topics: 5,6-Dihydroxytryptamine; Adrenergic Agents; Amphetamine; Analysis of Variance; Animals; Antiparkinson Agents; Buspirone; Cell Count; Creatinine; Disease Models, Animal; Dopamine Agonists; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Female; Indoles; Levodopa; Motor Activity; Oxidopamine; Parkinson Disease; Pyridines; Rats; Rats, Sprague-Dawley; Serotonergic Neurons; Serotonin Receptor Agonists; Time Factors | 2012 |
The effect of piribedil on L-DOPA-induced dyskinesias in a rat model of Parkinson's disease: differential role of α(2) adrenergic mechanisms.
Topics: Adrenergic Agents; Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-2 Receptor Antagonists; Animals; Antiparkinson Agents; Benserazide; Clonidine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Dyskinesia, Drug-Induced; Dystonia; Facial Asymmetry; Idazoxan; Levodopa; Locomotion; Oxidopamine; Parkinson Disease; Piribedil; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-2; Statistics, Nonparametric; Upper Extremity | 2013 |
L-DOPA-induced dysregulation of extrastriatal dopamine and serotonin and affective symptoms in a bilateral rat model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Anxiety; Behavior, Animal; Brain; Chromatography, High Pressure Liquid; Disease Models, Animal; Dopamine; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Serotonin | 2012 |
Impact of dopamine versus serotonin cell transplantation for the development of graft-induced dyskinesia in a rat Parkinson model.
Topics: Adrenergic Agents; Amphetamines; Analysis of Variance; Animals; Antiparkinson Agents; Cell Transplantation; Central Nervous System Stimulants; Disease Models, Animal; Dopaminergic Neurons; Dyskinesias; Female; Functional Laterality; Levodopa; Nerve Fibers; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; RNA-Binding Proteins; Serotonergic Neurons; Statistics as Topic; Stereotyped Behavior; Tyrosine 3-Monooxygenase | 2012 |
Effect of L-ascorbic Acid on the climbing ability and protein levels in the brain of Drosophila model of Parkinson's disease.
Topics: Age Factors; alpha-Synuclein; Animals; Animals, Genetically Modified; Antioxidants; Antiparkinson Agents; Ascorbic Acid; Brain; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Drosophila; Drosophila Proteins; Gait Disorders, Neurologic; Humans; Levodopa; Membrane Proteins; Neurons; Parkinson Disease; Transcription Factors | 2012 |
MPEP, an mGlu5 receptor antagonist, reduces the development of L-DOPA-induced motor complications in de novo parkinsonian monkeys: biochemical correlates.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Dopamine Plasma Membrane Transport Proteins; Drug Administration Schedule; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Levodopa; Macaca fascicularis; Oximes; Parkinsonian Disorders; Putamen; Pyridines; Radioligand Assay; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate | 2013 |
Manganese mixture inhalation is a reliable Parkinson disease model in rats.
Topics: Administration, Inhalation; Analysis of Variance; Animals; Antiparkinson Agents; Brain; Disease Models, Animal; Feeding Behavior; Levodopa; Locomotion; Male; Manganese Compounds; Manganese Poisoning; Mice; Motor Activity; Neurologic Examination; Parkinson Disease; Phosphopyruvate Hydratase; Psychomotor Performance; Rats; Rats, Wistar; Tyrosine 3-Monooxygenase; Video Recording | 2012 |
[Effects of Chinese herbal medicine Tianqi Pingchan Granule on G protein-coupled receptor kinase 6 involved in the prevention of levodopa-induced dyskinesia in rats with Parkinson disease].
Topics: Animals; Disease Models, Animal; Drugs, Chinese Herbal; Dyskinesias; G-Protein-Coupled Receptor Kinases; Levodopa; Male; Parkinson Disease; Phytotherapy; Rats; Rats, Sprague-Dawley | 2012 |
Preclinical models of Parkinson's disease.
Topics: Animals; Disease Models, Animal; Levodopa; Macaca fascicularis; Macaca mulatta; Mice; Mice, Inbred C57BL; Motor Activity; MPTP Poisoning; Parkinson Disease; Rats; Rats, Sprague-Dawley | 2004 |
Effect of zonisamide co-administration with levodopa on global gene expression in the striata of rats with Parkinson's disease.
Topics: Animals; Anticonvulsants; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Drug Therapy, Combination; Gene Expression; Gene Expression Profiling; Isoxazoles; Levodopa; Male; Oligonucleotide Array Sequence Analysis; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Rats; Rats, Wistar; Zonisamide | 2012 |
Physical activity and environmental enrichment regulate the generation of neural precursors in the adult mouse substantia nigra in a dopamine-dependent manner.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2',3'-Cyclic-Nucleotide Phosphodiesterases; Adult Stem Cells; Analysis of Variance; Animals; Antigens; Bromodeoxyuridine; Calcium-Binding Proteins; Cells, Cultured; Disease Models, Animal; Dopamine; Dopamine Agents; Environment; Female; Green Fluorescent Proteins; Intermediate Filament Proteins; Levodopa; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microfilament Proteins; Motor Activity; MPTP Poisoning; Nerve Tissue Proteins; Nestin; Proteoglycans; Substantia Nigra; Tyrosine 3-Monooxygenase | 2012 |
Levodopa infusion does not decrease the onset of abnormal involuntary movements in parkinsonian rats.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Area Under Curve; Disease Models, Animal; Dyskinesias; Levodopa; Male; Medial Forebrain Bundle; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; Time Factors | 2013 |
Levodopa/benserazide microspheres reduced levodopa-induced dyskinesia by downregulating phosphorylated GluR1 expression in 6-OHDA-lesioned rats.
Topics: Animals; Antiparkinson Agents; Benserazide; Blotting, Western; Delayed-Action Preparations; Disease Models, Animal; Down-Regulation; Drug Carriers; Drug Combinations; Dyskinesia, Drug-Induced; Female; Lactic Acid; Levodopa; Microspheres; Oxidopamine; Parkinsonian Disorders; Phosphorylation; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rats; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; Receptors, AMPA | 2012 |
Beneficial effects of natural phenolics on levodopa methylation and oxidative neurodegeneration.
Topics: Adrenergic Uptake Inhibitors; Analysis of Variance; Animals; Antiparkinson Agents; Carbidopa; Catechin; Catechol O-Methyltransferase; Chromatography, High Pressure Liquid; Dihydroxyphenylalanine; Disease Models, Animal; Excitatory Amino Acid Agonists; Fluoresceins; Glial Fibrillary Acidic Protein; Hippocampus; Hydroxybenzoates; In Vitro Techniques; Kainic Acid; Levodopa; Male; Methylation; Mice; Nerve Degeneration; Neurons; Rats; Rats, Sprague-Dawley; Reserpine; Time Factors; Tyrosine | 2013 |
Levodopa improves motor deficits but can further disrupt cognition in a macaque Parkinson model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Antiparkinson Agents; Cognition Disorders; Conditioning, Operant; Disease Models, Animal; Levodopa; Macaca fascicularis; Male; Movement; MPTP Poisoning; Photic Stimulation; Time Factors | 2013 |
Dopamine transporter loss in 6-OHDA Parkinson's model is unmet by parallel reduction in dopamine uptake.
Topics: Animals; Biological Transport; Disease Models, Animal; Dopamine; Dopamine Plasma Membrane Transport Proteins; Gene Expression Regulation; Levodopa; Male; Neostriatum; Norepinephrine; Norepinephrine Plasma Membrane Transport Proteins; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Serotonin; Synapses; Synaptosomes; Tyrosine 3-Monooxygenase | 2012 |
IRC-082451, a novel multitargeting molecule, reduces L-DOPA-induced dyskinesias in MPTP Parkinsonian primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antioxidants; Antiparkinson Agents; Behavior, Animal; Chromatography, High Pressure Liquid; Cyclooxygenase Inhibitors; Disease Models, Animal; Dopamine Agents; Dyskinesias; Immunohistochemistry; Levodopa; Macaca fascicularis; Magnetic Resonance Imaging; Male; Neurons; Oxidative Stress; Parkinson Disease; Positron-Emission Tomography; Thiazoles | 2013 |
Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia.
Topics: Adamantane; Alternative Splicing; Animals; Antiparkinson Agents; Cocaine; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Gene Expression Regulation; Iodine Isotopes; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptors, AMPA; RNA, Messenger; Sympatholytics | 2013 |
The nicotine-mediated decline in l-dopa-induced dyskinesias is associated with a decrease in striatal dopamine release.
Topics: Animals; Antiparkinson Agents; Autoradiography; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Male; Nicotine; Nicotinic Agonists; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, Nicotinic | 2013 |
The effects of BMY-14802 against L-DOPA- and dopamine agonist-induced dyskinesia in the hemiparkinsonian rat.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine Agonists; Dyskinesia, Drug-Induced; Levodopa; Male; Motor Activity; Parkinson Disease; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D1 | 2013 |
Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia.
Topics: Amantadine; Amphetamine; Animals; Apomorphine; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Medial Forebrain Bundle; Motor Activity; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Piperazines; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Serotonin Receptor Agonists; Time Factors; Tyrosine 3-Monooxygenase | 2013 |
L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function.
Topics: Afferent Pathways; Animals; Bacterial Proteins; Behavior, Animal; Biomarkers; Brain Mapping; Caudate Nucleus; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Enkephalins; Female; Image Processing, Computer-Assisted; Levodopa; Motor Activity; Nerve Tissue Proteins; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Proto-Oncogene Proteins c-fos; Putamen; Rats; Rats, Sprague-Dawley; RNA, Messenger; Severity of Illness Index; Substantia Nigra; Sympathectomy, Chemical; Transcription Factors | 2002 |
Dopamine replacement therapy reverses abnormal synchronization of pallidal neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine primate model of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Action Potentials; Animals; Antiparkinson Agents; Bromocriptine; Carbidopa; Chlorocebus aethiops; Disease Models, Animal; Dopamine; Dopamine Agonists; Drug Therapy, Combination; Electrodes, Implanted; Female; Globus Pallidus; Levodopa; Neurons; Organic Chemicals; Parkinsonian Disorders | 2002 |
A site-specific mutation of tyrosine hydroxylase reduces feedback inhibition by dopamine in genetically modified cells grafted in parkinsonian rats.
Topics: Amino Acid Substitution; Animals; Aromatic-L-Amino-Acid Decarboxylases; Catecholamines; Cells, Cultured; Coculture Techniques; Corpus Striatum; Disease Models, Animal; Dopamine; Extracellular Space; Feedback, Physiological; Female; Fibroblasts; Genetic Therapy; Graft Survival; GTP Cyclohydrolase; Levodopa; Microdialysis; Mutagenesis, Site-Directed; Parkinsonian Disorders; Rats; Rats, Inbred F344; Transduction, Genetic; Tyrosine 3-Monooxygenase | 2002 |
Transcription factors involved in the pathogenesis of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Enkephalins; Gene Expression Regulation; Levodopa; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Proto-Oncogene Proteins c-fos; Rats; Sympatholytics; Transcription Factors | 2002 |
Quetiapine attenuates levodopa-induced motor complications in rodent and primate parkinsonian models.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antipsychotic Agents; Behavior, Animal; Dibenzothiazepines; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Quetiapine Fumarate; Rats; Receptor, Serotonin, 5-HT2A; Receptor, Serotonin, 5-HT2C; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Serotonin; Serotonin Antagonists | 2002 |
Killing of Caenorhabditis elegans by Cryptococcus neoformans as a model of yeast pathogenesis.
Topics: Animals; Caenorhabditis elegans; Cryptococcus; Cryptococcus neoformans; Cyclic AMP-Dependent Protein Kinases; Disease Models, Animal; Escherichia coli; Feeding Behavior; Free Radical Scavengers; Fungal Proteins; Genes, Fungal; Genes, Mating Type, Fungal; Heterotrimeric GTP-Binding Proteins; Laccase; Levodopa; Longevity; Melanins; Oxidoreductases; Polysaccharides; Signal Transduction; Species Specificity; Virulence | 2002 |
Dystonia is predictive of subsequent altered dopaminergic responsiveness in a chronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine+3-nitropropionic acid model of striatonigral degeneration in monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Dystonia; Female; Levodopa; Macaca fascicularis; Neurotoxins; Nitro Compounds; Parkinsonian Disorders; Propionates; Putamen; Striatonigral Degeneration; Substantia Nigra | 2002 |
Detection of behavioral impairments correlated to neurochemical deficits in mice treated with moderate doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Topics: 3,4-Dihydroxyphenylacetic Acid; Age Factors; Animals; Antiparkinson Agents; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Plasma Membrane Transport Proteins; Forelimb; Homovanillic Acid; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Mice; Mice, Inbred C57BL; Motor Activity; Nerve Tissue Proteins; Neuropeptides; Parkinsonian Disorders; Postural Balance; Recovery of Function; Tyrosine 3-Monooxygenase; Vesicular Biogenic Amine Transport Proteins; Vesicular Monoamine Transport Proteins; Walking | 2002 |
Beginning-of-dose and rebound worsening in MPTP-treated common marmosets treated with levodopa.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Motor Activity; Motor Skills; Neurologic Examination; Parkinsonian Disorders; Recurrence | 2002 |
AMPA receptor antagonist LY293558 reverses preproenkephalin mRNA overexpression in the striatum of 6-OHDA-lesioned-rats treated with L-dopa.
Topics: Animals; Disease Models, Animal; Dizocilpine Maleate; Dopamine; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Enkephalins; Excitatory Amino Acid Antagonists; Gene Expression Regulation; Isoquinolines; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Neostriatum; Nerve Tissue Proteins; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; RNA, Messenger; Tetrazoles | 2002 |
Both short- and long-acting D-1/D-2 dopamine agonists induce less dyskinesia than L-DOPA in the MPTP-lesioned common marmoset (Callithrix jacchus).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Callithrix; Disability Evaluation; Disease Models, Animal; Dopamine Agonists; Dyskinesia, Drug-Induced; Levodopa; Motor Activity; Parkinsonian Disorders; Pergolide; Receptors, Dopamine D1; Receptors, Dopamine D2; Severity of Illness Index | 2003 |
Effects of CB1 cannabinoid receptor modulating compounds on the hyperkinesia induced by high-dose levodopa in the reserpine-treated rat model of Parkinson's disease.
Topics: Adrenergic Uptake Inhibitors; Animals; Antiparkinson Agents; Behavior, Animal; Cannabinoid Receptor Modulators; Disease Models, Animal; Dose-Response Relationship, Drug; Fatty Acids, Unsaturated; Hyperkinesis; Levodopa; Male; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptors, Cannabinoid; Receptors, Drug; Reserpine; Time Factors | 2003 |
Role of adenosine in drug-induced catatonia in mice.
Topics: Adenosine; Animals; Antiparkinson Agents; Brain; Carbidopa; Catatonia; Catechol O-Methyltransferase Inhibitors; Catechols; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Female; Injections, Intraperitoneal; Levodopa; Male; Mice; Motor Activity; Perphenazine | 2002 |
Pattern of levodopa-induced striatal changes is different in normal and MPTP-lesioned mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Binding, Competitive; Chronic Disease; Corpus Striatum; Disease Models, Animal; Dopamine Plasma Membrane Transport Proteins; Enkephalins; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Mice; Mice, Inbred C57BL; Nerve Tissue Proteins; Neural Pathways; Neurons; Parkinsonian Disorders; Protein Precursors; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Dopamine D3; RNA, Messenger; Substantia Nigra; Tachykinins; Tyrosine 3-Monooxygenase | 2003 |
Cellular and behavioural effects of the adenosine A2a receptor antagonist KW-6002 in a rat model of l-DOPA-induced dyskinesia.
Topics: Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enkephalins; Female; Levodopa; Motor Activity; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Proto-Oncogene Proteins c-fos; Purinergic P1 Receptor Antagonists; Purines; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; RNA, Messenger; Treatment Outcome | 2003 |
Modification of ocular defects in mouse developmental glaucoma models by tyrosinase.
Topics: Albinism, Ocular; Animals; Anterior Eye Segment; Aryl Hydrocarbon Hydroxylases; Cornea; Cytochrome P-450 CYP1B1; Disease Models, Animal; DNA-Binding Proteins; Female; Forkhead Transcription Factors; Glaucoma; Intraocular Pressure; Iris; Levodopa; Male; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Monophenol Monooxygenase; Mutation; Phenotype; Pregnancy; Trabecular Meshwork; Transcription Factors | 2003 |
Effects of L-dopa and other amino acids against paraquat-induced nigrostriatal degeneration.
Topics: Amino Acids; Animals; Corpus Striatum; Disease Models, Animal; Levodopa; Male; Mice; Mice, Inbred C57BL; Neuroprotective Agents; Paraquat; Parkinson Disease, Secondary; Substantia Nigra; Tyrosine 3-Monooxygenase | 2003 |
Effects of benserazide on L-DOPA-derived extracellular dopamine levels and aromatic L-amino acid decarboxylase activity in the striatum of 6-hydroxydopamine-lesioned rats.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Aromatic-L-Amino-Acid Decarboxylases; Benserazide; Brain; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Humans; Levodopa; Male; Neurons; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; Time Factors | 2003 |
Levodopa treatment reverses endocannabinoid system abnormalities in experimental parkinsonism.
Topics: Amidohydrolases; Animals; Antiparkinson Agents; Arachidonic Acids; Binding, Competitive; Cannabinoid Receptor Modulators; Cerebellum; Corpus Striatum; Cyclohexanols; Disease Models, Animal; Endocannabinoids; Excitatory Postsynaptic Potentials; Fatty Acids, Unsaturated; Glutamic Acid; Glycerides; In Vitro Techniques; Levodopa; Oxidopamine; Parkinsonian Disorders; Patch-Clamp Techniques; Phospholipase D; Polyunsaturated Alkamides; Rats; Rats, Wistar; Receptors, Cannabinoid; Receptors, Drug | 2003 |
Riluzole, an inhibitor of glutamatergic transmission, suppresses levodopa-induced rotations in 6-hydroxydopamine-lesioned rats.
Topics: Animals; Antiparkinson Agents; Apomorphine; Disease Models, Animal; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Receptors, Glutamate; Riluzole; Synaptic Transmission | 2003 |
Antidyskinetic effect of magnesium sulfate in MPTP-lesioned monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca mulatta; Magnesium Sulfate; Motor Activity; Parkinsonian Disorders | 2003 |
Recovery of motor function and dopaminergic parameters in a mouse model of Parkinson's disease induced by co-administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and diethyldithiocarbamate.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Ditiocarb; Dopamine; Drug Synergism; Homovanillic Acid; Levodopa; Male; Mice; Mice, Inbred C57BL; Monoamine Oxidase Inhibitors; Motor Activity; Parkinsonian Disorders; Reaction Time; Recovery of Function; Selegiline; Serotonin | 2003 |
Effect of subthalamic nucleus or entopeduncular nucleus lesion on levodopa-induced neurochemical changes within the basal ganglia and on levodopa-induced motor alterations in 6-hydroxydopamine-lesioned rats.
Topics: Animals; Basal Ganglia; Corpus Striatum; Disease Models, Animal; Electron Transport Complex IV; Enkephalins; Entopeduncular Nucleus; Globus Pallidus; Glutamate Decarboxylase; In Situ Hybridization; Isoenzymes; Levodopa; Male; Motor Activity; Neurons; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Rats; Rats, Sprague-Dawley; RNA, Messenger; Substantia Nigra; Subthalamic Nucleus | 2003 |
Effect of acute and chronic administration of U50,488, a kappa opioid receptor agonist, in 6-OHDA-lesioned rats chronically treated with levodopa.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Drug Administration Schedule; Levodopa; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, Opioid, kappa; Time; Treatment Outcome | 2003 |
Treatment effects on nigrostriatal projection integrity in partial 6-OHDA lesions: comparison of L-DOPA and pramipexole.
Topics: Amphetamine; Animals; Antiparkinson Agents; Apomorphine; Autoradiography; Behavior, Animal; Benzothiazoles; Binding, Competitive; Corpus Striatum; Disease Models, Animal; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Motor Activity; Neuropeptides; Oxidopamine; Parkinsonian Disorders; Pramipexole; Rats; Rats, Sprague-Dawley; Substantia Nigra; Thiazoles; Treatment Outcome; Tritium; Vesicular Biogenic Amine Transport Proteins; Vesicular Monoamine Transport Proteins | 2003 |
Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa-induced dyskinesias.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Behavior, Animal; Benzazepines; Benzoxazines; Brain Chemistry; Cannabinoid Receptor Modulators; Chromatography, High Pressure Liquid; Disease Models, Animal; Dopamine Antagonists; Drug Interactions; Dyskinesia, Drug-Induced; Dyskinesias; Endocannabinoids; Gas Chromatography-Mass Spectrometry; Levodopa; Male; Morpholines; Mouth; Naphthalenes; Oxidopamine; Parkinson Disease; Piperidines; Pyrazoles; Raclopride; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Rimonabant; Substantia Nigra; Time Factors | 2003 |
Effect of levodopa chronic administration on behavioral changes and fos expression in basal ganglia in rat model of PD.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Levodopa; Male; Parkinson Disease; Proto-Oncogene Proteins c-fos; Random Allocation; Rats; Rats, Sprague-Dawley | 2003 |
Effects of (+/-)-idazoxan alone and in combination with L-DOPA methyl ester in MPTP-induced hemiparkinsonian monkeys.
Topics: Adrenergic alpha-Antagonists; Animals; Antiparkinson Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Idazoxan; Levodopa; Macaca nemestrina; Parkinson Disease, Secondary; Time Factors | 2003 |
3,4-methylenedioxymethamphetamine (ecstasy) inhibits dyskinesia expression and normalizes motor activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Callithrix; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Motor Activity; N-Methyl-3,4-methylenedioxyamphetamine; Parkinsonian Disorders; Receptor, Serotonin, 5-HT1B; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Serotonin Receptor Agonists | 2003 |
Modulation of striatal serotonin and opioid receptor mRNA expression following systemic N-methyl-norsalsolinol administration.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Gene Expression; Levodopa; Male; Neostriatum; Parkinson Disease; Rats; Rats, Wistar; Receptor, Serotonin, 5-HT2A; Receptors, Opioid, delta; Receptors, Opioid, mu; RNA, Messenger; Serotonin; Tetrahydroisoquinolines; Up-Regulation | 2003 |
Uptake of 6-[18F]fluoro-L-dopa and [18F]CFT reflect nigral neuronal loss in a rat model of Parkinson's disease.
Topics: Amphetamine; Animals; Apomorphine; Autoradiography; Behavior, Animal; Brain; Brain Mapping; Central Nervous System Stimulants; Dihydroxyphenylalanine; Disease Models, Animal; Dopamine Agonists; Functional Laterality; Immunohistochemistry; Levodopa; Male; Oxidopamine; Parkinson Disease; Propionates; Radioligand Assay; Rats; Rats, Sprague-Dawley; Stereotyped Behavior; Substantia Nigra; Sympatholytics; Tyrosine 3-Monooxygenase | 2004 |
Bilateral subthalamic nucleus lesion reverses L-dopa-induced motor fluctuations and facilitates dyskinetic movements in hemiparkinsonian rats.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesias; Functional Laterality; Levodopa; Male; Motor Activity; Movement; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Rotation; Stereotyped Behavior; Subthalamic Nucleus; Time Factors | 2004 |
Effects of orally administered levodopa on mesencephalic dopaminergic neurons undergoing a degenerative process.
Topics: Administration, Oral; Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Female; Immunohistochemistry; Injections, Intraventricular; Levodopa; Mesencephalon; Nerve Degeneration; Neurons; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Time Factors; Tyrosine 3-Monooxygenase | 2003 |
The effects of chronic L-DOPA therapy on pharmacodynamic parameters in a rat model of motor response fluctuations.
Topics: Animals; Antiparkinson Agents; Apomorphine; Autoradiography; Benzamides; Disease Models, Animal; Dopamine Agonists; Dyskinesias; Female; Forelimb; Immunohistochemistry; Levodopa; Medial Forebrain Bundle; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Receptors, Dopamine; Receptors, Presynaptic | 2003 |
Adenosine A2A and dopamine receptor interactions in basal ganglia of dopamine denervated rats.
Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Basal Ganglia; Behavior, Animal; Denervation; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Gene Expression; Glutamate Decarboxylase; Isoenzymes; Levodopa; Motor Activity; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Pyrimidines; Rats; Receptor, Adenosine A2A; Receptors, Dopamine; RNA, Messenger; Time; Triazoles | 2003 |
Adenosine A2A receptors in neuroadaptation to repeated dopaminergic stimulation: implications for the treatment of dyskinesias in Parkinson's disease.
Topics: Adenosine A2 Receptor Antagonists; Amphetamine; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dopamine; Dopamine Agonists; Drug Tolerance; Dyskinesia, Drug-Induced; Humans; Levodopa; Mice; Mice, Knockout; Neurons; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Purines; Pyrimidines; Receptor, Adenosine A2A; Synapses; Triazoles | 2003 |
Genetically modified human embryonic stem cells relieve symptomatic motor behavior in a rat model of Parkinson's disease.
Topics: Animals; Blotting, Western; Cells, Cultured; Disease Models, Animal; Embryo, Mammalian; Genetic Therapy; Graft Survival; GTP Cyclohydrolase; Humans; Immunohistochemistry; Levodopa; Motor Activity; Oxidopamine; Parkinsonian Disorders; Rats; Reverse Transcriptase Polymerase Chain Reaction; Stem Cell Transplantation; Stem Cells; Transfection; Tyrosine 3-Monooxygenase | 2003 |
Embryonic mesencephalic grafts increase levodopa-induced forelimb hyperkinesia in parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Forelimb; Hyperkinesis; Levodopa; Male; Mesencephalon; Neurons; Parkinson Disease; Postoperative Complications; Rats; Rats, Inbred F344 | 2003 |
Ropinirole versus L-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; Dyskinesia, Drug-Induced; Enkephalins; Gene Expression; In Situ Hybridization; Indoles; Levodopa; Male; Motor Activity; Opioid Peptides; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Rats; Rats, Sprague-Dawley; RNA, Messenger; Synaptic Transmission | 2004 |
Dopaminergic agonists and muscarinic antagonists improve lateralization in hemiparkinsonian rats in a novel exploratory Y-maze.
Topics: Animals; Antiparkinson Agents; Cholinergic Antagonists; Disease Models, Animal; Dizocilpine Maleate; Dopamine Agonists; Functional Laterality; Levodopa; Male; Muscarinic Antagonists; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar | 2004 |
S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropinirole.
Topics: Acetylcholine; Animals; Callithrix; Cells, Cultured; Disease Models, Animal; Dopamine Agonists; Dopamine Antagonists; Drug Interactions; Dyskinesias; Electrophysiology; Extracellular Space; Humans; Hypokinesia; Indoles; Levodopa; Male; Motor Activity; MPTP Poisoning; Neuroprotective Agents; Oxazines; Rats; Rats, Wistar; Receptors, Dopamine D2; Receptors, Dopamine D3; Reserpine; Rotation | 2004 |
Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease.
Topics: Amantadine; Animals; Anticonvulsants; Antiparkinson Agents; Callithrix; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Dyskinesias; Female; Levetiracetam; Levodopa; Male; MPTP Poisoning; Piracetam | 2004 |
Effect of a selective glutamate antagonist on L-dopa-induced dyskinesias in drug-naive parkinsonian monkeys.
Topics: Animals; Benzoxazoles; Corpus Striatum; Disease Models, Animal; Drug Interactions; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Glutamic Acid; Levodopa; Macaca fascicularis; Parkinson Disease; Piperidines; Receptors, N-Methyl-D-Aspartate; Treatment Outcome | 2004 |
A pulmonary formulation of L-dopa enhances its effectiveness in a rat model of Parkinson's disease.
Topics: Administration, Inhalation; Animals; Chemistry, Pharmaceutical; Corpus Striatum; Disease Models, Animal; Levodopa; Male; Parkinson Disease; Rats; Rats, Sprague-Dawley | 2004 |
Effects of pulsatile L-DOPA treatment in the double lesion rat model of striatonigral degeneration (multiple system atrophy).
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesias; Forelimb; Image Processing, Computer-Assisted; Levodopa; Male; Movement Disorders; Parkinson Disease; Rats; Striatonigral Degeneration | 2004 |
Antiparkinsonian activity of Ro 25-6981, a NR2B subunit specific NMDA receptor antagonist, in animal models of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Apomorphine; Callithrix; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Synergism; Levodopa; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Phenols; Piperidines; Rats; Rats, Wistar; Receptors, N-Methyl-D-Aspartate | 2004 |
Loss of D3 receptors in the zitter mutant rat is not reversed by L-dopa treatment.
Topics: Animals; Antiparkinson Agents; Brain-Derived Neurotrophic Factor; Disease Models, Animal; Disease Progression; Dopamine Plasma Membrane Transport Proteins; Heterozygote; Homozygote; Islands of Calleja; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Neostriatum; Nerve Tissue Proteins; Nucleus Accumbens; Olfactory Pathways; Oxidative Stress; Parkinsonian Disorders; Prosencephalon; Rats; Rats, Mutant Strains; Rats, Sprague-Dawley; Receptor, trkB; Receptors, Dopamine D2; Receptors, Dopamine D3; RNA, Messenger; Tyrosine 3-Monooxygenase | 2004 |
Behavioral and neurochemical effects of noradrenergic depletions with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine in 6-hydroxydopamine-induced rat model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Amphetamine; Analysis of Variance; Animals; Basal Ganglia; Behavior, Animal; Benzylamines; Brain Chemistry; Catalepsy; Disease Models, Animal; Dopamine; Dopamine Agents; Homovanillic Acid; Levodopa; Locus Coeruleus; Male; Motor Activity; Norepinephrine; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Serotonin; Statistics, Nonparametric; Tyrosine | 2004 |
Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Behavior, Animal; Brain; Brocresine; Chromatography, High Pressure Liquid; Deferoxamine; Disease Models, Animal; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Exploratory Behavior; Functional Laterality; Homovanillic Acid; Iron; Iron Chelating Agents; Levodopa; Male; Motor Activity; Neurodegenerative Diseases; Neurotransmitter Agents; Oxidopamine; Parkinson Disease; Piperazines; Quinolines; Rats; Rats, Sprague-Dawley; Time Factors | 2004 |
Tetrahydrobiopterin deficiency and dopamine loss in a genetic mouse model of Lesch-Nyhan disease.
Topics: Animals; Biopterins; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Hypoxanthine Phosphoribosyltransferase; Lesch-Nyhan Syndrome; Levodopa; Male; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Phenylalanine; Tyrosine | 2004 |
Novel dopamine releasing response of an anti-convulsant agent with possible anti-Parkinson's activity.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Antiparkinson Agents; Behavior, Animal; Carbidopa; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Homovanillic Acid; Isoxazoles; Levodopa; Microdialysis; Oxidopamine; Parkinson Disease; Rats; Zonisamide | 2004 |
SL25.1131 [3(S),3a(S)-3-methoxymethyl-7-[4,4,4-trifluorobutoxy]-3,3a,4,5-tetrahydro-1,3-oxazolo[3,4-a]quinolin-1-one], a new, reversible, and mixed inhibitor of monoamine oxidase-A and monoamine oxidase-B: biochemical and behavioral profile.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Benzophenones; Brain; Corpus Striatum; Disease Models, Animal; Dopamine; Drug Interactions; Levodopa; Maze Learning; Mice; Mice, Inbred C57BL; Monoamine Oxidase; Monoamine Oxidase Inhibitors; MPTP Poisoning; Nervous System Diseases; Nitrophenols; Oxazoles; Oxidopamine; Prefrontal Cortex; Quinolines; Rats; Rats, Sprague-Dawley; Serotonin; Stereotyped Behavior; Tolcapone; Tremor; Tyramine | 2004 |
Abnormal Ca2+-calmodulin-dependent protein kinase II function mediates synaptic and motor deficits in experimental parkinsonism.
Topics: Animals; Benzylamines; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Calcium-Calmodulin-Dependent Protein Kinases; Corpus Striatum; Denervation; Disease Models, Animal; Disks Large Homolog 4 Protein; Enzyme Inhibitors; Intracellular Signaling Peptides and Proteins; Levodopa; Male; Membrane Proteins; Motor Activity; Nerve Tissue Proteins; Neuronal Plasticity; Oxidopamine; Parkinsonian Disorders; Peptides; Phosphorylation; Rats; Rats, Wistar; Receptors, N-Methyl-D-Aspartate; Sulfonamides; Synaptic Transmission | 2004 |
Selective blockade of D(3) dopamine receptors enhances the anti-parkinsonian properties of ropinirole and levodopa in the MPTP-lesioned primate.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzopyrans; Brain; Callithrix; Disease Models, Animal; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Indoles; Levodopa; Parkinsonian Disorders; Pyrroles; Receptors, Dopamine D2; Receptors, Dopamine D3 | 2004 |
A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Male; Mazindol; Mice; Mice, Inbred C57BL; Motor Skills; Oxidopamine; Protein Binding; Substantia Nigra | 2004 |
The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease.
Topics: Animals; Callithrix; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Motor Activity; Parkinsonian Disorders; Piperidines; Range of Motion, Articular; Receptors, N-Methyl-D-Aspartate; Treatment Failure | 2004 |
Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease.
Topics: Adenosine; Adenosine A2 Receptor Agonists; Analysis of Variance; Animals; Antiparkinson Agents; Apomorphine; Cell Count; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; Drug Therapy, Combination; Dyskinesias; Immunohistochemistry; Levodopa; Male; Oxidopamine; Parkinson Disease; Phenethylamines; Rats; Rats, Sprague-Dawley; Stereotyped Behavior; Sympatholytics; Time Factors; Tyrosine 3-Monooxygenase | 2004 |
Differential effects of 5-HT1 and 5-HT2 receptor agonists on hindlimb movements in paraplegic mice.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Disease Models, Animal; Drug Interactions; Exercise Test; Hindlimb; Levodopa; Locomotion; Male; Mice; Movement; Paraplegia; Piperazines; Pyridines; Quipazine; Receptors, Serotonin, 5-HT1; Receptors, Serotonin, 5-HT2; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT2 Receptor Agonists; Serotonin Receptor Agonists; Spinal Cord Injuries | 2004 |
Prolongation of levodopa responses by glycineB antagonists in parkinsonian primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Disability Evaluation; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Glycine Agents; Levodopa; Macaca mulatta; Motor Activity; Parkinsonian Disorders; Pilot Projects; Psychomotor Performance; Receptors, Glycine | 2004 |
Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Analysis of Variance; Animals; Antiparkinson Agents; Autoradiography; Behavior, Animal; Blotting, Western; Cyclin-Dependent Kinase 5; Cyclin-Dependent Kinases; Disease Models, Animal; Dopamine and cAMP-Regulated Phosphoprotein 32; Dopamine Plasma Membrane Transport Proteins; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Female; Guanosine 5'-O-(3-Thiotriphosphate); Immunohistochemistry; In Situ Hybridization; Isotopes; Levodopa; Macaca fascicularis; Membrane Glycoproteins; Membrane Transport Proteins; Motor Activity; Nerve Tissue Proteins; Nortropanes; Parkinsonian Disorders; Phosphoproteins; Radioligand Assay; Receptors, Dopamine D1; Receptors, Dopamine D2; Signal Transduction; Substantia Nigra; Time Factors; Tyrosine 3-Monooxygenase | 2005 |
An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of Sinemet and protective effects of methylphenidate.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Carbidopa; Cell Count; Differential Threshold; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Immunohistochemistry; Levodopa; Male; Methylphenidate; Motor Activity; Movement; Nerve Degeneration; Neurons; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Rats; Rats, Long-Evans; Rotarod Performance Test; Substantia Nigra; Tyrosine 3-Monooxygenase | 2005 |
Topiramate reduces levodopa-induced dyskinesia in the MPTP-lesioned marmoset model of Parkinson's disease.
Topics: Animals; Anticonvulsants; Antiparkinson Agents; Callithrix; Disease Models, Animal; Dyskinesia, Drug-Induced; Fructose; Levodopa; MPTP Poisoning; Parkinson Disease; Topiramate | 2005 |
Dopamine agonist cabergoline inhibits levodopa-induced caspase activation in 6-OHDA-lesioned mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Cabergoline; Carbidopa; Caspases; Disease Models, Animal; Dopamine; Dopamine Agents; Dopamine Agonists; Drug Combinations; Drug Interactions; Enzyme Activation; Ergolines; Glutathione; Homovanillic Acid; Levodopa; Male; Mice; Mice, Inbred ICR; Neurotoxicity Syndromes; Oxidopamine; Thiobarbituric Acid Reactive Substances | 2005 |
Cerebral glutamate metabolism in Parkinson's disease: an in vivo dynamic (13)C NMS study in the rat.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Carbon Isotopes; Disease Models, Animal; Dopamine; Glutamic Acid; Glutaminase; Glutamine; Infusions, Intravenous; Levodopa; Lipid Metabolism; Magnetic Resonance Spectroscopy; Male; Neostriatum; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Sodium Acetate | 2005 |
Reversal of dyskinesias in an animal model of Parkinson's disease by continuous L-DOPA delivery using rAAV vectors.
Topics: Animals; Corpus Striatum; Dependovirus; Disease Models, Animal; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Gene Transfer Techniques; Genetic Therapy; Genetic Vectors; Levodopa; Parkinson Disease; Rats; Rats, Sprague-Dawley | 2005 |
L-DOPA reverses the MPTP-induced elevation of the arrestin2 and GRK6 expression and enhanced ERK activation in monkey brain.
Topics: Animals; Antiparkinson Agents; Arrestins; Basal Ganglia; beta-Adrenergic Receptor Kinases; Brain; Cyclic AMP-Dependent Protein Kinases; Disease Models, Animal; Extracellular Signal-Regulated MAP Kinases; Female; G-Protein-Coupled Receptor Kinases; Levodopa; Macaca fascicularis; Parkinsonian Disorders; Phosphoproteins; Phosphorylation; Protein Serine-Threonine Kinases; Receptors, G-Protein-Coupled; Up-Regulation | 2005 |
Early administration of entacapone prevents levodopa-induced motor fluctuations in hemiparkinsonian rats.
Topics: Animals; Benserazide; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Disease Models, Animal; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Levodopa; Male; Nitriles; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Treatment Outcome | 2005 |
Subcellular redistribution of the synapse-associated proteins PSD-95 and SAP97 in animal models of Parkinson's disease and L-DOPA-induced dyskinesia.
Topics: Adaptor Proteins, Signal Transducing; Animals; Behavior, Animal; Brain; Brain Chemistry; Cell Membrane; Corpus Striatum; Discs Large Homolog 1 Protein; Disease Models, Animal; Disks Large Homolog 4 Protein; Dyskinesias; Intracellular Signaling Peptides and Proteins; Levodopa; Male; Membrane Proteins; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; RNA, Messenger; Subcellular Fractions; Synapses | 2005 |
Functional interaction between mGlu 5 and NMDA receptors in a rat model of Parkinson's disease.
Topics: Animals; Disease Models, Animal; Dizocilpine Maleate; Drug Synergism; Levodopa; Male; Parkinsonian Disorders; Pyridines; Rats; Rats, Wistar; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Receptors, N-Methyl-D-Aspartate | 2005 |
Levodopa in the treatment of Parkinson's disease: current controversies.
Topics: Animals; Antiparkinson Agents; Apomorphine; Disease Models, Animal; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Haplorhini; Levodopa; Lisuride; Parkinson Disease; Pergolide | 2005 |
A modified MPTP treatment regime produces reproducible partial nigrostriatal lesions in common marmosets.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Calbindins; Callithrix; Corpus Striatum; Disability Evaluation; Disease Models, Animal; Dopamine Agents; Dose-Response Relationship, Drug; Drug Interactions; Female; Immunohistochemistry; Levodopa; Male; Motor Activity; Neurons; S100 Calcium Binding Protein G; Substantia Nigra; Time Factors; Tyrosine 3-Monooxygenase | 2005 |
New adenosine A2A receptor antagonists: actions on Parkinson's disease models.
Topics: Adenine; Adenosine; Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Behavior, Animal; Binding, Competitive; Catalepsy; CHO Cells; Cricetinae; Cricetulus; Disease Models, Animal; Drug Synergism; Levodopa; Male; Molecular Structure; Parkinson Disease; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; Tritium | 2005 |
The effects of L-DOPA and transcranial magnetic stimulation on behavioral reactions in kindled rats.
Topics: Analysis of Variance; Animals; Behavior, Animal; Disease Models, Animal; Dopamine Agents; Electric Stimulation; Electromagnetic Fields; Epilepsy; Exploratory Behavior; Feeding Behavior; Female; Kindling, Neurologic; Levodopa; Male; Picrotoxin; Rats; Rats, Wistar; Seizures; Sexual Behavior, Animal | 2005 |
Expression of GAD65 and GAD67 immunoreactivity in MPTP-treated monkeys with or without L-DOPA administration.
Topics: Animals; Basal Ganglia; Cell Count; Cerebral Cortex; Disease Models, Animal; Dopamine Agents; gamma-Aminobutyric Acid; Globus Pallidus; Glutamate Decarboxylase; Immunohistochemistry; Isoenzymes; Levodopa; Male; Neural Inhibition; Neurons; Parkinsonian Disorders; Saimiri; Transcriptional Activation; Up-Regulation | 2005 |
A serotonin 5-HT1A receptor agonist prevents behavioral sensitization to L-DOPA in a rodent model of Parkinson's disease.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antiparkinson Agents; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Drug Therapy, Combination; Dynorphins; Dyskinesia, Drug-Induced; Female; Glutamate Decarboxylase; In Situ Hybridization; Levodopa; Parkinson Disease; Rats; Rats, Wistar; Serotonin Receptor Agonists | 2005 |
Denervation and repeated L-DOPA induce complex regulatory changes in neurochemical phenotypes of striatal neurons: implication of a dopamine D1-dependent mechanism.
Topics: Animals; Corpus Striatum; Denervation; Disease Models, Animal; DNA-Binding Proteins; Dopamine; Dopamine Antagonists; Dynorphins; Enkephalins; Excitatory Amino Acid Transporter 2; Gene Expression Regulation; Levodopa; Male; Neurons; Neurotensin; Nuclear Receptor Subfamily 4, Group A, Member 1; Parkinson Disease; Phenotype; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Receptors, Dopamine D1; Receptors, Dopamine D3; Receptors, Steroid; RNA, Messenger; Transcription Factors; Tyrosine 3-Monooxygenase | 2005 |
Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.
Topics: Adenosine A2 Receptor Agonists; Adrenergic Agents; Amantadine; Animals; Antiparkinson Agents; Basal Ganglia; Buspirone; Disease Models, Animal; Disease Progression; Dopamine Agonists; Drug Administration Schedule; Dyskinesia, Drug-Induced; Indoles; Levodopa; Male; Mice; Mice, Inbred C57BL; Oxidopamine; Parkinsonian Disorders; Purines; Receptor, Adenosine A2A; Receptors, Dopamine D2; Reproducibility of Results; Riluzole; Treatment Outcome | 2005 |
Activation of mitochondrial ATP-sensitive potassium channels improves rotenone-related motor and neurochemical alterations in rats.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Catalepsy; Decanoic Acids; Diazoxide; Disease Models, Animal; Dopamine; Hydroxy Acids; Levodopa; Male; Motor Activity; Nitric Oxide Synthase; Nitric Oxide Synthase Type I; Nitric Oxide Synthase Type II; Parkinsonian Disorders; Potassium Channel Blockers; Potassium Channels; Propylamines; Rats; Rats, Sprague-Dawley; RNA, Messenger; Rotenone; Substantia Nigra | 2006 |
Effect of kynurenine 3-hydroxylase inhibition on the dyskinetic and antiparkinsonian responses to levodopa in Parkinsonian monkeys.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Female; Kynurenic Acid; Kynurenine 3-Monooxygenase; Levodopa; Macaca fascicularis; Mixed Function Oxygenases; Motor Activity; Parkinsonian Disorders; Quinolinic Acid; Sulfonamides; Thiazoles; Time Factors | 2005 |
Pramipexole has ameliorating effects on levodopa-induced abnormal dopamine turnover in parkinsonian striatum and quenching effects on dopamine-semiquinone generated in vitro.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Antiparkinson Agents; Benzoquinones; Benzothiazoles; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Drug Interactions; Electron Spin Resonance Spectroscopy; Functional Laterality; Homovanillic Acid; Levodopa; Male; Mice; Mice, Inbred ICR; Oxidopamine; Parkinson Disease; Pramipexole; Thiazoles; Time Factors | 2005 |
Naltrexone in the short-term decreases antiparkinsonian response to l-Dopa and in the long-term increases dyskinesias in drug-naïve parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dyskinesias; Female; Levodopa; Macaca fascicularis; Motor Activity; Naltrexone; Narcotic Antagonists; Ovariectomy; Parkinsonian Disorders; Statistics, Nonparametric; Time Factors | 2005 |
Does contraversive circling in the 6-OHDA-lesioned rat indicate an ability to induce motor complications as well as therapeutic effects in Parkinson's disease?
Topics: Adrenergic Agents; Animals; Behavior, Animal; Chlorobenzenes; Cyclobutanes; Disease Models, Animal; Dopamine Agents; Drug Interactions; Levodopa; Male; Models, Biological; Motor Activity; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; Rotarod Performance Test; Rotation; Stereotyped Behavior; Time Factors | 2006 |
Dopamine depletion alters phosphorylation of striatal proteins in a model of Parkinsonism.
Topics: Aging; Animals; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Calcium-Calmodulin-Dependent Protein Kinases; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine and cAMP-Regulated Phosphoprotein 32; Levodopa; Male; Nerve Tissue Proteins; Neural Pathways; Neuronal Plasticity; Parkinsonian Disorders; Phosphoprotein Phosphatases; Phosphoproteins; Phosphorylation; Presynaptic Terminals; Protein Phosphatase 1; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Substantia Nigra; Synaptic Membranes; Up-Regulation | 2005 |
Levodopa-induced dyskinesia in MPTP-treated macaques is not dependent on the extent and pattern of nigrostrial lesioning.
Topics: Animals; Antiparkinson Agents; Cell Count; Cell Death; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Female; Immunohistochemistry; Levodopa; Macaca fascicularis; Membrane Glycoproteins; Membrane Transport Proteins; Nerve Degeneration; Nerve Tissue Proteins; Neural Pathways; Neurons; Parkinsonian Disorders; Substantia Nigra; Tyrosine 3-Monooxygenase | 2005 |
Dopamine-independent locomotor actions of amphetamines in a novel acute mouse model of Parkinson disease.
Topics: alpha-Methyltyrosine; Amphetamines; Animals; Antiparkinson Agents; Basal Ganglia; Blepharoptosis; Disease Models, Animal; Dopamine; Dopamine Agents; Dopamine Antagonists; Dopamine Plasma Membrane Transport Proteins; Female; Levodopa; Male; Mice; Motor Activity; Nomifensine; Norepinephrine; Parkinson Disease, Secondary; Phenotype; Piperazines; Tyrosine 3-Monooxygenase | 2005 |
Differential expression of striatal synaptotagmin mRNA isoforms in hemiparkinsonian rats.
Topics: Animals; Apomorphine; Behavior, Animal; Benzazepines; Brain; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; Dopamine Antagonists; Drug Interactions; Female; Gene Expression; Gene Expression Regulation; In Situ Hybridization; Levodopa; Oxidopamine; Parkinsonian Disorders; Protein Isoforms; Rats; Rats, Wistar; RNA, Messenger; Rotation; Substantia Nigra; Synaptotagmins; Time Factors; Tyrosine 3-Monooxygenase | 2005 |
Dimerizer regulation of AADC expression and behavioral response in AAV-transduced 6-OHDA lesioned rats.
Topics: Animals; Antiparkinson Agents; Aromatic-L-Amino-Acid Decarboxylases; Cell Line; Corpus Striatum; Dependovirus; Dimerization; Disease Models, Animal; Dopamine; Gene Dosage; Gene Expression Regulation; Genetic Therapy; Genetic Vectors; Humans; Levodopa; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Recombination, Genetic; Sirolimus; Stereotyped Behavior; Transduction, Genetic | 2006 |
ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Blotting, Western; Corpus Striatum; Disease Models, Animal; Dopamine; Drug Administration Schedule; Dyskinesia, Drug-Induced; Dyskinesias; Enkephalins; Extracellular Signal-Regulated MAP Kinases; Gene Expression; Immunohistochemistry; In Situ Hybridization; Levodopa; Locomotion; Male; Mice; Mice, Inbred C57BL; Motor Activity; Oxidopamine; Parkinsonian Disorders; Phosphorylation; Protein Precursors; Proto-Oncogene Proteins c-fos; RNA, Messenger; Statistics, Nonparametric; Time Factors | 2006 |
Viral-mediated temporally controlled dopamine production in a rat model of Parkinson disease.
Topics: Animals; Aromatic-L-Amino-Acid Decarboxylases; Cell Line; Corpus Striatum; Dependovirus; Disease Models, Animal; Dopamine; Estrogen Receptor alpha; Estrogen Receptor Modulators; Genetic Therapy; Genetic Vectors; Humans; Integrases; Levodopa; Male; Mice; Neurons; Parkinson Disease; Rats; Rats, Wistar; Recombination, Genetic; Stereotyped Behavior; Tamoxifen; Tyrosine 3-Monooxygenase; Viral Proteins | 2006 |
Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD.
Topics: Amantadine; Animals; Antiparkinson Agents; Behavior, Animal; Benzazepines; Benzodiazepines; Disease Models, Animal; Dizocilpine Maleate; Dopamine Agents; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Interactions; Excitatory Amino Acid Antagonists; Haplorhini; Levodopa; Male; Motor Activity; Parkinson Disease, Secondary; Quinpirole; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Receptors, Glutamate; Receptors, N-Methyl-D-Aspartate; Rotarod Performance Test; Time Factors | 2005 |
Cross-sensitization between caffeine- and L-dopa-induced behaviors in hemiparkinsonian mice.
Topics: Adenosine A2 Receptor Antagonists; Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Caffeine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Levodopa; Mice; Mice, Inbred C57BL; Oxidopamine; Parkinson Disease, Secondary; Random Allocation; Time Factors | 2006 |
Coordinated and spatial upregulation of arc in striatonigral neurons correlates with L-dopa-induced behavioral sensitization in dyskinetic rats.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Adrenergic Agents; AIDS-Related Complex; Amphetamine; Analgesics, Non-Narcotic; Animals; Antiparkinson Agents; Behavior, Animal; Carrier Proteins; Central Nervous System Stimulants; Corpus Striatum; Disease Models, Animal; Drug Interactions; Dynorphins; Dyskinesia, Drug-Induced; Functional Laterality; Homer Scaffolding Proteins; Immunohistochemistry; In Situ Hybridization; Levodopa; Male; Motor Activity; Naloxone; Naltrexone; Narcotic Antagonists; Neurons; Oxidopamine; Protein Precursors; Proto-Oncogene Proteins c-fos; Rats; Rats, Wistar; Stereotyped Behavior; Substantia Nigra; Time Factors; Tyrosine 3-Monooxygenase; Up-Regulation | 2005 |
[Effects of different doses of levodopa on paraquat-induced neurotoxicity: an experiment with mice].
Topics: alpha-Synuclein; Animals; Blood-Brain Barrier; Disease Models, Animal; Dose-Response Relationship, Drug; Levodopa; Male; Mice; Mice, Inbred C57BL; Neurons; Paraquat; Substantia Nigra; Tyrosine 3-Monooxygenase | 2005 |
Validation of the l-dopa-induced dyskinesia in the 6-OHDA model and evaluation of the effects of selective dopamine receptor agonists and antagonists.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine Agonists; Dopamine Antagonists; Dyskinesia, Drug-Induced; Enkephalin, Methionine; Female; Levodopa; Oxidopamine; Parkinson Disease; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Receptors, Dopamine; Reproducibility of Results; Sympatholytics | 2005 |
Modulation of torsinA expression in the globus pallidus internus is associated with levodopa-induced dyskinesia in hemiparkinsonian rats.
Topics: Animals; Cell Count; Disease Models, Animal; Dopamine Agents; Down-Regulation; Dyskinesia, Drug-Induced; Entopeduncular Nucleus; Globus Pallidus; Levodopa; Male; Molecular Chaperones; Neural Pathways; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar | 2006 |
Focal striatal dopamine may potentiate dyskinesias in parkinsonian monkeys.
Topics: Animals; Antiparkinson Agents; Aromatic-L-Amino-Acid Decarboxylases; Behavior, Animal; Corpus Striatum; Dependovirus; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gene Transfer Techniques; Immunohistochemistry; Levodopa; Macaca mulatta; Magnetic Resonance Imaging; MPTP Poisoning; Neurons; Parkinson Disease, Secondary; Positron-Emission Tomography; Time Factors | 2006 |
The impact of graft size on the development of dyskinesia following intrastriatal grafting of embryonic dopamine neurons in the rat.
Topics: Amphetamine; Animals; Brain Tissue Transplantation; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Dopamine Uptake Inhibitors; Dyskinesia, Drug-Induced; Female; Levodopa; Movement; Neurons; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Rotation; Selective Serotonin Reuptake Inhibitors; Substantia Nigra; Transplantation Tolerance | 2006 |
Docosahexaenoic acid reduces levodopa-induced dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Docosahexaenoic Acids; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesias; Female; Levodopa; Macaca fascicularis; Motor Activity; MPTP Poisoning; Ovariectomy; Severity of Illness Index; Time Factors | 2006 |
Coadministration of entacapone with levodopa attenuates the severity of dyskinesias in hemiparkinsonian rats.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Catechols; Disease Models, Animal; Drug Therapy, Combination; Dyskinesias; Levodopa; Male; Nitriles; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Severity of Illness Index; Time Factors | 2006 |
Postmortem brain fatty acid profile of levodopa-treated Parkinson disease patients and parkinsonian monkeys.
Topics: Aged; Aged, 80 and over; Animals; Arachidonic Acid; Cerebral Cortex; Chromatography, Gas; Dietary Fats; Disease Models, Animal; Docosahexaenoic Acids; Dopamine Agents; Dyskinesia, Drug-Induced; Fatty Acids; Fatty Acids, Unsaturated; Female; Humans; Levodopa; Lipid Metabolism; Macaca fascicularis; Male; Neurons; Parkinson Disease; Parkinsonian Disorders; Postmortem Changes; Species Specificity | 2006 |
Histamine H3 receptor agonists reduce L-dopa-induced chorea, but not dystonia, in the MPTP-lesioned nonhuman primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Chorea; Disease Models, Animal; Female; Histamine Agonists; Levodopa; Parkinson Disease; Receptors, Histamine H3 | 2006 |
Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Extracellular Fluid; Female; Levodopa; Microdialysis; Microinjections; Neural Pathways; Oxidopamine; Parkinsonian Disorders; Prefrontal Cortex; Rats; Rats, Sprague-Dawley; Serotonin; Up-Regulation | 2006 |
Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Catalepsy; Disease Models, Animal; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesias; Functional Laterality; Haloperidol; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease; Pyridines; Quinolines; Rats; Rats, Sprague-Dawley; Reaction Time; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Rotarod Performance Test; Thiazoles; Time Factors | 2006 |
Expression of dyskinetic movements and turning behaviour in subchronic L-DOPA 6-hydroxydopamine-treated rats is influenced by the testing environment.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Environment; Housing, Animal; Levodopa; Male; Oxidopamine; Rats; Rats, Sprague-Dawley; Reproducibility of Results | 2006 |
Levodopa-induced dyskinesia and rotational behavior in hemiparkinsonian rats: independent features or components of the same phenomenon?
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Rotation; Time Factors | 2006 |
Brain transplantation of human neural stem cells transduced with tyrosine hydroxylase and GTP cyclohydrolase 1 provides functional improvement in animal models of Parkinson disease.
Topics: Animals; Blotting, Western; Brain Tissue Transplantation; Cell Line; Cell Transplantation; Chromatography, High Pressure Liquid; Disease Models, Animal; Dopamine; Female; GTP Cyclohydrolase; Humans; Immunohistochemistry; Levodopa; Multipotent Stem Cells; Neurons; Parkinson Disease; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; Stem Cell Transplantation; Transduction, Genetic; Tyrosine 3-Monooxygenase | 2006 |
Repeated l-DOPA treatment increases c-fos and BDNF mRNAs in the subthalamic nucleus in the 6-OHDA rat model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Brain-Derived Neurotrophic Factor; Cocaine; Disease Models, Animal; Dopamine Uptake Inhibitors; Drug Administration Schedule; Gene Expression Regulation; Levodopa; Male; Oxidopamine; Parkinson Disease; Protein Binding; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; RNA, Messenger; Subthalamic Nucleus; Tritium | 2006 |
Involvement of globus pallidus in the antiparkinsonian effects of adenosine A(2A) receptor antagonists.
Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Drug Interactions; Functional Laterality; Globus Pallidus; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Piperazines; Pyrimidines; Rats; Rats, Sprague-Dawley; Time Factors | 2006 |
Impaired behavioural and molecular adaptations to dopamine denervation and repeated L-DOPA treatment in Nur77-knockout mice.
Topics: Adaptation, Physiological; Animals; Antiparkinson Agents; Benserazide; Corpus Striatum; Denervation; Disease Models, Animal; DNA-Binding Proteins; Dopamine; Dopamine Agents; Drug Resistance; Enkephalins; Levodopa; Mice; Mice, Inbred C57BL; Mice, Knockout; Motor Activity; Neural Pathways; Neurotensin; Nuclear Receptor Subfamily 4, Group A, Member 1; Parkinson Disease; Receptors, Cytoplasmic and Nuclear; Receptors, Dopamine D3; Receptors, Steroid; Transcription Factors | 2006 |
Assessing nigrostriatal dysfunctions by pharmacological MRI in parkinsonian rhesus macaques.
Topics: Animals; Brain Mapping; Caudate Nucleus; Corpus Striatum; Disease Models, Animal; Dopamine; Female; Functional Laterality; Image Processing, Computer-Assisted; Levodopa; Macaca mulatta; Magnetic Resonance Imaging; Parkinsonian Disorders; Putamen; Substantia Nigra | 2006 |
Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Callithrix; Disability Evaluation; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Female; Grooming; Hallucinations; Levodopa; Parkinsonian Disorders; Psychomotor Agitation; Psychotic Disorders; Statistics, Nonparametric; Stereotyped Behavior | 2006 |
Dopamine receptor agonists and levodopa and inducing psychosis-like behavior in the MPTP primate model of Parkinson disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Disease Models, Animal; Dopamine Agonists; Drug Administration Routes; Drug Administration Schedule; Levodopa; Mental Disorders; Parkinsonian Disorders; Severity of Illness Index; Time Factors | 2006 |
Endothelial proliferation and increased blood-brain barrier permeability in the basal ganglia in a rat model of 3,4-dihydroxyphenyl-L-alanine-induced dyskinesia.
Topics: Animals; Antibodies, Monoclonal; Antigens; Basal Ganglia; Biomarkers; Blood-Brain Barrier; Bromodeoxyuridine; Cell Count; Cell Proliferation; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Endothelial Cells; Female; Intermediate Filament Proteins; Levodopa; Motor Activity; Neovascularization, Pathologic; Nerve Tissue Proteins; Nestin; Oxidopamine; Parkinsonian Disorders; Platelet Endothelial Cell Adhesion Molecule-1; Proteoglycans; Rats; Rats, Sprague-Dawley | 2006 |
Antiparkinsonian effects of the novel D3/D2 dopamine receptor agonist, S32504, in MPTP-lesioned marmosets: Mediation by D2, not D3, dopamine receptors.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Callithrix; Disease Models, Animal; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Indoles; Levodopa; Motor Activity; MPTP Poisoning; Oxazines; Piperidines; Receptors, Dopamine D2; Receptors, Dopamine D3; Time Factors | 2006 |
Chronic high-frequency stimulation of the subthalamic nucleus and L-DOPA treatment in experimental parkinsonism: effects on motor behaviour and striatal glutamate transmission.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, Radiation; Drug Interactions; Dyskinesias; Electric Stimulation; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Functional Laterality; Levodopa; Male; Membrane Potentials; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Subthalamic Nucleus; Time Factors | 2006 |
Normalization and expression changes in predefined sets of proteins using 2D gel electrophoresis: a proteomic study of L-DOPA induced dyskinesia in an animal model of Parkinson's disease using DIGE.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Electrophoresis, Gel, Two-Dimensional; Gene Expression Profiling; Levodopa; Macaca fascicularis; Movement Disorders; Nerve Tissue Proteins; Parkinson Disease, Secondary; Proteome | 2006 |
Age-related decline in striatal dopamine content and motor performance occurs in the absence of nigral cell loss in a genetic mouse model of Parkinson's disease.
Topics: Aging; Animals; Antiparkinson Agents; Blotting, Western; Corpus Striatum; Disease Models, Animal; Dopamine; Immunohistochemistry; Levodopa; Male; Mice; Mice, Mutant Strains; Motor Activity; Motor Skills; Nerve Degeneration; Parkinson Disease; Phosphorylation; Substantia Nigra; Tyrosine 3-Monooxygenase; Vesicular Monoamine Transport Proteins | 2006 |
Cellular and behavioral effects of 5-HT1A receptor agonist 8-OH-DPAT in a rat model of levodopa-induced motor complications.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antiparkinson Agents; Behavior, Animal; Benserazide; Brain; Disease Models, Animal; Drug Interactions; Dyskinesia, Drug-Induced; Female; Levodopa; Phosphorylation; Piperazines; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Receptors, AMPA; Serotonin; Serotonin 5-HT1 Receptor Agonists; Serotonin Antagonists; Serotonin Receptor Agonists; Synapses; Synaptic Transmission; Treatment Outcome | 2007 |
Tamoxifen effect on L-DOPA induced response complications in parkinsonian rats and primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Disease Models, Animal; Drug Administration Schedule; Drug Interactions; Dyskinesia, Drug-Induced; Haplorhini; Levodopa; Male; Models, Biological; Nerve Tissue Proteins; Oxidopamine; Parkinson Disease, Secondary; Protein Kinase C; Rats; Rats, Sprague-Dawley; Selective Estrogen Receptor Modulators; Tamoxifen; Time Factors | 2007 |
Levodopa-induced hyperactivity in mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Age Factors; Animals; Disease Models, Animal; Dopamine Agents; Hyperkinesis; Levodopa; Male; Mice; Mice, Inbred C57BL; Movement; Time Factors | 2007 |
Loss of dopaminergic responsiveness in a double lesion rat model of the Parkinson variant of multiple system atrophy.
Topics: Analysis of Variance; Animals; Apomorphine; Behavior, Animal; Disease Models, Animal; Functional Laterality; Levodopa; Male; Multiple System Atrophy; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Substantia Nigra | 2007 |
The novel adenosine A2a antagonist ST1535 potentiates the effects of a threshold dose of l-dopa in unilaterally 6-OHDA-lesioned rats.
Topics: Adenine; Adenosine; Adenosine A2 Receptor Antagonists; Animals; Brain; Disease Models, Animal; Dopamine Agents; Dose-Response Relationship, Drug; Drug Synergism; Exploratory Behavior; Levodopa; Male; Movement; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Receptor, Adenosine A2A; Sympatholytics; Triazoles | 2007 |
Abnormal involuntary movements (AIMs) following pulsatile dopaminergic stimulation: severe deterioration and morphological correlates following the loss of locus coeruleus neurons.
Topics: Adrenergic Uptake Inhibitors; Animals; Cell Death; Desipramine; Disease Models, Animal; Dopamine; Dopamine Agents; Drug Interactions; Dyskinesia, Drug-Induced; Functional Laterality; Levodopa; Locus Coeruleus; Male; Neurons; Norepinephrine; Oxidopamine; Rats; Rats, Wistar; Rotarod Performance Test; Severity of Illness Index; Tyrosine 3-Monooxygenase | 2007 |
Rat model of Parkinson's disease with bilateral motor abnormalities, reversible with levodopa, and dyskinesias.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Disease Progression; Dopamine; Dyskinesias; Extremities; Levodopa; Male; Mesencephalon; Nerve Degeneration; Parkinson Disease; Prosencephalon; Rats; Rats, Sprague-Dawley; Severity of Illness Index; Substantia Nigra; Tyrosine 3-Monooxygenase | 2007 |
Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model.
Topics: Adrenergic Agents; Animals; Cross-Over Studies; Disease Models, Animal; Double-Blind Method; Dyskinesia, Drug-Induced; Excitatory Amino Acid Agents; Levodopa; Male; Neurotransmitter Agents; Parkinsonian Disorders; Random Allocation; Rats; Rotarod Performance Test; Serotonin Agents; Statistics, Nonparametric | 2007 |
High-frequency stimulation of the subthalamic nucleus potentiates L-DOPA-induced neurochemical changes in the striatum in a rat model of Parkinson's disease.
Topics: Animals; Biomarkers; Deep Brain Stimulation; Denervation; Disease Models, Animal; Drug Synergism; Dyskinesias; Electron Transport Complex IV; Levodopa; Male; Motor Cortex; Neuropeptides; Parkinson Disease; Proto-Oncogene Proteins c-fos; Rats; Rats, Wistar; Subthalamic Nucleus | 2007 |
Synergistic effects of adenosine A2A antagonist and L-DOPA on rotational behaviors in 6-hydroxydopamine-induced hemi-Parkinsonian mouse model.
Topics: Adenosine A2 Receptor Antagonists; Adrenergic Agents; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Drug Synergism; Levodopa; Male; Mice; Mice, Inbred ICR; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Pyrimidines; Receptor, Adenosine A2A; Rotation; Triazoles | 2007 |
Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Brain; Disease Models, Animal; Drug Interactions; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; gamma-Aminobutyric Acid; Glutamic Acid; Levodopa; Microdialysis; Neural Inhibition; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Substantia Nigra; Synaptic Transmission | 2007 |
Chronic 3,4-dihydroxyphenylalanine treatment induces dyskinesia in aphakia mice, a novel genetic model of Parkinson's disease.
Topics: Afferent Pathways; Animals; Antiparkinson Agents; Aphakia; Corpus Striatum; Disease Models, Animal; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Levodopa; Mice; Mice, Inbred C57BL; Mice, Neurologic Mutants; Parkinsonian Disorders; Protein Precursors; Proto-Oncogene Proteins c-fos; Substantia Nigra | 2007 |
The effects of L-3,4-dihydroxyphenylalanine and dopamine agonists on dopamine neurons in the progressive hemiparkinsonian rat models.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Dopamine Agonists; Dose-Response Relationship, Drug; Functional Laterality; Levodopa; Male; Neurons; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Inbred F344; Substantia Nigra; Time Factors; Tyrosine 3-Monooxygenase | 2007 |
Proteomic analysis of striatal proteins in the rat model of L-DOPA-induced dyskinesia.
Topics: Analysis of Variance; Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Electrophoresis, Gel, Two-Dimensional; Levodopa; Male; Mass Spectrometry; Proteins; Proteomics; Rats; Rats, Sprague-Dawley; Time Factors | 2007 |
The differential effects of 5-HT(1A) receptor stimulation on dopamine receptor-mediated abnormal involuntary movements and rotations in the primed hemiparkinsonian rat.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Behavior, Animal; Biogenic Monoamines; Chromatography, High Pressure Liquid; Disease Models, Animal; Dopamine Agents; Drug Interactions; Dyskinesias; gamma-Aminobutyric Acid; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine; Serotonin Receptor Agonists; Stereotyped Behavior; Triglycerides | 2007 |
Chronic SKF83959 induced less severe dyskinesia and attenuated L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Analysis of Variance; Animals; Disease Models, Animal; Dopamine Agonists; Dopamine Antagonists; Drug Administration Schedule; Drug Interactions; Dyskinesia, Drug-Induced; Levodopa; Male; Movement; Oxidopamine; Parkinson Disease; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Serotonin Antagonists; Spiperone; Sympatholytics; Time Factors | 2007 |
Immunohistochemical detection of L-DOPA-derived dopamine within serotonergic fibers in the striatum and the substantia nigra pars reticulata in Parkinsonian model rats.
Topics: Animals; Antiparkinson Agents; Carbidopa; Corpus Striatum; Disease Models, Animal; Dopamine; Drug Interactions; Levodopa; Male; Nerve Fibers; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Serotonin; Substantia Nigra | 2007 |
Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia.
Topics: Animals; Brain; Cyclic AMP; Disease Models, Animal; Dopamine Agonists; Dopamine and cAMP-Regulated Phosphoprotein 32; Dyskinesia, Drug-Induced; Extracellular Signal-Regulated MAP Kinases; Histones; Levodopa; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Oxidopamine; Phosphorylation; Receptors, AMPA; Ribosomal Protein S6 Kinases, 90-kDa; Signal Transduction | 2007 |
Blockade of cannabinoid type 1 receptors augments the antiparkinsonian action of levodopa without affecting dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated rhesus monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Azetidines; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca mulatta; Male; Molecular Structure; Parkinson Disease; Receptor, Cannabinoid, CB1; Triazines | 2007 |
Serotonin neuron transplants exacerbate L-DOPA-induced dyskinesias in a rat model of Parkinson's disease.
Topics: Animals; Brain Tissue Transplantation; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Fetal Tissue Transplantation; Levodopa; Neurons; Parkinson Disease; Rats; Rats, Sprague-Dawley; Serotonin | 2007 |
Evaluation of levodopa dose and magnitude of dopamine depletion as risk factors for levodopa-induced dyskinesia in a rat model of Parkinson's disease.
Topics: Amphetamine; Animals; Antiparkinson Agents; Behavior, Animal; Brain; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Levodopa; Male; Parkinson Disease; Rats; Rats, Sprague-Dawley; Risk Factors; Tyrosine 3-Monooxygenase | 2007 |
Lesions of dopaminergic neurons in the substantia nigra pars compacta and in the ventral tegmental area enhance depressive-like behavior in rats.
Topics: Adrenergic Agents; Amphetamine; Analysis of Variance; Animals; Antidepressive Agents; Behavior, Animal; Citalopram; Depression; Disease Models, Animal; Functional Laterality; Helplessness, Learned; Levodopa; Male; Nerve Degeneration; Neurons; Oxidopamine; Rats; Rats, Wistar; Reaction Time; Rotarod Performance Test; Substantia Nigra; Tyrosine 3-Monooxygenase; Ventral Tegmental Area | 2007 |
L-Dopa treatment abolishes the numerical increase in striatal dopaminergic neurons in parkinsonian monkeys.
Topics: Adaptation, Physiological; Animals; Antiparkinson Agents; Cell Count; Corpus Striatum; Disease Models, Animal; Dopamine; Female; Immunohistochemistry; Interneurons; Levodopa; Macaca fascicularis; Parkinsonian Disorders; Phenotype; Tyrosine 3-Monooxygenase; Up-Regulation | 2008 |
Prolonged kynurenine 3-hydroxylase inhibition reduces development of levodopa-induced dyskinesias in parkinsonian monkeys.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Drug Interactions; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Female; Kynurenic Acid; Kynurenine; Kynurenine 3-Monooxygenase; Levodopa; Macaca fascicularis; Motor Activity; Parkinsonian Disorders; Quinolinic Acid; Sulfonamides; Thiazoles; Time Factors | 2008 |
Dopamine receptor agonists reverse behavioral abnormalities of alpha-synuclein transgenic mouse, a new model of Parkinson's disease.
Topics: alpha-Synuclein; Animals; Antiparkinson Agents; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dopamine Agonists; Exploratory Behavior; Humans; Levodopa; Male; Mice; Mice, Transgenic; Motor Activity; Parkinson Disease; Peptide Fragments; Pergolide; Receptors, Dopamine D2 | 2008 |
Intrastriatal inhibition of aromatic amino acid decarboxylase prevents l-DOPA-induced dyskinesia: a bilateral reverse in vivo microdialysis study in 6-hydroxydopamine lesioned rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Aromatic-L-Amino-Acid Decarboxylases; Behavior, Animal; Benserazide; Brain Injuries; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Drug Interactions; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Homovanillic Acid; Levodopa; Male; Microdialysis; Oxidopamine; Rats; Rats, Wistar | 2008 |
Systemic administration of an mGluR5 antagonist, but not unilateral subthalamic lesion, counteracts l-DOPA-induced dyskinesias in a rodent model of Parkinson's disease.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Levodopa; Male; Oxidopamine; Parkinson Disease; Proto-Oncogene Proteins c-fos; Pyridines; Rats; Subthalamic Nucleus; Time Factors; Tyrosine 3-Monooxygenase | 2008 |
Serotonergic activation after 2-week intrastriatal infusion of L-dopa and slow recovery of circling in rats with unilateral nigral lesions.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Hydroxyindoleacetic Acid; Infusion Pumps, Implantable; Levodopa; Male; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; Receptors, Dopamine D2; Serotonin; Substantia Nigra; Tryptophan Hydroxylase; Tyrosine 3-Monooxygenase; Up-Regulation | 2008 |
Normalization of GABAA receptor specific binding in the substantia nigra reticulata and the prevention of L-dopa-induced dyskinesias in MPTP parkinsonian monkeys.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Autoradiography; Behavior, Animal; Benzoxazoles; Binding, Competitive; Bridged Bicyclo Compounds, Heterocyclic; Convulsants; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Flunitrazepam; GABA Modulators; Isotopes; Levodopa; Macaca fascicularis; Ovariectomy; Parkinsonian Disorders; Piperidines; Protein Binding; Radiography; Receptors, GABA; Substantia Nigra | 2008 |
l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Drug Interactions; Dyskinesia, Drug-Induced; Electric Stimulation; In Vitro Techniques; Levodopa; Long-Term Potentiation; Long-Term Synaptic Depression; Male; Motor Activity; Neurons; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; Tyrosine 3-Monooxygenase | 2008 |
Levodopa ameliorates learning and memory deficits in a murine model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Analysis of Variance; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Frontal Lobe; Hippocampus; Learning Disabilities; Levodopa; Male; Maze Learning; Memory Disorders; Mice; Mice, Transgenic; Nootropic Agents; Recognition, Psychology | 2009 |
The newly synthesized pool of dopamine determines the severity of methamphetamine-induced neurotoxicity.
Topics: Adrenergic Uptake Inhibitors; Amphetamine-Related Disorders; Animals; Body Temperature; Brain; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Enzyme Inhibitors; Extracellular Space; Female; Gliosis; Levodopa; Methamphetamine; Mice; Mice, Inbred C57BL; Microglia; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Presynaptic Terminals; Reserpine; Tyrosine 3-Monooxygenase | 2008 |
Receptor-activity modifying protein 1 expression is increased in the striatum following repeated L-DOPA administration in a 6-hydroxydopamine lesioned rat model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Gene Expression; In Situ Hybridization; Intracellular Signaling Peptides and Proteins; Levodopa; Membrane Proteins; Motor Activity; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptor Activity-Modifying Protein 1; Receptor Activity-Modifying Proteins; RNA, Messenger | 2008 |
Specific induction of PAG608 in cranial and spinal motor neurons of L-DOPA-treated parkinsonian rats.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Brain; Disease Models, Animal; DNA-Binding Proteins; Drug Interactions; Functional Laterality; Gene Expression Regulation; Levodopa; Motor Neurons; Nuclear Proteins; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; RNA-Binding Proteins; Spinal Cord | 2008 |
Exogenous l-DOPA induce no dopamine immuno-reactivity in striatal astroglias and microglias of adult rats with extensive nigro-striatal dopaminergic denervation.
Topics: Animals; Astrocytes; Biomarkers; Calcium-Binding Proteins; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Glial Fibrillary Acidic Protein; Immunohistochemistry; Levodopa; Male; Microfilament Proteins; Microglia; Neural Pathways; Neuroglia; Oxidopamine; Parkinsonian Disorders; Presynaptic Terminals; Rats; Substantia Nigra | 2008 |
Evidence for a role of the 5-HT1B receptor and its adaptor protein, p11, in L-DOPA treatment of an animal model of Parkinsonism.
Topics: Animals; Autoradiography; Benzazepines; Corpus Striatum; Disease Models, Animal; Dopamine Antagonists; Immunohistochemistry; Levodopa; Male; Mice; Mice, Inbred BALB C; Mice, Knockout; Oxidopamine; Parkinson Disease, Secondary; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1B; RNA, Messenger; Serotonin Receptor Agonists | 2008 |
Structural, functional, and biochemical changes in the brain during modeling of dopamine system disturbances in rats.
Topics: Animals; Brain; Brain Chemistry; Disease Models, Animal; Dopamine; Emotions; Levodopa; Male; Monoamine Oxidase; Motor Activity; Neuroglia; Rats; Rats, Wistar; Tyrosine 3-Monooxygenase | 2007 |
Striatal proteomic analysis suggests that first L-dopa dose equates to chronic exposure.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Electrophoresis, Gel, Two-Dimensional; Levodopa; Macaca; Mass Spectrometry; Parkinson Disease; Protein Processing, Post-Translational; Proteomics; Rats | 2008 |
Sigma ligands, but not N-methyl-D-aspartate antagonists, reduce levodopa-induced dyskinesias.
Topics: Adrenergic Agents; Amphetamine; Animals; Anti-Anxiety Agents; Behavior, Animal; Dextromethorphan; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Levodopa; Ligands; Male; N-Methylaspartate; Neurotoxicity Syndromes; Oxidopamine; Pyrimidines; Rats; Rats, Sprague-Dawley; Time Factors | 2008 |
Striatal histone modifications in models of levodopa-induced dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acetylation; Animals; Chromatin; Chromosome Aberrations; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Extracellular Signal-Regulated MAP Kinases; Female; Histones; Levodopa; Macaca mulatta; Male; Methylation; Mice; Mice, Inbred C57BL; Parkinsonian Disorders; Phosphorylation; Protein Processing, Post-Translational; Species Specificity | 2008 |
Neurokinin B/NK3 receptors exert feedback inhibition on L-DOPA actions in the 6-OHDA lesion rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Autoradiography; Behavior, Animal; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Cocaine; Disease Models, Animal; Dopamine; Feedback; Functional Laterality; Gene Expression Regulation; Levodopa; Oxidopamine; Parkinson Disease; Peptide Fragments; Quinolines; Radioisotopes; Rats; Rats, Sprague-Dawley; Receptors, Neurokinin-3; Serine; Substance P; Sympatholytics; Tyrosine 3-Monooxygenase | 2008 |
Ratings of L-DOPA-induced dyskinesia in the unilateral 6-OHDA lesion model of Parkinson's disease in rats and mice.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Mice; Oxidopamine; Parkinsonian Disorders; Rats; Sympatholytics | 2007 |
Serotonergic neurones are not involved in action of L-dopa in Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain Stem; Disease Models, Animal; Dopa Decarboxylase; Dopamine; Homovanillic Acid; Levodopa; Parkinson Disease; Raphe Nuclei; Rats; Serotonin; Tyrosine 3-Monooxygenase | 1980 |
Neurotransmitters and epilepsy: distinguishing characteristics and unifying precepts.
Topics: Animals; Brain; Disease Models, Animal; Electroshock; Epilepsy; gamma-Aminobutyric Acid; Kindling, Neurologic; Levodopa; Mice; Neurotransmitter Agents; Norepinephrine; Papio; Rats; Seizures; Serotonin | 1984 |
A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Brain Chemistry; Disease Models, Animal; Dopamine; Female; Homovanillic Acid; Hydroxyindoleacetic Acid; Levodopa; Macaca mulatta; Male; Neurons; Parkinson Disease; Posture; Pyridines; Substantia Nigra | 1983 |
Dopamine receptors: effects of chronic L-dopa and bromocriptine treatment in an animal model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Bromocriptine; Corpus Striatum; Disease Models, Animal; Dopamine; Humans; Hydroxydopamines; Kinetics; Levodopa; Male; Membranes; Oxidopamine; Parkinson Disease; Rats; Rats, Inbred Strains; Receptors, Dopamine; Spiperone; Stereotyped Behavior; Substantia Nigra | 1984 |
Neonatal-6-hydroxydopamine treatment: model of susceptibility for self-mutilation in the Lesch-Nyhan syndrome.
Topics: Age Factors; Animals; Animals, Newborn; Disease Models, Animal; Humans; Hydroxydopamines; Lesch-Nyhan Syndrome; Levodopa; Male; Oxidopamine; Rats; Receptors, Dopamine; Self Mutilation | 1984 |
Manganese and extrapyramidal disorders (a critical review and tribute to Dr. George C. Cotzias).
Topics: Animals; Basal Ganglia; Basal Ganglia Diseases; Brain Chemistry; Catecholamines; Disease Models, Animal; Humans; Levodopa; Manganese; Manganese Poisoning; Melanins; Melanocyte-Stimulating Hormones; Parkinson Disease; Substantia Nigra | 1984 |
L-Dopa methyl ester--a candidate for chronic systemic delivery of L-Dopa in Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Levodopa; Limbic System; Male; Mice; Parkinson Disease; Reserpine | 1984 |
Assessment of renal dopaminergic system activity in the nitric oxide-deprived hypertensive rat model.
Topics: Amino Acid Oxidoreductases; Animals; Arginine; Aromatic-L-Amino-Acid Decarboxylases; Blood Pressure; Disease Models, Animal; Dopamine; Drinking; Heart Rate; Hypertension; Kidney; Kinetics; Levodopa; Male; NADPH Dehydrogenase; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase; Rats; Rats, Wistar; Urination | 1995 |
Long-term behavioral recovery in parkinsonian rats by an HSV vector expressing tyrosine hydroxylase.
Topics: Animals; Base Sequence; Corpus Striatum; Denervation; Disease Models, Animal; Dopamine; Gene Transfer Techniques; Genetic Therapy; Genetic Vectors; Humans; Levodopa; Male; Molecular Sequence Data; Motor Activity; Neurons; Parkinson Disease; Rats; Rats, Sprague-Dawley; Simplexvirus; Tyrosine 3-Monooxygenase | 1994 |
Supersensitization of neurochemical responses by L-DOPA and dopamine receptor agonists in the striatum of experimental Parkinson's disease model rats.
Topics: Acetylcholine; Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; GTP Phosphohydrolases; Levodopa; Male; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; RNA, Messenger | 1995 |
Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Analysis of Variance; Animals; Apomorphine; Brain Tissue Transplantation; Carbidopa; Dextroamphetamine; Disease Models, Animal; Dopamine; Dopamine Agonists; Ergolines; Female; Fetal Tissue Transplantation; Forelimb; Functional Laterality; Levodopa; Motor Activity; Movement Disorders; Norepinephrine; Oxidopamine; Parkinson Disease; Quinpirole; Rats; Rats, Sprague-Dawley; Rotation; Substantia Nigra; Transplantation, Heterotopic | 1995 |
Premature avian melanocyte death due to low antioxidant levels of protection: fowl model for vitiligo.
Topics: alpha-MSH; Animals; Catalase; Cell Death; Cells, Cultured; Chickens; Disease Models, Animal; Feathers; Glutathione; Glutathione Peroxidase; Hypopigmentation; Levodopa; Melanocytes; Models, Biological; Mutation; Oxidative Stress; Reactive Oxygen Species; Species Specificity; Superoxide Dismutase; Vitiligo | 1994 |
Beneficial effects of co-administration of catechol-O-methyltransferase inhibitors and L-dihydroxyphenylalanine in rat models of depression.
Topics: Analysis of Variance; Animals; Avoidance Learning; Behavior, Animal; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Depression; Desipramine; Dihydroxyphenylalanine; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Levodopa; Male; Motor Activity; Nitriles; Nitrophenols; Rats; Rats, Wistar; Swimming; Tolcapone | 1995 |
Adrenal medulla and Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenal Medulla; Animals; Carbidopa; Catecholamines; Disease Models, Animal; Drug Combinations; Humans; Levodopa; Male; Mice; Mice, Inbred C57BL; Parkinson Disease, Secondary | 1994 |
Antiparkinsonian activity of talipexole in MPTP-treated monkeys: in combination with L-dopa and as chronic treatment.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Antiparkinson Agents; Azepines; Callithrix; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Injections, Intraperitoneal; Injections, Intravenous; Injections, Subcutaneous; Levodopa; Male; Motor Activity; MPTP Poisoning; Parkinson Disease, Secondary | 1994 |
Chronic haloperidol: neural correlates of motor disorders in an invertebrate model.
Topics: Animals; Catecholamines; Disease Models, Animal; Dopamine; Fluorescence; Glyoxylates; Haloperidol; Histocytochemistry; Leeches; Levodopa; Locomotion; Movement; Movement Disorders; Neurotransmitter Agents | 1994 |
L-dopa induced increases in brain uric acid in an animal model of Parkinson's disease: a relationship to behavioral activation.
Topics: Animals; Behavior, Animal; Brain; Disease Models, Animal; Dopamine; Levodopa; Male; Neurons; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Substantia Nigra; Sympathectomy, Chemical; Uric Acid; Ventral Tegmental Area | 1994 |
Roles of dopamine and its receptors in generation of choreic movements.
Topics: Afferent Pathways; Animals; Brain Mapping; Cerebral Cortex; Choline O-Acetyltransferase; Chorea; Corpus Striatum; Disease Models, Animal; Dopamine; gamma-Aminobutyric Acid; Glutamates; Glutamic Acid; Kainic Acid; Levodopa; Macaca; Neurons; Receptors, Dopamine; Receptors, Dopamine D2; Spiperone; Substantia Nigra; Synapses; Tyrosine 3-Monooxygenase | 1993 |
Dopaminergic functional supersensitivity: effects of chronic L-dopa and carbidopa treatment in an animal model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Biopterins; Brain Diseases; Carbidopa; Corpus Striatum; Cyclic AMP; Disease Models, Animal; Dopamine; Dopamine D2 Receptor Antagonists; Homovanillic Acid; Levodopa; Male; Oxidopamine; Parkinson Disease; Rats; Rats, Inbred F344; Receptors, Dopamine D1; Receptors, Dopamine D2; Sensitivity and Specificity; Substantia Nigra; Time Factors | 1993 |
Developing a stable bilateral model of parkinsonism in rhesus monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Carbidopa; Carotid Arteries; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Feeding Behavior; Female; Injections, Intra-Arterial; Levodopa; Macaca mulatta; Motor Activity; Parkinson Disease, Secondary | 1993 |
GM1 ganglioside rescues substantia nigra pars compacta neurons and increases dopamine synthesis in residual nigrostriatal dopaminergic neurons in MPTP-treated mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; G(M1) Ganglioside; Levodopa; Mice; Mice, Inbred C57BL; Neurons; Parkinson Disease; Substantia Nigra | 1995 |
L-DOPA inhibits spontaneous acetylcholine release from the striatum of experimental Parkinson's model rats.
Topics: Acetylcholine; Analysis of Variance; Animals; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; Drug Synergism; Ergolines; Levodopa; Male; Oxidopamine; Parkinson Disease, Secondary; Quinpirole; Rats; Rats, Sprague-Dawley; Tetrahydronaphthalenes | 1995 |
Esters of L-dopa: structure-hydrolysis relationships and ability to induce circling behaviour in an experimental model of hemiparkinsonism.
Topics: Animals; Behavior, Animal; Chemical Phenomena; Chemistry, Physical; Disease Models, Animal; Esters; Humans; Hydrolysis; Levodopa; Male; Parkinson Disease, Secondary; Prodrugs; Rats; Rats, Wistar; Solubility; Structure-Activity Relationship | 1995 |
Levodopoa but not bromocriptine induces AP-1 and creb DNA-binding activity in the dopamine-depleted striatum of the rat.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antiparkinson Agents; Base Sequence; Behavior, Animal; Bromocriptine; Corpus Striatum; Cyclic AMP Response Element-Binding Protein; Disease Models, Animal; Dopamine; Dopamine Agonists; Levodopa; Male; Molecular Sequence Data; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Transcription Factor AP-1 | 1996 |
Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Animals; Antiparkinson Agents; Callithrix; Carbidopa; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Synergism; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Neurologic Examination; Parkinson Disease, Secondary | 1995 |
Dopaminergic transplants alter in vivo activity of tryptophan hydroxylase in the striatum in a rat model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Brain Tissue Transplantation; Disease Models, Animal; Dopamine; Female; Fetal Tissue Transplantation; Levodopa; Mesencephalon; Microdialysis; Neostriatum; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Wistar; Tryptophan Hydroxylase | 1996 |
Longitudinal behavioral and 6-[18F]fluoro-L-DOPA-PET assessment in MPTP-hemiparkinsonian monkeys.
Topics: Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Fluorine Radioisotopes; Levodopa; Macaca; Male; Parkinson Disease; Tomography, Emission-Computed | 1996 |
Motor actions of eliprodil in the normal and monoamine-depleted mouse: a role in the treatment of Parkinson's disease?
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Behavior, Animal; Biogenic Monoamines; Disease Models, Animal; Dopamine Agents; Dopamine Agonists; Dose-Response Relationship, Drug; Efferent Pathways; Excitatory Amino Acid Antagonists; Levodopa; Locomotion; Male; Mice; Mice, Inbred Strains; Motor Neurons; Parkinson Disease; Phenethylamines; Piperidines; Receptors, Dopamine D1; Reserpine; Sympatholytics | 1996 |
Effects of catechol-O-methyltransferase inhibition on the rates of uptake and reversibility of 6-fluoro-L-Dopa trapping in MPTP-induced parkinsonism in monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzophenones; Catechol O-Methyltransferase; Disease Models, Animal; Enzyme Inhibitors; Levodopa; Macaca mulatta; Nitrophenols; Parkinson Disease; Tolcapone | 1997 |
Somatic delivery of catecholamines in the striatum attenuate parkinsonian symptoms and widen the therapeutic window of oral sinemet in rats.
Topics: Administration, Oral; Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Carbidopa; Cell Transplantation; Disease Models, Animal; Dopamine; Drug Combinations; Drug Synergism; Levodopa; Male; Movement Disorders; Neostriatum; Parkinson Disease, Secondary; PC12 Cells; Rats; Rats, Sprague-Dawley; Rotation | 1997 |
Role of aromatic L-amino acid decarboxylase for dopamine replacement by genetically modified fibroblasts in a rat model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Aromatic-L-Amino-Acid Decarboxylases; Catecholamines; Cell Transplantation; Corpus Striatum; Denervation; Disease Models, Animal; Dopamine; Female; Fibroblasts; Genetic Therapy; GTP Cyclohydrolase; Homovanillic Acid; Levodopa; Microdialysis; Parkinson Disease; Rats; Rats, Inbred F344; Recombinant Proteins; Transfection; Tyrosine 3-Monooxygenase | 1997 |
A chronic MPTP model reproducing the slow evolution of Parkinson's disease: evolution of motor symptoms in the monkey.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Cell Count; Chronic Disease; Disease Models, Animal; Disease Progression; Dopamine Agents; Levodopa; Macaca fascicularis; Movement; Neurons; Parkinson Disease, Secondary; Tyrosine 3-Monooxygenase | 1997 |
An animal model of copulatory disorder induced by social stress in male mice: effects of apomorphine and L-dopa.
Topics: Aggression; Animals; Apomorphine; Copulation; Disease Models, Animal; Dopamine Agents; Dopamine Agonists; Dose-Response Relationship, Drug; Levodopa; Male; Mice; Mice, Inbred ICR; Sexual Behavior, Animal; Sexual Dysfunction, Physiological; Social Environment; Stress, Psychological | 1997 |
Evaluation of risperidone in the neonatal 6-hydroxydopamine model of Lesch-Nyhan syndrome.
Topics: Animals; Animals, Newborn; Behavior, Animal; Benzazepines; Disease Models, Animal; Dopamine Agents; Dopamine Antagonists; Dose-Response Relationship, Drug; Female; Lesch-Nyhan Syndrome; Levodopa; Male; Motor Activity; Oxidopamine; Rats; Rats, Sprague-Dawley; Risperidone; Self Mutilation; Sympatholytics | 1998 |
Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions.
Topics: Amphetamine; Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Carrier Proteins; Disease Models, Animal; Dopamine; Dopamine Agonists; Dopamine Antagonists; Dopamine Plasma Membrane Transport Proteins; Dopamine Uptake Inhibitors; Female; Iodine Radioisotopes; Levodopa; Membrane Glycoproteins; Membrane Transport Proteins; Nerve Fibers; Nerve Tissue Proteins; Neuropeptides; Neurotransmitter Agents; Oxidopamine; Parkinson Disease, Secondary; Prosencephalon; Radioimmunoassay; Rats; Rats, Wistar; Substantia Nigra; Sulpiride; Sympatholytics; Tyrosine 3-Monooxygenase; Ventral Tegmental Area; Vesicular Biogenic Amine Transport Proteins; Vesicular Monoamine Transport Proteins | 1998 |
Modification of levodopa responses by deprenyl (selegiline): an electrophysiological and behavioral study in the rat relevant to Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Drug Synergism; Electrophysiology; Injections, Intraperitoneal; Levodopa; Male; Membrane Potentials; Motor Activity; Parkinson Disease, Secondary; Rats; Rats, Wistar; Selegiline | 1998 |
Characterization of intrastriatal recombinant adeno-associated virus-mediated gene transfer of human tyrosine hydroxylase and human GTP-cyclohydrolase I in a rat model of Parkinson's disease.
Topics: Animals; Apomorphine; Behavior, Animal; Corpus Striatum; Dependovirus; Disease Models, Animal; Dopamine Agents; Dopamine Agonists; Gene Expression Regulation, Enzymologic; Gene Transfer Techniques; GTP Cyclohydrolase; Humans; Levodopa; Male; Microdialysis; Neurons; Parkinson Disease, Secondary; Rats; Rats, Inbred F344; Recombinant Proteins; Rotation; Tyrosine 3-Monooxygenase | 1998 |
In vivo L-DOPA production by genetically modified primary rat fibroblast or 9L gliosarcoma cell grafts via coexpression of GTPcyclohydrolase I with tyrosine hydroxylase.
Topics: 3T3 Cells; Animals; Antioxidants; Antiparkinson Agents; Apomorphine; Behavior, Animal; Biopterins; Corpus Striatum; Dihydroxyphenylalanine; Disease Models, Animal; Fibroblasts; Gene Expression Regulation, Enzymologic; Genetic Therapy; Gliosarcoma; GTP Cyclohydrolase; Humans; Levodopa; Male; Mice; Microdialysis; Parkinson Disease, Secondary; Rats; Rats, Inbred F344; Recombinant Fusion Proteins; Retroviridae; Transformation, Genetic; Transgenes; Tumor Cells, Cultured; Tyrosine 3-Monooxygenase | 1998 |
Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Antiparkinson Agents; Behavior, Animal; Bromocriptine; Clonidine; Disease Models, Animal; Dopamine; Dopamine Uptake Inhibitors; Dyskinesia, Drug-Induced; Levodopa; Lisuride; Locomotion; Male; Mazindol; Methoxydimethyltryptamines; Oxidopamine; Parkinson Disease, Secondary; Prosencephalon; Rats; Rats, Sprague-Dawley; Sympatholytics; Tritium; Yohimbine | 1998 |
The overall rod performance test in the MPTP-treated-mouse model of Parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dopamine Agonists; Levodopa; Male; Mice; Mice, Inbred C57BL; Motor Activity; Neurons; Parkinson Disease, Secondary; Tyrosine 3-Monooxygenase | 1998 |
Comparison between the decrease of dopamine transporter and that of L-DOPA uptake for detection of early to advanced stage of Parkinson's disease in animal models.
Topics: Animals; Biological Transport; Brain; Carrier Proteins; Cocaine; Disease Models, Animal; Dopa Decarboxylase; Dopamine Plasma Membrane Transport Proteins; Female; Gene Expression Regulation; Levodopa; Membrane Glycoproteins; Membrane Transport Proteins; Motor Activity; Nerve Tissue Proteins; Neuropeptides; Parkinson Disease, Secondary; Radioligand Assay; Rats; Rats, Wistar; Rotation; Vesicular Biogenic Amine Transport Proteins; Vesicular Monoamine Transport Proteins | 1999 |
Actions of the D1 agonists A-77636 and A-86929 on locomotion and dyskinesia in MPTP-treated L-dopa-primed common marmosets.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adamantane; Animals; Benzopyrans; Callithrix; Disease Models, Animal; Dopamine Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Female; Levodopa; Locomotion; Male; Quinolones; Receptors, Dopamine D1; Thiophenes | 1999 |
Pergolide potentiates L-DOPA-induced dopamine release in rat striatum after lesioning with 6-hydroxydopamine.
Topics: 3,4-Dihydroxyphenylacetic Acid; Amphetamine; Animals; Disease Models, Animal; Dopamine; Dopamine Agonists; Drug Synergism; Homovanillic Acid; Hydroxyindoleacetic Acid; Levodopa; Male; Microdialysis; Motor Activity; Neostriatum; Neurons; Oxidopamine; Parkinson Disease, Secondary; Pergolide; Rats; Rats, Wistar | 1999 |
Functional MRI of basal ganglia responsiveness to levodopa in parkinsonian rhesus monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Basal Ganglia; Disease Models, Animal; Dopamine Agents; Female; Levodopa; Macaca mulatta; Magnetic Resonance Imaging; Microdialysis; Parkinson Disease, Secondary; Treatment Outcome | 1999 |
Narrow beneficial effect of dextromethorphan on levodopa-induced motor response alterations in an experimental model of parkinsonism.
Topics: Animals; Antiparkinson Agents; Dextromethorphan; Disease Models, Animal; Excitatory Amino Acid Antagonists; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Rotation; Treatment Outcome | 1999 |
The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenergic Antagonists; Animals; Antiparkinson Agents; Brain; Callithrix; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Drug Synergism; Dyskinesias; Female; Idazoxan; Levodopa; Male; Receptors, Adrenergic, alpha-2; Time Factors; Yohimbine | 1999 |
Discovery of subtype-selective NMDA receptor ligands: 4-benzyl-1-piperidinylalkynylpyrroles, pyrazoles and imidazoles as NR1A/2B antagonists.
Topics: Animals; Disease Models, Animal; Imidazoles; Levodopa; Ligands; Molecular Structure; Oxidopamine; Parkinsonian Disorders; Piperidines; Pyrazoles; Pyrroles; Rats; Receptors, N-Methyl-D-Aspartate | 1999 |
Multipotential marrow stromal cells transduced to produce L-DOPA: engraftment in a rat model of Parkinson disease.
Topics: Animals; Bone Marrow Cells; Brain; Cell Survival; Cell Transplantation; Cells, Cultured; Disease Models, Animal; Genetic Therapy; GTP Cyclohydrolase; Humans; Immunohistochemistry; Levodopa; Male; Parkinson Disease; Rats; Rats, Inbred Lew; Stromal Cells; Transduction, Genetic; Tyrosine 3-Monooxygenase | 1999 |
Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease.
Topics: Animals; Antisense Elements (Genetics); Bacterial Proteins; Biomarkers; Cell Count; Disease Models, Animal; Dyskinesias; Enkephalins; Female; Levodopa; Neostriatum; Nerve Degeneration; Neurons; Parkinsonian Disorders; Protein Precursors; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; RNA, Messenger; Substantia Nigra; Transcription Factors; Ventral Tegmental Area | 1999 |
Alterations in subunit expression, composition, and phosphorylation of striatal N-methyl-D-aspartate glutamate receptors in a rat 6-hydroxydopamine model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Cell Membrane; Corpus Striatum; Disease Models, Animal; Levodopa; Male; Neurons; Oxidopamine; Parkinson Disease, Secondary; Phosphorylation; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate | 2000 |
Effect of acute L-Dopa pretreatment on apomorphine-induced rotational behavior in a rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Carbidopa; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Levodopa; Male; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Inbred F344; Rotation; Substantia Nigra; Sympatholytics | 2000 |
Comparison of eight clinical rating scales used for the assessment of MPTP-induced parkinsonism in the Macaque monkey.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dopamine Agents; Female; Levodopa; Macaca fascicularis; Motor Activity; MPTP Poisoning; Neurologic Examination; Severity of Illness Index | 2000 |
Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Animals; Callithrix; Carbidopa; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Injections, Intraperitoneal; Levodopa; Male; Motor Activity; Parkinson Disease, Secondary; Purinergic P1 Receptor Antagonists; Purines; Quinpirole; Receptor, Adenosine A2A; Receptors, Dopamine D1; Receptors, Dopamine D2 | 2000 |
AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzodiazepines; Dioxoles; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Levodopa; Macaca fascicularis; Male; Motor Activity; Parkinson Disease, Secondary; Piperidines; Receptors, AMPA; Severity of Illness Index | 2000 |
Toward a primate model of L-dopa-unresponsive parkinsonism mimicking striatonigral degeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Brain Mapping; Corpus Striatum; Diagnosis, Differential; Disease Models, Animal; Dopamine; Levodopa; Macaca fascicularis; Male; Multiple System Atrophy; Nerve Degeneration; Neurotoxins; Nitro Compounds; Parkinson Disease, Secondary; Propionates; Striatonigral Degeneration | 2000 |
5-HT(2C) receptor antagonists enhance the behavioural response to dopamine D(1) receptor agonists in the 6-hydroxydopamine-lesioned rat.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Benzazepines; Disease Models, Animal; Dopamine Agonists; Indoles; Levodopa; Locomotion; Male; Oxidopamine; Parkinson Disease, Secondary; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT2C; Receptors, Dopamine D1; Receptors, Serotonin; Serotonin Antagonists | 2000 |
Effects of oligonucleotide antisense to dopamine D(1A) receptor messenger RNA in a rodent model of levodopa-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Apomorphine; Autoradiography; Behavior, Animal; Cocaine; Denervation; Disease Models, Animal; Dopamine Antagonists; Dopamine Uptake Inhibitors; Dyskinesia, Drug-Induced; Gene Expression; Levodopa; Male; Oligonucleotides, Antisense; Oxidopamine; Phenotype; Raclopride; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; RNA, Messenger; Rotation; Substantia Nigra; Sympatholytics; Tritium | 2000 |
The expression of the calcium binding protein calretinin in the rat striatum: effects of dopamine depletion and L-DOPA treatment.
Topics: Animals; Calbindin 2; Calcium-Binding Proteins; Cell Count; Corpus Striatum; Disease Models, Animal; Dopamine; Drug Administration Schedule; Immunohistochemistry; Injections, Intraperitoneal; Levodopa; Male; Medial Forebrain Bundle; Microinjections; Neuropil; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Wistar; S100 Calcium Binding Protein G; Tyrosine 3-Monooxygenase | 2000 |
Autoradiographic analysis of N-methyl-D-aspartate receptor binding in monkey brain: effects of 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine and levodopa treatment.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Brain Chemistry; Disease Models, Animal; Dizocilpine Maleate; Dopamine Agents; Excitatory Amino Acid Antagonists; Iodine Radioisotopes; Levodopa; Parkinson Disease, Secondary; Radioligand Assay; Receptors, N-Methyl-D-Aspartate; Saimiri | 2000 |
L-DOPA produces strong induction of c-fos messenger RNA in dopamine-denervated cortical and striatal areas of the common marmoset.
Topics: Animals; Benzazepines; Blotting, Western; Callithrix; Cerebral Cortex; Corpus Striatum; Denervation; Disease Models, Animal; Dopamine; Dopamine Agents; Dopamine Antagonists; Enkephalins; Gene Expression; Genes, Immediate-Early; Levodopa; Nerve Degeneration; Oxidopamine; Parkinson Disease; Protein Precursors; Proto-Oncogene Proteins c-fos; Raclopride; Radioligand Assay; Receptors, Dopamine D1; Receptors, Dopamine D2; RNA, Messenger; Substance P; Substantia Nigra; Sympatholytics; Tritium | 2000 |
Dopamine-receptor stimulation: biobehavioral and biochemical consequences.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Basal Ganglia; Disease Models, Animal; Dopamine Agonists; Dyskinesia, Drug-Induced; Haplorhini; Levodopa; Neural Inhibition; Neuropeptides; Parkinsonian Disorders; Proto-Oncogene Proteins c-fos; Receptors, Dopamine; Receptors, GABA; Receptors, Glutamate; Signal Transduction | 2000 |
GDNF reverses priming for dyskinesia in MPTP-treated, L-DOPA-primed common marmosets.
Topics: Animals; Antiparkinson Agents; Body Weight; Callithrix; Corpus Striatum; Disease Models, Animal; Dopamine Uptake Inhibitors; Dyskinesia, Drug-Induced; Enkephalins; Female; Gene Expression; Glial Cell Line-Derived Neurotrophic Factor; Levodopa; Locomotion; Male; Mazindol; MPTP Poisoning; Nerve Growth Factors; Nerve Tissue Proteins; Neuroprotective Agents; Protein Precursors; Recovery of Function; RNA, Messenger; Substantia Nigra; Tachykinins; Tritium; Tyrosine 3-Monooxygenase | 2001 |
Overstimulation of the alpha1B-adrenergic receptor causes a "seizure plus" syndrome.
Topics: Adrenergic alpha-Antagonists; Animals; Antiparkinson Agents; Brain; Cerebral Cortex; Disease Models, Animal; Dopamine Agents; Epilepsy, Tonic-Clonic; Humans; Inclusion Bodies; Levodopa; Mice; Nerve Tissue Proteins; Neurodegenerative Diseases; Parkinsonian Disorders; Prazosin; Receptors, Adrenergic, alpha-1; Shy-Drager Syndrome; Syndrome; Synucleins; Tyrosine 3-Monooxygenase | 2001 |
Alterations in cortical and basal ganglia levels of opioid receptor binding in a rat model of l-DOPA-induced dyskinesia.
Topics: Animals; Basal Ganglia; Behavior, Animal; Binding Sites; Cerebral Cortex; Diprenorphine; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Enkephalins; Female; Levodopa; Narcotic Antagonists; Oxidopamine; Protein Precursors; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptors, Opioid; Receptors, Opioid, delta; Receptors, Opioid, kappa; Receptors, Opioid, mu; RNA, Messenger; Sympatholytics; Tritium | 2001 |
Coadministration of (-)-OSU6162 with l-DOPA normalizes preproenkephalin mRNA expression in the sensorimotor striatum of primates with unilateral 6-OHDA lesions.
Topics: Animals; Autoradiography; Callithrix; Caudate Nucleus; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Drug Administration Schedule; Drug Therapy, Combination; Enkephalins; Female; In Situ Hybridization; Injections, Subcutaneous; Levodopa; Ligands; Male; Oxidopamine; Parkinson Disease, Secondary; Piperidines; Protein Precursors; Putamen; RNA, Messenger; Tritium | 2001 |
Establishment of L-3,4-Dihydroxyphenilalaninde-induced pharmacological dementia model mouse.
Topics: Administration, Oral; Animals; Antiparkinson Agents; Avoidance Learning; Cognition Disorders; Dementia; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Levodopa; Male; Memory Disorders; Mice; Mice, Inbred C57BL; Stereoisomerism | 2001 |
Chronic L-DOPA administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, in rats with partial 6-OHDA or FeCl(3) nigrostriatal lesions.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Antiparkinson Agents; Benserazide; Chlorides; Chromatography, High Pressure Liquid; Disease Models, Animal; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Ferric Compounds; Immunoenzyme Techniques; Levodopa; Male; Neostriatum; Nerve Net; Neurons; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Substantia Nigra; Tyrosine 3-Monooxygenase | 2001 |
The frissonnant mutant mouse, a model of dopamino-sensitive, inherited motor syndrome.
Topics: Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Electromyography; Female; Genes, Recessive; Immunohistochemistry; Indoles; Levodopa; Male; Memory Disorders; Mice; Mice, Inbred C3H; Mice, Neurologic Mutants; Motor Activity; Neurons; Parkinson Disease, Secondary; Postural Balance; Selegiline; Tyrosine 3-Monooxygenase | 2001 |
Mu- and delta-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Disease Models, Animal; Drug Therapy, Combination; Dyskinesias; Female; Hypokinesia; Levodopa; Male; Morphinans; Motor Activity; Naltrexone; Narcotic Antagonists; Parkinsonian Disorders; Posture; Receptors, Opioid, delta; Receptors, Opioid, mu | 2001 |
Assessment of motor behavior using a video system and a clinical rating scale in parkinsonian monkeys lesioned by MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Basal Ganglia; Behavior, Animal; Chronic Disease; Disability Evaluation; Disease Models, Animal; Dopamine Agents; Drug Administration Schedule; Dyskinesias; Female; Image Processing, Computer-Assisted; Levodopa; Macaca mulatta; Motor Activity; Parkinsonian Disorders; Video Recording | 2001 |
Functional effect of adeno-associated virus mediated gene transfer of aromatic L-amino acid decarboxylase into the striatum of 6-OHDA-lesioned rats.
Topics: Animals; Apomorphine; Aromatic-L-Amino-Acid Decarboxylases; Dependovirus; Disease Models, Animal; Dopamine; Gene Transfer Techniques; Genetic Therapy; Genetic Vectors; Levodopa; Neostriatum; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Rotation; Transduction, Genetic | 2001 |
Stereoselective effect of (R)- and (S)-1-methyl-1,2,3,4-tetrahydroisoquinolines on a mouse model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Carbidopa; Cell Count; Disease Models, Animal; Dopamine; Dopamine Antagonists; Drug Interactions; Homovanillic Acid; Hydroxyindoleacetic Acid; Hypokinesia; Immunohistochemistry; Isoquinolines; Levodopa; Male; Mice; Mice, Inbred C57BL; Neurons; Neuroprotective Agents; Neurotoxins; Parkinsonian Disorders; Serotonin; Stereoisomerism; Substantia Nigra; Tetrahydroisoquinolines; Tyrosine 3-Monooxygenase | 2001 |
Persistent changes in striatal gene expression induced by long-term L-DOPA treatment in a rat model of Parkinson's disease.
Topics: Animals; Bromocriptine; Denervation; Disease Models, Animal; Dopamine Agents; Dopamine Agonists; Drug Administration Schedule; Enkephalins; Female; Gene Expression Regulation; Immunohistochemistry; Levodopa; Neostriatum; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; RNA, Messenger; Sympatholytics | 2001 |
MK-801 alters the effects of priming with L-DOPA on dopamine D1 receptor-induced changes in neuropeptide mRNA levels in the rat striatal output neurons.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Disease Models, Animal; Dizocilpine Maleate; Dopamine Agents; Dopamine Agonists; Drug Interactions; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Excitatory Amino Acid Antagonists; Immunohistochemistry; Levodopa; Male; Motor Activity; Neostriatum; Neurons; Neuropeptides; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Rats; Rats, Wistar; Receptors, Dopamine D1; Receptors, N-Methyl-D-Aspartate; RNA, Messenger; Tachykinins; Tyrosine 3-Monooxygenase | 2002 |
Effects of pharmacological agents upon a transgenic model of Parkinson's disease in Drosophila melanogaster.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; alpha-Methyltyrosine; alpha-Synuclein; Animals; Animals, Genetically Modified; Antiparkinson Agents; Bromocriptine; Disease Models, Animal; Drosophila melanogaster; Genotype; Levodopa; Motor Activity; Nerve Tissue Proteins; Neurons; Parkinson Disease; Pergolide; Postural Balance; Synapses; Synucleins | 2002 |
Effects of short- and long-acting dopamine agonists on sensitized dopaminergic neurotransmission in rats with unilateral 6-OHDA lesions.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Cabergoline; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; Drug Antagonism; Ergolines; Levodopa; Male; Oxidopamine; Rats; Rats, Sprague-Dawley; Stereotyped Behavior; Synaptic Transmission | 2002 |
Levodopa-induced dyskinesias in normal squirrel monkeys.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Saimiri | 2002 |
The role of dopamine in motor symptoms in the R6/2 transgenic mouse model of Huntington's disease.
Topics: Aging; Animals; Behavior, Animal; Brain; Brain Chemistry; Central Nervous System Stimulants; Cocaine; Diabetes Complications; Diabetes Mellitus; Disease Models, Animal; Disease Progression; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Female; Glucose Tolerance Test; Huntington Disease; Levodopa; Methamphetamine; Mice; Mice, Inbred C57BL; Mice, Transgenic; Motor Activity; Spatial Behavior; Survival Rate | 2002 |
A pharmacologic model of Huntington's chorea.
Topics: Animals; Carbachol; Catheterization; Clozapine; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Haloperidol; Huntington Disease; Hydrazines; Levodopa; Male; Phentolamine; Rats; Trifluoperazine; Tyramine | 1976 |
Substitute and alternative neurotransmitters in neuropsychiatric illness.
Topics: Amines; Amino Acids; Animals; Brain; Catecholamines; Disease Models, Animal; Hemodynamics; Hepatic Encephalopathy; Humans; Levodopa; Liver; Nerve Endings; Neurocognitive Disorders; Neurotransmitter Agents; Serotonin; Sympatholytics; Synaptic Transmission | 1977 |
[Metabolic disorders in experimental hepatic insufficiency and parenteral feeding].
Topics: 5-Hydroxytryptophan; Amino Acids; Ammonia; Animals; Blood Coagulation; Blood Transfusion; Choline; Disease Models, Animal; Dogs; Female; Hepatectomy; Hepatic Encephalopathy; Kidney Function Tests; Levodopa; Male; Parenteral Nutrition; Postoperative Care; Time Factors | 1977 |
Experimental neuropathy with Parkinson-like muscular rigidity. A suitable model for testing dopaminergic agonists and neuroleptic drugs.
Topics: 6-Aminonicotinamide; Animals; Antipsychotic Agents; Baclofen; Brain; Brain Chemistry; Bromocriptine; Central Nervous System Diseases; Disease Models, Animal; Dopamine; Drug Evaluation, Preclinical; Electromyography; Gluconates; Levodopa; Lisuride; Male; Motor Neurons; Muscle Contraction; Niacinamide; Parkinson Disease, Secondary; Rats; Reserpine; RNA; Spinal Cord; Sugar Phosphates | 1978 |
Gamma hydroxybutyrate in the monkey. II. Effect of chronic oral anticonvulsant drugs.
Topics: Administration, Oral; Animals; Anticonvulsants; Disease Models, Animal; Electroencephalography; Epilepsy, Absence; Ethosuximide; Haplorhini; Hydroxybutyrates; Levodopa; Macaca mulatta; Phenobarbital; Phenytoin | 1978 |
Experimental torticollis in the marmoset produced by injection of 6-hydroxydopamine into the ascending nigrostriatal pathway.
Topics: Amphetamine; Animals; Apomorphine; Benserazide; Callitrichinae; Disease Models, Animal; Drug Therapy, Combination; Haloperidol; Haplorhini; Hydroxydopamines; Hypothalamus; Levodopa; Locus Coeruleus; Male; Torticollis | 1979 |
A study of psychomotor epilepsy with "kindled" cat preparations.
Topics: Amygdala; Animals; Cats; Disease Models, Animal; Dopamine; Electric Stimulation; Electroencephalography; Epilepsy, Temporal Lobe; Fenclonine; Hippocampus; Levodopa; Methyltyrosines; Norepinephrine; Reserpine; Seizures; Septum Pellucidum; Serotonin | 1976 |
Acute dystonia as an idiosyncratic response to neuroleptics in baboons.
Topics: 5-Hydroxytryptophan; Acute Disease; Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Haloperidol; Haplorhini; Humans; Levodopa; Movement Disorders; Papio; Parasympatholytics; Physostigmine; Pimozide; Receptors, Dopamine; Reserpine; Syndrome; Tranquilizing Agents | 1977 |
Hemiparkinsonism. A human model for studying dopaminergic supersensitivity.
Topics: Animals; Antiparkinson Agents; Bromocriptine; Carbidopa; Dextroamphetamine; Disease Models, Animal; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease, Secondary; Receptors, Dopamine | 1979 |
Excessive bracing reactions and their control by atropine and L-DOPA in an animal analog of Parkinsonism.
Topics: Animals; Atropine; Brain; Disease Models, Animal; Dopamine; Forelimb; Hydroxydopamines; Levodopa; Locomotion; Male; Norepinephrine; Parkinson Disease, Secondary; Postural Balance; Rats | 1979 |
Lisuride, a potent drug in the treatment of muscular rigisity in rats.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Ergolines; Levodopa; Male; Muscle Rigidity; Rats; Urea | 1977 |
Levodopa-induced dopamine receptor hypersensitivity.
Topics: Animals; Apomorphine; Dextroamphetamine; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Levodopa; Mice; Receptors, Dopamine; Stereotyped Behavior | 1977 |
Receptor-cell sensitivity modification (RSM) as a model for pathogenesis and treatment of tardive dyskinesia.
Topics: Animals; Carbidopa; Disease Models, Animal; Drug Combinations; Dyskinesia, Drug-Induced; Hydrazines; Levodopa; Rats; Receptors, Dopamine | 1978 |
Dopaminergic agonists in animal models of parkinsonism.
Topics: Amphetamine; Animals; Antiparkinson Agents; Apomorphine; Cats; Disease Models, Animal; Haplorhini; Levodopa; Parkinson Disease, Secondary; Piribedil; Rats; Reserpine; Tyrosine | 1975 |
Effect of centrally acting drugs on experimental torticollis in monkeys.
Topics: Acetates; Alkaloids; Aminooxyacetic Acid; Animals; Brain Stem; Chlorocebus aethiops; Disease Models, Animal; Drug Evaluation, Preclinical; Electromyography; Haloperidol; Haplorhini; Harmaline; Humans; Levodopa; Macaca mulatta; Methyltyrosines; Muscle Tonus; Pimozide; Tegmentum Mesencephali; Torticollis | 1976 |
Parkinsonism: animal analogues of the human disorder.
Topics: Animals; Butyrophenones; Chlorpromazine; Disease Models, Animal; Haplorhini; Hydroxydopamines; Levodopa; Methyltyrosines; Mice; Parkinson Disease; Rats; Reserpine; Substantia Nigra; Tremor | 1976 |
Pathogenesis of spontaneous hypertension as a model for essential hypertension.
Topics: Acetylcholinesterase; Animals; Blood Pressure; Brain; Carboxy-Lyases; Disease Models, Animal; Hypertension; Levodopa; Proline; Rats; Renin; Vascular Resistance | 1977 |
Toxicity of mild prenatal carbon monoxide exposure.
Topics: Animals; Animals, Newborn; Behavior, Animal; Birth Weight; Body Weight; Brain; Carbon Monoxide; Disease Models, Animal; Dopamine; Female; Fetus; Levodopa; Maternal-Fetal Exchange; Motor Activity; Nerve Tissue Proteins; Norepinephrine; Pregnancy; Rats; Smoking | 1977 |
Reinstatement of eating by dopamine agonists in aphagic dopamine denervated rats.
Topics: Animals; Apomorphine; Denervation; Disease Models, Animal; Dose-Response Relationship, Drug; Eating; Humans; Hydroxydopamines; Hypothalamus; Levodopa; Male; Motor Activity; Nerve Degeneration; Parkinson Disease; Piperazines; Rats; Receptors, Dopamine; Stereotyped Behavior; Stimulation, Chemical | 1976 |
Amphetamine-induced dopaminergic hypersensitivity in guinea pigs. Implications in psychosis and human movement disorders.
Topics: Amphetamine; Animals; Apomorphine; Behavior; Behavior, Animal; Disease Models, Animal; Dopamine Antagonists; Dose-Response Relationship, Drug; Guinea Pigs; Humans; Levodopa; Movement Disorders; Psychoses, Substance-Induced; Reaction Time; Receptors, Drug; Schizophrenia; Stereotyped Behavior; Substance-Related Disorders | 1975 |
Relationship between animal models and clinical parkinsonism.
Topics: Animals; Brain; Disease Models, Animal; Dopamine; Humans; Levodopa; Norepinephrine; Parkinson Disease; Parkinson Disease, Secondary; Rats; Reserpine; Substantia Nigra | 1975 |
Actions of dopaminergic agonists on motor function.
Topics: Amantadine; Animals; Apomorphine; Behavior; Dextroamphetamine; Disease Models, Animal; Dopamine Antagonists; Humans; Hyperkinesis; Levodopa; Methylphenidate; Motor Activity; Movement Disorders; Phenethylamines; Piribedil; Rats; Stereotyped Behavior; Tyrosine | 1975 |
Supersensitivity to d-amphetamine- and apomorphine-induced stereotyped behavior induced by chronic d-amphetamine administration.
Topics: Animals; Apomorphine; Behavior; Corpus Striatum; Dextroamphetamine; Disease Models, Animal; Dopamine; Humans; Levodopa; Male; Mice; Movement Disorders; Parkinson Disease; Receptors, Drug; Stereotyped Behavior; Time Factors | 1975 |
Levodopa-enhanced recovery from paralysis induced by air embolism.
Topics: Animals; Disease Models, Animal; Embolism, Air; Female; Levodopa; Paralysis; Rats; Solvents | 1976 |
Fowl model for vitiligo: genetic regulation on the fate of the melanocytes.
Topics: alpha-MSH; Animals; Cell Death; Cells, Cultured; Chick Embryo; Chickens; Culture Media; Disease Models, Animal; Feathers; Gene Expression Regulation; Genotype; Levodopa; Melanocytes; Models, Biological; Poultry Diseases; Vitiligo | 1992 |
Motor impairments after methamphetamine-induced neurotoxicity in the rat.
Topics: Animals; Avoidance Learning; Disease Models, Animal; Dopamine; Fenfluramine; Levodopa; Male; Methamphetamine; Motor Activity; Nervous System Diseases; Parkinson Disease; Rats; Serotonin | 1992 |
Experimental model of autoimmune hemolytic anemia induced in mice with levodopa by intraperitoneal injection or oral feeding.
Topics: Administration, Oral; Anemia, Hemolytic, Autoimmune; Animals; Antibody Specificity; Autoantibodies; Disease Models, Animal; Erythrocytes; Female; Humans; Immunoglobulin A; Immunoglobulin G; Immunoglobulin M; Injections, Intraperitoneal; Levodopa; Mice; Mice, Inbred A; Sheep; Species Specificity | 1992 |
Nanomolar L-dopa facilitates release of dopamine via presynaptic beta-adrenoceptors: comparative studies on the actions in striatal slices from control and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated C57 black mice, an animal model for Par
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; In Vitro Techniques; Isoproterenol; Levodopa; Mice; Mice, Inbred C57BL; Parkinson Disease, Secondary; Receptors, Adrenergic, beta; Synapses | 1991 |
[Biochemical aspects of the pathogenesis of autonomic and emotional disorders in functional disorders of the dopamine system].
Topics: Animals; Autonomic Nervous System Diseases; Choline O-Acetyltransferase; Cholinesterase Inhibitors; Disease Models, Animal; Dopamine; Hypothalamus; Levodopa; Male; Mood Disorders; Parasympathetic Nervous System; Rats; Rats, Inbred Strains; Synaptosomes | 1991 |
L-dopa-responsive movement disorder caused by Nocardia asteroides localized in the brains of mice.
Topics: Animals; Brain; Disease Models, Animal; Female; Inclusion Bodies; Levodopa; Mice; Mice, Inbred BALB C; Movement Disorders; Nocardia asteroides; Nocardia Infections; Parkinson Disease; Tyrosine 3-Monooxygenase | 1991 |
Synergism of the AMPA-antagonist NBQX and the NMDA-antagonist CPP with L-dopa in models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Analysis of Variance; Animals; Callithrix; Disease Models, Animal; Drug Synergism; Ibotenic Acid; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease, Secondary; Piperazines; Quinoxalines; Rats; Rats, Inbred Strains; Receptors, N-Methyl-D-Aspartate; Substantia Nigra | 1991 |
Naloxone reverses L-dopa induced overstimulation effects in a Parkinson's disease animal model analogue.
Topics: Animals; Carbidopa; Chromatography, High Pressure Liquid; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Drug Administration Schedule; Dyskinesia, Drug-Induced; Hydroxydopamines; Levodopa; Male; Mesencephalon; Naloxone; Oxidopamine; Parkinson Disease; Rats; Rats, Inbred Strains; Time Factors | 1991 |
[The effect of chronic treatment of deprenyl in animal models of Parkinson's disease].
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Drug Administration Schedule; Levodopa; Macaca mulatta; Male; Mice; Mice, Inbred C57BL; Parkinson Disease; Rotation; Selegiline | 1991 |
Neuroleptic-induced catalepsy as a model of Parkinson's disease. I. Effect of dopaminergic agents.
Topics: Animals; Antipsychotic Agents; Catalepsy; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Fluphenazine; Levodopa; Male; Methamphetamine; Microinjections; Parkinson Disease; Rats; Sulpiride | 1990 |
Exogeneous expression of L-dopa and dopamine in various cell lines following transfer of rat and human tyrosine hydroxylase cDNA: grafting in an animal model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Disease Models, Animal; DNA; Dopamine; Enzyme Induction; Graft Survival; Levodopa; Male; Neuroblastoma; Parkinson Disease; Rats; Rats, Inbred Strains; Recombinant Fusion Proteins; Transplantation, Heterotopic; Tumor Cells, Cultured; Tyrosine 3-Monooxygenase | 1990 |
Oral levodopa dose-response study in MPTP-induced hemiparkinsonian monkeys: assessment with a new rating scale for monkey parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Animals; Antiparkinson Agents; Carbidopa; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Combinations; Levodopa; Macaca mulatta; Neurologic Examination; Parkinson Disease, Secondary; Stereotyped Behavior | 1991 |
Chronic neurochemical and behavioral changes in MPTP-lesioned C57BL/6 mice: a model for Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Body Weight; Corpus Striatum; Disease Models, Animal; Dopamine; Hydrazines; Levodopa; Male; Methyltyrosines; Mice; Mice, Inbred C57BL; Motor Activity; Parkinson Disease, Secondary; Receptors, Dopamine; Stereotyped Behavior | 1990 |
Preliminary report on adrenal medullary grafting and cografting with sural nerve in the treatment of hemiparkinson monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenal Medulla; Animals; Apomorphine; Behavior, Animal; Carbidopa; Caudate Nucleus; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Macaca mulatta; Motor Activity; Parkinson Disease; Sural Nerve; Transplantation, Heterotopic | 1990 |
CCK-8S inhibits L-dopa-induced dyskinesias in parkinsonian squirrel monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Parkinson Disease, Secondary; Saimiri; Sincalide | 1990 |
Grafting fibroblasts genetically modified to produce L-dopa in a rat model of Parkinson disease.
Topics: Animals; Cell Line; Disease Models, Animal; DNA; Fibroblasts; Genetic Vectors; Levodopa; Moloney murine leukemia virus; Parkinson Disease; Plasmids; Rats; Transfection; Tyrosine 3-Monooxygenase | 1989 |
Experimental model of autoimmune hemolytic anemia induced in mice with levodopa.
Topics: Anemia, Hemolytic, Autoimmune; Animals; Autoantibodies; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Erythrocytes; Female; Levodopa; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Species Specificity | 1989 |
Timing of levodopa therapy: evidence from MPTP-treated primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Levodopa; Macaca fascicularis; Parkinson Disease; Parkinson Disease, Secondary; Pyridines; Time Factors | 1987 |
MPTP-induced parkinsonian model in mice: biochemistry, pharmacology and behavior.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dopamine; Droxidopa; Levodopa; Mice; Mice, Inbred C57BL; Parkinson Disease, Secondary; Pyridines; Receptors, Muscarinic; Somatostatin | 1987 |
L-dopa esters as potential prodrugs: behavioural activity in experimental models of Parkinson's disease.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Female; Hydroxydopamines; Levodopa; Male; Mice; Movement Disorders; Oxidopamine; Parkinson Disease; Rats; Rats, Inbred Strains; Reserpine; Stereotyped Behavior | 1987 |
Experimental study on resting tremor and L-dopa-induced dyskinesia.
Topics: Animals; Cercopithecus; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Macaca; Movement Disorders; Receptors, Dopamine; Receptors, Dopamine D2; Tegmentum Mesencephali; Tremor | 1987 |
[A model of Parkinson's disease: effect of L-dopa therapy on movement parameters and electromyographic activity in monkeys treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Carbidopa; Disease Models, Animal; Drug Combinations; Electromyography; Levodopa; Macaca mulatta; Movement Disorders; Parkinson Disease, Secondary; Pyridines | 1985 |
Favorable effect of catechol-O-methyltransferase inhibition by OR-462 in experimental models of Parkinson's disease.
Topics: Animals; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Ketones; Levodopa; Male; Mice; Motor Activity; Parkinson Disease; Pentanones; Rats; Rats, Inbred Strains; Rotation | 1988 |
Amine fluorescence histochemical investigation of the striatum in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine(MPTP)-induced parkinsonian mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Histocytochemistry; Levodopa; Male; Mice; Mice, Inbred C57BL; Microscopy, Fluorescence; Parkinson Disease, Secondary; Pyridines | 1988 |
A new device for the quantitative assessment of dopaminergic drug effects in unilateral MPTP-lesioned monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Disease Models, Animal; Equipment Design; Feeding Behavior; Levodopa; Macaca fascicularis; Male; Movement; Parkinson Disease, Secondary; Pyridines; Receptors, Dopamine | 1988 |
Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Brain; Brain Chemistry; Carbidopa; Carotid Artery, Internal; Disease Models, Animal; Dominance, Cerebral; Dopamine; Homovanillic Acid; Injections, Intra-Arterial; Levodopa; Macaca fascicularis; Movement; Neurons; Parkinson Disease, Secondary; Pyridines | 1986 |
Recent research advances in Parkinson's disease: Part I.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Humans; Levodopa; Parkinson Disease; Pyridines; Research; Substantia Nigra | 1986 |
Levodopa-induced dyskinesia and response fluctuations in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Macaca fascicularis; Parkinson Disease, Secondary; Pyridines | 1987 |
Terguride, a mixed dopamine agonist-antagonist, in animal models of Parkinson's disease.
Topics: Amphetamine; Animals; Apomorphine; Behavior, Animal; Brain; Disease Models, Animal; Ergolines; Levodopa; Lisuride; Male; Motor Activity; Parkinson Disease; Rats; Rats, Inbred Strains; Receptors, Dopamine; Stereotyped Behavior | 1987 |
[Modelling of the parkinsonian syndrome by the administration of kainic acid into the caudate nucleus].
Topics: Animals; Caudate Nucleus; Disease Models, Animal; Drug Evaluation, Preclinical; Electrodes, Implanted; Electroencephalography; Female; Injections; Kainic Acid; Levodopa; Male; Parkinson Disease, Secondary; Rats; Time Factors; Trihexyphenidyl | 1987 |
A simple quantitative bradykinesia test in MPTP-treated mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain Chemistry; Disease Models, Animal; Dopamine; Levodopa; Mice; Mice, Inbred C57BL; Motor Activity; Norepinephrine; Parkinson Disease, Secondary; Pyridines | 1985 |
Animal models of myoclonus using 1,2-dihydroxybenzene (catechol) and chloralose.
Topics: Acetylcholine; Animals; Brain; Catecholamines; Catechols; Chemical Phenomena; Chemistry; Chloralose; Disease Models, Animal; Electromyography; Evoked Potentials; Female; gamma-Aminobutyric Acid; Glycolysis; Levodopa; Monoamine Oxidase Inhibitors; Myoclonus; Rats; Reserpine | 1986 |
Dopaminergic and cholinergic mechanisms in relation to postural tremor in the monkey and circling movements in the cat.
Topics: Acetylcholine; Amphetamine; Animals; Cats; Corpus Striatum; Disease Models, Animal; Dopamine; Frontal Lobe; Haloperidol; Haplorhini; Levodopa; Mesencephalon; Methyltyrosines; Mice; Movement Disorders; Parkinson Disease; Posture; Rats; Reserpine; Substantia Nigra; Tegmentum Mesencephali; Thalamic Nuclei; Tremor | 1974 |
Importance of the cerebellar hemisphere in production of tremulous movement or choreo-dystonic movement in monkeys.
Topics: Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Cerebellum; Chorea; Disease Models, Animal; Drug Combinations; Enzyme Inhibitors; Levodopa; Macaca; Muscular Diseases; Tremor | 1974 |
L-DOPA: chemical modifications and biological evaluation.
Topics: Animals; Antiparkinson Agents; Blepharoptosis; Catatonia; Disease Models, Animal; Humans; Hypothermia; Levodopa; Male; Mice; Oxotremorine; Parkinson Disease; Reserpine; Structure-Activity Relationship; Tremor | 1974 |
Behavioral, physiological, and neurochemical changes after 6-hydroxydopamine-induced degeneration of the nigro-striatal dopamine neurons.
Topics: Amphetamine; Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Drinking Behavior; Electric Stimulation; Electromyography; Feeding and Eating Disorders; Feeding Behavior; Humans; Hydroxydopamines; Levodopa; Motor Neurons; Muscle Contraction; Nerve Degeneration; Neural Pathways; Parkinson Disease; Parkinson Disease, Secondary; Perceptual Disorders; Rats; Reflex, Stretch; Substantia Nigra | 1974 |